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RESUMO 
 
A leucemia linfoblástica aguda de linfócitos T (LLA-T) é uma patologia hematológica 
maligna que afeta essencialmente crianças e adultos jovens e é fatal na ausência de um 
diagnóstico precoce e uma terapêutica apropriada. É do conhecimento geral que a LLA-T tem 
origem em precursores dos linfócitos T, também designados por timócitos, que sofrem um 
bloqueio da diferenciação e expansão clonal. As células imaturas transformadas disseminam-
se pela corrente sanguínea e invadem a medula óssea e vários órgãos como o baço, fígado, 
gânglios linfáticos e, por vezes, o sistema nervoso central. Apesar das melhorias observadas 
em termos de prognóstico nas últimas décadas, vários problemas clínicos persistem incluindo 
o prognóstico reservado nas recidivas e no subgrupo de LLA-T caracterizado pela presença 
de células leucémicas mais imaturas, o crescente número de casos resistentes à terapêutica e 
as graves sequelas derivadas da terapêutica agressiva com recurso a quimioterapia em altas 
doses e/ou radiação. Logo, a identificação de novos alvos terapêuticos para usar 
possivelmente em terapêutica combinada, o que permitiria reduzir as doses de fármacos 
quimioterapêuticos, constitui um objetivo prioritário. 
 Na origem do desenvolvimento da LLA-T encontram-se sucessivas alterações 
genéticas em timócitos como, por exemplo, translocações cromossómicas que levam à sobre-
expressão de fatores de transcrição oncogénicos ou criam genes de fusão aberrantes, 
deleções, duplicações e mutações específicas em proto-oncogenes ou em genes supressores 
de tumores. Estas alterações acabam por desregular processos cujo controlo tem uma 
importância extrema e que acabam por conduzir as células transformadas a um bloqueio da 
sua diferenciação, a adquirir capacidades de auto-renovação, de subverter os controlos da 
proliferação e de resistir a sinais pro-apoptóticos.  
 Apesar da grande maioria dos conhecimentos adquiridos até à data sobre o 
desenvolvimento da LLA-T referirem-se a alterações genéticas acumuladas nas células 
leucémicas, a importância dos fatores do microambiente onde estas células se desenvolvem 
tornou-se evidente nas últimas décadas. Acredita-se que as células neoplásicas podem 
interagir com células do estroma modificando a composição do microambiente onde se 
desenvolvem, em termos celulares e expressão de fatores, de modo a favorecer o 
desenvolvimento das primeiras. Como se pensa que a LLA-T poderá ter origem no timo e 
este órgão é caracterizado por um microambiente dinâmico, rico em fatores de crescimento, 
citoquinas e contactos linfo-estromais diretos indispensáveis ao desenvolvimento dos 
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timócitos e das próprias células do estroma tímico, será razoável acreditar que as células que 
constituem o estroma do timo poderão intervir de alguma forma no desenvolvimento da 
doença em questão. Recentemente, estudos realizados utilizando um modelo murino de LLA-
T demonstraram que a proteína RelB, pertencente à família de fatores de transcrição NF-κB, 
quando expressa em células do estroma, é importante para o desenvolvimento desta doença. 
Esta descoberta apoia a hipótese de que sinais moleculares produzidos por timócitos 
transformados podem, através da ativação do fator de transcrição RelB em células do estroma 
tímico, levar à constituição de um microambiente favorável ao desenvolvimento de leucemia. 
Contudo, a identidade das células do estroma e/ou os sinais provenientes do estroma tímico 
que favorecem o desenvolvimento da LLA-T constituem ainda uma incógnita.  
 No timo, o fator de transcrição RelB é ativado em células do estroma por membros da 
superfamília de recetores TNF como, por exemplo, o recetor da linfotoxina beta (LTβR) ou o 
recetor ativador do NF-κB (RANK) e, tal como no caso da proteína RelB, a sua ausência em 
células do estroma tímico leva a defeitos na microestruturais. Estes defeitos, em parte 
caracterizados por uma diminuição do número e maturação das células epiteliais medulares 
do timo, são causados pela ausência de comunicação bidirecional entre timócitos que 
expressam os ligandos do LTβR e RANK (i.e., LTα1β2, LIGHT e RANKL) e as células do 
estroma que expressam os respetivos recetores. Para além de afetar a homeostasia de células 
que fazem parte do estroma, a ativação dos referidos recetores induz a ativação das vias 
clássica e alternativa do NF-κB, conduzindo a diferentes padrões de expressão génica. A 
ativação dos heterodímeros p50/RelA (via clássica) resulta essencialmente na expressão de 
citoquinas pro-inflamatórias. Por outro lado, a ativação dos heterodímeros p52/RelB (via 
alternativa) resulta por exemplo, na expressão de quimiocinas como CCL19, CCL21, 
CXCL12 ou CXCL13. Destas, as quimiocinas CCL19 e CCL21 e o seu recetor CCR7 que é 
expresso por timócitos, foram previamente implicadas na disseminação de células leucémicas 
do tipo LLA-T. Estudos recentes sugeriram também o envolvimento da via de sinalização 
LTα1β2/LTβR no desenvolvimento de leucemia e linfoma com origem em linfócitos B, 
nomeadamente na indução de nichos pro-tumorigénicos que suportam a viabilidade das 
células malignas.  
 É portanto possível que a interação dos ligandos, expressos em timócitos 
transformados, com o LTβR em células do estroma tímico promova a ativação do fator de 
transcrição RelB e consequente expansão das células do estroma que compõem o 
microambiente do timo e/ou a expressão de genes-alvo que podem eventualmente favorecer o 
desenvolvimento da LLA-T.  
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 A realização deste trabalho teve portanto como objetivo geral determinar se a via de 
sinalização do LTβR poderá ser ativada e desempenhar um papel relevante no 
desenvolvimento da LLA-T. Para este fim, recorreu-se ao murganho transgénico TEL-JAK2 
como modelo pois desenvolve LLA-T a partir de timócitos que expressam a referida proteína 
de fusão. Estes animais desenvolvem LLA-T com características histológicas e patológicas 
bastante similares à doença em humanos e períodos de latência variáveis que resultam da 
acumulação de alterações genéticas secundárias e do maior ou menor suporte de fatores do 
microambiente no qual as células leucémicas se desenvolvem. 
 Ao estudar a expressão de RNA mensageiro em linfomas tímicos de murganhos 
transgénicos TEL-JAK2, verificou-se expressão do gene Ltbr. Por outro lado, detetou-se 
expressão aumentada dos genes que codificam os ligandos LTα1β2 (i.e., Lta e Ltb) e LIGHT 
nas células T leucémicas quando comparadas com timócitos normais. Recorrendo ao uso de 
inibidores farmacológicos, identificou-se a via de sinalização NF-κB como sendo a principal 
responsável pela indução da expressão de Lta, Ltb e Light nas células leucémicas, 
provavelmente através da ativação dos recetores de células T, i.e., pre-TCR/TCR. Para além 
disso, a expressão de Lta parece ser também induzível pela via JAK/STAT. É portanto 
possível que a sinalização pelo LTβR esteja ativa em linfomas tímicos de ratinhos TEL-
JAK2, tal como acontece no timo normal. Todavia, apenas a expressão de LTα1β2, em 
detrimento de LIGHT, foi detetada à superfície de células T leucémicas cultivadas ex vivo ou 
estimuladas com mitogénios, i.e., PMA e ionomicina. Além disso, verificou-se diminuição da 
expressão de LTα1β2 à superfície in vivo quando estas células contactam células do estroma 
que expressam o LTβR, pois aquele ligando é facilmente detetado quando as células 
permanecem em ambientes desprovidos do recetor. Portanto, as dificuldades encontradas em 
termos de deteção dos ligandos em microambientes com expressão do LTβR serão 
consequência de um controlo apertado em termos de expressão superficial do ligando e/ou 
sinalização continuada seguida por clivagem do mesmo. 
 De forma a avaliar se o desenvolvimento da leucemia induzida pela proteína de fusão 
TEL-JAK2 é comprometido na ausência do LTβR, cruzaram-se murganhos transgénicos 
TEL-JAK2 com murganhos nos quais a expressão do gene Ltbr foi geneticamente eliminada, 
de forma a gerar 2 coortes: TEL-JAK2;Ltbr-/- e TEL-JAK2;Ltbr+/- (controlo). Neste contexto, 
verificou-se que a inativação do LTβR levou a um atraso significativo no desenvolvimento da 
leucemia apesar da carga tumoral em órgãos linfóides e o fenótipo celular de superfície das 
células leucémicas não serem significativamente diferentes entre os dois grupos na fase 
terminal da doença. Curiosamente, numa fase precoce, quando os animais ainda não 
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apresentariam sinais de doença, verificou-se uma expansão diminuída de timócitos malignos, 
caracterizados pela expressão de CD8 e CD25, no timo de murganhos transgénicos TEL-
JAK2;Ltbr-/- em relação a TEL-JAK2;Ltbr+/-, o que implica o eixo de sinalização 
LTα1β2/LTβR na fase inicial do desenvolvimento da leucemia. Além disto, a expressão de 
RANKL por células T leucémicas e do seu recetor RANK em linfomas tímicos, abrem 
caminho à possibilidade de os dois receptores, LTβR e RANK, colaborarem na indução do 
nicho adequado para suportar o desenvolvimento de células leucémicas no murganho 
transgénico TEL-JAK2.   
 De forma a verificar se as observações descritas poderão ser transpostas para LLA-T 
humana, procedeu-se inicialmente ao estudo de linhas celulares humanas. Várias 
semelhanças foram verificadas no que diz respeito ao padrão de expressão de LTα1β2 e à sua 
regulação por NF-κB. Para além disso, detetou-se a expressão dos genes que codificam LTα e 
LTβ em amostras de doentes com LLA-T, encontrando-se significativamente aumentada no 
subtipo molecular TAL/LMO.   
 Assim, pode-se concluir que a ativação do recetor LTβR no microambiente por 
células T leucémicas que expressam o ligando LTα1β2 contribui para o desenvolvimento de 
LLA-T numa fase precoce da doença. É portanto essencial o desenvolvimento de mais 
estudos visando clarificar os mecanismos pelos quais a comunicação entre células leucémicas 
e células do estroma através do eixo de sinalização LTα1β2/LTβR poderá apoiar a LLA-T e 
determinar a utilidade da inibição desta via como nova estratégia terapêutica.  
 
 
PALAVRAS-CHAVE: Leucemia linfoblástica aguda de linfócitos T, modelo murino 
transgénico TEL-JAK2, timo, microambiente tumoral, recetor da linfotoxina beta, fator 
nuclear κB. 
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ABSTRACT 
 
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic malignancy that 
arises from the combination of genetic and epigenetic alterations in thymic T-cell precursors 
and extracellular signals provided by the microenvironment. It was previously found that 
RelB expression in non-hematopoietic stromal cells promoted T-cell leukemogenesis in the 
EµSRalpha-TEL-JAK2 transgenic (TJ2-Tg) mouse model. In thymic stromal cells, RelB is a 
transcription mediator of lymphotoxin-beta receptor (LTβR). Lymphotoxin-mediated 
activation of LTβR has been implicated in physiological crosstalk between T cells and 
lymphoid organ stromal cells, but also pathological processes, including carcinogenesis. 
Since its role in T-ALL has remained elusive, we aimed to determine whether LTβR 
signaling is activated and playing a role in TEL-JAK2-induced leukemogenesis. In TJ2-Tg 
thymic lymphomas, activation of LTα1β2-LTβR signaling axis was supported by LTβR-
encoding gene expression, while the genes encoding its cognate ligand, lymphotoxin (LT)-α 
and LTβ, were found to be expressed by leukemic T cells, in an NF-κB-dependent manner. 
LTα1β2 protein was detected at the surface of TJ2-Tg leukemic cells only upon ex vivo 
culture or mitogenic stimulation. Moreover, we found that cell-surface LTα1β2 is 
downmodulated in vivo, indicating ongoing signaling. Further supporting a role for 
lymphotoxin signaling, LTβR genetic deficiency delayed TEL-JAK2-induced leukemia 
onset, but the tumor load in lymphoid organs and leukemia cell surface phenotype were 
comparable in end-stage disease. In accordance, the detection of reduced proportions of 
malignant thymocytes in TJ2-Tg;Ltbr-/- mice with no signs of disease implicated LTβR in 
early stages of leukemia development. Together, these data indicate that T-ALL-derived 
lymphotoxin activates LTβR signaling in thymic stromal cells, promoting leukemogenesis. 
Importantly, lymphotoxin-encoding genes were expressed in T-ALL patient samples, 
indicating that these may be also involved in human disease. Thus, future studies should 
provide a better understanding on how cellular crosstalk mediated by the lymphotoxin-LTβR 
axis supports T-ALL and assess the utility of blocking LTβR signaling as a novel therapeutic 
approach. 
 
 
KEYWORDS:  T-cell acute lymphoblastic leukemia, TEL-JAK2 transgenic mouse model, 
thymus, tumor microenvironment, lymphotoxin-beta receptor, nuclear factor kappaB. 
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“To study the abnormal is the best way to understanding the normal.”  
 
Although this famous statement from William James (American philosopher and 
psychologist) addressed character studies, it may be applied in the context of malignancy to 
state that there is no sharp line drawn between healthy/good or unhealthy/bad players in 
cancer development. Also, studying the normal context where a specific type of cancer 
develops may reveal hints on how cells become malignant/abnormal. In the specific case of 
T-cell acute lymphoblastic leukemia (T-ALL), several studies support the notion that in order 
to become transformed, T-ALL cells undergo cell-intrinsinc alterations and evolve by taking 
advantage of normal developmental mechanisms. 
 In this first chapter, a review of the literature on normal T-cell development and the 
determinants of transformation leading to T-ALL is presented. Possible therapeutic targeting 
approaches and experimental models used currently to study T-ALL are also revisited. In 
addition, important notions on signaling and functions attributed to two TNF superfamily 
receptors, lymphotoxin-beta receptor (LTβR) and receptor activator of NF-κB (RANK) are 
provided.  
 
 
1.1. HEMATOPOIESIS AND T LYMPHOCYTE DEVELOPMENT 
 
 
All mature blood cell types are derived from bone marrow (BM) resident hematopoietic stem 
cells (HSCs), through a developmental process called hematopoiesis. Throughout this 
process, HSCs experience progressive loss of self-renewal properties as they differentiate to 
multipotent progenitors (MPPs), which lack the ability to self-renew. In addition, HSC 
multilineage differentiation capabilities are also progressively restrained while the cell 
commits to a particular lineage (Lai and Kondo, 2008). 
Two conflicting lines of evidence defend that the first step towards lineage restriction 
occurs in different phases of hematopoiesis. The so-called classic model states that MPPs 
originate symmetrically either a common myeloid progenitor (CMP) or a common lymphoid 
progenitor (CLP) (Akashi et al., 2000; Kondo et al., 1997). These common progenitors have 
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differentiation potentials restricted to all cell types within their respective lineage: 
megakaryocytes, erythrocytes, granulocytes, and macrophages are originated by CMPs, while 
T, B and NK lymphocytes derive from CLPs. Challenging this model, an alternative version 
in which common progenitors are generated asymmetrically from MPPs was put forward. 
Accordingly, myeloid cells were shown to potentially diverge from different subsets of 
MPPs, while lymphoid differentiation appeared to surpass multiple obligatory lineage 
restriction steps in such a way that CLPs are generated when the cells lose all abilities to 
generate myeloid cells (Adolfsson et al., 2005; Lai and Kondo, 2006). Furthermore, the 
existence of CLPs in the BM is also controversial. In fact, some studies demonstrated that the 
B lineage branch is segregated from the T cell pathway before a branch point for the T versus 
myeloid lineage (Bell and Bhandoola, 2008; Porritt et al., 2004; Wada et al., 2008). In spite 
of these debatable issues concerning hematopoiesis, the notion that in normal conditions BM-
derived progenitors have to migrate to the thymus in order to originate self-tolerant, 
functional T lymphocytes (also known as T cells) is widely accepted (Sitnicka, 2009).   
Like the BM, the thymus is a primary lymphoid organ but its only known function is 
to support the development of T lymphocytes from T-cell progenitors (Heinonen and 
Perreault, 2008). In humans, the thymus is located in the upper anterior mediastinum and 
lower part of the neck and is most active during childhood, reaching a peak weight at 
puberty, after which it undergoes slow involution (Gray et al., 2008). It is composed by two 
lobes and invested externally by a loose collagenous capsule. Each lobe is further divided in 
lobules by incomplete septa, which contain a peripheral dark cortical area densely populated 
by lymphoid cells, and a light medullary area composed of many voluminous pale cells and 
less abundant lymphoid cells (Milićević et al., 2008; Rezzani et al., 2008). A transitional area 
rich in blood vessels, known as cortico-medullary region (CMR) separates the thymic cortex 
and medulla (Figure 1.1). This is the entry site for early T cell precursors (ETPs), which 
derive from progenitors that emigrate from the BM to the thymus (Lind et al., 2001), and also 
the exit site for the end-product of thymopoiesis, naïve mature T lymphocytes (Jin et al., 
2006). T-cell precursors developing in the thymus, also known as thymocytes, make up 
approximately 90% of the thymic cellular compartment and form a heterogeneous population 
composed of cells in different stages of differentiation. According to the cell phenotypes 
defined by expression of CD4 and CD8 coreceptors, thymocytes can be divided into four 
major subsets that represent consecutive steps in development namely, CD4-CD8- double 
negative (DN), CD4+CD8+ double positive (DP), CD4+CD8- single positive (CD4 SP), and 
CD4-CD8+ single positive (CD8 SP). Mouse DN thymocytes are further classified from DN1 
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to DN4 based on different profiles of CD117 (also known as c-kit), CD25 and CD44 
expression (Godfrey et al., 1993) (Figure 1.2). 
 
	  
Figure 1.1. Thymus Structure. Hematoxilin-eosin staining of a thymus section showing the 
thymic structure, composed of an external region, the cortex (C), an internal region, the 
medulla (M), separated by the cortico-medullary region (CMR). 
 
 
	  
Figure 1.2. Scheme depicting T-cell developmental stages in the thymus, and murine 
and human thymocyte markers. The different thymocyte subpopulations defined by 
CD4/CD8 expression are shown along with the thymic region where they are located, their 
immunophenotypes, and the main checkpoints found during T-cell development. Differences 
between murine and human markers are shown.  	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 In the thymus, T cell precursors interact with stromal cells, mainly dendritic cells 
(DC), fibroblasts, macrophages, endothelial cells, and epithelial cells, which make up a three-
dimensional network and distinct microenvironments characterized by the production of 
diverse sets of cytokines, growth factors, and adhesion molecules (Petrie and Zúñiga-
Pflücker, 2007; Takahama, 2006). Recent thymic immigrants acquire T-lineage potential and 
progress through distinct developmental stages by migrating through diverse inductive 
microenvironments of the thymus guided by factors produced by stromal cells. In such 
locations, they interact with stromal cells or are simply exposed to factors that control defined 
steps in T-cell development, such as proliferation, differentiation, T-cell receptor (TCR) gene 
rearrangements, and selection (Takahama, 2006).  
 For the initial TCR-independent proliferation and differentiation until the DN3 stage, 
thymocytes are exposed to signals derived from cortical stromal cells as they migrate to the 
subcapsular region and begin to rearrange their Tcr loci (Capone et al., 1998; Lind et al., 
2001). The complementary expression patterns of both cytokines and their receptors 
determine their function at every stage of T-cell maturation. For example, gradients of 
chemokines like chemokine (C-X-C motif) ligand 12 (CXCL12), chemokine (C-C motif) 
ligand 25 (CCL25), CCL19 or CCL21 were shown to attract and mediate migration of 
thymocytes expressing their cognate receptors (i.e., CXCR4, CCR9 and CCR7, respectively) 
(Fu and Chen, 2004; Sitnicka, 2009; Takahama, 2006). Furthermore, expansion and 
proliferation of immature progenitors are dependent on stem cell factor (SCF) binding to c-kit 
in thymocytes and on signals delivered by interleukin-7 (IL-7) (Peschon et al., 1994; 
Rodewald et al., 1997), whereas Notch-mediated signals through binding of Delta-like 1 
(DLL1) and Delta-like 4 (DLL4) ligands are also required for T lineage specification at the 
expense of B lineage (Pui et al., 1999; Radtke et al., 1999; Wilson et al., 2001). After T 
lineage commitment, DN thymocytes rearrange the genes encoding β, γ, and δ TCR chains. A 
small proportion of thymocytes productively rearrange γ and δ chains, express TCR γδ at 
their surface, and are named accordingly as γδ T cells. These cells do not differentiate further 
in the thymus and have functions related to innate immunity. On the other hand, the vast 
majority of thymocytes rearrange the TCRβ loci and express a functional TCRβ chain that 
associates with pre-TCRα (pTα), generating the pre-TCR complex at the cell surface. 
Through the pre-TCR complex, thymocytes receive specific survival and proliferation signals 
required for further differentiation to immature CD4+ single positive (ISP) (CD8+ISP in mice) 
and DP thymocytes (Figure 1.2). In addition, DP thymocytes that rearrange the TCRα loci to 
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form the TCRαβ complex, undergo TCR-mediated positive and negative selection through 
interaction with major histocompatibility (MHC) complexes expressed by cortical TECs 
(cTECs) and DCs (Goldrath and Bevan, 1999). Low-affinity recognition of self-MHC, 
promotes thymocyte survival and CCR7 expression, which drives migration to CCL19 and 
CCL21 produced by medullary TECs (mTECs) (Ueno et al., 2004), and determines 
commitment to either the CD4 or CD8 SP lineage. In the medulla, SP thymocytes that are 
reactive to tissue-specific antigens promiscuously presented by mTECs are deleted, a process 
termed negative selection, which is essential for the establishment of central tolerance (Chen, 
2004; Takahama, 2006). Finally, the egress of mature T cells from the thymus was also 
shown to rely on thymic stromal-derived elements either by chemorepulsion or loss of 
responsiveness to thymic retention signals. In addition, a third mechanism was also described 
involving chemoattraction to peripheral signals (Jin et al., 2006). 
In addition to the multiple roles attributed to stromal cells in thymocyte development, 
SP thymocytes reciprocally support mTEC organization and differentiation mainly through 
the action of members of the tumor necrosis factor (TNF) superfamily of ligands and 
receptors, such as LTα1β2/LTβR, RANKL/RANK, and CD40L/CD40 (Boehm et al., 2003; 
van Ewijk et al., 2000; Hikosaka et al., 2008; Klug et al., 1998). In general, these lympho-
stromal bidirectional exchanges are referred to as thymic crosstalk. In normal conditions, 
hematopoiesis is tightly regulated by an exquisite balance between expression and extinction 
of transcription factor action in various combinations and their associated chromatin 
remodeling factors. Furthermore, it is controlled by the diverse array of factors that mediate 
complex bidirectional interactions between the microenvironment and hematopoietic stem 
cells or progenitors. Importantly, these two cell-intrinsic and microenvironmental factors are 
closely linked since certain transcription factors are inducible by microenvironmental cues 
(Kittipatarin and Khaled, 2007; Mohtashami et al., 2013; Peschon et al., 1994; Schmitt et al., 
2004). When the regulation of proliferation, differentiation and/or survival fails, 
hematopoietic malignancies such as leukemia and lymphoma may arise. These are designated 
after the affected cell lineage as myeloid or lymphoid and, when untreated, can range from 
being rapidly fatal (acute) to slowly growing (chronic). 
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1.2. T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 
 
 
The predominant types of pediatric cancers are leukemia, lymphoma, and cancers of the brain 
and central nervous system (CNS). Acute lymphoblastic leukemia (ALL) is the most 
common childhood malignancy and represents about 80% of all leukemia cases in children 
and 56% in adolescents. This percentage is significantly lower in adults (American Cancer 
Society, 2015). ALL consists of a group of malignancies of lymphoid cells that 
morphologically and immunophenotypically resemble B-lineage (B-ALL) and T-lineage 
precursor cells (T-ALL). These neoplasms may present predominantly with primary 
involvement of the bone marrow and peripheral blood (ALL) or may be limited to tissue 
infiltration, with absent or only limited bone marrow involvement, being in this case 
designated as lymphoblastic lymphomas (LBL). A combination of the two presentations 
often coexists. In this case, the disease is classified as leukemia when 25% or more 
lymphoblasts are detected in the bone marrow, even in the presence of tumor masses in 
organs such as lymph nodes or thymus (Vardiman et al., 2009).  
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic 
malignancy that originates from T-cell precursors. In comparison with B-ALL, T-ALL is 
relatively rare and, importantly, is overall characterized by an inferior treatment outcome (Pui 
et al., 1990). This disease affects mainly children and adolescents but also adults and 
accounts for about 15% and 25% of ALL in pediatric and adult cohorts, respectively (Pui et 
al., 2004). T-ALL is characterized by high white blood cell counts, higher or lower 
replacement of the bone marrow cellular population with the malignant clone, which 
interferes with normal development of blood cells, and variable infiltration of organs like the 
lymph nodes, spleen, liver and the CNS. In some cases, a mediastinal mass is present with or 
without pleural effusions, which may lead to respiratory distress (Longo, 2012; Pui et al., 
1990). Therefore, although this neoplastic disorder originates either in the BM or in the 
thymus, leukemic cells metastasize throughout the body and it is rapidly fatal without 
appropriate therapy. It is though a heterogeneous disease regarding clinical presentation. 
The precise cell-of-origin is still debated but T-ALL cells share numerous cellular, 
immunophenotypic, and molecular properties with thymocytes at different stages of 
differentiation. Therefore, transformation events most likely occur in crucial stages of T-cell 
development, and thymocytes are considered the normal counterparts of T-ALL (Asnafi et 
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al., 2003; Crist et al., 1988; Ferrando and Look, 2003; Reinherz et al., 1980). Furthermore, it 
was previously shown that altering the cell-of-origin in mice produces leukemic cells that 
model the intrinsic genetic heterogeneity of human T-ALL (Berquam-Vrieze et al., 2011). 
Due to the heterogeneity found in leukemic cells from different patients, T-ALL is normally 
classified in different subgroups relying either on the immunophenotype, or on the gene 
expression profile. Each subgroup has in turn been associated with a particular disease 
prognosis, yet not sufficiently compelling to justify its use to determine the use of different 
treatment protocols (Ferrando et al., 2002; Homminga et al., 2011; Soulier et al., 2005).  
 Three main classifications segregate T-ALL in different subtypes based on the 
presence or absence of immunophenotypic markers. The European Group for the 
immunological characterization of leukemias (EGIL) classifies T-ALL as pro-T or T-I 
(CD7+, CD2-, CD5-), pre-T or T-II (CD7+, CD2+, CD5+/-), cortical T or T-III (CD1a+), and 
mature T or T-IV (mCD3+, CD1a-) (Bene et al., 1995), from the most immature to the mature 
stage. In addition, the more recently proposed TCR-based classification system, divides T-
ALL in four stages: immature stage (cytoplasmic (c) TCRβ-, surface (s) CD3-), pre-αβ stage 
(cTCRβ+, sCD3-, pTα+), TCRαβ (sCD3+, TCRαβ+), and TCRγδ (sCD3+, TCRγδ+) (Asnafi et 
al., 2003). T-ALL can also be classified in genetic subgroups (i.e., immature, HOXA, 
proliferative, TLX1/3, and TAL/LMO) according to different gene expression profiles or 
signatures, which are associated with the underlying expression of particular oncogenes 
(Ferrando et al., 2002; Homminga et al., 2011; Soulier et al., 2005). 
Similarly to other types of cancer, T-ALL genesis and progression are driven by a 
combination of intrinsic genetic lesions and extrinsic events that are dependent on the 
interaction with the stroma. The cooperating effects of these alterations culminate in 
differentiation arrest, uncontrolled cell growth, and clonal expansion of T-cell precursors. 
 
1.2.1. Cell-intrinsic mechanisms  
Although T-ALL presents often with a normal diploid karyotype, numerical and structural 
chromosomal abnormalities may also occur. Indeed, many studies have identified several 
structural chromosomal abnormalities that contribute to leukemogenesis in addition to other 
genetic alterations. These genetic abnormalities are variably present and were classified in 
type A and type B (Meijerink, 2010; Van Vlierberghe et al., 2008). Type A abnormalities 
usually involve chromosomal translocations, large genomic deletions or amplifications that 
are essentially mutually exclusive and define T-ALL subgroups (Table 1.1). Chromosomal 
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translocations involving TCR gene rearrangements and gene fusions are a common 
consequence of physiologic TCR rearrangements that occur in normal T cell development. 
Frequently, these lead to ectopic expression of oncogenic transcription factors in developing 
thymocytes and differentiation arrest (Ferrando and Look, 2003; Ferrando et al., 2002; 
Reinherz et al., 1980). Therefore, type A abnormalities are generally considered driving 
chromosomal abnormalities or initiating events. Although the oncogenes involved are usually 
activated by chromosomal rearrangements, they can also be overexpressed by other means, 
such as activating deletions or other mutations, epigenetic mechanisms, or upstream 
regulatory molecules (Ferrando and Look, 2003; Ferrando et al., 2002; de Leval et al., 2009; 
Van Vlierberghe et al., 2008). T-ALL oncogenic transcription factors include basic helix-
loop-helix (bHLH) family members such as TAL1/SCL, TAL2, LYL1; LIM-only domain 
(LMO) genes like LMO1 and LMO2; homeobox family members including TLX1/HOX11, 
TLX3/HOX11L2, HOXA, and NKX2-1; and also MYB proto-oncogene and MEF2C 
(Homminga et al., 2011; Van Vlierberghe et al., 2008). Frequently, chromosomal 
translocations or inversions result in gene fusions that are expressed as constitutively 
activated chimeric oncoproteins (e.g., SIL-TAL1, PICALM-MLLT10, and MLL-MLLT1) 
(Van Vlierberghe et al., 2008).  
  
Table 1.1. Common type A genetic abnormalities detected in T-ALL.	  
Genetic 
abnormality 
Genes involved Subgroup Effect 
Translocations 
involving TCR 
and 
Gene Fusions 
TAL1, LMO2, LYL1 
TLX1, TLX3 
HOXA cluster 
MYB, NKX2-1/NKX2-2 
MEF2C 
TAL/LMO 
TLX1/3 
HOXA 
Proliferative 
Immature Differentiation 
impairment 
SIL-TAL1 
PICALM-MLLT10 
MLL-MLLT1 
SET-NUP214 
TAL/LMO 
HOXA 
HOXA 
HOXA 
 
 Type B abnormalities include gene-specific small deletions, translocations, 
duplications and point mutations in proto-oncogenes or tumor suppressor genes (Table 1.2). 
These are found in different combinations throughout all major T-ALL subgroups and seem 
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to synergize with type A abnormalities during T-cell leukemogenesis. Several genes 
encoding members of signaling pathways are affected by activating point mutations and 
include RAS, JAK1, JAK3, FLT3, IL7R (Zhang et al., 2012), PI3K, and AKT (Gutierrez et al., 
2009). Similarly, and besides being involved in low frequency T-ALL translocations, the 
NOTCH1 proto-oncogene can also carry activating mutations, as reported for more than 50% 
of T-ALL patients (Palomero et al., 2007; Weng et al., 2004). The Notch signaling pathway 
is also activated in T-ALL due to inactivating point mutations in its negative regulator 
FBXW7 (Thompson et al., 2007). Other inactivating mutations or deletions occur in the Ras 
inhibitor NF1 (Balgobind et al., 2008) and in the PI3K negative regulator PTEN (Gutierrez et 
al., 2009), leading to activation of Ras and PI3K/AKT/mTOR signaling pathways, 
respectively. Gene fusions like ETV6/TEL-JAK2 or BCR-ABL1 are translated as 
constitutively active kinases and lead to aberrant signaling activation (Carron et al., 2000; De 
Keersmaecker et al., 2005). In addition, deletions in CDKN2A cell cycle regulator lead to 
disruption of p53-induced apoptosis pathway (Hebert et al., 1994). Cell cycle defects are also 
originated due to inactivating deletions in RB1, which encodes the tumor suppressor 
retinoblastoma (Rb) protein, and to translocations in CCND2 that lead to the activation of 
cyclin-D2, and consequent inactivation of Rb (Van Vlierberghe and Ferrando, 2012). Tumor 
suppressor transcription factors have also been shown to be inactivated in T-ALL including 
WT1, LEF1, GATA3, RUNX1 or BCL11B (Gutierrez et al., 2010, 2011; Tosello et al., 2009; 
Zhang et al., 2012). Recent studies have also shown high frequency of somatic mutations in 
epigenetic regulators. Inactivating mutations in PHF6 and EZH2 leading to chromatin 
remodeling alterations were reported in addition to alterations in genes involved in DNA 
methylation/demethylation such as TET1 (Peirs et al., 2015). Finally, mutations affecting 
ribosomal proteins, which are essential components of the translational machinery, were also 
recently revealed (De Keersmaecker et al., 2013).   
When reviewing the current list of oncogenes and tumor suppressor genes involved in 
T-ALL development, it becomes clear that these are linked to thymocyte differentiation and 
self-renewal or general cellular functions like proliferation and survival, cell cycle control, 
and DNA repair (De Keersmaecker et al., 2005).  
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Table 1.2. Common type B genetic abnormalities detected in T-ALL. 
Genetic 
abnormality 
Genes 
involved 
Function Main effects 
Activating 
Mutations 
NOTCH1 Transcription activation mediated by ICN Self-renewal 
LCK Signal transduction from the TCR complex Proliferation  
FLT3 Cytokine receptor  Proliferation 
and survival 
JAK1 / JAK3 Signal transduction from cytokine 
receptors 
Proliferation 
and survival 
RAS Signal transduction Proliferation 
and survival 
IL7R Common γ-chain cytokine receptor Proliferation 
and survival 
AKT Signal transduction Proliferation 
and survival 
PI3K Signal transduction Proliferation 
and survival 
Inactivating 
Mutations and 
Deletions 
FBXW7 Cyclin E, Myc and NOTCH1 targeting Self-renewal 
NF1 Ras inhibition Proliferation 
and survival 
PTEN Signal transduction (PI3K inhibition) Proliferation 
and survival 
WT1 Tumor supressor transcription factor Survival 
LEF1 Tumor supressor transcription factor Proliferation 
and survival 
PHF6 Epigenetic regulator Chromatin 
remodeling 
EZH2 Epigenetic regulator Chromatin 
remodeling 
CDKN2A Cell cycle regulator Cell cycle (CC) 
activation 
RB1 Cell cycle regulator CC activation 
Translocations CCND2 Cell cycle regulator CC activation  
MYC Cell growth transcription factor 
Proliferation 
and survival 
ABL1 fusions Signal transduction 
Proliferation 
and survival 
TEL-JAK2 Signal transduction Proliferation 
and survival 
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1.2.2. Microenvironmental factors 
Although the roles of genetic lesions and epigenetic alterations as steps toward T-ALL 
development have been largely appreciated, the various aspects on the impact of the 
microenvironment have been mostly overlooked. It is now recognized that cancers develop in 
complex microenvironments composed of a dynamic and interactive mixture of different cell 
types and cytokines plus growth factors, which may sustain cancer-cell growth, invasion, and 
metastization (Tlsty and Coussens, 2006).  In lymphoid cancers, the microenvironment often 
consists of variable numbers of malignant cells intermixed in a matrix of the so-called 
stromal cells (e.g., endothelial and epithelial cells, fibroblasts, DCs, macrophages), and also 
often non-malignant lymphocyte infiltration (Herreros et al., 2008). In fact, tumor cells and 
the surrounding stroma evolve together through continuous communication through paracrine 
and/or juxtacrine signaling, which culminates in the creation of permissive or selective 
microenvironments that support malignant cells to survive, grow, and resist to immune 
recognition and elimination. An altered microenvironment may disrupt the homeostasis and 
favor the early steps of transformation, or even promote protection against therapeutic 
intervention (Raaijmakers, 2010; Zhang et al., 2012). In this context, the malignant cells may 
respond passively to physiological signals or even become unresponsive to deleterious 
signals provided by their local microenvironment. Alternatively, cancer cells may more 
actively modulate stromal cells to change their gene expression profile and thus create more 
appropriate microenvironments for cancer cell growth and survival (Hanahan and Weinberg, 
2000). Importantly, there is reliable evidence that neoplastic cells may interact with the 
surrounding environment in a bidirectional manner resulting in the acquisition of a 
competitive advantage by the malignant cells during oncogenesis (Colmone et al., 2008; 
Scupoli et al., 2003, 2007).  
Notably, the thymus, an organ specialized in T cell development, contains a dynamic 
microenvironment with an high concentration of growth factors, cytokines and stromal cells 
necessary for thymopoiesis, making it also a potential permissive location for 
leukemogenesis and tumor progression. Normal thymocytes arise in the thymus where they 
interact with thymic stromal cells (TSCs) and thus promote T-cell development process and 
to maintenance of the stromal cell pool and its three-dimensional organization (Boehm et al., 
2003). Normal thymocytes divide, differentiate and egress the thymus whereas leukemic T 
cells undergo a differentiation block and continue to grow possibly under the support of 
TSCs until some of them eventually acquire the capacity of microenvironment-independent 
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growth (Hiai et al., 1981). The absolute requirement for the presence of the thymus in murine 
leukemogenesis is illustrated by results showing that thymectomy impairs T-cell leukemia 
development induced by γ-irradiation (Kaplan, 1950), murine leukemia viruses (McEndy et 
al., 1944) or Ikaros protein deficiency (Dumortier et al., 2006). Moreover, a recent study has 
shown that lack of competition between bone marrow-derived progenitors and T-cell 
precursors developing in the thymus causes T-cell leukemia that shares many properties with 
human T-ALL (Martins et al., 2014). Cell competition was thus considered a tumor 
suppressor mechanism because it acts to eliminate older precursors in the thymus that may 
display upregulated or mutated genes responsible for stemness and thus become genomically 
unstable during the ageing process, favoring transformation. Also, the age-related gradual 
loss of thymic structure and function (termed involution), possibly in combination with other 
factors, was shown to impact on T-ALL development. In a study, each T-ALL subtype was 
shown to correlate closely with the stage of thymocyte maturation arrest regardless of age, 
but the incidence of the different subtypes differed markedly (Asnafi et al., 2004), probably 
reflecting age-related alterations in the thymocytes at risk of oncogenic transformation, 
alterations in stroma composition, or variable latency. In addition, a recent genome-wide 
sequencing study reported a correlation between age and number of somatic mutations in T-
ALL, showing that particular genes are preferentially affected in adults versus children (De 
Keersmaecker et al., 2013). 
In addition to their role in normal T-cell development, the establishment of adhesive 
contacts and the release of cytokines have crucial roles in regulating growth and survival of 
leukemic cells within the microenvironments where T-ALL develops (Balkwill, 2004). For 
instance, stromal cells expressing ICAM-1 were reported to favor the survival of T-ALL cells 
expressing lymphocyte function-associated antigen 1 (LFA-1) integrin (Winter et al., 2001). 
Likewise, chemokines produced by the bone marrow, thymic stromal cells, and other organs 
are important signaling molecules involved in T-ALL survival, proliferation, but mostly 
infiltration. For example, T-ALL cells with activated Notch signaling were shown to express 
CCR7, which promoted leukemic cell migration to CCL19-expressing CNS and infiltration 
(Buonamici et al., 2009; Ma et al., 2014). Moreover, the chemokine receptors CXCR4 and 
CCR9 expressed by leukemic cells were shown to mediate extramedullary organ infiltration 
in response to their ligands (Crazzolara et al., 2001; Qiuping et al., 2004). In addition, CCL25 
to CCR9 signaling was reported to mediate T-ALL resistance to apoptosis and proliferation 
(Qiuping et al., 2004). In another study, CCR9 expression was shown to be induced by 
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NOTCH1 in T-ALL cells and to regulate proliferation and chemotaxis towards its ligand 
(Mirandola et al., 2012). 
Additional reports have provided experimental evidence implicating stromal cell-
induced activation of signaling in T cells during T-ALL leukemogenesis. Thymic and BM 
epithelial cells have been shown to promote T-ALL cell survival and proliferation in vitro by 
producing interleukin (IL)-7 (Scupoli et al., 2003, 2007). IL-7 was also reported to be 
involved in T-ALL progression and dissemination in vivo (Silva et al., 2011). Another 
cytokine, IL-18 produced by BM-derived stromal cells in inflammatory microenvironments, 
was also shown to support T-ALL progression in vivo probably due to enhanced proliferation 
(Uzan et al., 2014). 
Cytokines and growth factors provided by stromal cells exert a protective effect not 
only on the bulk of the leukemic cell population, but also on leukemia initiating cells (LICs). 
LICs constitute a rare population of leukemic cells that are enriched in its ability to initiate 
leukemia in serial transplantation in immunodeficient mice (Cox et al., 2007). In T-ALL, 
Notch signaling activation induced by stromal cells is required for LIC activity mainly 
through the maintenance of self-renewal and engraftment abilities of these cells (Armstrong 
et al., 2009). Moreover, NOTCH1-induced high-level insulin-like growth factor (IGF)-1 
receptor (IGF1R) expression was proved to be required for LIC activity in T-ALL. Moreover, 
inhibition of IGF1R signaling in response to IGF1/2 in the microenvironment halts T-ALL 
cell growth, survival, and interferes with disease establishment and progression (Medyouf et 
al., 2011). 
In addition, sustained calcineurin activity in leukemic cells has been detected in 
mouse models of T-ALL induced by TEL-JAK2 or ICN1. In vitro culture of leukemic cells in 
the absence of stromal cells showed that calcineurin activity was rapidly lost, suggesting that 
specific signals from the tumor microenvironment may be essential for its maintenance 
(Medyouf et al., 2007). A recent study has also shown that calcineurin activation in T-ALL 
cells was important for survival, proliferation and motility in ex vivo studies. In vivo, it was 
essential to promote LIC activity but the stromal-derived factors responsible for its activation 
and consequent effects remain unknown (Gachet et al., 2013). 
Notch signaling induction in leukemic cells was also reported to occur by 
microenvironmental elements. For instance, the escape of human T-ALL cells from 
dormancy to acquire a tumorigenic phenotype was associated with DLL4 expression by 
endothelial cells in the tumor microenvironment and increased NOTCH3 signaling in human 
T-ALL cells. Moreover, neutralization of DLL4 greatly reduced endothelial-cell mediated 
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activation of NOTCH3 signaling in T-ALL cells and blocked tumorigenesis (Indraccolo et 
al., 2009). Indeed, in addition to NOTCH1 point mutations found in T-ALL samples, 
overexpression of the NOTCH3 protein has been reported in virtually all cases of T-ALL, 
irrespective of any gross abnormalities in the NOTCH3 locus (Bellavia et al., 2002). In 
addition to its expression in endothelial cells (Mailhos et al., 2001), DLL4 is also expressed 
by TECs, where it is indispensable for T-cell development (Hozumi et al., 2008). 
Interestingly, NOTCH1 activation in T-ALL cells also enhances the receptivity of T-ALL 
cells for signals provided by the microenvironment by inducing the expression of receptors 
for extracellular ligands, such as the IL-7 receptor (i.e., IL-7R) (González-García et al., 
2009), the CCL19/CCL21 and CCL25 chemokine receptors (i.e., CCR7 and CCR9, 
respectively) (Buonamici et al., 2009; Mirandola et al., 2012), and IGF1R (Medyouf et al., 
2011). 
Recently, a role for the microenvironment in the activation of another signaling 
pathway commonly involved in T-ALL was unveiled. Ras enhanced signaling has been 
implicated in the pathogenesis of approximately 50% of T-ALL cases (von Lintig et al., 
2000) but activating mutations in key components such as KRAS and NRAS are rare (Ahuja 
et al., 1990) and mostly found in ETP-ALL (Zhang et al., 2012). By studying Ras signaling 
activation in the absence of RAS somatic mutations, increased expression of the Ras activator 
guanine nucleotide exchange factor (RasGRP1) was found to cooperate with cytokine 
receptor signaling to activate Ras and contribute to T-ALL proliferation and leukemogenesis 
(Hartzell et al., 2013). 
Finally, adding to the widely known involvement of NF-κB signaling pathways in 
malignant cells, one study uncovered a role for RelB transcription factor in the crosstalk 
between thymic stromal and T-ALL cells. This NF-κB family member activated by the 
alternative signaling pathway was shown to play a pro-oncogenic role, not in tumor cells, but 
rather in cells that compose the tumor microenvironment, thus leading to accelerated 
leukemia onset and increased severity of TEL-JAK2-induced mouse leukemia (dos Santos et 
al., 2008). As T-ALL in this mouse model originates in the thymus (Carron et al., 2000; dos 
Santos et al., 2007), RelB-dependent non-hematopoietic thymic stromal cells are most likely 
involved in T-ALL leukemogenesis (Dos Santos et al., 2010).  
 Altogether, T-cell development is strictly regulated by cytokines and growth factors 
produced by the microenvironments where they develop. Several of these factors may also 
support malignant T cells and thus be involved in the pathogenesis of T-ALL. Signaling 
pathways activated by these factors impact on strictly controlled processes such as 
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proliferation, cell cycle control, and survival of T-lymphocytes undergoing thymopoiesis. 
Moreover, molecular cues provided by stromal cells were also proven to be essential for T-
ALL cell dissemination and LIC activity. Nevertheless, microenvironmental dependence of 
T-ALL may rely on the context of cell-intrinsic alterations found in T-ALL cells. If occurring 
aberrations alter the activity of members of signaling pathways normally activated by 
molecular cues provided by stromal cells (e.g., IL7R mutations), the pro-oncogenic role of 
these cells may be attenuated or even become irrelevant. In other situations, mutant proteins 
may render T-ALL cells more responsive to extracellular signals, as exemplified by PTEN 
mutations allowing more sustained Akt activation. Nevertheless, the identification of 
mutations in genes encoding components of signaling pathways commonly activated by 
stromal cell-derived signals further confirms their key role in T-ALL development. 
 
1.2.3. Contribution of cell-autonomous and noncell-autonomous factors to T-ALL 
development 
From the previously mentioned studies, it is clear that T-ALL develops by a multistep 
process whereby thymocytes accumulate genetic and epigenetic alterations. Although these 
cell-intrinsic mechanisms are major contributors to the molecular pathogenesis of T-ALL, 
cooperation from extrinsic factors produced by microenviromental cells constitutes a 
requisite for the development of overt T-ALL. 
 The way all these factors cooperate and contribute to leukemogenesis may be 
complex, but one hypothesis considers a hierarchical model in which leukemic stem cells 
(LSCs) are generated from T-cell progenitors before fully malignant T-ALL cells are 
generated. LSCs correspond to cancer stem cells that were detected in hematological 
malignancies including T-ALL and have the ability to initiate the disease when transplanted 
to recipient mice (Chiu et al., 2010), meaning that these have LIC activity. According to this 
model, a subset of T-cell progenitors suffer the initiating genetic event, which consists 
usually in genetic lesions that lead to the ectopic expression of oncogenic transcription 
factors (Type A abnormalities; Table 1.1). These cells are designated pre-LSCs because they 
acquire self-renewal abilities but they need to acquire further genetic mutations (Type B 
abnormalities; Table 1.2) to clonally evolve and generate LSCs. Interestingly, some of these 
secondary events are activating mutations in cytokine-activated signaling pathways that 
promote clonal expansion of LSCs independently of the thymic niche (e.g., NOTCH1, IL7R, 
MYC, KRAS, and PTEN) to generate overt T-ALL and dissemination (Gerby et al., 2014; 
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Tremblay and Curtis, 2014).  Moreover, some studies support the notion that disease relapse 
is originated by a population of pre-LSCs that resist to therapeutic interventions (Mullighan 
et al., 2008; Tzoneva et al., 2013). 
 
 Table 1.3. Microenvironmental factors involved in T-ALL development. 
Factors involved 
Effect on T-ALL cells References 
Stromal cells T-ALL 
ICAM-1 LFA-1 Survival (Winter et al., 2001) 
CXCL12 CXCR4 
Chemotaxis, extramedullary 
organ infiltration 
(Crazzolara et al., 2001) 
CCL25 CCR9 
Chemotaxis, infiltration, 
resistance to apoptosis, 
proliferation 
(Qiuping et al., 2004) 
(Mirandola et al., 2012) 
IL-7 IL-7R 
Survival, proliferation, T-ALL 
progression  
(Scupoli et al., 2003, 
2007) 
Silva et al., 2011 
IL-18 IL-18R 
Proliferation, T-ALL 
progression  
(Uzan et al., 2014) 
DLL4 NOTCH3 
Angiogenesis, tumor growth in 
vivo and escape from dormancy; 
T-ALL progression 
(Indraccolo et al., 2009) 
(Minuzzo et al., 2015) 
IGF1 IGF1R 
Survival, proliferation, LIC 
activity 
(Medyouf et al., 2011) 
unknown Calcineurin  
Survival, proliferation, motility, 
LIC activity  
(Medyouf et al., 2007) 
(Gachet et al., 2013) 
Il-2, Il-7, Il-9 
Cytokine 
receptors  
Proliferation, T-ALL 
leukemogenesis 
(Hartzell et al., 2013) 
         
 
1.2.4. T-ALL therapeutics and potential new targets  
T-ALL was once profoundly associated with dismal prognosis, but the introduction of 
intensive combination chemotherapy protocols has led to remarkable improvements in 
survival. Some patients are also treated with radiotherapy and, in case of high-risk or relapsed 
disease, a bone marrow transplant is indicated. Thus, over 80% of children with T-ALL 
achieve long lasting complete remissions (Pui et al., 2008). Still, an unresolved issue in the 
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treatment of T-ALL is its propensity to relapse and chemoresistance development (Pui and 
Evans, 2006). In contrast to the favorable response to therapy in patients at diagnosis, the 
prognosis of T-ALL patients with relapsed leukemia remains poor (Aifantis et al., 2008). 
Moreover, these patients may develop long-term adverse effects derived from therapeutics 
that include neurocognitive defects, growth deficiency, and increased risk of developing 
second cancers, including acute myeloid leukemia (AML) and CNS tumors (Robison, 2011). 
Therefore, one of the current challenges is to develop efficient targeted therapeutic strategies 
for T-ALL minimizing the emergence of resistant cases and the detrimental side-effects 
associated with conventional chemotherapy regimens. 
 When envisioning a therapeutic strategy for T-ALL, several players in disease 
development may constitute targets for rational therapy. First, the common oncogenic 
transcription factor(s) aberrantly expressed in T-ALL would be appealing targets. Even 
though their activation is not sufficient to induce leukemogenesis in the absence of secondary 
alterations, in some cases targeting the initiating event is enough to eliminate leukemic cells 
since the secondary events are unlikely to replace its function (so-called oncogenic 
addiction). For instance, the Lmo2 complex was successfully targeted in T-ALL by inhibition 
of interactions with other molecules proven essential for its oncogenic function (Appert et al., 
2009). Second, signaling pathways aberrantly activated due to mutations or upstream 
activating mechanisms constitute key events in the pathogenesis of T-ALL and an excellent 
opportunity for molecular targeting. In fact, different combinations of factors cause T-ALL 
but it usually results in the deregulation of common signaling pathways for which several 
inhibitors have been already developed (Zhao, 2010). The potential targets are integrative 
members of signaling pathways such as the phosphatidylinositol 3-kinase/Akt/mammalian 
target of rapamycin (PI3K/Akt/mTOR) pathway (Bertacchini et al., 2015), Notch pathway 
(Weng et al., 2004), nuclear factor-kappaB (NF-κB) pathway (Dos Santos et al., 2010; Zhao, 
2010), and Ras pathway (Gibbs et al., 1994; von Lintig et al., 2000). Recently, new studies 
supported the value of targeting the Calcineurin/Nuclear Factor of Activated T Cells (NFAT) 
pathway (Gachet et al., 2013), Wnt signaling pathway (Ng et al., 2014), and janus 
kinase/signal transducer and activator of transcription (JAK/STAT) pathway (Maude et al., 
2015). Third, the evidence that inappropriate regulation of epigenetic factors is perturbed by 
for instance mutations in key players responsible for DNA methylation or post-translational 
histone modifications (Peirs et al., 2015) or imbalances in micro RNA (miRNA) expression 
(Mavrakis et al., 2011) during malignant transformation, created an interest in targeting 
epigenetic mechanisms. Finally, some of the signaling pathways aberrantly activated in T-
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ALL are induced by microenvironmental factors rather than cell-intrinsic mechanisms. In this 
case, the receptors responsible for receiving survival signals in T-ALL cells or the tumor 
stroma itself should be considered for targeted therapy. One argument favoring the latter 
approach is that unlike malignant cells, the stromal cells that compose the tumor 
microenvironment are genetically stable and thus pose potentially a reduced risk of resistance 
and tumor recurrence. However, specifically disrupting the tumor microenvironment is 
challenging since it has diverse capacities to induce both beneficial and adverse 
consequences for tumorigenesis.  
 In fact, tailored therapies consisting of a combination of drugs directed to a specific 
molecular target plus chemotherapy, or several drugs targeting different members of 
signaling pathways (e.g., combined inhibition of PI3K/AKT and NOTCH1) (Bertacchini et 
al., 2015) should be adapted to take into account the disease intrinsic heterogeneity and the 
extensive crosstalk between signaling pathways in this context (Zhao, 2010). Therefore, 
understanding the underlying disease mechanisms is of great value to be translated into more 
rational and effective therapeutic strategies. To this end, the T-ALL models that were 
developed have been of extreme importance not only to unveil T-ALL pathologic 
mechanisms, but also to test new experimental therapeutic approaches (Appert et al., 2009). 
 
1.2.5. Models to study T-ALL  
Since the first report of the establishment of a T-ALL cell line in 1965 (Foley et al., 1965), 
several cell lines have become available for immunological and molecular studies either as 
models for T-cell leukemias/lymphomas or even as representatives of its respective normal 
counterpart in the thymus. These cell lines provide unique in vitro model systems for 
studying cellular and molecular events involved in the proliferation and differentiation of 
normal and leukemic T cells. Importantly, these cell lines were often established from 
primary T-ALL cells collected from patients (Morikawa et al., 1978; Pegoraro et al., 1985; 
Schneider et al., 1977; Smith et al., 1988) and also reflect the wide heterogeneity regarding 
immunophenotypic and genotypic characteristics (Burger et al., 1999). Therefore, when using 
T-ALL cell lines as experimental models for malignant or normal T cells, it is necessary to 
consider the particular differentiation stage and gene expression profile of each individual 
line. Importantly, T-ALL human cell lines and primary samples are also currently studied in 
vivo following transplantation to immunodeficient mice as xenograft models (Maude et al., 
2015; Poglio et al., 2015; Silva et al., 2011).  
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 These xenograft models and other animal models provide an invaluable tool for 
understanding the mechanism of leukemogenesis and testing new therapies. Although 
alternative models like transgenic zebrafish (Danio rerio) overexpressing Notch (Chen et al., 
2007) or c-Myc (Langenau et al., 2003) under the control of Rag2 promoter have been 
developed (Stoletov and Klemke, 2008), the mouse (Mus musculus) is still the most widely 
used experimental organism to model human T-ALL. Mice have one enormous advantage 
over other experimental organisms: they are genomically, physiologically and anatomically 
the closest to humans of any animal for which powerful genetic approaches and tools are 
feasible.  
 One mouse model of T-ALL widely used was developed by transduction of bone 
marrow cells with activated intracellular NOTCH1 (ICN1) and transplantation to lethally 
irradiated mice (Aster et al., 2000; Pear et al., 1996). Bone marrow reconstituted mice 
develop aggressive leukemia, showing NOTCH1 oncogenicity when constitutively activated. 
Moreover, transgenic mice can be created by introducing engineered genes carrying 
molecular alterations similar to those recognized in cases of human T-ALL into the mouse 
genome and expressing it in the appropriate cellular compartment. Transgenic mice 
overexpressing known oncogenes, such as LMO2 (Drynan et al., 2001), TAL1 (O’Neil et al., 
2001), or LYL1 (Zhong et al., 2007), develop T-cell leukemia that exhibits pathologic 
characteristics similar to human T-ALL. In some cases, leukemia presents with long 
latencies, not only due to particular timing and levels of transgene expression, but also due to 
requirements for additional genetic mutations to occur or other events that allow T-cell 
leukemogenesis to develop independently of the thymic cell niche, thus mimicking the 
multistage nature of human T-ALL. 
 The TEL-JAK2 fusion gene, identified in a t(9;12)(p24;p13)-positive T-ALL patient, 
was also used to create a transgenic mouse model. A transgene bearing the TEL-JAK2 
complementary DNA was placed under the transcriptional control of the EµSRα 
enhancer/promoter to express the fusion protein in lymphoid cells (Carron et al., 2000). The 
expression of TEL-JAK2 resultes in constitutively activated Janus tyrosine kinase 2 (JAK2) 
(Lacronique et al., 1997) and TEL-JAK2 transgenic (TJ2-Tg) mice were found to develop T-
cell leukemia with high penetrance, which was fatal in 8 to 22 weeks of age (Carron et al., 
2000). TEL-JAK2-induced leukemia was histological and phenotypically similar to human T-
ALL, the leukemic cells being mainly a mixed population of CD24-positive CD4+CD8+ DP 
thymocytes, an immunophenotype normally only seen in the thymus, and immature CD8+ SP 
thymocytes (Carron et al., 2000; dos Santos et al., 2007). In TJ2-Tg mice, the expression of 
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the TEL-JAK2 fusion protein functions as the initial genetic “hit” in T-ALL initiation. 
Therefore, additional secondary events accumulate during the disease latency, which may be 
variable and acquired in a different order between different mice. This notion is supported by 
the phenotypic heterogeneity observed in diseased mice, the oligoclonality observed in 
leukemic cells collected from these mice, and the extended time for disease development, all 
in accordance with the multistep nature of T-ALL (Carron et al., 2000; Ihle and Gilliland, 
2007).  
The TEL-JAK2 oncoprotein appears to activate substrates similar to those activated 
by the normal JAK2 tyrosine kinase. Among them, the STAT5 transcription factor is 
essential to its transforming activity in cellular and animal models (Lacronique et al., 2000; 
Schwaller et al., 2000). Moreover, TEL-JAK2 can activate other effectors that are not 
normally involved in JAK2 signaling but are critical to its oncogenic properties. Supporting it 
is the fact that IKKα-dependent NF-κB activation was shown to contribute to cell survival 
mediated by the TEL-JAK2 fusion protein in the murine lymphoid Ba/F3 cell line (Malinge 
et al., 2006; Santos et al., 2001). 
 This model is considered highly relevant to study human T-ALL because although 
JAK2 gene fusions, like TEL-JAK2 and PCM1-JAK2, are rare in T-ALL/LBL (Adélaïde et 
al., 2006), the JAK/STAT signaling pathway is frequently activated (Benekli et al., 2003; 
Vainchenker and Constantinescu, 2013; Weber-Nordt et al., 1996) by several mechanisms 
including IL7R, JAK1, STAT5B, and PTPN2 mutations. Moreover, transgenic expression of 
STAT5 mutant induces murine T-ALL (Kelly et al., 2003). Notably, JAK inhibitors have 
shown therapeutic potential in xenograft models (Maude et al., 2015; Waibel et al., 2013). 
 
 
1.3. THE LTα1β2/LIGHT TO LTβR SIGNALING AXIS 
 
 
1.3.1. The lymphotoxin-β receptor  
The human Lymphotoxin-β Receptor (LTβR) genetic locus (TNFRSF3 or LTBR) is located 
on chromosome (Chr) 12 (mouse Chr 6), adjacently to the TNFR1 gene (TNFRSF1A) and 
CD27 genes (Crowe et al., 1994; Force et al., 1995). The LTBR locus contains 10 exons 
spanning 16.2 kb. Its promoter region resembles that of a housekeeping gene (Force et al., 
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1995). Nevertheless, it has been shown to be regulated by compounds such as dexamethasone 
(Muller et al., 2001). Alternative LTβR transcript variants encoding different isoforms have 
been reported such as a transcript encoding an NH2-terminally truncated form of the LTβR 
identified in a pancreatic ductal carcinoma cell line (Fujiwara et al., 2005). The LTβR full-
length transcript is approximately 2.2 kb in size and encodes a 435-amino acid type I 
glycosylated protein consisting of an extracellular domain (ECD), a transmembrane domain 
(TMD), and an intracellular domain (ICD), also known by cytoplasmic domain (CD) (Figure 
1.3). Like other TNF superfamily receptors, LTβR displays four TNF cysteine-rich domains 
(CRD) in the ECD domain, which confer the specificity and the affinity for its cognate 
ligands (Crowe et al., 1994). Unlike other TNFR superfamily members, LTβR does not 
contain a death domain in the cytoplasmic tail but contains rather a proline-rich membrane 
proximal region (Crowe et al., 1994) and two binding sites for members of the TNF 
Receptor-Associated Factors (TRAF) family of zinc RING finger proteins (Ganeff et al., 
2011). Indeed, TRAF-2 (Kuai et al., 2003), -3 (VanArsdale et al., 1997), -4 (Krajewska et al., 
1998) and -5 (Nakano et al., 1996) have been reported to associate with the LTβR. Moreover, 
within this domain, distinct regions mediate self-interaction and trafficking of the receptor, 
and the activation of downstream signaling pathways like NF-κB and others leading to cell 
death (Figure 1.3) (Force et al., 2000).  
 The murine LTβR shows high homology with its human counterpart and binds the 
homologous ligands with similar specificity. Furthermore, the murine and human LTβR-
encoding genes are located in a region of conserved synteny in close linkage with the 
TNFR1-encoding gene (Force et al., 1995).  
As expected from having a housekeeping gene-like promoter, LTβR has been shown 
to be constitutively expressed on a wide variety of cells of lymphoid and visceral tissues such 
as epithelial and endothelial cells, follicular dendritic cells (FDCs), fibroblasts, and myeloid 
cells (e.g., monocytes, dendritic cells, and mast cells), but strikingly not on lymphocytes 
(Force et al., 1995; Murphy et al., 1998; Seach et al., 2008; Stopfer et al., 2004). Since the 
only two known ligands for LTβR, LTα1β2 and LIGHT, are expressed in lymphocytes 
(Browning et al., 1997; Mauri et al., 1998; Ware et al., 1992), this pattern of expression 
suggests that signals mediating LTβR activation are paracrine in nature.  
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Figure 1.3. Schematic representation of human LTβR structure. LTβR main domains, 
and mapping of discrete regions determined by deletion mutant studies and functional 
outcomes. ECD, extracellular domain; TMD, transmembrane domain; ICD, intracellular 
domain; CRD, cysteine-rich domains 
 
1.3.2. The LTβR ligands: LTα1β2 and LIGHT 
The genes encoding lymphotoxin (LT) α, the TNF superfamily, member 1 (TNFSF1 or LTA) 
and LTβ, the TNF superfamily, member 3 (TNFSF3 or LTB), reside in a tightly linked locus 
within the MHC class III region on Chr 6 in humans (Chr 17 in mice), flanking the gene 
encoding TNFα (TNFSF2 or TNFA), while the LTβ-encoding gene is oriented in the opposite 
direction of TNFα- and LTα-encoding genes (Browning et al., 1993; Lawton et al., 1995; 
Nedospasov et al., 1986; Nedwin et al., 1985).  
The LTA locus spans approximately 2 kb and contains 4 exons (Nedwin et al., 1985). 
The full-length mRNA (1.4 kb) encodes a 205-amino acid glycosylated (N- and O-linked) 
protein, LTα or TNFβ (20-25 kDa), in which exon 1 encodes the 5’ untranslated region 
(UTR), exon 2 encodes the remainder of the 5’ UTR and the majority of the signal peptide, 
and exons 3 and 4 encode the mature protein. In addition, exon 4 contains a long 3’ UTR 
(Nedwin et al., 1985). In immune cells, the LTA promoter region has been shown to contain 
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NFAT, STAT, AP-1, NF-κB and Sp1 transcription factor binding sites (Shebzukhov and 
Kuprash, 2011). The respective murine counterpart is highly homologous, including the 
promoter region (Paul and Ruddle, 1988). In addition, an alternate core promoter responsible 
for transcriptional regulation was identified in the region between the transcription and 
translation initiation sites (downstream segment) in T and B human cell lines that contains an 
additional Sp1 binding site and an initiator element (Inr). Additionally, the same group 
reported a T-cell specific repressor element that may be responsible for transcription 
inhibition in unstimulated T cells (Yokley et al., 2013). Interestingly, several transcript 
variants were identified in human T lymphocytes (Yokley et al., 2013) and peripheral blood 
mononuclear cells (PBMC) (Smirnova et al., 2008), which presented different levels of 
expression before and after induction upon specific stimulation conditions. Although their 
functional significance is not fully understood, the LTA transcripts and their relative 
abundance are likely influenced by the cell type and the nature of the stimuli. These 
transcripts have been shown to be inducible by T cell mitogens (Zinetti et al., 1998), phorbol 
ester and ionomycin (Voon et al., 2001), TCR activation through anti-CD3/28 treatment or 
TCR cross-linking (Millet and Ruddle, 1994), cytokines (e.g., IL-4, IL-2) (Lu et al., 1998; 
Worm et al., 1998), viral proteins (Lee et al., 2005; Paul et al., 1990) and by the LTα3 soluble 
protein form (Messer et al., 1990).  
Similarly to LTA, the human LTB locus spans approximately 2 kb and contains 4 
exons (Browning et al., 1993). The full-length mRNA is 0.9 kb long and encodes LTβ, a 244-
amino acid glycosylated transmembrane protein (33 kDa) (Browning et al., 1993). The exon 
4, which encodes the extracellular domain, is highly conserved between the mice and human 
LTβ-encoding genes. Additionally, the murine and human genes are organized similarly and 
have an equivalent location in the MHC locus, but they are differently spliced (Pokholok et 
al., 1995): the murine mRNA retains the region corresponding to intron 2 in the human LTB 
locus, thus converting exons 2 and 3 into a single large exon that results in the creation of a 
long stalk between the extracellular domain and the transmembrane domain of the LTβ 
protein (Lawton et al., 1995; Pokholok et al., 1995). Two transcript variants of human LTβ 
mRNA were identified: the functional one consisting of 4 exons, and an alternative one, in 
which the exon 2 is eliminated resulting in a LTβ truncated form that lacks the majority of the 
extracellular domain of the native protein, impairing its normal assembly with LTα 
(Warzocha et al., 1997). Regardless this observation, the physiological significance of the 
LTβ truncated form is still unknown. In the upstream sequence of the putative transcription 
initiation site of LTB, which is highly conserved between mice and humans, the presence of 
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some binding sites for known transcription factors such as NF-κB, Ets, MyoD and Sp1/Egr-1 
(Kuprash et al., 1996; Pokholok et al., 1995; Shebzukhov and Kuprash, 2011) have been 
reported. LTB has been shown to be constitutively expressed (Kuprash et al., 2002; Millet and 
Ruddle, 1994; Voon et al., 2004) but still inducible to higher levels by several stimuli such as 
T cell mitogens (Zinetti et al., 1998), phorbol ester and ionomycin (Voon et al., 2001), TCR 
activation (anti-CD3/28 or TCR cross-linking) (Millet and Ruddle, 1994), cytokines (e.g., IL-
7, TNFα, LTα3) (Honda et al., 2001; Voon et al., 2001, 2004) and viral proteins, especially in 
hepatocytes (Haybaeck et al., 2009; Simonin et al., 2013). 
LTα- and LTβ-encoding genes display a restricted and similar pattern of expression, 
being expressed in hematopoietic cells such as activated T, B and NK lymphocytes 
(Browning et al., 1997; Ware et al., 1992), DCs (De Trez et al., 2008) and lymphoid-tissue 
inducer (LTi) cells (Cupedo et al., 2004). In contrast to the LTα mature protein, which lacks a 
transmembrane domain, LTβ is a type II transmembrane glycoprotein (N-linked) consisting 
on a short N-terminal cytoplasmic domain, a transmembrane domain and a C-terminal 
extracellular domain (Browning et al., 1993). Therefore, when expressed in the absence of 
LTβ, LTα forms soluble LTα3 homotrimers stabilized primarily by interactions between 
hydrophobic and aromatic side chains (Eck et al., 1992; Force et al., 1995; Williams-Abbott 
et al., 1997). When LTα is expressed together with LTβ, these proteins oligomerize 
generating cell-surface LTα1β2 heterotrimers (Androlewicz et al., 1992; Browning et al., 
1995; Force et al., 1995). The LTα subunit contributes primarily to the conformation of the 
heterotrimer (Williams-Abbott et al., 1997), while the LTβ subunit provides the membrane 
anchor for the LTα1β2 heterotrimer and the specificity for LTβR binding (Crowe et al., 1994). 
Following cell activation, LTA induction is faster than LTB induction (Browning et al., 1993), 
so the basal levels of LTB mRNA may be important to transport LTα to the cell surface as the 
LTα1β2 heterotrimer (instead of LTα2β1 or even soluble LTα), and LTα production is 
probably the rate-limiting step this process (Browning et al., 1993; Kuprash et al., 2002; 
Millet and Ruddle, 1994). Cell-surface LTα1β2 heterotrimers are upregulated through 
lymphocyte activation, but also by cytokine and chemokine induction including IL-2 on 
human peripheral blood T cells (Ware et al., 1992), and IL-4 and IL-7 cytokines in addition 
to the CCL19 and CCL21 chemokines in murine splenic T cells (Luther et al., 2002). 
Abnormal expression of LTα1β2 in infected hepatocytes (Haybaeck et al., 2009; Simonin et 
al., 2013) and in the cervical epithelium (Kim et al., 2011) by viral proteins was also reported 
and shown to be involved in cancer development. 
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 The other known LTβR ligand is encoded by the human TNF superfamily, member 
14 (TNFSF14) or LIGHT gene and spans 5.1 kb. It is located within an MHC-like region on 
Chr 19 (Chr 17 in the mouse), recognized as an MHC paralog region, adjacent to other TNF 
superfamily member genes such as the CD27 ligand (TNFSF7) and the CD137 ligand 
(TNFSF9) (Granger et al., 2001; Misawa et al., 2000).  LIGHT expression is inducible and its 
promoter presents the motifs for AP-1, NF-κB and Oct-1 binding, as other TCR signaling-
inducible genes (Granger et al., 2001). The LIGHT full-length transcript is composed of 4 
exons (2.8 kb) and is translated in a 29 kDa N-glycosylated type II transmembrane protein 
(Granger et al., 2001). The first exon encodes the cytoplasmic tail, the transmembrane 
domain and the beginning of the extracellular stalk region, exons 2 and 3 encode the 
remaining stalk region and part of the trimerization domain, and finally, exon 4 encodes the 
remainder of the trimerization domain plus the receptor-binding domain (Granger et al., 
2001). LIGHT monomers form homotrimers at the cell surface of activated lymphocytes 
(Mauri et al., 1998), which can be shed upon proteolytic cleavage (Granger et al., 2001). An 
alternative, less abundant spliced isoform that contains an internal deletion and encodes a 
nonglycosylated cytosolic protein lacking the transmembrane domain was also identified, but 
its function remains unknown (Granger et al., 2001). Similarly to lymphotoxins, the LIGHT-
encoding gene displays a restricted expression pattern being mainly expressed on activated 
peripheral blood T lymphocytes (Mauri et al., 1998), monocytes, granulocytes and immature 
dendritic cells (Tamada et al., 2000; De Trez et al., 2008; Zhai et al., 1998). Conversely, in 
mucosal tissues, CD4+ T cells and NK cells were shown to constitutively express cell-surface 
LIGHT (Cohavy et al., 2005). Its gene was shown to be expressed also in thymic stromal 
cells such as DCs, fibroblasts, endothelial and epithelial cells (Seach et al., 2008).  
LTβR signaling and its output is complex due to overlapping patterns of ligand-
receptor binding involving LTα/LTβ-composed ligands and LIGHT (Figure 1.4). LTβ and/or 
LTα form 3 distinct ligands: soluble LTα3 and two lymphotoxin membrane-bound 
heterotrimers with different stoichiometry, LTα1β2 (major form) and LTα2β1, which is likely 
an extemporaneous minor form, expressed in vitro, representing less than 10% of LTαβ 
heterotrimers (Browning et al., 1995). LTα3 binds TNFR1, TNFR2 (Bossen et al., 2006; 
Chaplin and Fu, 1998), and herpes virus entry mediator (HVEM) (Bossen et al., 2006; Mauri 
et al., 1998). Since its discovery, LTβR is still the only known receptor for LTα1β2 (Browning 
et al., 1995), while LTα2β1 may bind LTβR with low affinity (Browning et al., 1995; Crowe 
et al., 1994; Williams-Abbott et al., 1997), and bind both TNFR1 and TNFR2 (Mauri et al., 
1998). LIGHT forms only homotrimers, which can bind and activate both LTβR and HVEM 
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(Mauri et al., 1998), a receptor expressed by T, B and NK lymphocytes, DCs and monocytes 
(Kwon et al., 1997), and the soluble decoy receptor 3 (DcR3), which acts as a negative 
regulator (Yu et al., 1999).  
Although published in vitro studies report several putative interactions between 
ligands and receptors, their physiological relevance in vivo still remains questionable. While 
the role of LTα1β2 and LIGHT to LTBR signaling and LIGHT to HVEM have been 
increasingly characterized, the role of LTα3-mediated TNFR activation and the functional 
significance of the LTα2β1 minor form in vivo are not completely understood. 
Even though both LTα1β2 heterotrimers and LIGHT homotrimers are often anchored 
to the cell membrane, in certain contexts they can be shed from the cell surface. For instance, 
LTα1β2 can be shed from activated human T cells, upon proteolysis mediated by matrix 
metalloproteinase (MMP)-8 and TNFα converting enzyme (TACE), to induce the expression 
of pro-inflammatory genes on synovial fibroblasts from rheumatoid arthritis patients (Young 
et al., 2010). LIGHT can also be actively shed from the cell surface of CD4+ T lymphocytes 
by MMPs in rheumatoid arthritis (Pierer et al., 2007) but also in the context of immune cell 
regulation (Murphy and Murphy, 2010). Although the shed soluble form of LIGHT also 
binds and activates HVEM, the membrane-bound homotrimer shows enhanced effects 
(Cheung et al., 2009; Granger et al., 2001; Morel et al., 2000). Interestingly, the membrane-
bound form of LIGHT expressed in T lymphocytes has been shown to co-stimulate these 
cells upon ligation of the TCR, when bound to an agonistic antibody or to its receptor DcR3, 
a phenomenon denominated reverse signaling (Ware, 2005). Nevertheless, the biological 
significance of these different forms is still not fully understood especially regarding LTβR 
activation. In certain contexts LIGHT shedding may induce distal functional effects on LTβR 
activation or may serve as a mechanism of inactivation.  
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Figure 1.4. LTβR as part of a network of shared ligand-receptor interactions within the 
TNF superfamily. LTα1β2 and LIGHT bind LTβR. In addition, LIGHT binds also HVEM 
and DcR3 (in human cells). LTα3 binds HVEM with low affinity in addition to TNFR1 and 
TNFR2, which are the two known receptors for TNFα. A minor form of the LTαβ 
heterotrimer, LTα2β1, binds LTβR and also TNFR1 and TNFR2. (Dashed lines indicate weak 
interactions; arrowheads indicate known signaling directions). 
 
1.3.3. LTβR activation, signal transduction and target genes 
The TNFR superfamily members are typically activated by ligand-induced trimerization or 
even higher order clustering through binding to monomer-monomer interfaces (Ware, 2005). 
As expected, the central initiating event for LTβR signaling is receptor aggregation but, 
differently from other TNF receptors, LTβR binds only two sites in the LTα1β2 heterotrimer, 
the LTα-LTβ (higher affinity) and LTβ-LTβ’ (lower affinity) interfaces (Sudhamsu et al., 
2013). Similarly, LIGHT has been shown to present only two high-affinity binding sites for 
LTβR (Eldredge et al., 2006). The binding of LTα1β2 or LIGHT to LTβR brings 2 receptor 
molecules in close proximity (Eldredge et al., 2006; Sudhamsu et al., 2013) and the LTβR 
self-interaction region in the cytoplasmic domain promotes receptor aggregation and 
consequent conformational changes (Force et al., 2000). Since like other TNFSF receptors, 
LTβR has no intrinsic kinase or other enzymatic activity encoded by its cytosolic domain, the 
previous events lead to the sequential recruitment of cytosolic adaptor proteins to the 
cytoplasmic region of LTβR forming the so-called LTβR-induced signaling complexes. The 
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main adaptors are TRAF proteins as suggested by the ability of LTβR to bind TRAF2, 3, 4, 
and 5. These proteins may activate or repress signaling initiation leading to gene transcription 
through different signaling pathways such as the classical and alternative NF-κB, c-Jun N-
terminal kinase (JNK), or even signaling pathways leading to cell death (Norris and Ware, 
2007). LTβR-dependent downstream signaling can also be initiated independently of its 
cognate ligands either by anti-LTβR agonistic antibodies that mimic receptor aggregation 
(Mackay et al., 1996; VanArsdale et al., 1997), or by overexpression of the receptor in cell 
lines leading to self-association (Dhawan et al., 2008; Wu et al., 1999). These observations 
support the existence of regulatory mechanisms that limit the expression and/or aggregation 
of the receptor. Also, although the naturally occurring ligands are membrane-bound, the 
recombinant soluble forms of LTα1β2 and LIGHT are also capable of binding and activating 
LTβR (Chen et al., 2000; Ganeff et al., 2011; Kim et al., 2005). Other TNFSF ligands are 
subject to proteolysis, allowing them to act in a soluble form (e.g., TNFα and RANKL) (Grell 
et al., 1995; Lum et al., 1999) or to inhibit signaling (e.g., FasL) (Voss et al., 2008). The fate 
of LTα1β2 and LIGHT following LTβR binding, and whether these two ligands can induce 
reverse signaling in this context, remains unveiled (Juhász et al., 2013).  
Despite LTβR activation has been reported to induce gene expression through ASK-
MKK-JNK-dependent AP-1 activation (Chang et al., 2002; Kim et al., 2005) and LTβR 
interacts with the AP2 adaptor complex/clathrin to mediate unknown NF-κB-independent 
functions (Ganeff et al., 2011), its role on cell death and NF-κB activation has been a major 
topic of research. Despite the fact that LTβR lacks a cell death domain in its cytosolic 
domain, it has been shown to induce cell death in certain cellular contexts. In some cancer 
cell lines (e.g., HT-29, WiDr, Hep3BT2 and MCF-7), recombinant forms of its ligands, 
LTα1β2 and LIGHT, and LTβR agonistic antibodies induce cell death with slow kinetics (36-
72h) in the presence of IFN-γ (Browning et al., 1996; Chen et al., 2000) or through LTβR 
overexpression and self-association independently of ligands and IFN-γ (Wu et al., 1999). 
Furthermore, LTβR activation was reported to arrest tumor growth in xenograft models 
(Browning et al., 1996; Lukashev et al., 2006). However, the molecular mechanism is 
currently not fully understood. Some studies reported that recruitment of mainly TRAF3, but 
also TRAF2 and TRAF5 (Force et al., 1997; Kim et al., 2005; Kuai et al., 2003; VanArsdale 
et al., 1997), to LTβR and the consequent production of reactive oxygen species (ROS) (Chen 
et al., 2000, 2003) induce cell death with mixed characteristics of apoptosis and necrosis 
(Wilson and Browning, 2002). A caspase-independent mechanism involving the activation of 
the apoptosis signal-regulating kinase 1 (ASK1) has been suggested (Chen et al., 2003). On 
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the other hand, LTβR was shown to induce caspase activation and mitochondrial-dependent 
apoptosis (Hu et al., 2013; Kuai et al., 2003). In addition to its inherent complexity, the 
mechanism of cell death induced by LTβR has not been fully understood because it may vary 
depending on cell type and the nature of the LTβR-activating stimulus. Furthermore, the 
activation of the receptor on one cell using soluble recombinant ligands or LTβR agonists 
may not fully mimic the effects of membrane-bound LIGHT or LTα1β2 expressed on another 
cell. 
It is generally accepted that LTβR signaling bifurcates at the level of receptor-bound 
TRAF proteins with TRAF3 leading to cell death and NF-κB inhibition, since some TRAF3 
mutants block cell death but not NF-κB activation (VanArsdale et al., 1997). Two distinct 
signaling pathways that lead to the activation of NF-κB transcription factors have been 
described, termed classical (or canonical) and alternative (or noncanonical). These are often 
activated by different stimuli in a cell type-specific manner, require different IκB kinase 
(IKK) complexes, and induce different NF-κB complexes that translocate to the nucleus and 
target distinct genes (Hayden and Ghosh, 2014). Unlike the prototypical TNF receptors that 
activate exclusively the classical NF-κB pathway (e.g., TNFR1 and TNFR2), LTβR binding 
by its ligands leads to both classical and alternative NF-κB pathway activation (Dejardin et 
al., 2002; Ganeff et al., 2011). The activation of one or the other NF-κB signaling pathway is 
spatially and temporally regulated by LTβR trafficking (Ganeff et al., 2011) and varying 
levels of receptor cross-linking may be required for distinct conformational changes and the 
activation of different signal transduction pathways. Furthermore, the classical and 
alternative NF-κB signaling pathways control distinct patterns of gene expression (Dejardin 
et al., 2002) and may be differentially involved in the functions attributed to LTβR signaling.  
To activate the classical NF-κB signaling pathway, LTβR engagement leads to 
TRAF2 recruitment to its cytoplasmic domain and IκBα phosphorylation and degradation by 
the proteasome (Bista et al., 2010) mediated by IKKβ and IKKγ. These events lead to the 
activation of p50-RelA heterodimers (Dejardin et al., 2002; Müller and Siebenlist, 2003). 
TRAF3 has been shown to inhibit TRAF2 recruitment when upregulated by an unapparent 
mechanism (Bista et al., 2010). When LIGHT or LTα1β2 accumulates at the surface of 
inducer cells, higher-order clusters of LTβR may form on the target cell, that seemingly 
trigger dynamin-2-dependent endocytosis of the receptor (Ganeff et al., 2011). During this 
process, the LTβR tail was shown to remain exposed towards the cytosol and to compete with 
NIK for the binding of its inhibitory complex composed by TRAF3/TRAF2/cIAP1/2. As a 
consequence, the constitutive proteasomal degradation of NIK is alleviated, leading to NIK 
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accumulation and activation of IKKα. These events lead to p100 processing to p52 and the 
translocation of p52/RelB dimers to the nucleus (Ganeff et al., 2011; Sanjo et al., 2010). In 
this case, TRAF3 inhibits NF-κB signaling by being part of a complex that mediates NIK 
targeting to proteasome degradation and, thus inhibits the processing of p100 to p52 (Bista et 
al., 2010). The activation of the alternative NF-κB pathway through NIK and IKKα, 
constitutes an essential component downstream the LTβR for lymphoid organogenesis, 
whereas for thymic organogenesis it is activated in cooperation with other receptor, namely 
the receptor activator of NF-κB (RANK) (Matsushima et al., 2001; Mouri et al., 2011). 
In terms of kinetics, ligand binding to LTβR can induce a rapid and transient 
activation of the classical NF-κB pathway, followed by a delayed but sustained activation of 
the alternative pathway (Dejardin et al., 2002; Müller and Siebenlist, 2003). The delayed 
activation of the alternative pathway may be at least partially due to the necessity of Nfkb2 
gene transcription (encoding p100), which is mediated by the classical pathway (Dejardin et 
al., 2002; Müller and Siebenlist, 2003). Alternatively, LTβR activation may induce the 
alternative pathway alone to eventually produce NF-κB dimers containing RelA and RelB 
(Basak et al., 2007). Through the activation of p50/RelA heterodimers, LTβR signaling 
promotes for instance the upregulation of proinflammatory molecules including the 
CCL4/macrophage inflammatory protein (MIP)-1β, MIP-2 and vascular-cell adhesion 
molecule 1 (VCAM-1) in mouse embryonic fibroblasts (MEFs) (Dejardin et al., 2002), and 
CXCL1 and CXCL2, intercellular adhesion molecule 1 (ICAM-1), VCAM-1 and E-selectin 
in endothelial cells (Madge et al., 2008). Conversely, LTβR-mediated activation of p52/RelB 
heterodimers results in the production of lymphoid chemokines such as the EBl1-ligand 
chemokine (ELC/CCL19), secondary lymphoid tissue chemokine (SLC/CCL21), stromal 
cell-derived factor-1α (SDF-1α/CXCL12), B lymphocyte chemoattractant (BLC/CXCL13) 
and the cytokine B cell activation factor (BAFF), being all involved in lymphoid 
organogenesis and homeostasis (Dejardin et al., 2002; Seach et al., 2008). Gene Ontology 
analysis performed by Lovas et al. (2008), confirmed that LTβR-NF-κB target genes were 
predominantly involved in the regulation of immune responses. However, other biological 
processes like apoptosis/cell death, cell cycle progression, angiogenesis, taxis and adipogenic 
differentiation, were shown to be also potentially regulated by LTβR signaling (Lovas et al., 
2008). The previously described findings on LTβR-mediated signal transduction and related 
effects are summarized in Figure 1.5. 
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Figure 1.5. Summary of LTβR-mediated signal transduction for target-gene expression 
and cell death. Activation of LTβR signaling axis by LIGHT or LTα1β2 induces gene 
expression and cell death. NF-κB classical pathway induction involves activation of IKK 
complex, IKK-mediated IκBα phosphorylation, and subsequent degradation, resulting in 
nuclear translocation of RelA/p50 heterodimers, which induce the expression of pro-
inflammatory cytokines, chemokines, and adhesion molecules. On the other hand, the 
alternative NF-κB pathway relies on NIK and IKKα-dependent processing of p100 into p52, 
leading to the translocation of RelB/p52 dimers to the nucleus where they activate the 
expression of genes mainly involved in lymphoid organogenesis and homeostasis. LTβR was 
also shown to activate JNK and AP-1-induced gene expression. Furthermore, LTβR 
activation induces cell death by poorly characterized mechanisms involving reactive oxygene 
species (ROS) production, ASK-1, and either caspase-independent or caspase-dependent 
apoptosis. 
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1.3.4. Biological functions of the LTβR signaling pathway 
Like other members of the TNF superfamily of ligands and receptors, LTα1β2/LIGHT to 
LTβR signaling is critically involved in lymphoid organogenesis and the maintenance of 
secondary lymphoid structures, in addition to its roles related to the regulation of immune 
responses, including inflammation, tissue homeostasis, and innate immunity. These functions 
are in keeping with the profile of gene expression induced by LTα1β2/LIGHT through LTβR 
signaling. 
Lymphoid organogenesis is largely associated with signaling by the LTα1β2 
heterotrimer through LTβR as shown in studies where the signaling was blocked (Ettinger et 
al., 1996; Rennert et al., 1996), and reverse genetic modeling studies in which LTβR, LTα, 
LTβ and LIGHT targeted gene knockouts were generated (Fütterer et al., 1998; Koni et al., 
1997; Scheu et al., 2002; De Togni et al., 1994). LTβR knockout mice lack most secondary 
lymphoid organs, including peripheral and mesenteric lymph nodes (LNs), Peyer´s patches 
and gut-associated lymphoid tissues (GALT) (Fütterer et al., 1998). LTα knockout mice lack 
peripheral LNs and Peyer´s patches although some mesenteric lymph node-like structures 
were observed in few mice (Banks et al., 1995; De Togni et al., 1994). Unexpectedly, most 
LTβ knockout mice conserved mesenteric LNs and cervical lymph node-like structures 
(Alimzhanov et al., 1997; Koni et al., 1997), a phenotype that could be improved by LIGHT-
deletion, meaning that LIGHT can compensate for LTβ absence in mesenteric lymph node 
development (Scheu et al., 2002).  In addition, all LTα-, LTβ- and LTβR-deficient mice, but 
not LIGHT-deficient mice presented splenic structural defects. Discrepancies in the effects of 
ligand/receptor gene inactivation led to the assumption that an alternative, yet unknown 
ligand for LTβR or nonspecific interactions may account for these differences.  
In the adult, LTβR signaling was reported to be critically involved in the adaptive 
immune response against pathogens due to its intervention in processes such as DCs 
homeostasis and expansion (Kabashima et al., 2005; Wang et al., 2005), and lymphocyte 
maturation and survival (Banks et al., 2005; Elewaut et al., 2000; Silva-Santos et al., 2005; 
Wang and Fu, 2003). Furthermore, its activation is continuously required for the maintenance 
of the integrity and organization of microenvironments from secondary lymphoid organs 
(Ettinger et al., 1996; Fütterer et al., 1998; Rennert et al., 1996). For example, LTβR is 
important for the development and structural maintenance of fibroblastic reticular cells 
(FRCs) in LNs and spleen (Chai et al., 2013; Zhao et al., 2014). In the spleen its activation 
was also shown to be essential for FDC differentiation (Tumanov et al., 2002). Accordingly, 
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LTβR-deficient mice present disrupted FDC and germinal center formation and, consequently 
deficient B cell affinity maturation (Fütterer et al., 1998). LTβR signaling is also important 
for the trafficking of lymphoid and other hematopoietic cells, namely in the recruitment, 
migration and organization inside the organs, and emigration to other tissues (Ansel et al., 
2000; Boehm et al., 2003; Luther et al., 2002; Seach et al., 2008). Moreover, it is involved in 
the regulation of acute inflammatory reactions and in the development of inflammation-
associated neolymphoid structures (Cupedo et al., 2004; Kratz et al., 1996). In this process, 
LTβR-dependent stromal cell differentiation into reticular networks and induction of 
chemokines, cytokines and adhesion molecules play a critical role. Furthermore, it favors the 
recruitment of hematopoietic cells to lymphoid compartments by instructing the development 
and function of high endothelial venules (HEVs) (Browning et al., 2005). 
Importantly, LTβR signaling has been shown to be a key player for thymic medullary 
epithelial cell differentiation (Mouri et al., 2011) and the maintenance of the thymic structure 
(Boehm et al., 2003), considered essential for central tolerance induction. In this context, T 
cell development and selection, and the maintenance of the thymic microenvironments 
require reciprocal interactions between thymocytes and stromal cells and the LTβR signaling 
is a critical mediator of this thymic crosstalk (Boehm et al., 2003). LTβR is expressed on 
virtually all stromal cells of the thymus (Seach et al., 2008). Conversely, the LTβR ligands 
are expressed in CD4 SP and CD8 SP thymocytes (Boehm et al., 2003). This expression 
pattern and the fact that LTβR stimulates the expression of adhesion molecules and 
chemokines, suggests that this receptor may be involved in the creation of 
microenvironments suitable for productive T cell interactions. The thymi of LTβR-deficient 
mice exhibit an aberrant microarchitecture characterized by a blurred demarcation between 
cortex and medulla and reduction of essentially Aire- mTEC subset (Boehm et al., 2003; 
Lkhagvasuren et al., 2013; Milićević et al., 2008; Venanzi et al., 2007). Further studies 
showed that SP thymocytes could activate LTβR leading to TRAF3 derepression and NIK-
induced alternative NF-κB signaling pathway activation, which is indispensable for mTEC 
development (Burkly et al., 1995; Jenkinson et al., 2013; Kajiura et al., 2004). The LTβR-
deficient mice also exhibit signs of autoimmunity characterized by the development of auto-
antibodies to multiple organs (Boehm et al., 2003) and the presence of lymphocytic infiltrates 
in the perivascular areas of various organs (Fütterer et al., 1998), as previously reported also 
for LTα-, LTβ and LIGHT-deficient mice (Alimzhanov et al., 1997; Banks et al., 1995; 
Scheu et al., 2002). These autoimmune and inflammatory effects are believed to be a 
secondary effect of thymic structural defects in Ltbr knockout mice, resulting from the 
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impaired development of mTECs (Boehm et al., 2003), reduced expression of TEC-derived 
CCL19 and CCL21 chemokines and consequent defects in thymocyte migration from the 
cortex to the medulla (Lkhagvasuren et al., 2013; Seach et al., 2008; Zhu et al., 2007), but 
also reduced expression of some Aire-independent tissue-restricted antigens (TRAs) (e.g., 
casein β, casein κ and C-reactive protein) (Seach et al., 2008).  
Altogether, the information extracted from experiments with LTβR knockout mice 
corroborates the conclusion that, in the thymus of adult mice, lymphocytes bearing LTα1β2 
and inducing LTβR signaling in mTECs, in association with signals mediated by RANK and 
CD40 (Akiyama et al., 2008; Hikosaka et al., 2008; White et al., 2008), have an important 
role in maintaining the integrity, organization and function of thymic microenvironments and 
in the control of autoimmunity. Furthermore, since LTβR and RANK have a cooperative 
action on immature mTECs from fetal thymus, these receptors share also a role in thymic 
organogenesis. In this context, it was reported that LTβR activation induces RANK 
expression, the activation of which by RANKL-expressing lymphoid tissue inducer cells is 
vital for mTEC development (Mouri et al., 2011). A possible similar mechanism involving 
the adult thymus was not clearly demonstrated to date. 
In addition to these studies based on genetic inactivation, other reports revealed that 
excessive LTβR signaling has a dramatic impact in the thymus. LTα and LTβ overexpression 
in T lymphocytes induced thymic atrophy mediated by a synergistic effect of TNFR1 and 
LTβR signaling in radioresistant stromal cells (Heikenwalder et al., 2008; Liepinsh et al., 
2009). In this context, thymic involution was most likely caused by stromal cell death, 
especially involving cortical TECs, by alterations in the microarchitecture of the thymus and 
by aberrant T-cell development. Consequently it resulted in compromised immune 
competence. These reports suggest that LTβR and TNFR1 signaling may contribute to 
thymic atrophy upon chronic infection or inflammation (Liepinsh et al., 2009) and during 
aging (Heikenwalder et al., 2008), and highlight the importance of the strict control of LTα3 
and LTα1β2 expression in the thymus. Likewise, T-cell restricted overexpression of LIGHT, 
resulted in a similar phenotype regarding the reduced size and altered structure of the thymus 
(Wang et al., 2001). Furthermore, it promoted the apoptosis of DP thymocytes. As LIGHT 
blockade was shown to result in the rescue of thymocytes from apoptosis, a role for LIGHT 
to LTβR signaling in T-cell negative selection and central tolerance induction was disclosed 
(Wang and Fu, 2003; Wang et al., 2001). In contrast, LIGHT overexpression was shown to 
activate mature T cells in the periphery, leading to inflammation and tissue destruction, 
mainly in the intestinal mucosa (Shaikh et al., 2001). These peripheral effects were not 
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unexpected since LIGHT is a costimulatory molecule for T-cell activation, proliferation and 
IFN-γ secretion. However, these functions are likely mediated by LIGHT to HVEM signaling 
(Scheu et al., 2002). In fact, LIGHT studies are complicated to interpret by the fact that it 
binds both LTβR and HVEM and, in specific contexts, LTβR binding may be attenuated by 
HVEM (Bechill and Muller, 2014). Furthermore, LIGHT to LTβR and HVEM binding can 
be competitively limited by the DcR3 decoy receptor. 
Considering the pleiotropic functions of LTβR signaling it is thus not unexpected that, 
when deregulated, it leads to autoimmune and inflammatory diseases (Tumanov et al., 2007) 
like rheumatoid arthritis (Bekiaris et al., 2013; Young et al., 2010), Sjögren´s syndrome 
(Gatumu et al., 2009), autoimmune pancreatitis (Seleznik et al., 2014), hepatitis (Haybaeck et 
al., 2009) or colitis (Stopfer et al., 2004). Although LTβR and its ligands are recognized as 
key players in immunity, currently it is known that they are involved in many other biological 
processes such as liver regeneration (Anders et al., 2005; Tumanov et al., 2009), hepatitis 
(Chen et al., 1997; Lowes et al., 2003), hepatic lipid metabolism (Lo et al., 2007), and 
adipocyte differentiation (Bénézech et al., 2012). Importantly, LTβR signaling has also been 
reported to be involved, not only in cell death and tumor growth inhibition, but also in cancer 
development and progression (Drutskaya et al., 2010; Wolf et al., 2010), what explains the 
paradoxical roles identified in this context. The context-dependent roles for LTβR signaling 
in cancer are reviewed next. 
 
 
1.4. LTβR SIGNALING IN CANCER DEVELOPMENT 
 
 
LTα, also known as TNFβ, was the first of the two lymphotoxins to be discovered and it was 
named this way because it was a cytokine similar to TNFα that induced cytotoxicity when 
added to cells in culture (Ruddle, 2014). Indeed, several studies reported that when LTβR 
was directly activated in some carcinoma and sarcoma cells it promoted growth inhibitory 
and apoptotic effects (Browning et al., 1996; Dhawan et al., 2008; Hu et al., 2013; Lukashev 
et al., 2006). In addition, LTβR was shown to mediate anti-tumor effects also by other 
mechanisms such as tumor sensitization to chemotherapeutic agents and radiation (Hu et al., 
2013; Lukashev et al., 2006), and stimulation of host-mediated anti-tumor immune responses. 
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In the latter case, the anti-tumoral effects were achieved either by inducing the expression of 
pro-inflammatory cytokines and chemokines that function as chemoattractants for activated 
lymphocytes (Lukashev et al., 2006; Winter et al., 2007), or by inducing the differentiation of 
high endothelial venules that mediate lymphocyte trafficking to normal organs and tumors 
(Browning et al., 1995; Martinet et al., 2013).  
 Paradoxically, a wide body of evidence has implicated LTβR in pro-carcinogenic 
mechanisms. In a variety of contexts, LTβR was shown to have direct cell-intrinsic oncogenic 
properties in cancer cells due to overexpression and self-oligomerization without the 
requirement for ligand-induced activation (Dhawan et al., 2008; Force et al., 2000; Fujiwara 
et al., 2005; Or et al., 2010). Conversely, when induced by ligand expressing cells, it can 
promote tumor angiogenesis (Daller et al., 2011; Hehlgans et al., 2002), chronic 
inflammation (Ammirante et al., 2010; Haybaeck et al., 2009; Wolf et al., 2014), and 
modulate cancer microenvironments into pro-growth and survival niches (Heinig et al., 2014; 
Lau et al., 2014; Rehm et al., 2011). Indirect effects in the thymus or in the local 
microenvironment may also lead to the suppression of anti-tumor immune responses (Kim et 
al., 2011; Zhou et al., 2009). LTβR involvement in cancer is not unexpected since, in addition 
to the fact that several cancer cells from different origins express LTβR (Dhawan et al., 2008; 
Hu et al., 2013; Lukashev et al., 2006), in some cases its expression has been shown to be 
upregulated throughout cancer progression and metastization (Dhawan et al., 2008; Hu et al., 
2013; Or et al., 2010). Furthermore, LTβR activation and NF-κB induction are closely linked 
and NF-κB constitutive activation has been increasingly recognized as a hallmark of several 
types of cancer. LTβR-mediated NF-κB signaling activation in cancer cells may result from 
either exposure to pro-inflammatory stimuli in the tumor microenvironment or from genetic 
alterations in components of this pathway.  
Usually, immune cells either normal or malignant, and cancer cells infected by virus, 
such as human papillomavirus 16E6 (HPV16) (Simonin et al., 2013) and hepatitis C virus 
(HCV) (Kim et al., 2011), express the LTα1β2 and/or LIGHT ligands. On the other hand, 
LTβR is mainly expressed by stromal cells such as FDCs and fibroblasts (Heinig et al., 2014; 
Lau et al., 2014; Rehm et al., 2011), and cancer cells (Ammirante et al., 2010; Daller et al., 
2011), excluding B, T and NK cells (Table 1.4).  
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1.4.1. LTβR cell-intrinsic pro-carcinogenic roles 
As mentioned before, LTβR may act as an oncogene promoting the survival and/or 
proliferation of cancer cells. One of the first studies reporting LTβR transforming ability was 
done in the context of pancreatic ductal carcinoma (PDC). Construction of a retroviral cDNA 
expression library from total RNA isolated from the PDC cell line MiaPaCa-2 led to 
detection of an NH2-terminally truncated form of LTβR with transforming activity in vitro 
and in vivo. Interestingly, full-length LTβR protein was also shown to display transforming 
activity (Fujiwara et al., 2005). Supporting the notion that LTβR was pro-oncogenic, LTβR 
was found to be overexpressed and consistently activated in 7.3% cases of nasopharyngeal 
carcinoma (NPC) due to a 12p13.3 amplification (Or et al., 2010). In a nasopharyngeal 
epithelial cell line, LTβR overexpression was shown to contribute to increased NF-κB 
activity and cancer cell proliferation. Importantly, LTβR knockdown inhibited in vivo tumor 
growth in an NPC xenograft model (Or et al., 2010). Further demonstrating the importance of 
NF-κB activation in NPC development, genetic alterations affecting NF-κB signaling were 
identified in cases without LTBR gene amplification (Chung et al., 2013).  
 Further highlighting the role of LTβR as an activator of NF-κB in cancer promotion, a 
search for genetic abnormalities in multiple myeloma revealed mutations in multiple 
members of classical and alternative NF-κB pathways including LTBR amplifications in one 
cell line and one primary patient sample. This mutation was shown to result in LTβR 
overexpression and constitutive activation of the noncanonical NF-κB pathway (Keats et al., 
2007).  
LTβR was also reported to be oncogenic in melanoma. Dhawan and coworkers have 
shown that LTβR expression is upregulated in human melanoma cells and melanocytic 
lesions, when compared to normal melanocytes. As a result, the NF-κB pathway was often 
activated leading to cell proliferation and increased invasiveness (Dhawan et al., 2008). 
Activation of LTβR ex vivo appeared to be ligand-independent, as ligand expression was not 
detected in cultured melanoma cells and inhibition of LTβR ligand binding had no effect in 
NF-κB activation or cell growth (Dhawan et al., 2008). Nonetheless, in a previous study it 
was shown that LIGHT is frequently expressed in human melanoma metastasis and 
melanoma-derived microvesicles, and it was suggested that LIGHT interaction with LTβR in 
stromal cells may induce the T-cell attractant CCL21 chemokine and play a role in regulating 
T-cell infiltration of neoplastic tissue (Mortarini et al., 2005).  
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1.4.2. LTβR pro-carcinogenic roles mediated by interactions with the tumor 
microenvironment 
It is generally accepted that the interaction of immune cells with tumor cells can either 
restrain or promote tumor progression. Thus, depending on the chemokine milieu in the 
tumor microenvironment, tumor-infiltrating immune cells can mediate a response against 
tumor-specific antigens to repress tumor growth or rather help tumors to subvert the adaptive 
immune responses. Likewise, as a signaling axis involved in immune cell communication, 
LTβR can also contribute to tumor microenvironmental alterations that may promote 
inflammation and angiogenesis.  
Tumor and stromal cells respond to injury, infection, and tissue damage by producing 
cytokines and chemokines that chemoattract immune cells (Chovatiya and Medzhitov, 2014). 
As a result, immune cells migrate to the tumor microenvironment where they secrete 
inflammatory, pro-angiogenic and in some cases pro-tumorigenic growth and survival 
factors, therefore having pro-carcinogenic actions that facilitate tumor growth, invasiveness, 
and metastization (Coussens and Werb, 2002).  
 
1.4.2.1. LTβR-induced angiogenesis 
The importance of angiogenesis for the growth of solid tumors is well recognized. As tumor 
growth and metastasis require persistent new blood vessel formation, under selective 
pressure, a developing tumor transits from an avascular phase to an angiogenic phase, the so-
called angiogenic switch (Hanahan and Folkman, 1996). This switch is controlled by a 
balance between pro- and anti-angiogenic factors that may be secreted by the tumor cells 
themselves or by cells in the tumor microenvironment, in particular immune cells and other 
stromal cells. It is known that the expression of pro- and anti-angiogenic factors by cancer 
cells is controlled directly by oncogenes, tumor suppressor genes and transcription factors, 
but also indirectly by microenvironmental factors. Yet, the roles and the interplay among the 
various inflammatory cytokines and chemokines during the angiogenic switch are still not 
completely understood. 
Shedding light on a role for LTβR in angiogenesis, Hehlgans and colleagues have 
shown that LTβR signaling ablation inhibits angiogenesis and tumor growth (Hehlgans et al., 
2002). In this report and further studies using the methylcholanthrene-induced murine 
fibrosarcoma model (BFS-1), it was show that LTβR activation by LTα1β2-expressing T and 
B lymphocytes and also LIGHT, induced the expression of the angiogenic mediator 
CHAPTER 1 - INTRODUCTION 
MT Fernandes 41 
CXCL2/MIP-2 through NF-κB activation and, consequently, increased angiogenesis and 
solid tumor growth in vivo. The described pro-tumorigenic effect of LTβR activation was 
shown to be due to modulation of the tumor microenvironment and not cell-intrinsic 
mechanisms because ex vivo treatment of fibrosarcoma cells with an agonistic anti-LTβR 
monoclonal antibody did not increase proliferation or survival (Daller et al., 2011; Hehlgans 
et al., 2002).  Recently, the same investigators have identified another player in this process. 
They found that host-derived tumor-infiltrating CD45+ hematopoietic cells expressed the 
mouse β-defensin 14 (mBD14), which was shown to mediate CD19+ and B220+ lymphocyte 
chemoattraction through CCR6 stimulation. These lymphocytes expressed LTα1β2 and 
possibly LIGHT that, by interaction with LTβR in fibrosarcoma cells induced CXCL2 
expression and initiated a proangiogenic pathway leading to increased tumor vascularization 
and growth (Röhrl et al., 2012).  
 
1.4.2.2. LTβR-induced chronic inflammation 
In the above-mentioned studies on the role of LTβR in fibrosarcoma development, tumor-
infiltrating immune cells were responsible for the initiation of an acute inflammatory 
response. This, in turn created a permissive microenvironment for tumor progression through 
angiogenesis induction (Daller et al., 2011; Hehlgans et al., 2002; Röhrl et al., 2012). 
Differently from this situation, inflammation often contributes to cancer development when it 
is not clearly resolved and becomes persistent. Indeed, it is well established that chronic 
inflammation in the tumor microenvironment constitutes a hallmark of cancer (Colotta et al., 
2009; Mantovani et al., 2008). Furthermore, NF-κB signaling has been pinpointed as a key 
molecular link between chronic inflammation and cancer (DiDonato et al., 2012). As an 
upstream activator of NF-κB, LTβR has also been found to be involved in immune cell 
infiltration, chronic inflammation, and carcinogenesis in models of hepatocellular carcinoma 
(HCC) and prostate cancer (Ammirante et al., 2010; Haybaeck et al., 2009; Wolf et al., 
2014).  
Haybaeck and coworkers have described the involvement of LTβR signaling in the 
development of chronic virus-induced hepatitis and HCC. First, LTβR and its ligands LTα, 
LTβ and LIGHT, but also proinflammatory chemokines like CCL2, CCL3, and CXCL10, 
were foun to be upregulated in human primary samples of hepatitis B virus (HBV)- or HCV-
induced chronic hepatitis and HCC. Furthermore, a causal link between HCV infection and 
LTBR, LTA, LTB, LIGHT and inflammatory chemokine expression was shown in vitro using 
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the human hepatoma cell line Huh-7.5. In transgenic mice expressing high levels of LTα and 
LTβ in the liver, LTβR signaling induced chronic hepatitis characterized by inflammation 
with lymphocytic infiltrates of T and B cells and hepatocyte apoptosis. Both B and T 
lymphocytes, which expressed LTβR ligands (including LTα1β2), and canonical NF-κB 
signaling pathway induction following LTβR activation in hepatocytes, were shown to be 
required for LTβR-induced chronic hepatitis and HCC development. In this mouse model, 
rather than having direct oncogenic properties, LTβR signaling generated an inflammatory 
hepatic microenvironment driving oncogenesis (Haybaeck et al., 2009). Supporting the 
previous study, Simonin and coworkers have shown that LTβ expression is induced by the 
HCV core protein NS5B in Huh7 human hepatoma cells. Using a transgenic mouse model of 
inflammation-induced liver tumorigenesis with targeted expression of the full length HCV 
open reading frame in hepatocytes, it was shown that LTβ expression induction in 
hepatocytes was followed by NF-κB activation, chemokine neosynthesis, and intra-tumoral 
recruitment of macrophages and T and B lymphocytes (Simonin et al., 2013). Using another 
model in which mice are exposed to long-term choline-deficient high-fat diet, Wolf and 
colleagues identified CD8+ T and NKT cells recruited to the liver as key players in the 
development of steatosis and its progression to hepatocellular carcinoma (Wolf et al., 2014). 
They found that these immune cells interacted with hepatocytes leading to their activation 
and to the release of soluble factors including LIGHT and lymphotoxin, which induced liver 
tumorigenesis through LTβR-induced classical NF-κB signaling activation in hepatocytes 
(Wolf et al., 2014).  
Cancer therapy-induced cell death can also elicit an inflammatory response that may 
contribute to therapeutic failure rather than to success. This is the case of castration-resistant 
metastatic prostate carcinoma, the emergence of which constitutes a major clinical 
complication and is responsible for most prostate cancer mortality. Using subcutaneous 
allografts of the mouse androgen-dependent prostate cancer (CaP) cell line myc-CaP in 
castrated FVB mice, Ammirante and colleagues unveiled a mechanism underlying the 
emergence of castration-resistant prostate cancer. They have found that following androgen 
ablation therapy, the death of androgen-deprived cancer cells induced an inflammatory 
response with concomitant production of CXCL13 and other inflammatory chemokines, and 
recruitment of leukocytes, most importantly B cells, into the regressing tumor. IKKβ 
activation in B cells, presumably by inflammatory cytokines, induced the expression of 
LTα1β2. Through LTβR activation in prostate cancer cells, these proteins led to IKKα 
activation and nuclear translocation to promote androgen-independent growth and survival, 
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together with STAT3 activated by other non-identified factors (Ammirante et al., 2010). In 
this study, it was not determined the mechanism by which death of androgen-deprived CaP 
triggers the inflammatory response. However, it is known that the uncontrolled tumor growth, 
which leads to disruption of tissue architecture and lack of blood supply, may result in 
necrosis and the consequent release of damage associated molecular patterns (DAMPs). 
These molecules are produced by cells and tissues involved in host defense against microbial 
infections (defensins), passively released by necrotic cells or actively secreted by stimulated 
inflammatory cells (expressing HMGB1) (Scaffidi et al., 2002). In a recent study by He and 
coworkers using the TRAMP model of human prostate cancer, HMGB1 was shown to be 
induced during tumor progression and to be required for the activation and accumulation of T 
cells within the prostate tumor. The tumor-infiltrating T cells expressed LTα1β2 and, through 
LTβR activation, promoted the recruitment of macrophages into the tumor presumably by 
inducing monocyte chemotactic protein 1 (MCP-1) upregulation. This mechanism 
contributed to the progression from hyperplasia to invasive prostate carcinoma (He et al., 
2013). Differently from the study by Ammirante and coworkers, the inflammatory response 
in this case was mediated by LTα1β2-expressing T cells rather than B cells, and LTβR 
signaling contributed to cancer progression from hyperplasia to malignant carcinoma (He et 
al., 2013). Together, these studies show that LTβR may contribute to several developmental 
phases of the same type of cancer and involving different cellular players.   
 
1.4.2.3. Immune evasion mediated by LTβR 
Another mechanism through which LTβR signaling was described to be involved in cancer 
development is by interfering with the host anti-cancer adaptive immune response. Because 
LTα1β2-LTβR plays a role in self-tolerance induction (Boehm et al., 2003; Fütterer et al., 
1998; Seach et al., 2008; Zhu et al., 2007), blocking this signaling axis might rescue tumor-
reactive T cells from clonal deletion in the thymus and therefore prevent cancer development. 
To test this hypothesis, Zhou and coworkers used the TRAMP model, bearing a T-cell 
receptor specific for the SV40 large T antigen. They found that targeted inactivation of the 
LTα gene impaired efficient negative selection of tumor-reactive T cells in the thymus, 
resulting in a decrease in cancer incidence and in a milder malignant phenotype. Confirming 
the impact of LTβR signaling in prostate cancer development, short-term blocking of LTβR 
also rescued T cells from clonal deletion and consequently reduced the progression of 
primary prostate cancer and prevented metastasis (Zhou et al., 2009). Since LTβR signaling 
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increased the host resistance to prostate cancer, this mechanism was suggested as a non-
antigen-based strategy of immune prevention for patients with high genetic risk for cancer. 
Similarly, cervical cancer was reported to develop due to suppression of cellular immunity, 
but in this case through a mechanism involving lymphotoxin signaling locally in the tumor 
microenvironment. In this context, Kim and colleagues have shown that the E6 oncogene 
from HPV16, which is responsible for oncogenic transformation of the cervical epithelium, 
induces LTα, LTβ and LTβR gene expression in HeLa cervical cancer cells. This resulted in 
NF-κB activation and consequent MHC I downregulation followed by resistance to cytotoxic 
T-lymphocyte-mediated lytic activity and cancer cell evasion (Kim et al., 2011).  
 
1.4.2.4. Induction of a pro-tumorigenic niche supported by LTβR-expressing stromal 
cells 
Recently, some studies of great relevance to this thesis, unveiled a role for LTβR signaling in 
lymphoid malignancies. In this context, LTα1β2-LTβR signaling was shown to mediate 
paracrine tumor-stromal interactions conditioning the microenvironment to establish 
attractive tumor-permissive niches in secondary lymphoid organs. Rehm and colleagues 
identified the homeostatic chemokine receptor CCR7 as a determinant factor in dictating the 
location and survival of B-cell lymphoma cells within secondary lymphoid organs. In the Eµ-
Myc transgenic mouse model of aggressive human B-cell lymphoma, they found that CCR7 
regulates lymphoma cell dissemination to LNs and to the T-cell zone of the spleen, where 
through LTα1β2 expression, cancer cells stimulate LTβR in glycoprotein 38-positive FRCs. 
This crosstalk results in the expansion of the stromal FRC network and in the release of 
chemoattractant homeostatic chemokines (e.g., CCR7 ligands, CCL19 and CCL21), and 
trophic factors (e.g., indian hedgehog) from FRCs that confer a survival advantage to 
lymphoma cells (Rehm et al., 2011). In another recent report, the authors used the murine Eµ-
Tcl1 model of B-cell chronic lymphocytic leukemia (B-CLL) to show that the CXCR5-
CXCL13 signaling axis mediates leukemic B cell access to a stromal compartment enriched 
with FDCs in the spleen. In this location, leukemic B cells and FDCs engaged an LTβR-
mediated reciprocal crosstalk in which LTα1β2-expressing leukemic cells stimulate the 
differentiation of FDC networks and CXCL13 production. On the other hand, FDCs provide 
protection and proliferative stimuli to leukemic cells presumably by producing B-cell growth 
factors (Heinig et al., 2014). In both studies, the inhibition of LTβR-mediated interactions 
between malignant cells and their microenvironment impaired disease progression and 
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though was pointed as a possible strategy to complement traditional cytotoxic therapies 
(Heinig et al., 2014; Rehm et al., 2011).  
In addition to hematopoietic malignancies, solid cancers can also take advantage of 
LTβR signaling to modulate the tumor microenvironment in their favor. In a recent report, it 
was shown that ovarian cancer cells maintain reciprocal interactions with stromal cells 
through LTβR (Lau et al., 2014). It was demonstrated that human ovarian cancer primary 
cells overexpress LTα1β2 and induce chemokine expression in LTβR-expressing cancer-
associated fibroblasts through NF-κB signaling. One of the chemokines induced in stromal 
fibroblastic cells was CXCL11, which promoted proliferation and migration of ovarian 
cancer cells. This specific expression pattern of LTβ and LTβR was also identified in 
endometrial cancer, suggesting that it may be a common phenomenon in gynecologic 
malignancies (Lau et al., 2014).  
 
1.4.3. Determinants of LTβR anti- and pro-carcinogenic roles 
Altogether, the studies previously described have disclosed several but perhaps not all factors 
influencing the pro- or anti-carcinogenic activities of LTβR signaling. Several variables such 
as the tumor type, the progression stage, the cancer-intrinsic genetic and epigenetic 
alterations, the status of activated signaling pathways, the microenvironmental factors, and 
the experimental model used may ultimately determine if the overall effect of LTβR 
activation should be pro- or anti-tumorigenic. Moreover, the mechanisms by which LTβR 
may lead to foster or impede tumor progression are not completely understood. Nevertheless, 
the classical and alternative NF-κB signaling pathways seem to be commonly activated by 
LTβR in any scenarios, which corroborates the dual role of NF-κB signaling in cancer 
observed in different contexts (Klein and Ghosh, 2011).  
Another important issue to consider when studying LTβR role in carcinogenesis is the 
mechanism of activation. It may be constitutively activated due to overexpression and self-
oligomerization, or it may be activated only in the presence of its ligands. In the latter case, 
heterotypic interactions with cells present in the tumor microenvironment are usually 
involved (Figure 1.6). Furthermore, it is important to determine which ligand may exert the 
observed effects, if LTα1β2, LIGHT or both. Importantly, the way by which ligand-induced 
activation of LTβR is achieved (membrane-bound or soluble ligand) or experimentally 
mimicked (e.g., lymphoid cells expressing the ligand, recombinant soluble ligand or soluble 
or immobilized agonistic LTβR antibody) should be carefully considered. These factors are 
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highly relevant since they may lead to different cellular outcomes. For instance, it is known 
that the degree of receptor clustering and the varying lifetime of the oligomerized states may 
lead to diverse cellular responses following receptor activation (Browning et al., 1996; 
Mackay et al., 1996; VanArsdale et al., 1997). Also, during the course of LTβR stimulation, 
which may be short or prolonged, different NF-κB complexes are activated and may result in 
the expression of different sets of target genes (Dejardin et al., 2002; Müller and Siebenlist, 
2003). 
	  
Figure 1.6. LTβR pro-tumorigenic roles in the tumor microenvironment. Activation of 
LTβR signaling axis favors carcinogenesis due to crosstalks between malignant cells and 
cells from the tumor microenvironment by four main mechanisms. When activated in tumor 
cells by its ligands expressed in lymphocytes, LTβR activates the expression proangiogenic 
factors, leading to angiogenesis induction and tumor progression. In another settings, LTβR 
ligand-expressing lymphocytes activate LTβR in tumor cells, which produce chemokines that 
attract other inflammatory cells, resulting in tumor-promoting inflammation. LTβR activation 
in tumor cells may also affect the recognition of tumor cells, resulting in resistance to T-cell 
induced lysis and immune evasion. Finally, malignant cells expressing LTβR ligands can 
activate the receptor in stromal cells, leading to stroma expansion and activation, followed by 
production of pro-survival factors and further attraction of malignant cells. All these 
interactions lead to the creation of a pro-tumorigenic niche. 
 
 Due to its pro-carcinogenic functions and with the exception of cancers presenting 
constitutive activation of LTβR, blocking of LTβR signaling between tumor cells and 
microenvironmental cells has been proposed as a therapy (Bjordahl et al., 2013). 
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Unfortunately, because of its dual functions in cancer development and progression, to 
develop a rational and effective cancer therapy and prevent deleterious side effects, it is 
imperative to learn more about the mechanisms and contexts in which contexts LTβR may 
exert pro-carcinogenic effects. 
 
Table 1.4. LTβR-induced pro-carcinogenic effects in different cellular contexts. 
Cancer Type LTαβ LIGHT LTβR Context Reference 
Solid Cancers 
Nasopharyngeal 
Carcinoma 
- - Carcinoma LTβR amplification 
causing activation of 
NF-κB 
(Or et al., 
2012) 
Pancreatic Ductal 
Carcinoma 
- - Carcinoma LTβR transforming 
activity 
(Fujiwara et 
al., 2005) 
Melanoma - - Melanoma Autonomous growth of 
melanoma cells 
(Dhawan et al., 
2008) 
Fibrosarcoma T, B 
Lymphocytes 
n.i. Fibrosarcoma Induction of 
angiogenesis and tumor 
growth 
(Hehlgans et 
al., 2002) 
(Daller et al., 
2010) 
Liver Cancer 
 
T and B 
Lymphocytes 
(mainly) 
Hepatocytes 
(HV-infected) 
T and B 
Lymphocytes  
Hepatocytes  
(mainly) 
Virus-induced chronic 
hepatitis and HCC 
(Haybaeck et 
al., 2009) 
(Simonin et al., 
2013) 
CD8+ and 
NKT 
Lymphocytes 
CD8+ and 
NKT 
Lymphocytes 
Hepatocytes Diet-induced 
nonalcoholic 
steatohepatitis and 
HCC 
(Wolf et al., 
2014) 
Prostate 
Carcinoma 
 
 
B 
Lymphocytes  
n.d. Carcinoma Emergence of 
castration-resistant CaP  
(Ammirante et 
al., 2010) 
T 
Lymphocytes 
- Prostate 
epithelial cells 
Progression from pre-
neoplasia to carcinoma 
(He et al., 
2013) 
Cervical 
Carcinoma 
Cervical 
Cancer Cells 
(HPV-
infected) 
n.d. Cervical 
Cancer Cells 
Immune escape (Kim et al., 
2011) 
Ovarian 
Carcinoma 
Ovarian 
Cancer Cells 
n.d. CAFs Promotion of a pro-
carcinogenic niche 
(Lau et al., 
2014) 
Multiple 
Myeloma 
- - MM cells LTβR amplification 
causing activation of 
NF-κB 
(Keats et al., 
2007) 	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Table 1.4 (cont.). LTβR-induced pro-carcinogenic effects in different cellular contexts.  
Hematological Cancers 
B-cell 
Lymphoma 
Malignant B 
Cells 
n.d. FRCs Promotion of a pro-
carcinogenic niche 
(Rehm et al., 
2011) 
B-CLL Malignant B 
Cells 
n.d. FDCs Promotion of a pro-
carcinogenic niche 
(Heinig et al., 
2014) 
Ovarian 
Carcinoma 
Ovarian 
Cancer Cells 
n.d. CAFs Promotion of a pro-
carcinogenic niche 
(Lau et al., 
2014) 
-, not expressed; n.i., the cells expressing it were not identified; n.d., not determined; B-CLL, B-cell chronic lymphocytic 
leukemia; CAFs, cancer-associated fibroblasts; CaP, prostate carcinoma; FDCs, follicular dendritic cells; FRCs, fibroblastic 
reticular cells; HCC, hepatocellular carcinoma; HV, hepatitis virus; HPV, human papilloma virus. 
 
 
1.5. THE RANKL TO RANK SIGNALING AXIS 
  
 
1.5.1. The receptor activator of NF-κB 
The receptor activator of NF-κB (RANK) genetic locus (TNFRSF11A or RANK) is located in 
Chr 18 in humans (mouse Chr 1) and it contains 10 exons spanning approximately 61 kb 
(Anderson et al., 1997). Through alternative splicing, the RANK gene produces different 
isoforms truncated either in its ICD or ECD (Sirinian et al., 2013). The RANK full-length 
transcript is approximately 4.5 kb in size and encodes a 616 amino acid glycosylated type I 
transmembrane protein, consisting of an ECD with a signal secretion peptide, four CRDs, and 
a long cytoplasmic domain (Anderson et al., 1997). The cytoplasmic domain of RANK 
consists of 383 amino acids and like LTβR does not contain a death domain. It contains also 
several putative TRAF-binding sites that cluster in distinct regions: one located in the most 
C-terminal 93 amino acids, which is able to bind TRAF2/TRAF5 and TRAF6, and another 
membrane-proximal, which binds TRAF6 (Darnay et al., 1998; Hsu et al., 1999; Wong et al., 
1998). Moreover, within the cytoplasmic domain, a region comprising amino acids 524 to 
550 mediates ligand-independent oligomerization and signal transduction (Das et al., 2014; 
Kanazawa and Kudo, 2005). The murine RANK shows high homology with its human 
counterpart (Anderson et al., 1997) and binds the homologous ligand with similar specificity 
(see below).  
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RANK is expressed on mature DCs (Josien et al., 1999) and osteoclasts (Hsu et al., 
1999), in mammary epithelial cells (Fata et al., 2000), thymic medullary epithelial cells 
(Hikosaka et al., 2008) and, at low levels, in activated T cells (Anderson et al., 1997; Josien 
et al., 1999) and activated B cells (Josien et al., 1999). In addition, its expression may be 
constitutive or, in certain contexts, inducible. Indeed, RANK expression has been shown to 
be inducible by TCR/CD3 activation on peripheral blood T cells (Josien et al., 1999), CD40L 
on DCs (Anderson et al., 1997), macrophage colony-stimulating factor (M-CSF) on 
osteoclast precursor cells (Arai et al., 1999), and LTβR activation on fetal thymic mTECs 
(Mouri et al., 2011).  
 
1.5.2. The RANK ligand 
The only known ligand for RANK has been designated receptor activator of NF-κB ligand 
(RANKL) or TNFSF11 but several alternative names such as TNF-related activation-induced 
cytokine (TRANCE), osteoclast differentiation factor (ODF) or osteoprotegerin ligand 
(OPGL) may also be found in the literature.  
The human RANKL genomic locus (TNFSF11 or RANKL) consists of 5 exons 
spanning approximately 45 kb on Chr 13 in humans (murine Chr 14) (Anderson et al., 1997). 
The full-length RANKL mRNA encodes a glycosylated type II transmembrane protein of 317 
amino acids (Anderson et al., 1997; Wong et al., 1997). The murine and human RANKL 
proteins are highly homologous (Anderson et al., 1997). The exon 1 encodes the 5’ UTR, the 
ICD and TMD, while exons 2 to 5 encode the ECD (Walsh et al., 2013). The ECD of 
membrane-bound RANKL can be cleaved by TACE at amino acids 139-140 to produce a 
soluble active protein (Lum et al., 1999). Nevertheless, alternatively spliced transcript 
variants lacking exon 1 and the TMD can occur. These encode functional soluble protein 
isoforms composed of only the ECD (Nagai et al., 2000; Walsh et al., 2013). 
RANKL is expressed in activated peripheral T cells and predominantly in CD4 SP 
thymocytes, but also in CD8 SP and CD4/CD8 DN thymocytes (Anderson et al., 1997; 
Hikosaka et al., 2008; Josien et al., 1999; Wong et al., 1997). In T cells, RANKL expression 
was shown to be inducible through TCR activation using anti-CD3/CD28 or PMA plus 
ionomycin stimulation and is controlled by calcineurin-regulated transcription factors (Josien 
et al., 1999; Walsh et al., 2013; Wong et al., 1997). A regulatory region proximal to exon 1A 
was reported to contain consensus-binding sites for transcription factors such as 
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NFAT/STAT, AP-1/STAT, or STAT, which are important for transduction of activation 
signals in T cells (Walsh et al., 2013).  
In addition to T cells and its precursors, RANKL expression was also reported in pro-
B cells (Anderson et al., 1997), mature DCs (Josien et al., 1999), osteoblasts and bone 
marrow stromal cells (Lacey et al., 1998; Yasuda et al., 1998), and osteocytes (Nakashima et 
al., 2011). Various osteoactive factors including glucocorticoids, vitamin D, and TNFα have 
been reported to induce RANKL expression in osteoblasts (Walsh and Choi, 2014). 
RANKL binds and activates RANK, its functional receptor but binds also 
osteoprotegerin (OPG), a secreted TNFR-related decoy receptor that sequesters RANKL, 
impairing RANK engagement and signaling activation (Hsu et al., 1999; Lacey et al., 1998). 
 
1.5.3. RANK activation, signal transduction and molecular effects 
Engagement of RANK with RANKL promotes its trimerization (Kanazawa and Kudo, 2005), 
which leads to conformational changes and recruitment of adaptor factors and docking 
proteins to the receptor. RANK has been shown to interact with TRAFs 1, 2, 3, 5 and 6 
(Darnay et al., 1998; Wong et al., 1998). In general, interaction with TRAF family members 
mediates RANK-induced NF-κB and JNK pathway activation (Darnay et al., 1998; Hsu et al., 
1999) in various cell types. When overexpressed, RANK self-assembles in trimers in the 
absence of the ligand and this is sufficient to activate NF-κB and JNK (Hsu et al., 1999). NF-
κB and JNK can be also activated by recombinant soluble RANKL and RANK agonist 
antibodies on cells expressing RANK (Anderson et al., 1997; Hsu et al., 1999; Wong et al., 
1997). Activation of these pathways promotes translocation and activation of transcripton 
factors including NFATc1, CREB, NF-κB, AP-1, and MITF (Walsh and Choi, 2014). 
Moreover, RANK-mediated gene transcription may differ depending on cell type but often 
involves the induction of transcription factors like c-fos and NFATc1/NFATc2 (Ishida et al., 
2002; Matsuo et al., 2000). 
 TRAF6 is a major transducer downstream of RANK activation. Nevertheless, most 
studies on RANK signaling were done using osteoclast precursor cells as a model and some 
of the mechanisms appear to be specific to osteoclastogenesis. In this context, TRAF6 is 
critical for the activation of MAPKs such as p38 and JNK, as well as the classical NF-κB 
pathway (Darnay et al., 1999; Lomaga et al., 1999; Naito et al., 1999). Moreover, in 
combination with TRAF2, TRAF6 is able to activate the TAB1/2/TAK1 complex, which in 
combination with other upstream kinases, leads to activation of IKKβ and NF-κB, and 
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MAPKs and AP-1 (Mizukami et al., 2002). In addition, TRAF6, c-Src and Cbl scaffolding 
protein interaction with the RANK cytoplasmic tail following receptor activation, leads to 
PI3K and Akt activation (Arron et al., 2001; Wong et al., 1999). Interestingly, TRAF6-
dependent RANK signaling was shown to be negatively regulated by IFNγ-induced 
ubiquitination and degradation of TRAF6 through the lysosome/autophagy system 
(Takayanagi et al., 2000). RANK signaling can also regulate calcium homeostasis in 
combination with other factors (Yang et al., 2007). Also functioning in some settings as a 
negative regulation mechanism of RANK function, RANK ectodomain can be shed from 
osteoclast precursor cells by the TACE (Hakozaki et al., 2010). 
Similarly to LTβR, RANK is one of the TNFR superfamily members capable of 
activating both the classical and alternative NF-κB pathways. RANK-associated TRAF3 has 
been shown to play a key role in negatively regulating the alternative NF-κB pathway. When 
RANK is activated, it overcomes NIK inhibition by triggering the degradation of TRAF3 
(Xiu et al., 2014). For example, in mTECs, RANK engagement induces both TRAF6/IKKβ 
and NIK/IKKα, which activate the classical and the alternative NF-κB pathways, respectively 
culminating in the expression of target genes such as Aire and various TRAs (e.g., C-reactive 
protein, insulin 2, and salivary protein 1) (Akiyama et al., 2005, 2008; Kajiura et al., 2004). 
Moreover, the TRAF6-induced NF-κB classical signaling pathway was shown to induce 
RelB expression, while NIK stabilization contributed to RelB activation and translocation to 
the nucleus (Akiyama et al., 2008).  
Another property common to some members of TNFSF ligands and receptors is the 
capacity to induce reverse signaling. Besides RANK-induced signaling activation in adjacent 
cells, binding of RANK to RANKL-expressing cells leads to signaling pathway activation. 
For example, reverse signaling through RANKL induces IFNγ secretion by T cells, via a p38-
dependent pathway, when these interact with RANK-expressing DCs (Wang et al., 2001).   
 
1.5.4. Biological functions of the RANK signaling pathway 
Studies employing genetically deficient mouse models have demonstrated the critical role of 
RANKL to RANK signaling in bone and immunity. By generating RANK knockout mice, 
Dougall and coworkers found that it is essential for osteoclast differentiation and bone 
resorption, and also lymph node organogenesis, but not for mucosal-associated lymphoid 
tissues, although these were reduced in the knockout mice (Dougall et al., 1999). Similarly, 
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RANKL genetic ablation resulted in osteopetrosis and lymph node absence, in addition to B- 
and T-cell defects (Kong et al., 1999). 
Highlighting its essential role in bone metabolism, the RANKL-RANK-OPG system 
was shown to be involved in diseases like postmenopausal osteoporosis, familial expansile 
osteolysis and Paget’s disease of bone (Silva and Branco, 2011). In addition, it was shown to 
play a role in the so-called cancer skeletal-related events (SREs) (e.g., pain, hypercalcemia, 
and fractures) that are mediated by some types of cancer that metastasize to the bone, like 
breast and prostate cancer (Buckle et al., 2012; Fizazi et al., 2009). RANK activation in 
breast and prostate tumor cells was also recognized as a player in metastization to the bone 
(Casimiro et al., 2013) since RANKL expression in the bone seems to chemo-attract RANK-
expressing cancer cells (Jones et al., 2006). Moreover, a role for osteolysis in cancer 
development was supported by studies showing that osteolysis induces the release of tumor-
promoting factors such as insulin-like growth factor-1 and hypoxia-inducible factor 
(Kuchimaru et al., 2014). 
Besides their critical roles in lymph node organogenesis, RANKL/RANK signaling 
was also shown to be important for adaptive immunity, for example, mediating the 
interaction between T cells and DCs, thus favoring T-cell proliferation and DC function and 
survival (Anderson et al., 1997). Moreover, RANKL to RANK signaling is essential for 
thymic organogenesis and the establishment of central tolerance. In RANKL and RANK 
knockout mice the number of mTECs is reduced and the thymic medulla is underdeveloped, 
as a consequence of reduced crosstalk between developing thymocytes and mTECs. Since 
this is essential for negative selection/deletion of potentially self-reactive T cells, these mice 
develop autoimmune diseases (Akiyama et al., 2013; Hikosaka et al., 2008; Rossi et al., 
2007). Recently, this crosstalk was shown to contribute also to the selection and survival of 
immunossupressive regulatory T cells (Cowan et al., 2013). Supporting a role for RANKL-
RANK signaling in regulatory T-cell functions, RANKL expression on these cells was 
reported to ameliorate intestinal inflammation in chronic colitis (Totsuka et al., 2009).  
Interestingly, several immunopathologies like rheumatoid arthritis, periodontitis and 
Crohn’s disease are often accompanied by osteoclast activation and bone loss, a phenotype 
shown to be induced by T cells (Cochran, 2008; Gough et al., 1994; Moschen et al., 2005). 
This observation links immune function and bone metabolism, and is the basis of a new field 
named osteoimmunology.   
Recently, RANK activation in mammary lobuloalveolar cells was implicated in 
physiological proliferation and development of the lactating mammary gland during 
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pregnancy (Fata et al., 2000). In this context, hormones and in particular progesterone, were 
shown to promote RANKL expression (Schramek et al., 2010). This finding prompted studies 
finding that the RANK-RANKL-OPG axis is implicated in breast cancer tumorigenesis and 
metastatic spread to bone and lungs (Palafox et al., 2012; Schramek et al., 2010; Tan et al., 
2011). In one study, the critical source of RANKL that promoted RANK activation and 
induction of breast cancer-derived pulmonary metastases were regulatory T cells recruited to 
the tumor microenvironment (Tan et al., 2011). This observation implicates inflammatory 
factors recruited to the tumor microenvironment in RANKL-driven metastization. 
Similarly, RANKL and RANK were also shown to be expressed in the brain 
(Kartsogiannis et al., 1999); hence it was disclosed a role for this signaling axis in 
inflammatory fever response via RANK-induced prostaglandin E2 (PGE2) expression by 
astrocytes, and physiological thermoregulation in females (Hanada et al., 2009). Furthermore, 
the high expression of RANKL in glioma cells was shown to mediate RANK-induced 
activation of the classical NF-κB pathway and expression of cytokines in microenvironmental 
astrocytes that promote glioblastoma invasiveness (Kim et al., 2014). 
Dysregulated RANKL-to-RANK signaling was also reported in other types of solid 
cancer, such as osteosarcoma (Bago-Horvath et al., 2014) and oral squamous cell carcinoma 
(Grimm et al., 2015; Sambandam et al., 2013), and in hematologic malignancies as well. In 
B-cell chronic lymphocytic leukemia (B-CLL), the enhancement of leukemic cell survival 
was reported to rely on IL-8 induction through RANKL reverse signaling in these cells 
(Secchiero et al., 2006), while in acute myeloid leukemia (AML), RANK signaling is 
responsible for the impairment of NK cell-dependent immunesurveilance (Schmiedel et al., 
2013).  
Therefore, it is not surprising that the RANKL-RANK-OPG signaling axis has 
increasingly been recognized as a therapeutic target in several types of cancer. Indeed, this 
pathway is already being targeted (through the monoclonal antibody denosumab) in order to 
reduce SREs due to bone metastases for instance in breast cancer, prostate cancer and 
multiple myeloma (Buckle et al., 2012; Fizazi et al., 2009). 
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1.6. THESIS RATIONALE AND OBJECTIVES 
 
 
Despite the improved prognosis in T-ALL therapy due to aggressive multi-agent 
chemotherapy, a significant subset of patients has still a poor clinical outcome as a result of 
massive leukemic cell dissemination and infiltration of several organs, emergence of 
resistance to therapy, and disease relapse. T-ALL leukemogenesis results from the 
combination of cell-intrinsic alterations and microenvironmental factors (Buonamici et al., 
2009; Indraccolo et al., 2009; Silva et al., 2011; Van Vlierberghe and Ferrando, 2012). 
Moreover, the microenvironment where T-ALL develops has been implicated in protection 
from therapy (Gilbert and Hemann, 2010, 2011) and stimulation of LIC activity (Armstrong 
et al., 2009; Medyouf et al., 2011), which is believed to be linked to disease relapse. So far, 
only few microenvironmental factors favoring leukemogenesis have been identified as 
opposed to the widely explored genetic landscape of T-ALL. 
 In this context, RelB expression in radio-resistant, non-hematopoietic cells was 
reported to favor leukemia development in TJ2-Tg mice (dos Santos et al., 2008). Since T-
cell leukemia originates spontaneously in the thymus of this mouse model and RelB is 
essential for thymic stromal cell development (Weih et al., 1995), thymic stromal cells are the 
potential microenvironmental cells supporting leukemogenesis. However, the upstream 
activators of RelB and the downstream players were not identified yet. Receptors known to 
activate RelB and playing a role in thymic function include members of the TNF superfamily 
such as LTβR, RANK and CD40 (Akiyama et al., 2012). These receptors and their cognate 
ligands are important mediators of thymocyte to stromal cell crosstalk modulating the thymic 
microenvironments to support normal T-cell development (Akiyama et al., 2012). Thus, it is 
plausible that T-ALL cells may also modulate the thymic microenvironment in their favor 
through these signaling axes.  
 The recently uncovered role for LTβR in cancer development in diverse contexts 
(Ammirante et al., 2010; Haybaeck et al., 2009), particularly in the microenvironments of 
lymphoid malignancies (Heinig et al., 2014; Rehm et al., 2011) led us to hypothesize that an 
evolving crosstalk between leukemic thymocytes expressing lymphotoxin and/or LIGHT 
ligands and thymic stromal cells expressing their cognate receptor takes place to favor 
leukemogenesis (Figure 1.7).  
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 Importantly, a role for LTβR in T-cell leukemia was to the best of our knowledge 
never demonstrated and its potential involvement in T-ALL leukemogenesis could pave the 
way to use it as a target for therapy (Bjordahl et al., 2013). Therefore, the general aim of the 
present work was to investigate whether LTβR signaling may be activated and playing a role 
in the development of human T-ALL using the TJ2-Tg mouse model. 
 
	  
Figure 1.7. Working hypothesis. Based on previous studies, we hypothesize that during T-
ALL development, an evolving crosstalk between transformed thymocytes and stromal cells 
through LTβR signaling axis, alone or cooperating with RANK, takes place and modulates 
the microenvironment into a pro-leukemogenic niche. On one hand, malignant thymocytes 
may promote the maturation and expantion of the stromal network; on the other hand, the 
stromal network may support T-ALL by producing cytokines and growth factors, previously 
found to contribute to leukemogenesis.  
 
 
The specific aims at the outset of this work were: 
 (1) to verify if LTαβ/LIGHT-LTβR and RANKL-RANK signaling can occur in 
thymic lymphomas; 
 (2) to determine the mechanism by which LTβR and RANK ligands are induced in 
leukemic cells;  
 (3) to assess a possible role for LTβR an RANK in leukemogenesis; 
 (4) to determine if LTβR deficiency delays initial expansion of malignant cells in the 
thymus; 
 (5) to assess the tumorigenic potential of TJ2-Tg leukemic cells growing in different 
microenvironments (LTβR-deficient or -proficient) and their role in disease progression;  
 (6) to study the dynamics of lymphotoxin to LTβR signaling and determine if 
leukemic cells can benefit from the presence of stromal cells in terms of survival; 
RelB%
LTβR%
Ltα1β2%
LIGHT%
RANKL% RANK%
? 
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 (7) to test the therapeutic potential of LTβR signaling blockade; 
 (8) finally, to determine if the mechanisms identified in TJ2-Tg leukemic T cells are 
conserved in human T-ALL cells.  
 
 In Chapter 2, the materials and methods strategically used to attain the above listed 
aims are described. The original data obtained during this research project is presented in 
Chapter 3. First, the results of TNF receptor and ligand expression in TJ2-Tg leukemic versus 
normal thymi are presented. Second, we show that LTβR and other factors modulate 
lymphotoxin expression at the surface of TJ2-Tg leukemic cells. Third, the survival and 
characterization of TEL-JAK2-induced T-cell leukemia in LTβR-deficient mice are 
presented. Finally, some common features between human T-ALL and TEL-JAK2-induced 
leukemia are analyzed. These results are then discussed in Chapter 4 focusing on their 
significance, concordance with previously published studies, and the possible mechanism(s) 
that could account for the effects observed. Also in this last chapter, some questions left 
unanswered are addressed, together with recommendations for future research.  
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2.1. HUMAN PRIMARY SAMPLES 
 
 
For the Portuguese cohort, T-ALL samples were obtained at diagnosis from peripheral blood 
(PB) and/or bone marrow (BM) of pediatric patients with high leukemia involvement 
(>85%), and enriched by density centrifugation over Ficoll-Paque (GE Healthcare). The 
Brazilian cohort consisted of samples from 51 pediatric patients with newly diagnosed T-
ALL accrued from 2000 to 2013 at Centro Infantil Boldrini, Campinas, Brazil. Most patients 
(n=44) were treated according to the Brazilian GBTLI-99 Childhood ALL Treatment 
protocol . The use of patient samples was approved by the FCM/UNICAMP Research Ethics 
Committee (CAAE: 0014.0.144.146-08). Thymic samples, obtained from children 
undergoing cardiac surgery, were gently minced in culture medium and subsequently 
subjected to density centrifugation. Informed consent and Institutional Review Board 
approval were obtained for all sample collections in accordance with the Declaration of 
Helsinki.  
 
 
2.2. MOUSE PROCEDURES 
 
 
2.2.1. Mice 
EµSRα-TEL-JAK2 transgenic (TJ2-Tg) mice, which express the TEL-JAK2 fusion protein 
specifically in lymphoid cells and develop T-cell leukemia (Carron et al., 2000), were 
provided by Dr. Jacques Ghysdael (CNRS, Orsay, France). Ltbr knockout mice, in which the 
coding exons 1 to 5 of the Ltbr gene were targeted for inactivation (Fütterer et al., 1998), 
were kindly provided by Jorge Caamaño (Institute of Biomedical Research, Birmingham, 
UK). Ltbr heterozygotic (Ltbr+/-) and knockout (Ltbr-/-) embryos were used to prepare mouse 
embryonic fibroblasts (MEFs; procedure in section 2.3.3). Rag2 knockout mice (Shinkai et 
al., 1992) were obtained from the department of cryopreservation, distribution, typing, and 
animal archive (CDTA; CNRS, Orléans, France) and crossed to TJ2-Tg mice. 
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All mice were maintained in the CBME/UAlg Animal Facility (Faro, Portugal) and 
the experimental procedures followed recommendations for the care and use of laboratory 
animals from the European Commission (Directive 2010/63/UE) and Portuguese authorities 
(Decreto-Lei nº113/2013). 
 
2.2.2. Mouse breeding and survival 
TJ2-Tg mice were bred with Ltbr knockout mice on the C57BL/6 background to originate 
cohorts of TJ2-Tg;Ltbr+/- (controls) and TJ2-Tg;Ltbr-/- mice. Mice were monitored for the 
development of TEL-JAK2-induced malignancy (see 2.2.5). Only mice that succumbed to 
confirmed malignancy were included in survival analyses. For detection of malignant 
thymocytes at early stage T-ALL, TJ2-Tg mice were sacrificed at 8-weeks-of-age, and the 
percentage of CD8+CD25+ cells in thymocyte suspensions was determined by flow 
cytometry. 
 
2.2.3. Leukemic cell transplantation 
For transplantation experiments, single-cell suspensions of freshly collected primary TJ2-Tg 
leukemic T cells were prepared (procedure in section 2.2.5). For tumor establishment, 5×106 
cells in a volume of 100 µl of sterile phosphate-buffered saline (PBS) solution (Lonza) were 
injected intravenously into the tail vein of littermate Ltbr+/- and Ltbr-/- recipient mice (7 to 15 
weeks of age).  
 
2.2.4. LTβR-Fc treatment of mice  
To block LTβR signaling in vivo, TJ2-Tg mice received weekly intraperitoneal injections of 
100 µg mLTβR-mIgG (provided by Biogen Idec, Cambridge, USA) or control ChromPure 
mouse IgG (Jackson Immunoresearch) for 5 consecutive weeks, starting at 5-weeks-of-age. 
For detection of malignant thymocytes at early stage T-ALL, TJ2-Tg mice were killed at 8-
weeks-of-age, and the percentage of CD8+CD25+ cells in thymocyte suspensions was 
determined by flow cytometry. 
 
2.2.5. Sacrifice, necropsy and sample collection  
Unless the sacrifice time-point is stated, TJ2-Tg mice and transplantation recipient mice were 
monitored for leukemia development and killed by CO2 inhalation when manifesting signs of 
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disease (i.e., dyspnea, lethargy, enlarged LNs or enlarged abdomen). Age-matched C56BL/6 
mice were sacrificed to serve as controls, when required. 
Organs collected at necropsy were kept in cold PBS until weighing and sample 
processing. To prepare single-cell suspensions, the organs were washed in PBS and TJ2-Tg 
leukemic T cells were isolated from the stroma-enriched fraction by gentle compression 
against a 70 µm cell strainer (BD Biosciences) with a plunger and washing with cold PBS. 
BM single cell suspensions were obtained by flushing cold PBS through tibiae and femora. 
Mouse PB was collected from the submandibular vein by using blood lancets 
(Marienfeld superior). To this end, the location where the facial and submandibular veins 
meet at the rear end of the mandibular bone was punctured with a lancet and few drops were 
collected in a microtube containing 50 mM EDTA (approximarely 1 volume of EDTA 
(Sigma) for 10 volumes of blood). To determine white blood cell (WBC) counts in the PB, 
the kit Leuco-TIK® (Bioanalytic), based on Türk’s solution staining of leucocyte nuclei after 
red blood cell lysis, was used following the manufacturer´s instructions. 
 
 
2.3. CELL CULTURE 
 
 
Culture of cell lines and primary TJ2-Tg leukemic T cells was performed in a laminar flow 
cabinet (HERAsafe Heraeus) under aseptic conditions. Cells were maintained in a incubator 
(HERAcell 150 Heraeus) at 37ºC under a humidified atmosphere with 5% CO2. Monitoring 
of cell culture growth and cell counting on a hemocytometer (see 2.3.5) was performed on an 
inverted light microscope (Leica).  
 
2.3.1. Cell lines 
DND41, PF382, P12, and SUPT1 human T-ALL cell lines were provided by Hind Medyouf 
and Andrew P. Weng (BC Cancer Agency Research Centre, Vancouver, Canada). Human 
cutaneous T-cell lymphoma HUT-78 cell line was provided by Neil Perkins (ICaMB, 
Newcastle, UK), and Jurkat and Nalm6 cell lines were provided by João T. Barata (IMM, 
Lisbon). Murine MS5 bone marrow stroma (Itoh et al., 1989) and 1C6 mTEC (Mizuochi et 
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al., 1992) cell lines were provided by Françoise Pflumio (CEA-IRCM, Fontenay-aux-Roses, 
France) and Georg Hollander (University of Basel, Germany), respectively.  
 
2.3.1.1. Maintenance and treatments 
Leukemic cell lines were cultured in complete RPMI medium (Lonza) supplemented with 
10% heat-inactivated fetal bovine serum (FBS; PAA), 2 mM L-glutamine (Lonza), and 100 
U/ml penicillin plus 100 µg/ml streptomycin (Lonza). For activation and/or signaling 
pathway inhibition, leukemic cell lines were cultured at 1x106 cells/ml and treated for 10 h 
with either DMSO (Sigma, control), 50 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma-
Aldrich) and/or 10 µM BMS-345541 (IKKi; Calbiochem). 
MS5 and 1C6 mTEC stromal cell lines were maintained in minimum essential 
medium alpha (αMEM; Gibco) or Dulbecco’s modified eagle medium (DMEM; Lonza), 
respectively supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, and 100 U/ml 
penicillin plus 100 µg/ml streptomycin. 
 
2.3.1.2. Freezing and thawing  
For cryopreservation, adherent cells were washed with PBS, dissociated by 0.25% Trypsin 
(Lonza), and resuspended in supplemented medium to halt trypsin action. Dissociated 
adherent cells or suspension cells were then centrifuged at 300 ×g for 5 minutes and the 
pellet was resuspended in freezing solution (90% calf serum (Lonza), 10% DMSO (Sigma)) 
at 2.5-5×106 cells per ml, and preserved in 2 ml cryotubes (Bioline). These were kept in a Mr 
FrostyTM freezing container (Thermo Scientific) at -80ºC overnight, and then transferred to a 
liquid nitrogen tank for long-term storage. Cells were thawed by rapid warming in a 37°C 
water bath.  These were resuspended in prewarmed culture medium, centrifuged at 300 ×g 
for 5 min to discard the supernatant containing DMSO, and plated in fresh, prewarmed 
supplemented medium. 
 
2.3.2. Primary TJ2-Tg leukemic T cells 
2.3.2.1. Isolation of TJ2-Tg leukemic T cells 
Single cell suspensions from freshly collected wild-type thymocytes and primary TJ2-Tg 
leukemic T cells for transplantation experiments, ex vivo treatments and co-cultures, were 
obtained from wild-type thymi and TJ2-Tg thymic lymphomas, respectively. These were 
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prepared under aseptic conditions by gentle dissociation and filtration through sterile 70 µm 
nylon cell strainers (BD Biosciences) and washing with PBS sterile solution (Lonza). 
 
2.3.2.2. Maintenance and treatments 
Wild-type thymocytes and primary leukemic T cells were cultured in complete RPMI 
medium supplemented with 10% heat-inactivated FBS (PAA), 2 mM L-glutamine (Lonza), 
and 100 U/ml penicillin plus 100 µg/ml streptomycin (Lonza) at 2×106 cells/ml. For 
molecular analyses, primary cells were treated with either DMSO (control), 1 µg/ml 
actinomycin D (ActD), 50 µg/ml cycloheximide (CHX), 10 ng/ml PMA and 250 ng/ml 
ionomycin (PMA+Iono) (all from Sigma-Aldrich), 10 µM Tetracyclic Pyridone 6 (InSolution 
Jak Inhibitor I, JAKi) or 10 µM BMS-345541 (IKKi) (both from Calbiochem), as indicated.  
 
2.3.2.3. Freezing and thawing 
Primary leukemic T cells (25×106) pelleted from single cell suspensions were resuspended in 
1 ml of freezing solution (90% calf serum (Lonza), 10% DMSO (Sigma)) and preserved in 2 
ml cryotubes (Bioline). These were kept in a Mr FrostyTM freezing container (Thermo 
Scientific) at -80ºC overnight, and then stored in a liquid nitrogen tank. Cells were thawed by 
rapid warming in a 37°C water bath. These were resuspended in ice-cold PBS, centrifuged at 
300 ×g for 5 min to discard the supernatant containing DMSO, and processed for analysis. 
 
2.3.3. Primary mouse embryonic fibroblasts (MEFs) 
2.3.3.1. Isolation of primary MEFs 
Ltbr+/- and Ltbr-/- embryos were collected from pregnant female mice at embryonic day 13.5 
to 14.5. Briefly, pregnant females were sacrificed by CO2 inhalation, the ventral surface was 
cleaned with 70% ethanol, and the placenta was dissected as described elsewhere (Freshney, 
2006) and transferred to a clean Petri dish with PBS. In each embryo handled separately, 
internal organs, head and blood system cells were discarded with the free membranes and 
placenta. The remainder, consisting of the carcass, was then transferred to a clean Petri dish 
and washed five times with PBS in a laminar flow hood. Subsequently, the carcasses were 
transferred to sterile 10 cm cell culture dishes with 5 ml of 0.05% Trypsin/0.53 mM EDTA 
(Gibco) and cut finely with a razor blade. The resulting suspension was resuspended and 
homogenized by pipetting up and down six to seven times in order to break up the tissue, and 
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then placed in the incubator at 37ºC for 15 minutes. Next, 5 ml of Trypsin/EDTA was added 
to the plate and repeatedly pipetted up and down followed by another 10-minute incubation. 
Following homogenization, the cellular suspension was passed through a sterile 100 µm 
nylon cell strainer (BD Biosciencies) to remove large pieces of undigested tissue. The cell 
strainer was rinsed with 5 ml of PBS and the permeated suspension was collected in the same 
plate. The cellular suspension was transferred to a 50 ml conical tube and centrifuged at 200 ×g for 8 min at room temperature (RT). The supernatant was discarded and the cell pellet 
resuspended in MEF culture medium (composition in section 2.3.3.2). The cellular content of 
each embryo was plated in one 75 cm2 T-flask and incubated at 37 ºC with 5% CO2. The 
medium was changed after six hours and one day. When a confluence of 70% was reached, 
MEFs were either cryopreserved or subcultured.  
 
2.3.3.2. Maintenance  
MEFs were cultured in DMEM medium (Lonza) supplemented with 10% heat-inactivated 
FBS (PAA), 2 mM L-glutamine (Lonza), 100 U/ml penicillin plus 100 µg/ml streptomycin 
(Lonza), and 0.1 mM 2-mercaptoethanol (Gibco). The medium was changed every two days 
and cells were split between 1:3 and 1:5 as they reached 70% confluency. 
 
2.3.3.3. Freezing and thawing 
For cryopreservation, primary MEFs were washed with PBS, dissociated by 0.05% Trypsin / 
0.53 mM EDTA (Gibco), and resuspended in supplemented medium to inactivate trypsin. 
These were then centrifuged at 300 ×g for 5 minutes, the pellet was resuspended in freezing 
solution (45% DMEM, 40% FBS, 15% DMSO) at 1×106 cells per ml, and preserved in 2 ml 
cryotubes (Bioline). The cryotubes were kept in a Mr FrostyTM freezing container (Thermo 
Scientific) at -80ºC overnight, and then transferred to a liquid nitrogen tank for long-term 
storage. MEFs were thawed by rapid warming in a 37°C water bath. These were resuspended 
in prewarmed medium, centrifuged at 300 ×g for 5 min to discard the supernatant containing 
DMSO, and plated in fresh, prewarmed supplemented medium. 
 
2.3.4. Co-cultures 
TJ2-Tg leukemic T cells (1x106 cells/ml) were co-cultured in triplicate with confluent MS5 
cells or Ltbr+/- and Ltbr-/- MEFs in complete RPMI medium as previously described. Co-
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culture images were obtained using a Leica DM IL microscope (magnification 400x) and 
captured using Leica DC500 camera and Adobe Photoshop CS2 software. 
 For flow cytometry analysis, co-cultured leukemic cells in suspension (non-adherent) 
were collected. The remaining culture was washed twice with PBS and then dissociated by 
incubation at 37ºC with enzyme-free cell dissociation buffer (Gibco). In flow cytometry 
analyses, dissociated leukemic cells (adherent) were discriminated from MS5 or MEFs using 
the Thy1.2 T-cell marker. 
 
2.3.5. Cell counts 
To determine cell number and viability, one volume of 0.4% trypan blue solution (Sigma) 
was added to one volume of cell suspension and incubated for 1 min. The suspension was 
mixed, introduced on a hemocytometer (Loptik Labor), and cells were counted using an 
inverted light microscope. Viable cells (colorless) and nonviable cells (blue) were counted in 
five 1 mm2- squares of one chamber and the average number of cells per square (Average 
count/square) was determined. The following formula was used to estimate the total number 
of cells in the original suspension (Total N cells):  
Total N cells = Average count/square × 104 × Dilution factor × Total suspension volume  
This method was also used to determine thymocyte cellularity (total cell number in a 
whole thymus). 
 
 
2.4. FLOW CYTOMETRY AND CELL SORTING 
 
 
Single cell suspensions were stained with fluorescein isothiocyanate (FITC)-, R-
phycoerythrin (PE)-, PE-cyanine 5 (PE-Cy5)-, or allophycocyanin (APC)-conjugated 
antibodies, and detected by a FACS Calibur flow cytometer (BD Biosciences) or sorted using 
a FACSAria I (BD Biosciences), as indicated. Nonviable cells were excluded from analyses 
by propidium iodide (PI; Sigma-Aldrich) or 7-Aminoactinomycin D (7-AAD; BioLegend) 
staining, and appropriate gating. The data were analyzed using CellQuest (BD Biosciences) 
software.   
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When mouse PB was analyzed by flow cytometry, the samples were treated to lyse 
red blood cells before initiating the staining protocol. PB samples collected in anticoagulant 
were transferred to 15 ml conical tubes and centrifuged at 300 ×g for 5 min at 4°C. After 
discarding the supernatant, the pellet was resuspended in 5 ml of red blood cell (RBC) lysis 
solution (composition in Table 2.5), and incubated for 5 min at RT. Then, the samples were 
centrifuged at 300 ×g for 5 min at 4°C, the supernatant was discarded, and the pellets were 
resuspended in cold PBS. 
 
2.4.1. Immunostaining for detection of T-cell markers and RANKL 
A volume of single cell suspension containing 1×106 cells, was added to each 5 ml round-
bottom polystyrene tube (BD Falcon) plus 1 ml of ice-cold FACS solution (composition in 
Table 2.5). After centrifugation at 300 ×g for 5 minutes at 4ºC, the cells were stained with 
fluorochrome-labeled antibodies alone or in combination at the indicated dilutions (Table 
2.1) in 50 µl of FACS solution, and incubated for 1 hour on ice, in the dark. Then, the cells 
were washed twice with 1 ml of cold FACS solution and resuspended in 1 ml of 10 mM 
NaN3 in PBS solution, and analyzed. Isotype negative controls and cells stained with each 
antibody individually were also prepared to adjust the FACS instrument settings 
 
2.4.2. Detection of intracellular lymphotoxin-β (LTβ)  
Intracellular lymphotoxin-β was detected using a hamster anti-mouse LTβ (BBF6.BF12) 
monoclonal antibody (Browning et al., 1997). This antibody and the negative control, anti-
KLH armenian hamster IgG Ha4/8, were provided by Jeff Browning (Boston University 
School of Medicine, Boston, USA). Both primary antibodies were visualized using FITC-
conjugated goat anti-hamster (Armenian) IgG (BioLegend) secondary antibody. More 
specifically, a volume of suspension containing 0.5×106 cells was transferred to each 5 ml 
round-bottom polystyrene tube (BD Falcon) and washed with 1 ml of ice-cold PBS. For 
washing, cells were centrifuged at 300 ×g for 5 minutes at 4ºC and the supernatant was 
discarded. Then, cells were fixed with 200 µl of 0.5% paraformaldehyde (PFA; Merck) for 
20 minutes at RT. To permeabilize the membranes, cells were washed 2 times with 
permeabilization solution (composition in Table 2.5). After discarding completely the 
supernatant, 1 µg of LTβ antibody (or the negative control) diluted in 100 µl of 
permeabilization solution was added and incubated for 1 hour on ice. Next, cells were 
washed two times using permeabilization solution, incubated with 0.5 µg of secondary 
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antibody in 50 µl of permeabilization solution, and incubated for 1 hour on ice in the dark. 
Finally, cells were washed 2 more times with permeabilization solution and resuspended with 
500 µl of 10 mM NaN3 in PBS solution. 
 
2.4.3. Detection of membrane-bound LTβR ligands 
Membrane-bound LTβR ligands were detected using the murine LTβR-hIgG (mLTβR-Fc) 
(Browning et al., 1997) and visualized using PE-conjugated AffiniPure F(ab’)2 fragment 
donkey anti-human IgG (H+L) (Jackson ImmunoResearch Laboratories) secondary antibody, 
which was also used alone as a negative control. The mLTβR-Fc fusion protein and human 
IgG were provided by Jeff Browning (Boston University School of Medicine, Boston, USA). 
All antibodies were prepared in 2% normal mouse serum (NMS; Jackson Immunoresearch 
Laboratories) in PBS to prevent non-specific staining. 
To detect LTβR ligands at the cell surface alone or in combination with T-cell 
markers, we applied an adapted immunostaining protocol based on the one described by 
Ansel and coworkers (Ansel et al., 2000). In detail, a suspension containing 1×106 cells was 
transferred to each 5 ml round-bottom polystyrene tube (BD Falcon) and washed with 1 ml of 
ice-cold FACS solution (composition in Table 2.5). After washing, cells were centrifuged at 
300 ×g for 5 minutes at 4ºC and the supernatant was discarded. To block Fc receptors prior 
to immunostaining, the cells were pre-incubated with Trustain fcXTM (anti-mouse CD16/32; 
BioLegend) at 1 µg in 100 µl of PBS for 10 minutes on ice. Cells were washed, the 
supernatant was discarded carefully, and 50 µl of 2% NMS containing 1 µg of mLTβR-Fc 
(human IgG or just 2% NMS in the negative control tubes) was added. After a 1-hour 
incubation on ice, the cells were washed two times with FACS solution. When indicated, 
cells were incubated for 1 hour on ice, in the dark with T-cell marker antibodies (Table 2.1) 
and then washed two more times with FACS solution. Next, cells were resuspended in 50 µl 
of 2.5 µg/ml donkey anti-human secondary antibody and incubated for 45 minutes on ice, in 
the dark. Finally, cells were washed 2 more times with FACS solution and resuspended in 1 
ml of 10 mM NaN3 in PBS solution. Where indicated, LTβ expressed at the cell surface was 
pre-blocked through 20 minute incubation with 1 µg of BBF6.BF12 in 200 µl of 2% NMS. 
Then, the cells were washed 2 times with FACS solution before the incubation with LTβR-
Fc. To detect LTβ expressed at the cell surface, 1 µg of BBF6.BF12 monoclonal antibody in 
50 µl of FACS solution (incubated at 4ºC for 1 hour) was used, and it was visualized using 
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FITC-conjugated goat anti-hamster (Armenian) IgG (0.5 µg in 50 µl of FACS solution and 
incubation for 1 hour at 4ºC, in the dark). 
Negative controls and cells stained with each antibody individually were also 
prepared to adjust the FACS instrument settings and fluorochrome compensation. 
 
Table 2.1. Antibodies used for flow cytometry analyses of T-cell markers and RANKL. 
Antigen Antibody
* 
Clone Fluorochrome Concentration 
(mg/ml) 
Dilution 
 
Isotype Control 
 
 
Rat IgG2a, κ 
 
RTK2758 
 
FITC 
 
0.5 1/200 
 
Isotype Control Rat IgG2a, κ RTK2758 PE 0.2 1/200 
 
Isotype Control Rat IgG2a, κ RTK2758 PE/Cy5 0.2 1/400 
 
Isotype Control Rat IgG2a, κ RTK2758 APC 0.2 1/100 
 
Murine CD3ε Hamster IgG 145-2C11 FITC 0.5 1/200 
 
Murine CD4 
 
 
Rat IgG2b, κ 
 
GK1.5 
 
FITC 
 
0.5 
 
1/200 
Murine CD4 Rat IgG2b, κ GK1.5 PE 0.2 1/200 
 
Murine CD8 Rat IgG2b, κ 53-6.7 PE/Cy5 0.2 1/600 
 
Murine CD24 (HSA) 
 
Rat IgG2b, κ M1/69 APC 0.2 1/400 
 
Murine CD25 Rat IgG1, λ PC61 FITC 0.5 1/400 
 
Murine CD44 
 
Rat IgG2b, κ IM7 APC 0.2 1/400 
Murine CD69 
 
Hamster IgG 
 
M1.2F3 FITC 0.5 1/200 
Murine CD90.2 
(Thy1.2) 
 
Rat IgG2b, κ 30-H12 FITC 0.5 1/500 
Murine CD254 
(RANKL) 
Rat IgG2b, κ IK22/5 PE 0.2 1/200 
* All antibodies were purchased from BioLegend. 
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2.5. GENOTYPING 
 
 
2.5.1. DNA extraction  
Mouse tail tips, other tissues collected at necropsy or MEFs were digested, using 100 µg/ml 
proteinase K (Fermentas) in 500 µl of lysis buffer (composition in Table 2.5), and incubating 
at 55ºC overnight. The next day, the suspension was vortex mixed and incubated at 90ºC for 
10 minutes to inactivate proteinase K. Then, the lysate was cooled and centrifuged at 16 100 ×g for 15 minutes. The supernatant was transferred to a new microtube, 500 µl of 
isopropanol (BDH Prolabo) was added, and it was mixed. To collect the precipitated DNA, 
the suspension was centrifuged at 16 100 ×g for 10 min. After discarding the supernatant, the 
DNA pellet was washed with 500 µl of 70% ethanol (BDH Prolabo) and the microtube was 
inverted several times to mix the contents. Then, after a centrifugation at 16 100 ×g for 5 
min, the supernatant was discarded and the pellet was allowed to dry at room temperatute 
(RT). Finally, DNA was resuspended in TE buffer, pH 7.4 (composition in Table 2.5) and 
stored at 4 ºC until genotyping. 
 
2.5.2. Polymerase Chain Reaction (PCR) 
Mouse tail and MEFs genotyping was performed by PCR. To this end, 2 µl of extracted DNA 
was added to a mixture containing GoTaq Flexi Buffer, 15 mM MgCl2, 0.2 mM PCR 
nucleotide mix, primers (Sigma-Aldrich, as indicated in Table 2.2), 1.25 U GoTaq DNA 
polymerase (Promega) and sterilized deionized water to complete a PCR volume of 25 µl. 
PCR amplification was performed on a C1000 Thermal Cycler (Bio-Rad), under the 
following conditions: initial denaturation at 95ºC for 5 minutes; 30 cycles of denaturation at 
95ºC for 45 seconds; annealing at 57ºC (Rag2) or 63ºC (Ltbr and TEL-JAK2) for 45 seconds; 
extension at 72ºC for 1 minute; a final extension step at 72ºC for 10 minutes was also 
performed, ending the reaction at 12ºC. PCR products were analyzed by electrophoresis 
(Power Pack Basic, BioRad) in a 2% agarose (Lonza) gel prepared in TAE buffer 
(composition in Table 2.5) and visualized by ethidium bromide staining under UV light 
(Gene Flash, Syngene BioImaging).  
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Table 2.2. Primers used for genotyping and expected PCR results. 
Target Primer Primer Sequence 
(5’- 3’) 
Expected 
Bands 
Concentration 
 PCR mix 
(µM) 
 
Ltbr 
 
 
LTBR4 
 
CTG GTA TGG GGT TGA CAG CG 
 
Wild-type 
640 bp 
 
0.35 
 LTBR7 TGT CAG CCG GGG ATG TCC TG  
Knockout 
0.35 
 
 HSV-TK 
 
ATT CGC CAA TGA CAA GAC GCT GG 200 bp 0.20 
TEL-
JAK2 
TG-TJ2(+) GGG AAG GGA AGC CCA TCA ACC Positive 
441 bp 
0.50 
 TG-TJ2 (-) CCG CAC TGT AGC ACA CTC CC  0.50 
 
Rag2 
 
RAG2a 
 
ATG TCC CTG CAG ATG GTA ACA 
 
Wild-type 
246 bp 
 
0.25 
 
 RAG2b GCC TTT GTA TGA GCA AGT AGC  
Knockout 
0.25 
 
 Neo 204 GCT ATT CGG CTA TGA CTG GG 706 bp 0.25 
 
 Neo 909 GAA GGC GAT AGA ACG CGA TG  0.25 
 
 
 
2.6. mRNA EXPRESSION ANALYSIS 
 
 
2.6.1. RNA extraction 
The pellet collected from a cell suspension containing 10×106 cells or 50-100 mg of thymic 
tissue was resuspended in 1 ml of Trizol reagent (Invitrogen). To homogenize the cells and 
tissues, these were pipetted up and down several times using a 1000 µl sterile filter tip 
followed by consecutive passages through sterile needles with decreasing internal diameters 
(21G, 23G, and 26G). Then, the sample in Trizol was incubated at room temperature for 5 
CHAPTER 2 – MATERIALS & METHODS 
MT Fernandes 71 
minutes to allow the complete dissociation of nucleoprotein complexes and it was stored at  -
80ºC until further use. 
Total RNA was isolated using RNase-free materials and following Trizol (Invitrogen) 
manufacturer´s instructions. Briefly, for phase separation 200 µl of chloroform (BDH 
Prolabo) per ml of Trizol was added to each homogenized sample and vigorously shaken by 
hand for 15 seconds, followed by a 5-minute incubation at RT. The samples were centrifuged 
(Centrifuge 3K15, Sigma) at 12 000 ×g, for 15 minutes at 4ºC. The aqueous upper phase was 
transferred to a clean microtube and 500 µl of isopropanol (BDH Prolabo) was added to 
precipitate the RNA. The samples were gently mixed and incubated at RT for 10 minutes. 
Then, these were centrifuged at 12 000 ×g, for 10 minutes at 4ºC and the supernatant was 
discarded. To wash the RNA pellet, 1 ml of 75% ethanol (Merck Millipore) was added to the 
microtube and its contents were mixed. The samples were then centrifuged at 7 500 ×g for 5 
minutes at 4ºC, the supernatant was discarded and the pellet was left to dry at RT for about 
10 minutes. Then, the pellet was resuspended in 50 µl of DEPC-treated water (Sigma-
Aldrich) by passing the solution a few times through a pipette tip, and by incubating for 10 
minutes at 55ºC. Alternatively, RNA extraction from Trizol was made by using Direct-zol 
RNA miniprep (Zymo Research), following the manufacturer´s instructions.  
The quantity and quality of the total RNA were assessed by measuring the optical 
density in Nanodrop 2000c spectrophotometer (Thermo Scientific) and by running it in an 
agarose gel or using Experion automate electrophoresis system (Bio-Rad). The samples were 
kept at -80ºC for long-term storage. 
Possible DNA contamination from RNA samples was reduced by digestion with 
DNase I (Fermentas). Briefly, the corresponding volume of 1 µg total RNA was added to 1 µl 
of reaction buffer, 1 U DNase I and DEPC-treated water up to 10 µl. The samples were 
mixed and the drops collected by brief centrifugation before being incubated at 37ºC for 30 
minutes. To inactivate the enzyme and terminate the reaction, 1 µl of 25 mM EDTA was 
added and the samples were heated at 65ºC for 10 minutes. 
 
2.6.2. Complementary DNA (cDNA) synthesis 
Total RNA was reverse-transcribed (RT) using the First Strand cDNA Synthesis Kit 
(Fermentas), according to the manufacturer´s instructions. Briefly, 1 µg of total RNA was 
treated with 0.5 µg of oligo(dT)18 primers, 20 U of Ribolock ribonuclease inhibitor, 1 mM 
dNTP mix, 200 U of M-MuLV Transcriptase, 1× reaction buffer, and nuclease-free water up 
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to 20 µl were used. Non-template controls (NTC) containing no RNA and non-enzyme 
controls (NEC) were included. The samples were kept at -20ºC until used for PCR 
amplification or at -80ºC for long-term storage. 
 For quantification of LTA and LTB expression in T-ALL Brazilian cohort, total RNA 
(1 µg) was reverse transcribed using the ImProm II Reverse Transcriptase enzyme (Promega) 
and random hexamers (25 µM). 
 
2.6.3. Semi-quantitative Reverse Transcription (RT)-PCR     
In order to determine and compare the expression of a gene transcript, the cDNA resulting 
from the RT reaction was used as a template for PCR with gene-specific primers (Table 2.3). 
Unless a reference is indicated, all primers were designed using Primer 3 on the WWW for 
general users and for biologist programmers (Rozen & Skaletsky). 
Template cDNA (2 µl diluted 1:20) was amplified in a PCR mixture containing 
GoTaq Flexi Buffer, 15 mM MgCl2, 0.2 mM dNTP mix, 12.5 µM of each respective forward 
and reverse primers, 1.25 U GoTaq DNA polymerase (Promega) and sterile deionized water 
to complete a PCR volume of 25 µl. 
The PCR reaction was performed on a C1000 Thermal Cycler (Bio Rad), under the 
following conditions: initial denaturation at 94ºC for 5 minutes; 26 to 30 cycles of 
denaturation at 94ºC for 45 seconds; annealing at 60ºC for 45 seconds; extension at 72ºC for 
1 minute; and a final extension step at 72ºC for 7 minutes. PCR products were analyzed by 
electrophoresis in a 2% agarose gel and visualized by ethidium bromide staining under UV 
light, as described for genotyping. 
  
2.6.4. Quantitative RT-PCR (RT-qPCR) 
Quantitative PCR was performed on a C1000 Thermal Cycler coupled to a CFX 96 Real-time 
PCR detection system (Bio-Rad), using SsoFast EvaGreen Supermix (Bio-Rad) and murine 
or human gene-specific primers (Tables 2.3 and 2.4), according to the manufacturer´s 
instructions. Briefly, in a 96-well low-profile PCR micro-plate (Thermo Scientific), 18 µl of 
master mix (containing 10 µl of SsoFast EvaGreen Supermix, 300 nM of each primer and 
sterile RNase/DNase-free water) were added to 2 µl of each cDNA sample previously diluted 
1:20. The wells were sealed with adhesive PCR film (Thermo Scientific) and the PCR was 
performed under the following conditions: initial denaturation and polymerase activation at 
95ºC for 30 seconds, 40 cycles of denaturation at 95ºC for 5 seconds, followed by annealing 
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and extension at 60ºC for 20 seconds. To validate the reaction specificity, a melting curve 
was generated for each sample by submitting it to temperatures from 65ºC to 95ºC in 0.5ºC 
increments (2-5 seconds/step). All samples were tested in triplicate and the results expressed 
as the mean ± range. Negative controls, more specifically no template controls, were always 
included in the analyses.  
RT-qPCR results were analyzed using BioRad CFX Manager software, version 3.0, 
and treated using the comparative CТ method (2-∆∆C(T) method), and the mean fold change in 
expression of the target gene was calculated after normalization to expression values obtained 
for the following reference genes: Gapdh, Hprt1 (TJ2-Tg leukemic cells), GAPDH (human 
T-ALL cell lines), or 18S (human thymocytes and primary T-ALL samples).  
To analyze LTA and LTB expression in the Brazilian T-ALL patient cohort, RT-qPCR 
was performed using the TaqMan® method. PCR reactions were carried out in 15 µl 
containing 5 µl of 1:25 diluted cDNA, 7.5 µl Maxima Probe/ROX qPCR Master Mix 
(Fermentas), 300 nM of each primer and 200 nM of TaqMan probe (primers and probes in 
Table 2.4). Amplifications were performed in a 7500 Fast Real-Time PCR System (Life 
Technologies, Carlsbad, USA). Expression values of LTA and LTB were calculated by the 2-
∆∆C(T) method, using ABL1 as endogenous normalizer and Jurkat cells as calibrator. 
Efficiencies for both the normalizer and target genes were 100% ±10%.  
 
2.6.5. Oligonucleotide array analysis                        
Oligonucleotide array analyses were performed by our collaborators, Dr. J.A. Yunes and his 
team, in Department of Pediatrics, University of Campinas, Brazil. Briefly, total RNA was 
extracted from 51 pediatric T-ALL samples using the Illustra RNAspin Mini RNA Isolation 
Kit (GE Healthcare). Total RNA from 2 human thymocyte samples was extracted with Trizol 
(Life Technologies). RNA samples were processed with the WT Expression Kit (Ambion) 
and GeneChip WT Terminal Labeling and Controls Kit (Affymetrix), and hybridized on 
Human Gene 1.0 ST Arrays (Affymetrix). Array files are publicly available through the Gene 
Expression Omnibus (GEO) database under the accessions GSE50999 and GSE66638. 
Expression values were obtained with the iterPLIER+16 algorithm in the Affymetrix 
Expression Console, and transformed to Z-score in a log2 scale. Molecular subtypes were 
classified by Hierarchical Clustering Analysis (Pearson correlation and pair wise-average 
linkage; http://genepattern.broadinstitute.org/) according to the expression of genes 
previously associated with each T-ALL subtype (Homminga et al., 2011). The Affymetrix 
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Complex Match table was used to identify probe sets in the original Human Genome U133 
Plus 2.0 Array (Homminga et al., 2011) most related to probe sets available in the Human 
Gene 1.0 ST Array. Two out of the 51 T-ALL samples could not be classified and thus were 
excluded from analysis. 
 
Table 2.3. Primer sequences used for RT-PCR analysis (murine). 
Gene Primer Primer sequences 
(5’- 3’) 
Ref. 
Gapdh 
(NM_001289726.1/NM_008084.3) 
Forward 
Reverse 
GGT GAA GGT CGG TGT GAA CG 
ACC ATG TAG TTG AGG TCA ATG AAG G 
(Seach et 
al., 2008) 
Hprt 
(NM_013556.2) 
Forward 
Reverse 
GCT GGT GAA AAG GAC CTC T 
CAC AGG ACT AGA ACA CCT GC 
(dos Santos 
et al., 2007) 
Tnfsf14 
(NM_019418.3) 
Forward 
Reverse 
GCA CAT CTT ACA GGA GCC AAC GCC 
CGG GTA GCG GGA TGT GCG CT 
This study 
Lta 
(NM_010735.2) 
Forward 
Reverse 
GCT GCT CAC CTT GTT GGG TA 
GTG GAC AGC TGG TCT CCC TT 
This study 
Ltb 
(NM_008518.2) 
Forward 
Reverse 
TAC ACC AGA TCC AGG GGT TC 
ACT CAT CCA AGC GCC TAT GA 
(Haybaeck 
et al., 2009) 
Ltbr 
(NM_010736.3) 
Forward 
Reverse 
CCA GAT GTG AGA TCC AGG GC 
GAC CAG CGA CAG CAG GAT G 
(Seach et 
al., 2008) 
Tnfsf11 (Rankl) 
(NM_011613.3) 
Forward 
Reverse 
CGC CTC CCG CTC CAT GTT CC 
GTT CCT TCT GCA CGG CCC CC 
This study 
Tnfrsf11a (Rank) 
(NM_009399.3) 
Forward 
Reverse 
TGC TTG GTG CAT AAA GTC TG 
AGG TTT GCA TTT GTC TGT GG 
This study 
Nfkb2 
(NM_001177369.1/370.1/ 
NM_019408.3) 
Forward 
Reverse 
TGG AAC AGC CCA AAC AGC 
CAC CTG GCA AAC CTC CAT 
(Cuesta et 
al., 2010) 
Socs2 
(NM_007706.4/NM_001168655.1/ 
656.1/657.1) 
Forward 
Reverse 
GTT GCC GGA GGA ACA GTC CC 
TCG GTC CAG CTG ACG TCT TAA C 
(Zellmer et 
al., 2009) 	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Table 2.4. Primer sequences used for RT-PCR analysis (human). 
Gene Primer Primer sequences (5’- 3’) Ref. 
GAPDH 
(NM_002046.4/ 
NM_001256799.1) 
Forward 
Reverse 
ACA TCA TCC CTG CCT CTA CTG 
ACC ACC TGG TGC TCA GTG TA 
(Villablanca 
et al., 2008) 
18S rRNA 
 
Forward 
Reverse 
GGA GAG GGA GCC TGA GAA ACG 
CGC GGC TGC TGG CAC CAG ACTT 
(Cardoso et 
al., 2011) 
LTA 
(NM_001159740.2/ 
NM_000595.3) 
Forward 
Reverse 
CCC ACC AGT GGC ATC TAC TT 
CAG CCC TGG ATA CAC CAT CT 
This study 
LTB 
(NM_009588.1) 
Forward 
Reverse 
GAG GAC TGG TAA CGG AGA CG 
GGG CTG AGA TCT GTT TCT GG 
(Haybaeck 
et al., 2009) 
LTA (Taqman) 
(NM_001159740.2/ 
NM_000595.3) 
Forward 
Reverse 
Probe 
CCT CAA ACC TGC TGC TCA CCT 
AAC CAT CCT GGA GGA AGG CA 
TTG GAG ACC CCA GCA AGC AGA ACT CA 
 
This study 
LTB (Taqman) 
(NM_009588.1/ 
NM_002341.1) 
Forward 
Reverse 
Probe 
CAG AGG AGG AGC CAG AAA CAG A 
TAG CCC CTG CCC CTT CAG 
GAG CGC CTA TGA GGT GGG CAG CTG 
This study 
ABL1 (Taqman) 
(NM_007313.2/ 
NM_005157.5) 
Forward 
Reverse 
Probe 
TGG AGA TAA CAC TCT AAG CAT AAC TAA AGG T 
GAT GTA GTT GCT TGG GAC CCA 
CCA TTT TTG GTT TGG GCT TCA CAC CAT T 
This study 
 
 
2.7. PROTEIN EXPRESSION ANALYSIS 
 
 
2.7.1. Protein extraction 
Adherent cells were washed with PBS, trypsinized, and resuspended in the indicated culture 
medium. These cells and cells growing in suspension were collected by centrifugation, 
washed with ice-cold PBS and centrifuged again to discard the supernatant. The cell pellet 
was homogenized in 100 µl of RIPA buffer (composition in Table 2.5) with freshly added 
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protease inhibitor cocktail (CompleteTM, Roche), and incubated on ice for 20 minutes. Cell 
debris were removed by a 16 100 ×g centrifugation at 4°C for 15 minutes. The supernatant 
containing total protein extract was collected for further use.  
 
2.7.2.  Measurement of protein concentration 
Protein concentrations were determined using Micro BCATM Protein Assay Kit (Thermo 
Scientific) according to the manufacturer’s instructions. 
 
2.7.3.  SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The extract containing 30 µg of total protein was mixed with loading buffer (composition in 
Table 2.5) and boiled at 95°C for 5 minutes. The samples were cooled on ice and collected by 
brief centrifugation. Protein samples were separated in an 8% SDS-polyacrylamide mini-gel 
(composition in Table 2.5), in a vertical chamber (Bio-Rad) filled with running buffer 
(composition in Table 2.5). When the bromophenol blue front of migration exited the gel, the 
latter was recovered and used for Western blotting analysis. 
 
2.7.4. Western Blotting  
The proteins separated in the SDS-PAGE mini-gel were transferred a nitrocellulose 
membrane (AmershamTMProtranTM, GE Healthcare) in a wet electrotransfer procedure using 
Tris-glycine transfer buffer (composition in Table 2.5). The membrane was recovered and, to 
block non-specific proteins, it was incubated in blocking solution (PBS containing 0.1% 
Tween 20 (Merck) and 5% non-fat milk powder (Merck)) for 1 h at RT, with gentle agitation. 
Then, the membrane was incubated at 4°C overnight with gentle agitation with a solution 
containing the indicated primary antibodies in blocking solution. The next day, the membrane 
was washed three times for 5 minutes in PBS-T (0.1% Tween 20 in PBS solution), and the 
membrane was further incubated with the appropriate secondary antibodies conjugated with 
horseradish peroxidase (HRP) for 2 hours at RT with gentle agitation. The primary antibodies 
used were anti-LTβR goat polyclonal IgG (W-15, Santa Cruz) at 0.4 µg/ml and anti-actin 
mouse monoclonal IgG (clone C4, MP Biomedicals) diluted at 1 to 10000. The secondary 
antibodies used were peroxidase-conjugated Affinipure mouse anti-goat IgG (H+L) and 
peroxidase-conjugated Affinipure goat anti-mouse IgG (H+L) (Jackson ImmunoResearch 
Laboratories) at 0.16 µg/ml. After three more washes in PBS-T, the proteins were detected by 
incubating the membrane with enhanced chemiluminescence solution (ECL; Pierce® ECL 
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Western Blotting Substrate, Thermo Scientific) and exposing to FUJI Medical X-Ray films 
(FUJIFILM). X-Ray films were processed using G153 developer (AGFA) and G354 fixer 
(AGFA) in AGFA CP1000 film processor (AGFA Healthcare).        
 
 
2.8. HISTOLOGY AND HISTOCHEMISTRY METHODS 
 
2.8.1. Histology  
Mouse organs collected during necropsy were fixed in FAA solution (composition in Table 
2.5) for 2 hours. Then, these were washed with PBS solution and kept at 4ºC in PBS, 
protected from light. Fixed specimens were processed for paraffin embedding by dehydration 
through an ethanol gradient (50% for 1 hour, 70% for 3 hours, 80% for 1 hour, and 96% for 1 
hour), followed by further incubation with 100% ethanol (two consecutive 5-hour 
incubations), 50% ethanol/50% xylene solution (2 hour incubation), 100% xylenes (two 
consecutive 2 hour incubations), and melted paraffin (MP 52-54ºC, Merck; two consecutive 4 
hour incubations), using an automatic tissue processor (Tissue Processor Tissue-Tek® II, 
Sakura). Using metal base molds, the specimens were then embedded in melted paraffin and 
allowed to harden using a tissue embedding console system (Tissue-Tek® thermal, dispensing 
and cryoconsole: Sakura). Five to seven µm thick sections were cut from the paraffin blocks 
using Microm HM 340 E rotary microtome (Thermo Scientific). Sections were flattened on a 
37ºC-heated water bath, collected onto microscope slides (VWR) pre-treated with 
aminopropyltriethoxysilane (APTES, Sigma), and allowed to dry. 
 Before proceeding for hematoxylin and eosin staining, the sections were 
deparaffinized and rehydrated (2 consecutive incubations in xylenes for 10 minutes, 100% 
ethanol for 5 minutes, 90% ethanol for 5 minutes, 70% ethanol for 5 minutes, 40% ethanol 
for 5 minutes, and 2 consecutive incubations with bi-distilled water for 2.5 minutes). Then, 
the sections were stained by immersing the slides in Accustain® Hematoxylin solution (GILL 
N. 3 – 6 g/l, Sigma-Aldrich) diluted 1:5 for 5 minutes, followed by a washing step in tap 
water for 10 minutes, a 2 minute incubation with 0.5% Eosin solution (Fluka Analytical), and 
one last washing step. Next, the sections were dehydrated and diaphonized by incubation 
with ethanol and xylene (40% ethanol for 5 minutes, 70% ethanol for 5 minutes, 100% 
ethanol for 5 minutes, and 2 consecutive incubations in xylenes for 5 minutes). Finally, the 
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sections were mounted between the slide and a coverslip using Entellan® mounting medium 
(Merck Millipore). After drying overnight, slides were visualized under white-light in an 
Axio Imager Z2 fluorescence microscope (Carl Zeiss). 
 
2.8.2. Immunohistochemistry (IHC)  
Mouse thymi collected during necropsy were cleaned and frozen directly in Tissue-Tek® 
O.C.T.TM Compound (Sakura) by rapidly cooling on dry ice. Five-µm thick frozen sections 
were cut using Research Cryostat Leica CM 3050 S, and collected in Superfrost® Plus 
adhesion slides (Thermo Scientific). The sections were fixed in acetone previously cooled at  
-20ºC for 10 minutes, at RT with gentle agitation, rehydrated with PBS in 3 quick passages, 
and washed three times for 5 minutes with PBS-T solution (0.1% Tween-20 in PBS solution) 
under gentle agitation. Then, these were incubated in blocking solution (20% FBS (PAA), 
10% bovine serum albumin (BSA, Sigma-Aldrich) and 0.1% Tween 20 in PBS solution) for 
1 hour, followed by an overnight incubation at 4ºC in a humidified chamber with primary 
antibodies diluted in blocking solution: 0.16 µg/ml rat anti-mouse CD31 (clone MEC 13.3; 
BD Biosciences) and 1 µg/ml rabbit anti-mouse keratin 5 (Krt5) polyclonal (AF 138; 
Covance) antibodies, or 10 µg/ml rabbit anti-mouse Exodus-2 (Ccl21; Peprotech) and anti-
mouse Krt8 rat IgG diluted at 1:100 (TROMA 1; provided by Rolf Kemler, Max Planck 
Institute, Freiburg, Germany). After 3 washes in PBS-T solution, sections were incubated for 
1 hour at RT in a humidified chamber with 1.5 µg/ml DyLight 488-conjugated AffiniPure 
Goat anti-Rat IgG (H+L) and DyLight 594-conjugated AffiniPure Goat anti-Rabbit IgG 
(H+L) (Jackson ImmunoResearch Laboratories) secondary antibodies followed by 3 more 
washes in PBS-T solution. The slides were mounted in Mowiol (4-88, Sigma) with DAPI 
(Biotium) at 1.5 µg/ml by covering with coverslips, and allowed to dry overnight at RT in the 
dark. The next day, stained sections were visualized using an Axio Imager Z2 fluorescence 
microscope (Carl Zeiss). 
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2.9. STATISTICS 
 
Statistical analyses were performed using GraphPad Prism 5 software. Statistical tests were 
used as indicated in figure legends. Kaplan-Meier survival curves were plotted and the P-
value was calculated using the log-rank Mantel Cox test. A P-value below 0.05 was 
considered statistically significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001. Only 
statistically significant results were indicated in figures. 
 
 
2.10. MICROARRAY DATA SETS AND DATA ANALYSIS  
 
Analyses of publically available microarray data sets were performed by our collaborator, Dr. 
Ravi K. Kalathur. Briefly, microarray data sets from publicly available Gene Expression 
Omnibus database were obtained, including gene expression data from the Microarray 
Innovations In Leukemia (MILE) study (GSE 13159) to evaluate the expression of LTA and 
LTB in subtypes of leukemia compared to non-leukemia and healthy bone marrow (Haferlach 
et al., 2010). To compare the expression profile of TJ2-Tg mouse T-ALL with that of 
different stages of mouse thymocyte differentiation, thymocyte gene expression data was 
obtained from the Immunological Genome Project (Heng et al., 2008) and expression data 
from TJ2-Tg leukemic cells (Waibel et al., 2013) (GSE15907 and GSE51243, respectively). 
All datasets were pre-processed using RMA (Robust Multi-array Average) as implemented in 
the R/Bioconductor environment (Gentleman et al., 2004). The log2 signal intensities of the 
annotated genes were obtained and the co-efficient variation for each gene was computed. 
The top 1% (n=163) of genes was thus obtained, which showed least co-efficient variation. 
Further, hierarchical clustering of samples was performed using the complete linkage 
analysis method implemented in the TM4 software on the above mentioned mouse datasets. 
In addition to the clustering analysis, functional enrichment analysis of the 163 gene dataset 
was performed using Gene Set Enrichment Analysis (GSEA) to identify enriched biological 
processes, molecular functions and pathways (Subramanian et al., 2005). The statistical 
significance of enrichment was estimated and all the functional categories and pathways 
whose FDR was ≤ 0.05 were considered.  
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Table 2.5. Commonly used solutions and gels. 
 
PB sample 
treatment 
 
RBC Lysis 
Solution 
pH 7.2 
160 mM NH4Cl   
170 mM Tris-HCl, pH 7.4   
Mix 1 volume of 170mM Tris-HCl with 
9 volumes of 160 mM NH4Cl 
Sigma-Aldrich 
Sigma-Aldrich 
 
 
Flow 
Cytometry 
 
 
 
 
FACS Solution 
 
PBS 
3% FBS 
10 mM NaN3 
Sigma-Aldrich 
PAA 
Sigma-Aldrich 
Permeabilization 
Solution 
PBS   
0.5% BSA  
0.1% Saponin  
Sigma-Aldrich 
Sigma-Aldrich 
BDH Prolabo 
Histology FAA Solution 
10% Formaldehyde   
75% Ethanol 
5% Glacial acetic acid 
Sigma-Aldrich 
BDH Prolabo 
BDH Prolabo 
 
DNA 
Extraction 
 
 
Lysis Buffer 
 
200 mM NaCl 
100 mM Tris-HCl, pH 8.3 
 5 mM EDTA 
 1% Triton X-100 
BDH Prolabo 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
TE Buffer, pH 
7.4 
10 mM Tris-HCl, pH 7.4 
1 mM EDTA, pH 8 
Sigma-Aldrich 
Sigma-Aldrich 
Agarose 
Electrophoresis 
TAE Buffer,  
pH 8.3 
40 mM Tris base 
20 mM glacial acetic acid 
1 mM EDTA 
Sigma-Aldrich 
BDH Prolabo 
Sigma-Aldrich 
 
 
 
SDS-PAGE 
and 
Western 
Blotting 
 
 
 
 
PBS, pH 7.4 
 
130 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
BDH Prolabo 
Merck 
Merck 
Merck 
 
RIPA Buffer 
 
10 mM Tris pH 7.4 
150 mM NaCl 
1 mM EDTA 
1% Triton X100 
0.5% Sodium deoxycholate 
0.1% SDS 
Sigma-Aldrich 
Merck 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
MP Biomedicals 
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Table 2.5 (cont.). Commonly used solutions and gels. 
SDS-PAGE 
and 
Western 
Blotting 
 
 
4× Loading 
Buffer 
 
62.5 mM Tris pH 6.8 
20% Glycerol 
2% SDS 
5% β-mercaptoethanol 
0.5% Bromophenol blue 
Sigma-Aldrich 
BDH Prolabo 
MP Biomedicals 
Sigma 
Sigma-Aldrich 
 
 
Separating Gel 
 
 
4.2 ml double-distilled water 
1.6 ml 40% Acrylamide/bisacrylamide 
2 ml 1.5M Tris pH 8.8 
80 µl 10% SDS 
80 µl 10% APS 
8 µl TEMED 
 
Fisher Scientific 
Sigma-Aldrich 
MP Biomedicals 
Sigma 
Sigma 
 
Stacking Gel 
 
2.9 ml double-distilled water 
0.75 ml 40% Acrylamide/bisacrylamide 
1.25 ml 0.5M Tris pH 6.8 
50 µl 10% SDS 
50 µl 10% APS 
5 µl TEMED 
 
Fisher Scientific 
Sigma-Aldrich 
MP Biomedicals 
Sigma 
Sigma 
Electrophoresis 
Buffer 
25 mM Tris pH 8.3 
192 mM Glycine 
0.1% SDS 
Sigma-Aldrich 
Carl Roth GmbH 
MP Biomedicals 
Transfer 
Buffer 
25 mM Tris pH 8.3 
192 mM Glycine 
20% Methanol 
Sigma-Aldrich 
Carl Roth GmbH 
BDH Prolabo 
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3.1. LTβR LIGAND EXPRESSION AND REGULATION IN TJ2-TG LEUKEMIC 
THYMI 
 
3.1.1. Leukemic T cells from TEL-JAK2 transgenic mice express lymphotoxin-β 
receptor ligands 
TEL-JAK2-induced murine leukemia is characterized by the expansion of a mixture of 
monoclonal or oligoclonal immature CD8 single-positive (SP), and CD4 and CD8 double-
positive (DP) T cells, two phenotypes normally only seen in the thymus (Carron et al., 2000). 
Therefore, it is conceivable that in this animal model the disease originates in the thymus 
from a T cell precursor in a more precocious developing stage (dos Santos et al., 2007), and 
CD8 SP plus DP subpopulations represent the phenotype progression of the transformed 
clone (Carron et al., 2000).  
 To address a possible role for lymphotoxin-β receptor (LTβR) signaling in T-cell 
leukemogenesis using this mouse model, we assessed the expression levels of mRNAs 
encoding LTα, LTβ and LIGHT in primary leukemic cells collected from diseased TEL-
JAK2 transgenic (TJ2-Tg) mice. Lta, Ltb and Light expression was more heterogeneous in 
TJ2-Tg leukemic cells than in wild-type thymocyte whole population (Figure 3.1A). 
Importantly, these genes were significantly more expressed in leukemic cells as compared to 
wild-type thymocytes (on average 4- to 5-fold higher expression) (Figure 3.1A). Of note, Lta 
and Ltb expression levels were also higher in TJ2-Tg leukemic cells than in sorted DP and 
CD4 SP thymocytes, the main source of LTβR ligands in the thymus (Figure 3.1B) (Boehm 
et al., 2003; Hikosaka et al., 2008). Conversely, Light was previously shown to be expressed 
at equally low levels across the DN, DP, CD4 SP and CD8 SP thymocyte subpopulations 
(Hikosaka et al., 2008). Therefore, these data show that LTβR ligand expression is likely 
activated during T-cell leukemogenesis. 
 To determine the main source of LTβR in thymic lymphomas of TJ2-Tg diseased 
mice, LTβR expression was assessed by western blotting in T-cell enriched fractions 
prepared from wild-type thymi or thymic lymphomas. Low or undetectable levels of LTβR 
were found in leukemic cells, although comparable, with few exceptions to those of wild-type 
thymocytes (Figure 3.1C). Notably, Ltbr expression in TJ2-Tg leukemic cells was not 
detectable by RT-qPCR (data not shown). In contrast, Ltbr expression was detected in TJ2-
Tg thymic lymphomas (Figure 3.1D) regardless the decrease in the relative proportion of 
stromal cells when compared to wild-type thymi (data not shown). These results indicate that 
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in thymic lymphomas from TJ2-Tg leukemic mice, leukemic cells express LTβR ligands 
while LTβR is most likely derived from stromal cells, similarly to what was previously 
described for the normal thymus (Hikosaka et al., 2008; Seach et al., 2008).  
 
	  
Figure 3.1. LTβR and LTβR ligand expression in TJ2-Tg mice. (A) RT-qPCR 
quantification of Lta, Ltb and Light in thymocyte-enriched fractions collected from wild-type 
thymi (WT; n=4) and leukemic cell-enriched fractions collected from TJ2-Tg thymic 
lymphomas (n=11). (B) Lta and Ltb RT-qPCR analysis in WT thymocytes (n=2), TJ2-Tg 
leukemic cells (n=4), and sorted CD4/CD8 double-positive (DP; n=2) and CD4 single-
positive (CD4 SP; n=2) thymocytes. (C) LTβR protein quantification by western blotting and 
densitometric analysis in thymocyte-enriched fractions prepared from wild-type thymi (n=3) 
and leukemic cell-enriched fractions prepared from TJ2-Tg thymic lymphomas (n=11), using 
the Image J software. The results were normalized to the loading control (actin) and are 
represented as a percentage of the MS5 (positive control) band density. (D) Ltbr 
quantification by RT-qPCR in whole thymic lymphomas from TJ2-Tg mice (n=9) and whole 
wild-type thymi (n=3). All RT-qPCR results were normalized to Gapdh expression, and 
expressed as mean ± SEM. P-values were determined using two-tailed, unpaired Student´s t-
test with Welch´s correction. 
 
3.1.2. LTβR ligands are undetectable at the surface of TJ2-Tg leukemic in vivo 
Previous studies have focused mostly on LTβR ligand mRNA or total cellular protein 
expression (Ammirante et al., 2010; Hehlgans et al., 2002; Rehm et al., 2011). However, it is 
A 
 C 
B 
 D 
LTβR 
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widely accepted that LTβR ligands should be presented at the surface of T cells in order to 
activate LTβR signaling in another cell. Therefore, to determine whether transcription of the 
ligands was accompanied by specific cell-surface protein expression we used LTβR-Fc, a 
fusion decoy protein that binds both lymphotoxin (LT or LTα1β2) and LIGHT. LTβR-Fc 
binding was detected by staining with a PE-conjugated anti-human Fc antibody in flow 
cytometry. Despite the high expression levels of Lta, Ltb and Light mRNAs in TJ2-Tg 
leukemic cells, LTβR-Fc and anti-LTβ immunostaining revealed low to undetectable signals 
(Figure 3.2A). However, intracellular LTβ protein was detected on permeabilized, fixed cells 
(Figure 3.2C), suggesting that at least Ltb mRNA was indeed translated. Interestingly, upon 
ex vivo culture, both LTβ and LTβR ligands were clearly detectable on primary TJ2-Tg 
leukemic cell surface (Figure 3.2B,D). Importantly, anti-LTβ mAb pre-blocking showed that 
the LTβR-Fc fusion protein signal in ex vivo-cultured cells was derived from lymphotoxin 
only and not LIGHT expression (Figure 3.2B).  
 Altogether, these results suggest that LTβR ligand mRNA and protein are upregulated 
in leukemic cells during T-cell leukemogenesis but the surface expression of lymphotoxin is 
tightly regulated in vivo. 
 
	  
Figure 3.2. LTβR ligand expression at the surface of TJ2-Tg leukemic cells. Flow 
cytometry immunostaining of LTβR ligands (solid line) on representative TJ2-Tg leukemic 
cells with LTβR-Fc protein or anti-LTβ mAb (BBF6) on viable (A) freshly collected (in 
vivo), (B) cultured ex vivo for 22 h, or (C) fixed/permeabilized (ic) cells. The secondary 
antibody alone or non-specific mAb (HA4/8) were used as negative controls for LTβR-Fc 
and LTβ mAb, respectively (gray shading). LTβR-Fc immunostaining was also performed 
following anti-LTβ mAb pre-incubation (dashed line). (D) LTβR-Fc staining mean 
fluorescence intensity (MFI) for 7 different leukemic cell samples before (0 h) and after 22 h 
of ex vivo culture. P-value were determined using two-tailed, paired Student´s t-test. 
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3.1.3. Lymphotoxin expression in TJ2-Tg leukemic T cells is inducible by pre-
TCR/TCRαβ activation 
PMA (phorbol myristate acetate) has been previously reported to induce T and B cell 
activation together with LTα1β2 expression (Browning et al., 1995, 1997; Ware et al., 1992). 
Furthermore, TJ2-Tg leukemic cells proliferate and express T-cell activation markers (e.g., 
CD69) when stimulated in vitro with PMA alone or in combination with the calcium 
ionophore ionomycin (dos Santos et al., 2007). Therefore, to assess if lymphotoxin 
expression at the surface of TJ2-Tg leukemic cells could be inducible by extracellular signals, 
these cells were stimulated by PMA and ionomycin, a treatment that activates protein kinase 
C and calcium channels and therefore mimics signaling pathway activation following TCR 
engagement (Nau et al., 1988). Upon overnight treatment, surface LTβR ligands were 
detected in wild-type thymocytes (Figure 3.3A), as previously reported (Browning et al., 
1995, 1997; Ware et al., 1992), and more strongly so in TJ2-Tg leukemic cells (Figure 3.3B). 
Again, anti-LTβ mAb pre-blocking showed that the LTβR-Fc fusion protein signal detected 
in PMA/ionomycin-treated cells was derived from lymphotoxin rather than LIGHT 
expression (data not shown). Although we cannot exclude the possibility that LIGHT is 
expressed as a soluble form, these results indicate that, in addition to ex vivo-cultured, TJ2-Tg 
leukemic cells stimulated with PMA/ionomycin also express membrane-bound LTα1β2 
heterotrimers but not LIGHT homotrimers.  
Since Lta and Ltb expression is induced by pre-TCR (Silva-Santos et al., 2005) and 
during TCR-mediated thymocyte positive selection (Irla et al., 2012), we reasoned that pre-
TCR/TCR signaling could regulate lymphotoxin gene expression in these cells. To address 
this question, we assessed Lta, Ltb, and also Light expression levels in leukemic cells from 
TJ2-Tg;Rag2-/- mice, which arise from thymocytes blocked in the DN3 stage of T cell 
differentiation and lack both pre-TCR and TCRαβ gene expression (dos Santos et al., 2007). 
Ltb and Light, but not Lta expression was reduced in TJ2-Tg;Rag2-/- leukemic cells, as 
compared to pre-TCR/TCR-proficient TJ2-Tg leukemic cells (Figure 3.3D). Similarly to 
Rag2-proficient TJ2-Tg leukemic cells, TJ2-Tg;Rag2-/- leukemic cells did not express surface 
lymphotoxin, except when stimulated by PMA/ionomycin (Figure 3.3C). Although one 
cannot exclude that Rag2 inactivation could induce Ltb and Light downregulation through an 
indirect mechanism, these data support the notion that TCR expression in leukemic cells, like 
in normal thymocytes (Irla et al., 2012), contributes to Ltb gene expression in T-ALL. 
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Collectivelly, these results demonstrate that surface lymphotoxin expression occurs in 
TJ2-Tg leukemic cells, and may be modulated by extracellular stimuli. 
 
	  
Figure 3.3. Lymphotoxin cell surface expression in thymocytes and TJ2-Tg leukemic 
cells is induced through pre-TCR/TCRαβ activation. Surface LTβR-Fc and CD69 
immunostaining of (A) wild-type thymocytes, (B) TJ2-Tg, and (C) TJ2-Tg;Rag2-/- leukemic 
cells upon ex vivo treatment for 22 h with either PMA and ionomycin (PMA+Iono) or vehicle 
(DMSO). The percentage of cells is indicated in the respective quadrant. One representative 
of three independent experiments is shown. (D) RT-qPCR quantification of Lta, Ltb, and 
Light mRNA levels (normalized to Gapdh) in leukemic Rag2-deficient TJ2-Tg leukemic cells 
(TJ2-Tg;Rag2-/-; n=6) and control leukemic cells (TJ2-Tg; n=4). Results are expressed as the 
mean ± SEM. P-values were determined using two-tailed, unpaired Student´s t-test. 
 
3.1.4. Lymphotoxin expression in TJ2-Tg leukemic T cells depends on JAK/STAT and 
IKK/NF-κB signaling pathway activity  
Signaling pathway activation may control the expression of Lta and Ltb. Since JAK2 is 
constitutively activated in TJ2-Tg leukemic cells, one possible candidate is the JAK/STAT 
pathway (Carron et al., 2000). Moreover, it was previously shown that NF-κB is activated in 
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activation. Therefore, to know how LTβR ligand expression is induced in TJ2-Tg leukemic 
cells, we inhibited JAK/STAT and IKK/NF-κB signaling pathways, which are known to 
induce Lta and Ltb expression in other cell types (Shebzukhov and Kuprash, 2011).  
Treatment of leukemic cells with a pan-JAK inhibitor (JAKi) downregulated Lta (and 
the control Socs2 gene), but neither Ltb nor Light mRNA expression (Figure 3.4A). In 
contrast, treatment of leukemic cells with an IKK kinase inhibitor (IKKi) markedly 
downregulated Lta, Ltb, and Light mRNAs (and the control Nfkb2 gene) (Fig. 3.4B). 
Similarly, JAKi downregulated Lta expression, and IKKi downregulated both Lta and Ltb in 
wild-type thymocytes (data not shown). Therefore, JAK signaling may induce Lta, while NF-
κB may underlie Lta, Ltb and Light expression in thymocytes in physiological conditions, but 
JAK/STAT and IKK/NF-κB constitutive activation following thymocyte transformation may 
lead to higher and persistent activation of these genes. Furthermore, the IKK inhibitor could 
block Lta and Ltb induction by PMA/ionomycin in TJ2-Tg leukemic cells (Figure 3.4C).  
Regarding Light, it was not downregulated in PMA/ionomycin-stimulated cells following 
treatment with IKKi (Figure 3.4C). 
Together, these experiments define JAK and IKK kinases as key regulators of 
lymphotoxin gene expression in TJ2-Tg leukemic cells. 
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Figure 3.4. LTβR ligand gene expression in TJ2-Tg leukemic cells depends on IKK and 
JAK kinase activity. (A, B) Lta, Ltb, Light, Socs2, and Nfkb2 mRNA quantification by RT-
qPCR for three independent TJ2-Tg leukemic cell samples treated ex vivo for 10 h with either 
DMSO (control), a pan JAK inhibitor (JAKi) or an IKK inhibitor (IKKi). Results are 
expressed as mean ± SEM. P-values were determined using two-tailed, paired Student´s t-
test. (C) Lta, Ltb, Light, and Nfkb2 quantification by RT-qPCR in TJ2-Tg leukemic cells 
treated ex vivo with PMA+Iono and either IKK inhibitor (IKKi) or DMSO. Results are 
expressed as the mean ± range and represent one of three independent experiments. All RT-
qPCR results were normalized to Gapdh expression. 
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3.2. MODULATION OF LYMPHOTOXIN AT THE SURFACE OF TJ2-TG 
LEUKEMIC CELLS 
 
 
3.2.1. Lymphotoxin cell surface induction on TJ2-Tg leukemic T cells depends on de 
novo protein synthesis 
As previously shown, LTβR ligands were hardly detectable by flow cytometry 
immunostaining in freshly collected TJ2-Tg leukemic T cells (Figure 3.2A), but lymphotoxin 
was readily detected following ex vivo culture (Figure 3.2B,D). To gain an insight on the 
mechanism responsible for LTα1β2 upregulation, we first followed LTβR ligand expression at 
the surface of TJ2-Tg leukemic cells and wild-type thymocytes at particular time-points.  
Upon culture, LTβR ligands were upregulated in leukemic cells and DP plus CD8 SP normal 
thymocytes, peaking at 24 h and 12 h, respectively (Figure 3.5A). Notably, the intensity of 
LTβR-Fc staining in leukemic cells was more than three times higher than in its normal 
counterparts (Figure 3.5A). At 24h, more LT-expressing leukemic cells were also detected 
when compared with wild-type thymocytes (Figure 3.5C). Interestingly, the CD8 SP 
thymocyte subpopulation was the one that contributed mostly for LTβR ligand expression at 
the cell surface of wild-type thymocytes following ex vivo culture (Figure 3.5B,C). 
 Although TJ2-Tg leukemic cells were shown to express intracellular LTβ (Figure 
3.2C), we could not detect intracellular LTα and LIGHT due to the lack of an antibody 
suitable for flow cytometry immunostaining or western-blotting. Therefore, to determine if 
induction of Lta, Ltb or Light mRNA precedes the observed increase in LTβR ligand protein 
expression in cultured TJ2-Tg leukemic cells, quantitative RT-PCR analysis in freshly 
collected and leukemic cells cultured ex vivo for 10 hours was performed. Ltb mRNA 
expression was consistently induced following ex vivo culture while Light was often 
downregulated (Figure 3.6A). The effect of ex vivo culture on Lta expression was variable 
(Figure 3.6A). These results indicate that the increase in LTα1β2 surface expression can be 
due to Ltb gene induction. 
 The observed lymphotoxin cell surface expression following ex vivo culture and 
PMA/ionomycin stimulation could result from a combination of de novo protein synthesis 
and protein subcellular relocalization. To assess the role of de novo protein synthesis in 
surface lymphotoxin upregulation, we blocked translation and transcription by treating cells 
respectively with cycloheximide or actinomycin D. Both compounds blocked lymphotoxin 
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cell surface induction upon either ex vivo culture or PMA/ionomycin stimulation for 22 h 
(Figure 3.6B). At shorter term (6 h) ex vivo cultures, surface lymphotoxin was detected only 
after PMA/ionomycin stimulation, and in a protein synthesis-dependent manner (Figure 
3.6C), indicating that PMA/ionomycin treatment induced lymphotoxin protein surface 
expression in leukemic cells with faster kinetics than ex vivo culture.  
 Together, these results indicate that LTα1β2 expression at the surface of ex vivo-
cultured and stimulated leukemic cells depends on lymphotoxin gene transcription and 
continuous protein synthesis. 
 
	  
Figure 3.5. Lymphotoxin expression on TJ2-Tg leukemic cell surface is upregulated 
upon ex vivo culture. (A) Mean fluorescence intensity (MFI) determined by flow cytometry 
immunostaining with LTβR-Fc (after subtraction from the MFI of the secondary antibody 
alone) on TJ2-Tg leukemic cells and wild-type thymocytes (WT), in vivo (t = 0) or cultured 
ex vivo for the indicated periods of time. (B) Gating strategy used to analyze wild-type 
thymocyte subpopulations and TJ2-Tg leukemic cells. (C) Percentage of TJ2-Tg leukemic 
cells, WT thymocytes, and subpopulations expressing surface LTα1β2 determined by flow 
cytometry with LTβR-Fc. 
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Figure 3.6. Lymphotoxin expression on TJ2-Tg leukemic cell surface depends on de 
novo protein synthesis. (A) RT-qPCR analysis of Lta, Ltb, and Light mRNA levels in TJ2-
Tg leukemic cells freshly collected (0 h) or after ex vivo culture for 10 h (n=7). Results for 
each sample were normalized to Gapdh expression and are expressed as mean of triplicates. 
P-values were determined using two-tailed, paired Student´s t-test. (B, C) LTβR-Fc 
immunostaining of surface LTα1β2 (solid line) on TJ2-Tg leukemic cells in vivo or following 
ex vivo culture for 6h or 22h, as indicated. Cells we treated either with DMSO, ActD, CHX, 
PMA+Iono (P+I), and P+I in combination with ActD or CHX. Cells were also pre-incubated 
with anti-LTβ mAb before staining with LTβR-Fc (dashed line) or incubated with a negative 
control (gray shading). One representative of four independent experiments is shown. 
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The fact that TJ2-Tg leukemic cells expressed surface lymphotoxin upon ex vivo culture may 
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expression could be acting in TJ2-Tg leukemic cells in vivo. So, to assess the role of 
microenvironmental LTβR expression on membrane-bound lymphotoxin in leukemic cells, 
we transplanted TJ2-Tg leukemic cells into Ltbr+/- and Ltbr-/- mice. After a 3-week delay, 
expanded donor leukemic cells were collected from recipient mouse infiltrated organs, and 
the presence of LTβR ligands at the surface of leukemic cells (detected as CD8+CD25+cells) 
(Figure 3.7A) was analyzed. Interestingly, LTβR ligands were detected at the surface of 
leukemic cells freshly collected from the thymus, spleen, bone marrow and peripheral blood 
of Ltbr-/- but not Ltbr+/- recipient mice (Figure 3.7B-E). LTβ pre-blocking confirmed that 
LTβR ligand expression corresponded exclusively to lymphotoxin heterotrimers (data not 
shown). Because leukemic cells injected in the two groups were identical, these results 
demonstrate that LTα1β2 surface expression on TJ2-Tg leukemic cells, similarly to normal 
mature thymocytes (Boehm et al., 2003), is downmodulated when these cells are localized in 
LTβR-expressing tissue microenvironments, and suggest the lack of LT detection is an 
indication of ongoing LTβR signaling. Moreover, this experiment was repeated by 
transplanting leukemic cells collected from diseased TJ2-Tg;Ltbr-/- mice and identical results 
were obtained (data not shown), thus confirming that the Ltbr genetic status in leukemic cells 
does not influence lymphotoxin surface expression. 
 To study the mechanism by which LTα1β2 expression at the TJ2-Tg leukemic cell 
surface is downmodulated, a more simplistic co-culture-based model was used. The MS5 
stromal cell line, which expresses LTβR (Figure 3.8A), was shown to establish functional 
interactions and to sustain the viability of co-cultured TJ2-Tg leukemic cells (Figure 3.8B). 
Therefore, to verify whether downmodulation of LTα1β2 surface expression depends on direct 
cell contact, we co-cultured TJ2-Tg leukemic cells with MS5 stromal cells. As previously 
observed, lymphotoxin was upregulated following ex vivo culture in isolated TJ2-Tg 
leukemic cells (Figure 3.8C). Upon co-culture, leukemic cells adhering to the MS5 
monolayer showed lower levels of surface LTα1β2 than non-adhering co-cultured leukemic 
cells (Figure 3.8C,D). Furthermore, conditioned medium collected from co-cultured leukemic 
cells with MS5 cells did not induce LTα1β2 downmodulation in leukemic cells (Figure 
3.8E,F). This result further indicates that soluble factors produced in co-cultures are not 
responsible, at least alone, for LTα1β2 downmodulation and that direct contact with 
microenvironmental cells is required for lymphotoxin downmodulation on the leukemic cell 
surface. 
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Figure 3.7. Cell surface LTα1β2 expression on TJ2-Tg leukemic cells depends on LTβR 
expression in microenvironmental cells. (A) Cell surface immunostaining of CD8/CD25 on 
cells collected from the thymus of mice inoculated with TJ2-Tg leukemic cells or not 
(negative control) and flow cytometry gating stategy. (B-E) Cell surface immunostaining 
with LTβR-Fc (solid line) or the secondary antibody alone (negative control, gray shading) of 
CD8+CD25+ TJ2-Tg leukemic cells collected from the (B) thymus, (C) spleen, (D) bone 
marrow, and (E) peripheral blood, 3 weeks post-inoculation of Ltbr+/- and Ltbr-/- mice. LTβR-
Fc mean fluorescent intensities (MFIs) subtracted from control MFIs are also indicated. One 
representative of three independent experiments is shown as the mean ± SEM. P-values were 
determined using two-tailed, unpaired Student´s t-test. 
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Figure 3.8. Lymphotoxin downmodulation from the surface of TJ2-Tg leukemic cells 
requires direct contact with LTβR-expressing MS5 stromal cells. (A) Flow cytometry 
immunostaining of MS5 stromal cells with anti-mouse LTβR antibody (black line) or the 
secondary antibody alone (gray shading). (B) TJ2-Tg leukemic cell viability upon culture for 
3 days in culture medium alone (isolated) or on a layer of adherent murine MS-5 cells (+MS-
5), determined by propidium iodide (PI) exclusion. Results represent three independent 
experiments. (C) Cell surface LTβR-Fc immunostaining (solid line) of TJ2-Tg leukemic cells 
cultured for the indicated times in culture medium alone, or on a confluent layer of MS-5 
cells, detected by flow cytometry, and (D) corresponding LTβR-Fc MFIs of leukemic cells 
subtracted from the control MFIs. Leukemic cells adherent or non-adherent to MS-5 cells 
were analyzed by gating on Thy1.2+ cells. (E) Conditioned medium collected from TJ2-Tg 
leukemic and MS5 cells co-cultured for 72 h and diluted 1:2 (MS5+TJ2-Tg CM) was used to 
culture TJ2-Tg leukemic cells for 24 h. The LTα1β2 heterotrimer was detected as in (C). TJ2-
Tg leukemic cells cultured in RPMI complete medium (medium) or conditioned medium 
collected from MS5 cells alone (MS5 CM) were also analyzed as controls, and (F) all 
corresponding LTβR-Fc MFIs of leukemic cells subtracted from the control MFIs were 
plotted. The triplicates of two independent experiments are shown. All the results are 
expressed as the mean ± SEM of triplicates. P-values were determined using two-tailed, 
unpaired Student´s t-test. 
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To determine if lymphotoxin expression was modulated specifically by LTβR in 
stromal cells, TJ2-Tg leukemic cells were co-cultured with either Ltbr-/- or Ltbr+/- mouse 
embryonic fibroblasts (MEFs). After 24 h of incubation, leukemic cells localized under 
adherent fibroblasts (pseudoemperipolesis; Figure 3.9A) (Nishi et al., 1982). Interestingly, 
membrane-bound lymphotoxin was detected in leukemic cells growing in close contact 
(adherent) with Ltbr-deficient MEFs, but not in those cells adhering to Ltbr-proficient MEFs 
(Figure 3.9B), thus indicating that downmodulation of surface LT expression on leukemic 
cells is mediated by interaction with its cognate receptor in microenvironmental cells. These 
results were consistent with those obtained in vivo, and indicated that expression of leukemic 
cell surface lymphotoxin in Ltbr-deficient recipient mice was caused by lack of direct contact 
with LTβR expressed in microenvironmental cells, and not eventual indirect cellular or 
systemic defects.  
Finally, to determine if ligation of the extracellular domain of LTβR is sufficient to 
induce LTα1β2 downmodulation at the cell surface of TJ2-Tg leukemic T cells, we cultured 
these cells in the presence of LTβR-Fc for 24 h. By performing flow cytometry 
immunostaining using again LTβR-Fc, we found that LTβR-Fc added to the culture binds 
LTα1β2 heterotrimers at the cell surface but does not downmodulate it (data not shown).  
 
	  
Figure 3.9. Lymphotoxin downmodulation from the surface of TJ2-Tg leukemic cells 
requires direct contact specifically with LTβR expressed at the surface of stromal cells. 
(A) Phase contrast microscopy picture showing TJ2-Tg leukemic cells adhering (arrowhead) 
and non-adhering (arrow) to MEFs, after 24 h of co-culture. (B) Cell surface LTβR-Fc 
immunostaining of TJ2-Tg leukemic cells collected from 24 h co-cultures with Ltbr+/- or  
Ltbr-/- MEFs. Leukemic cells adherent or non-adherent to MEFs cells were analyzed by 
gating on Thy1.2+ cells in flow cytrometry. 
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3.3. IMPACT OF LTβR INACTIVATION ON TEL-JAK2-INDUCED 
LEUKEMOGENESIS 
 
3.3.1. LTβR inactivation delays leukemia onset in TEL-JAK2 transgenic mice 
To investigate if lymphotoxin expression in leukemic cells and associated LTβR activation 
are involved in T-cell leukemia development, we tested the impact of systemic Ltbr 
inactivation in leukemogenesis. To this end, TJ2-Tg mice were crossed with Ltbr knockout 
mice, which present no defects in CD4 and CD8 double-negative (DN) and DP thymocyte 
maturation (Boehm et al., 2003; Fütterer et al., 1998), the major targets for TJ2-Tg-induced 
malignant transformation (dos Santos et al., 2007). Demonstrating a role for LTβR in 
leukemogenesis, TJ2-Tg;Ltbr-/- mice developed leukemia with longer latency than TJ2-
Tg;Ltbr+/- mice, median survival of 23 versus 15 weeks, respectively (Figure 3.10A). Of note, 
like previously found for leukemic cells transplanted to Ltbr–/– mice, those collected from 
Ltbr-deficient, but not from Ltbr-proficient TJ2-Tg mice expressed surface LTα1β2 (Figure 
3.10B,C), thus confirming that LTα1β2 surface expression in both normal and malignant T 
cells is only detectable in the absence of the cognate receptor (Boehm et al., 2003). Since 
LTβR mRNA and protein was not or poorly expressed in leukemic T cells (Figure 3.1C and 
data not shown), our results indicate that LTβR expression in non-malignant 
microenvironmental cells promotes leukemogenesis. 
	  
Figure 3.10. LTβR inactivation delayed TEL-JAK2-induced leukemogenesis. (A) 
Kaplan-Meier leukemia-free survival curves for cohorts of TJ2-Tg;Ltbr+/- and TJ2-Tg;Ltbr-/- 
mice (P = 0.0001; log-rank Mantel Cox test). Tick marks represent leukemia-free mice 
followed until the indicated age. (B) FACS immunostaining with LTβR-Fc (solid line) and 
the secondary antibody alone (gray shading) of one representative sample of TJ2-Tg;Ltbr-/- 
leukemic cells collected from the thymus. Where indicated, cells were pre-incubated with 
anti-LTβ mAb (dashed line). (C) Graph showing the LTβR-Fc mean fluorescence intensity 
(MFI) of TJ2-Tg (n=11) and TJ2-Tg;Ltbr-/- (n=5) leukemic cells subtracted from the MFI of 
cells stained with secondary antibody alone. P-value determined using two-tailed, unpaired 
Student´s t-test with Welch´s correction. 
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3.3.2. Delayed leukemia onset in TEL-JAK2 transgenic mice is not due to developmental 
defects in the thymus of LTβR-deficient mice 
TJ2-Tg-induced T-ALL was previously shown to arise from DN/DP thymocytes (dos Santos 
et al., 2007). Moreover, the DP phenotype in T cells is exclusively found in the thymus under 
normal conditions. To confirm that the thymus is the organ where T-ALL originates, we 
analyzed young (8-week-old) TJ2-Tg mice presenting no signs of disease and searched for 
aberrant CD8+CD25+ cells in organs commonly affected by T-ALL in these mice. By doing 
so, we found variable proportions of leukemic cells in the thymus of most mice analyzed, 
while organs such as spleen, bone marrow, and the peripheral blood presented few or none 
(Figure 3.11). Thymocyte suspensions containing CD8+CD25+ cells generated secondary 
leukemias in transplanted Nude mice (data not shown), indicating that the latter cells are 
already transformed. Altogether, these results support the notion that leukemic cells arise in 
the thymus of young TJ2-Tg mice from developing thymocytes. 
Since LTβR activation is involved in thymic stromal cell crosstalk with thymocytes 
(Boehm et al., 2003), the observed delay in leukemogenesis in the absence of LTβR could be 
linked to thymocyte defects. Arguing against such possibility, we found that LTβR-deficient 
mice of 19-22 weeks, an age when most Ltbr-proficient TJ2-Tg mice have developed 
terminal disease, presented no major defects in thymocyte cellularity (Figure 3.12A,B) and 
differentiation (Figure 3.12C,D). Therefore, these results indicate that the delay in TEL-
JAK2-induced leukemogenesis caused by LTβR deficiency cannot be attributed to a 
reduction of cellular targets for transformation in the thymus. 
	  
Figure 3.11. CD8+CD25+ leukemic cells originate in the thymus of TJ2-Tg young mice 
with no signs of disease. Leukemic cells (CD8+CD25+) were detected by flow cytometry on 
cell suspensions prepared from the thymus, spleen, peripheral blood, and bone marrow of 8-
week-old TJ2-Tg mice. 
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Figure 3.12. Ltbr deficiency does not cause major thymic alterations regarding 
thymocyte subpopulations in 4-5 month-old mice. (A) Thymic weight and (B) thymocyte 
cellularity from Ltbr+/- (n=7) and Ltbr-/- (n=14) mice aged from 19 to 22 weeks. The results 
are presented as the mean ± SEM. (C, D) Flow cytometry double immunostaining of cell 
surface CD4 and CD8 co-receptors on (C) representative thymocyte samples from either 
Ltbr+/- and Ltbr-/- mice, and (D) thymocytes from mice of the indicated genotype. The 
percentage of each thymocyte subpopulation, DN (CD4-CD8-), DP (CD4+CD8+), CD4SP 
(CD4+CD8-), and CD8SP (CD4-CD8+), is indicated and presented as the mean ± SEM. P-
value determined using two-tailed, unpaired Student´s t-test. 
 
3.3.3. LTβR inactivation does not affect the malignant phenotype of end-stage diseased 
TEL-JAK2 transgenic mice 
Since Ltbr expression affected TEL-JAK2-induced leukemogenesis, we set out to 
characterize the malignant phenotype of end-stage diseased mice with or without Ltbr 
inactivation to identify possible alterations that could explain the differences in disease 
development observed for the two mouse cohorts. All TEL-JAK2;Ltbr-/- and TEL-
JAK2;Ltbr+/- diseased mice analyzed showed typical features of disseminated T-cell 
leukemia, including thymic enlargement, frequently associated with pleural effusion, 
splenomegaly, and often non-lymphoid organ invasion (e.g., liver and lungs) (Figure 3.13A 
and data not shown). Macroscopic examination allowed us to divide these mice in two 
subgroups: some showed a predominant thymic enlargement accompanied by relatively mild 
splenomegaly, while others showed severe splenomegaly accompanied by relatively little 
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thymic enlargement. In addition, some showed high tumor burden in lymph nodes (Figure 
3.13A). Notably, we found that Ltbr gene inactivation did not impact neither on the endpoint 
tumor load in lymphoid and visceral organs (Figure 3.13A), nor on the leukemic cell surface 
phenotype (expression of CD3, CD4, CD8, CD24 and CD25) characteristic of TJ2-Tg mice 
(dos Santos et al., 2007) (Figure 3.13B). The exception were lymph nodes, which were 
described to be absent in Ltbr knockout mice (Fütterer et al., 1998), and were also absent in 
TJ2-Tg;Ltbr-/- diseased mice (Figure 3.13A).  
 
	  
Figure 3.13. The malignant phenotype of end-stage diseased TJ2-Tg;Ltbr-/- leukemic 
mice is comparable to that of control TJ2-Tg;Ltbr+/- mice. (A) Plots representing the 
weights of the thymus, spleen, liver and lymph nodes (mandibular, axillary, subiliac and 
jejunal) collected from terminally ill TJ2-Tg;Ltbr+/- (+/-; n=51), TJ2-Tg;Ltbr-/- (-/-; n=33), 
and wild-type (WT; n=4) mice. (B) Flow cytometry cell surface immunostaining of CD4, 
CD8, CD3, CD24, CD25, and CD44 cell surface markers of six representative leukemic cell 
samples from either TJ2-Tg;Ltbr+/- or TJ2-Tg;Ltbr-/- mice. The percentage of cells expressing 
each marker in each sample is indicated by the mean ± SEM. P-values were determined using 
two-tailed, unpaired Student´s t-test with Welch´s correction. 
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Moreover, immunofluorescence analyses of medullary (Krt5), cortical and medullary 
(Krt8) and endothelial (CD31) markers showed that both diseased TEL-JAK2;Ltbr-/- and 
TEL-JAK2;Ltbr+/- mice presented increased vascularization and microstructural 
disorganization in the thymus, which did not differ significantly (data not shown). 
Altogether, these analyses demonstrate that TEL-JAK2;Ltbr-/- and TEL-JAK2;Ltbr+/- 
mice do not show great differences regarding the malignant phenotype at end-stage disease. 
Therefore, the potential mechanisms fostering leukemogenesis in LTβR-proficient mice may 
operate at an early stage of leukemia development. 
 
3.3.4. Lymphotoxin signaling fosters the early stages of leukemogenesis in the thymus 
We have found that T-cell leukemogenesis is delayed in TJ2-Tg LTβR-deficient mice (Figure 
3.10A), though LTβR signaling may play a role in leukemia initiation and/or maintenance. 
To investigate the timing of lymphotoxin gene upregulation during leukemogenesis, we 
analyzed gene expression in thymocytes from 8-week-old TJ2-Tg mice with no signs of 
disease and from nontransgenic littermates. Young TJ2-Tg mice were characterized by the 
expansion of CD8 SP and DP thymocyte subpopulations and aberrant CD8+CD25+ 
thymocytes (also characterized by elevated CD24 expression) at variable proportions (Figure 
3.14A and data not shown), before significant thymic enlargement (Figure 3.14B,C). The 
appearance of these aberrant thymocytes was associated with increased overall cell size as 
demonstrated by FSC-H increase in flow cytometry analyses (Figure 3.14D). Moreover, the 
increase in malignant thymocytes was associated with higher Lta and Ltb expression, as 
compared to thymocytes from TJ2-Tg mice with small proportions of CD8+CD25+ cells or 
from nontransgenic controls (Figure 3.14E,F). Concerning Light, a significant increase in 
expression was not detected (data not shown). Therefore, these data indicate that increased 
lymphotoxin gene expression occurs early in TJ2-Tg-induced leukemogenesis, and support 
the notion that lymphotoxin signaling promotes leukemogenesis at the initial steps of disease. 
To test this assumption, we searched for malignant (CD8+CD25+) thymocytes in 8-week old 
TJ2-Tg mice of different Ltbr genotypes that showed no signs of disease. We found that the 
proportion of malignant thymocytes in the thymus was significantly reduced in Ltbr-deficient 
mice, as compared to Ltbr-proficient mice (Figure 3.14G). These results indicate that when 
LTβR is inactivated, early leukemogenesis is impaired resulting in slower progression and 
leukemia onset. 
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Figure 3.14. Lta and Ltb expression in TJ2-Tg thymocytes correlates with the emergence 
of malignant thymocytes. (A) CD4/CD8 (gated on viable cells) and CD8/CD25 (gated on 
CD4/CD8 DP plus CD8SP, viable cells) double cell surface immunostaining of 
representative thymocytes collected from 8-week-old wild-type (WT; n=5) mice and 
asymptomatic TJ2-Tg mice with less (n=4) or more than 5% CD8+CD25+ malignant 
thymocytes (n=6) and (B) the respective thymic weights. (C) Percentage of CD8+CD25+ 
thymocytes in TJ2-Tg mice (n=10) plotted with thymic weights. A possible correlation was 
assessed by determining the Spearman coefficient and the P value (P = 0.4047). (D) 
Thymocyte size from WT and TJ2-Tg representative mice given by forward scatter 
measurement. (E) RT-qPCR analysis of Lta and Ltb expression in thymocytes collected from 
8-week-old WT (n=5) mice, asymptomatic TJ2-Tg mice with less (n=4) or more than 5% 
CD8+CD25+ malignant thymocytes (n=6). Results are normalized to Gapdh expression and 
presented as the mean ± SEM. P-value determined using two-tailed unpaired t-test with 
Welch´s correction. (F) Lta and Ltb mRNA expression levels plotted with the percentage of 
CD8+CD25+ thymocytes from 8-week-old asymptomatic TJ2-Tg mice (n=10) (mean of 
triplicates for each sample). The existence of possible correlations was assessed by 
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determining the Spearman coefficient and P values (Lta, P = 0.0008; Ltb, P = 0.0174).  r2 is a 
measure of goodness-of-fit of linear regression. (G) Proportion of malignant thymocytes (as 
identified by CD8 and CD25 positivity) in thymi from 8-week-old TJ2-Tg mice with the 
indicated phenotypes. Results are presented as the mean ± SEM. P-value determined using 
two-tailed, unpaired Student´s t-test with Welch´s correction. 
 
3.3.5. LTβR is not required for TJ2-Tg leukemic cell engraftment and dissemination  
Primary leukemic cells from TJ2-Tg mouse tumors can be transplanted to immunocompetent 
syngeneic recipient mice, resulting in bone marrow engraftment and invasion of lymphoid 
and visceral organs (Medyouf et al., 2007). To determine whether microenvironmental LTβR 
was also required for malignant cell leukemia engraftment and maintenance in recipient mice, 
TJ2-Tg leukemic cells were transplanted to Ltbr+/– and Ltbr–/– syngenic mice. When ill (after 
about 3-4 weeks), all recipient mice were sacrificed simultaneously for organ invasion 
assessment. Macroscopic and histological analyses of Ltbr+/– and Ltbr–/– recipients revealed 
similar dissemination to several organs including the thymus, spleen, liver, and bone marrow 
(Figure 3.15A,B), but not lymph nodes in Ltbr-/- recipients (data not shown).  
To analyze the thymi from recipient mice in further detail, histological analyses were 
performed. Representative thymic sections stained by hematoxylin and eosin showed an 
altered structure and infiltration of leukemic cells in both Ltbr-/- and Ltbr+/- mice (Figure 
3.15C). In addition, Ltbr+/- mice presented usually enlarged lymph nodes adjacent to the 
thymus (Figure 3.15C). Nevertheless, thymus-infiltrating leukemic cells could be identified 
in the vasculature and capsule of both mouse groups (data not shown). Immunofluorescence 
staining confirmed these observations and revealed that Ltbr deficiency did not impair the 
increased vascularization (CD31 endothelial cell staining) or altered thymic medullary 
structure (Krt5 epithelial cell staining) caused by leukemic cell infiltration of the thymus 
(Figure 3.15D). In addition, no differences were found between Ltbr+/– and Ltbr–/– infiltrated 
thymi regarding CCL21 chemokine expression, a well-known LTβR target (Figure 3.15E). 
Collectively, these results demonstrate that fully malignant leukemic cells invade equally 
well Ltbr+/– and Ltbr–/– recipient mouse organs. Therefore, LTβR expression and activation in 
stromal cells is seemingly not required for maintenance of TEL-JAK2-induced leukemia.  
Taken together, the last results suggest that LTβR expression and activation in stromal 
cells likely plays a determinant and likely unique role in the early stages of TEL-JAK2-
induced T-ALL.  
 
CHAPTER 3 – RESULTS	  
MT Fernandes 106 
	  
Figure 3.15. LTβR is not required for TJ2-Tg leukemia engraftment and dissemination 
in recipient mice. (A) Weight of organs collected from terminally ill Ltbr+/- (n=4) and Ltbr-/- 
(n=3) mice, 3 weeks post-inoculation with TJ2-Tg leukemic cells. Representative results of 4 
independent experiments are presented as mean ± SEM. (B) Percentage of CD8+CD25+ 
leukemic cells in organs from Ltbr+/- and Ltbr-/- recipient mice, as assessed by flow 
cytometry. (C) Hematoxylin and eosin staining of thymi collected from wild-type mice, and 
Ltbr+/- and Ltbr-/- mice injected with TJ2-Tg leukemic cells. Scale bar 500 µm. (D-E) 
Immunostaining of (D) CD31 and keratin 5 (Krt5), and (E) CCL21 and keratin 8 (Krt8) in 
representative thymi from leukemic Ltbr+/- and Ltbr-/- recipient mice. Scale bars, 100 µm. m, 
medulla; c, cortex. 
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3.3.6. LTβR pharmacological block impacts on TJ2-Tg leukemic cell export from the 
thymus and dissemination  
Since Ltbr knockout mice are born with no lymph nodes and other specific lymphoid defects, 
we sought to inhibit lymphotoxin signaling in phenotypically normal young, pre-leukemic 
TJ2-Tg mice through the administration of neutralizing LTβR-Fc fusion protein. 
Substantiating our previous results in which LTβR was genetically inactivated, LTβR-Fc 
treatment delayed leukemogenesis, with half of the mice outliving control-treated mice 
(Figure 3.16A). The median survival in treated mice was 15 versus 13 weeks in control mice; 
therefore, we could delay the median survival of TJ2-Tg mice in 2 weeks by blocking LTβR 
signaling from 5 until 10 weeks of age (Figure 3.16A). In addition, acute inhibition of 
lymphotoxin signaling resulted also in increased tumor burden in the thymus (Figure 3.16B) 
and a tendency for reduced infiltration in other organs such as the spleen, LNs (Figure 
3.16B), and BM (Figure 3.16C), suggesting that leukemic cell export from the thymus was 
reduced. Moreover, white blood cell counts in peripheral blood were generally lower in 
treated mice (Figure 3.16D). This finding suggests that less leukemic cells were circulating in 
the peripheral blood, the main route for T-ALL dissemination. 
In synthesis, although the low number of mice analyzed may have precluded the 
finding of statistically significant differences, LTβR signaling abrogation through 
pharmacological means may influence bloodborne leukemic cell dissemination to distant 
metastatic sites from the thymus, where it originates. 
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Figure 3.16. Pharmacological inhibition of LTβR signaling impairs leukemogensis in 
TJ2-Tg mice. TJ2-Tg mice received intraperitoneal injections of LTβR-Fc (or mouse 
polyclonal IgG as control) once a week for 5 weeks, starting at 5 weeks of age (arrows). (A) 
Kaplan-Meier survival curves for LTβR-Fc- and control-treated mice (P = 0.2693, log-rank 
Mantel Cox test). (B) Weights of thymus, spleen, liver and lymph nodes, (C) white blood cell 
(WBC) counts, and (D) leukemic cell (CD8+CD25+) bone marrow infiltration (P = 0.0553) in 
terminally ill LTβR-Fc- and control-treated TJ2-Tg mice. P-value determined using two-
tailed, unpaired Student´s t-test. 
 
 
3.4. LYMPHOTOXIN EXPRESSION AND REGULATION IN HUMAN T-ALL 
 
 
3.4.1. Human T-ALL cell lines express lymphotoxin through an NF-κB-dependent 
mechanism 
To determine if LTβR ligands are also expressed in human T-ALL, LTA and LTB mRNA 
levels were first assessed in a panel of established human cell lines. These genes were 
expressed at variable levels across all T-ALL cell lines analyzed (Figure 3.17A). 
Furthermore, these were found to be highly expressed in the HUT-78 cutaneous T-cell 
lymphoma cell line and weakly expressed in the Nalm6 B-cell precursor leukemia cell line 
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(Figure 3.17A). In contrast to LT genes, no significant LIGHT expression was detected in any 
cell line (data not shown).  
 By performing flow cytometry analysis, variable expression of LTβR ligands was also 
detected at the surface of all T-ALL cell lines studied, but not on the Nalm6 cell line (Figure 
3.17B). Although we did not have tools to analyze which LTβR ligand proteins were 
expressed in T-ALL cell lines, these were most likely LTα1β2 heterotrimers due to the lack of 
detection of LIGHT mRNA. Importantly, none of the T-ALL cell lines analyzed expressed 
LTβR as determined by western blotting (data not shown). 
To study the mechanism(s) of LTα and LTβ expression in human T-cell 
leukemia/lymphoma, we determined the impact of NF-κB activation using PMA, and NF-κB 
inhibition using an IKK inhibitor. Similarly to TJ2-Tg leukemic cells, PMA stimulation 
induced cell surface LTβR ligand expression in an IKK-dependent manner in T-ALL cell 
lines but not in the Nalm6 B-cell line (Figure 3.17D). In addition, LTA and LTB mRNA 
expression was found to be upregulated by PMA activation and downregulated by IKK 
inhibition in T-ALL cell lines (Figure 3.17C). Collectively, these experiments show that 
LTβR ligand expression can be found in both mouse and human leukemic T cells and these 
are similarly regulated. Furthermore, these data confirmed previous reports obtained with 
other T-ALL cell lines (Ware et al., 1992) indicating that the lymphotoxin genes and LTα1β2 
heterotrimers are expressed in human T-ALL cells and regulated by the activation of 
signaling pathways including the IKK/NF-κB pathway. 
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Figure 3.17. LTβR ligand expression in human T-ALL cell lines is induced by PMA 
stimulation and inhibited by IKK inhibitor treatment. (A) RT-qPCR quantification of 
LTA and LTB (normalized to GAPDH expression) in the indicated human T-ALL cell lines 
and non-T-ALL (HUT-78 and Nalm6) cell lines. Results are represented as the mean ± range. 
(B) Cell surface immunostaining with LTβR-Fc (solid line) and the secondary antibody alone 
(gray shading) by flow cytometry on the indicated cell lines. (C) LTA and LTB mRNA 
quantification by RT-qPCR on DND41, SUPT1, PF382, and Nalm6 cell lines treated for 10 h 
with either IKK inhibitor (IKKi), PMA or DMSO (control). (D) Flow cytometry cell surface 
immunostaining with LTβR-Fc (solid line) and secondary antibody alone (gray shading) on 
DND41, SUPT1, PF382, and Nalm6 cell lines treated for 10 h with either PMA, PMA plus 
IKKi, or DMSO. 
 
 
 
 
C D 
B A 
C
ou
nt
s 
LTβR-Fc 
DMSO 
PMA 
PMA + IKKi 
DND41 SUPT1 PF382 Nalm6 
DMSO DMSO DMSO 
PMA PMA PMA 
PMA + IKKi PMA + IKKi PMA + IKKi 
Jurkat 
PF382 SUPT1 
DND41 Nalm6 
P12 HUT-78 
C
ou
nt
s 
LTβR-Fc 
CHAPTER 3 – RESULTS 
MT Fernandes 111 
3.4.2. Human primary patient samples express lymphotoxin 
LTβR ligands have been previously shown to be expressed in malignant cells and contribute 
to chronic lymphocytic leukemia (CLL) and B-cell lymphoma development (Heinig et al., 
2014; Rehm et al., 2011). Moreover, analysis of a publically available large multicenter 
dataset of 2022 leukemia patient and 74 nonmalignant BM samples (Haferlach et al., 2010), 
showed that LTA and LTB genes were significantly more expressed in T-ALL and other 
lymphoid malignancies than in myeloid malignancies or nonmalignant BM (Figure 3.18A).  
 To determine whether LTA and LTB were also expressed in primary T-ALL cells, we 
performed RT-qPCR on pediatric patient samples collected at diagnosis from either BM or 
PB and on age-matched human control thymocytes (Table 3.1). LTA and LTB mRNA 
expression was found in normal thymocytes (as expected (Wolf and Cohen, 1992)) and 
patient samples, albeit heterogeneously in the latter. Some patient samples expressed similar 
or higher, while others lower levels than thymocytes (Figure 3.18B). Conversely, no 
significant LIGHT expression was detected in T-ALL primary samples (data not shown).  
To determine whether lymphotoxin gene expression was associated with particular T-
ALL molecular subgroups (Graux et al., 2006), LTA and LTB gene expression was assessed 
in a larger cohort of 49 primary T-ALL patients by microarray analysis followed by RT-
qPCR validation in a subset of 33 patients. Molecular subtypes were classified by 
Hierarchical Clustering Analysis (HCA) according to the expression of genes previously 
associated with each subtype (Table 3.2) (Homminga et al., 2011). The LTA and LTB genes 
were expressed at variable levels in the different molecular subtypes, but expression of LTA 
and most strikingly LTB was significantly higher in the TAL/LMO molecular subgroup than 
in the remaining samples (Figure 3.18C). RT-qPCR analyses corroborated that LTA and LTB 
were on average more expressed in samples from the TAL/LMO than other subgroups 
(Figure 3.18D and Table 3.2). No further correlations between LT gene expression and 
clinical or molecular data were found.  
Together, these data indicate that lymphotoxin expression is a common feature in T-
ALL with higher levels associated with TAL/LMO T-ALL. Furthermore, either LT 
expression does not correlate with any clinical characteristic of the disease studied, or our 
cohort is not large enough to account for the variability found when studying these potential 
effects. 
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Table 3.1. Clinical and immunophenotypical characteristics of primary T-ALL samples 
(Portuguese cohort). 
 
a Samples collected from bone marrow (BM) or peripheral blood (PB). 
b All cases were positive for cytoplasmic CD3. n.d., no data. Percentage of positive cells indicated when 
available. 
c LTA and LTB expression by RT-qPCR relative to expression in normal human thymocytes, which was 
arbitrarily set to 1 (normalized to GAPDH expression). 
 
 
Patient 
Age at 
diagnosis 
(years) 
Samplea Gender 
Immunophenotypeb Relative expressionc 
CD1a CD2 CD3 CD4 CD5 CD7 CD8 CD10 CD33 CD34 CD117 TdT LTA LTB 
46 4 BM F 88% 14% 90% 78% 90% 88% 85% n.d. 3% 0.3% n.d. 88% 0.06 0.44 
97 4 PB M 66% + n.d. - + + - n.d. n.d. 66% n.d. 66% 0.47 4.42 
111 6 BM F - + n.d. - - n.d. - n.d. - + + + 0.05 0.53 
112 10 BM M - n.d. n.d. - - + - n.d. n.d. n.d. + - 0.70 4.56 
115 4 BM M + + n.d. - + + + + n.d. - + + 0.06 0.10 
123 4 BM F - + - - + + - + n.d. 25% n.d. + 0.22 0.22 
178 13 PB M - + - - + + - + - - - + 0.99 0.83 
179 4 PB M n.d. + - - + + - - - - - + 1.54 2.47 !
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Table 3.2. Clinical, immunophenotypical and genetic characteristics of  
     primary T-ALL samples clustered in molecular subtypes (Brazilian cohort). 
 
                        aAge at diagnoses in years. 
                        bPositivity was considered when 20% or more cells were positive for each marker. 
Cohort % HOXA % Immature % Proliferative % TAL/LMO % TLX1/3 %
33 3 4 4 14 8
Clinical
Total (n) 22 2 4 4 13 7
Gender
Male 15 68 2 100 3 75 1 25 11 85 4 57
Female 7 32 0 0 1 25 3 75 2 15 3 43
Agea
Median 11.0 12.5 9.1 7.8 12.0 8.7
Range 1.7-17.6 11.5-13.5 1.7-22.6 2.9-16.2 3.4-17.6 6.7-15.6
WBC (^104/mm3)
Median 14.55 21.845 15.48 33.495 26.5 13.2
Range 1.79-98 1.99-41.7 6.51-62.1 2.02-98 5.28-61.2 1.79-36.8
Immunophenotypeb
CD34 (n) 30 1 4 3 14 8
Positive 10 33 0 0 2 50 0 0 6 43 2 25
CD33 (n) 29 2 3 4 13 7
Positive 2 7 0 0 0 0 0 0 1 8 1 14
CD1a (n) 20 1 3 1 10 5
Positive 12 60 1 100 1 33 1 100 4 40 5 100
CD2 (n) 32 2 4 4 14 8
Positive 29 91 1 50 3 75 3 75 14 100 8 100
CD3 (n) 32 2 4 4 14 8
Positive 32 100 1 50 4 100 4 100 13 93 4 50
CD4 (n) 20 1 3 1 10 5
Positive 16 80 1 100 1 33 1 100 7 70 5 100
CD8 (n) 20 1 3 1 10 5
Positive 16 80 0 0 2 67 1 100 9 90 4 80
CD4/8 (n) 10 1 1 1 5 2
Positive 7 70 0 0 1 100 1 100 5 100 0 0
CD5 (n) 32 2 4 4 14 8
Positive 31 97 2 100 3 75 4 100 14 100 8 100
CD7 (n) 32 2 4 4 14 8
Positive 32 100 2 100 4 100 4 100 14 100 8 100
CD10 (n) 31 1 4 4 14 8
Positive 11 35 1 100 1 25 3 75 2 14 4 50
TdT (n) 11 0 2 1 7 2
Positive 11 100 2 100 1 100 7 100 2 100
Genetic alterations
NOTCH (n) 23 2 1 4 9 6
Positive 11 48 2 100 0 0 4 100 2 22 3 50
WT1 (n) 22 2 1 4 9 5
Positive 1 5 0 0 0 0 0 0 0 0 1 20
PTEN (n) 23 2 1 4 9 6
Positive 2 9 0 0 0 0 0 0 1 11 1 17
IL7R (n) 22 2 1 4 9 5
Positive 5 23 0 0 0 0 0 0 1 11 3 60
Lymphotoxin expression
Total (n) 33 3 4 4 14 8
LTA 
Median 5.1 1.8 5.3 2.4 7.9 1.5
Mean 6.1 7.8 5.0 3.5 8.2 2.6
Range 0-20.7 0.9-20.7 0.6-8.8 0.0-9.3 0-20.1 0-8.5
LTB 
Median 179.6 194.6 142.8 115.6 376.7 65.6
Mean 264.7 179.1 165.0 121.6 403.9 106.4
Range 9.7-796.5 128.1-214.7 45.6-328.8 9.7-245.5 101.7-796.5 9-291.7
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Figure 3.18. T-ALL patient samples express lymphotoxin genes. (A) Microarray (GEO 
GSE 13159) analysis of LTA and LTB gene expression levels in several human samples: B-
ALL, B-cell acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; 
AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic 
myelogenous leukemia; MDS, myelodysplastic syndrome; Non-leukemia, non-leukemia and 
healthy bone marrow samples. Lines, bars, and whiskers represent the median, quartiles, and 
minimum and maximum values, respectively. (B) RT-qPCR quantification of LTA and LTB 
mRNA levels in human thymocytes (n=7) and T-ALL samples (n=8). Results were 
normalized to 18S rRNA expression and are expressed as the mean of three technical 
replicates. (C) LTA and LTB gene expression, as determined by microarray analysis, in 49 T-
ALL samples, classified in the HOXA (n=5), immature (n=4), proliferative (n=5), TLX 
(n=12), and TAL/LMO (n=23) molecular subtypes, and 2 human thymocyte samples. Results 
are represented as the mean (bar). (D) RT-qPCR quantification of LTA and LTB in 33 T-ALL 
patient samples (n=8) subdivided according to molecular subtype, normalized to ABL1 
expression and relative to expression in Jurkat cells. Results are expressed as the mean (bar). 
For (A), (C) and (D): P-values determined using two-tailed, unpaired Student´s t-test with 
Welch’s correction. 
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3.4.3. TEL-JAK2 transgenic mice model human T-ALL with cortical/mature 
immunophenotype  
The TAL/LMO molecular subtype of T-ALL has been associated with TCRαβ 
differentiation, cell surface expression of TCRαβ and CD3, and cortical/mature 
immunophenotype (Asnafi et al., 2004; Ferrando et al., 2002; Graux et al., 2006; Soulier et 
al., 2005). Moreover, TAL/LMO samples were shown to cluster preferentially with post-β-
selection human thymocyte subsets, including immature CD4 SP, CD4/CD8 DP, and mature 
CD4 and CD8 SP cells (Soulier et al., 2005). TJ2-Tg mouse leukemias are characterized by 
the presence of CD4/CD8 DP and CD8 SP leukemic cells expressing surface TCRαβ, CD3 
and CD5, and responsive to TCR stimulation (Carron et al., 2000; dos Santos et al., 2007). 
Furthermore, unsupervised clustering analysis of four TJ2-Tg leukemic samples and nine 
thymocyte subpopulations revealed that TJ2-Tg cells clustered with double negative stage 4 
(DN4), CD8 ISP and DP thymocytes (Figure 3.19). These results indicate that TJ2-Tg mouse 
leukemias, like most TAL/LMO T-ALL cases, are malignancies of late cortical, post-β-
selection thymocytes, and suggest that lymphotoxin signaling contributes for TAL/LMO T-
ALL development as it does for TJ2-Tg-induced leukemias. 
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Figure 3.19.	   TJ2-Tg leukemic cells clustered with post-β-selection immature 
thymocytes. Unsupervised hierarchical clustering of four TJ2-Tg samples (TJ2) (GEO 
GSE51243), and nine wild-type thymocyte subpopulations, in triplicate, from the ImmGen 
consortium (GSE15907) using the top 1 % most varying probe sets (n=163) across all 31 
datasets (mainly immune-related membrane-bound proteins). Hues of yellow and blue 
indicate higher to lower levels of relative fluorescence signal. Thymocyte subpopulations 
starting from the most immature are: preT.ETP, early T lineage precursor; preT.DN2, DN2 
thymocytes; preT.DN3A, DN3A thymocytes; preT.DN3B, DN3B thymocytes; T.DN4, 
double negative (DN) 4 thymocytes; T.ISP, intermediate SP, CD3- CD8+; T.DP, CD4/CD8 
double positive; T.4SP24-, CD4 single-positive (SP), mature; T.8SP24-, CD8 SP, mature. 
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3.5. ROLE OF RANK SIGNALING IN T-ALL: PRELIMINARY FINDINGS 
 
 
TNF superfamily receptors expressed in thymic stromal cells, including LTβR, CD40 and 
RANK, and their cognate ligands, expressed in developing T cells, are essential players in 
thymocyte-stroma molecular crosstalk. In some processes, these receptors cooperate, while in 
others, show redundant functions due to their shared ability to activate the alternative NF-κB 
pathway (Akiyama et al., 2012).  The above results suggest that disruption of lymphotoxin 
signaling dalays TJ2-Tg-induced leukemogenesis by hampering crosstalk between leukemic 
and stromal cells. As such, other TNFR superfamily members may be involved in this 
crosstalk. As a first approach to determine if CD40 or RANK may cooperate with LTβR 
signaling in T-ALL development, we addressed whether the respective ligands are also 
expressed in TJ2-Tg leukemic cells. RANK ligand gene (Rankl) was significantly more 
expressed in TJ2-Tg leukemic cells that in wild-type thymocytes (Figure 3.20A). In contrast, 
no CD40 ligand gene (Cd40l) expression was detected in TJ2-Tg leukemic cells (data not 
shown). Interestingly, a correlation between Lta and Rankl expression was found in TJ2-Tg 
leukemic cells (Figure 3.20B), suggesting that these may be activated by the same 
mechanisms. It was previously reported that in the mouse thymus, RANK is mainly 
expressed in mTECs, while mature CD4 SP thymocytes are the main source of RANK 
ligands (Hikosaka et al., 2008). Although TJ2-Tg leukemic cells include immature CD8 SP 
and DP cell populations in variable proportions, we found that these cells expressed high 
levels of Rankl mRNA, comparable to those in CD4 SP thymocytes (Figure 3.20C). 
Furthermore, Rank was detected in whole TJ2-Tg thymic lymphomas as it was in whole wild-
type thymi (Figure 3.20D), despite the accentuated decrease in mTEC proportion observed as 
the lymphoma develops (data not shown). These observations suggest that, similarly to what 
was previously reported in the wild-type thymus (Hikosaka et al., 2008), RANK and its 
ligand are present in the microenvironment where TEL-JAK2-induced leukemia originates.  
 To determine the mechanism(s) underlying Rankl expression in TJ2-Tg leukemic 
cells, these were treated in vitro with pharmacological inhibitors as described before. 
Similarly to Ltb and Light, Rankl expression in leukemic cells was reduced by IKKi treatment 
(Figure 3.21A), while the pan-JAK inhibitor had no effect (Figure 3.21B). These results 
indicate that NF-κB activation is an important mechanism underlying TNF ligand family 
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gene expression (comprising Lta, Ltb, Light, and Rankl) in TJ2-Tg leukemic T cells, as well 
as in wild-type thymocytes (data not shown). 
 
	  
Figure 3.20. RANK and RANK ligand expression in TJ2-Tg mice. (A) RT-qPCR 
quantification of Rankl in thymocyte-enriched fractions collected from wild-type thymi (WT; 
n=4) and leukemic cell-enriched fractions collected from TJ2-Tg thymic lymphomas (n=11). 
P-value determined using two-tailed, unpaired Student´s t-test with Welch’s correction. (B) 
Rankl relative expression plotted with Lta relative expression. r2 is a measure of goodness-of-
fit of linear regression. The existence of a significant correlation was assessed by determining 
the Spearman coefficient and the P value (P = 0.0440). (C) Rankl RT-qPCR analysis in WT 
thymocytes (n=2), TJ2-Tg leukemic cells (n=4), and sorted CD4/CD8 double-positive (DP; 
n=2) and CD4 single-positive (CD4 SP; n=2) thymocytes. (D) Rank expression detection by 
RT-PCR in whole thymic lymphomas from TJ2-Tg mice (n=2) and whole wild-type thymi 
(n=1). Hprt1 expression was detected as loading control. 
 
Further supporting a role for NF-κB activity in induction of Rankl expression in 
leukemic cells, this was upregulated in an NF-κB-dependent manner by PMA and ionomycin 
treatment (Figure 3.21C,D). Conversely, Rankl expression was similar in TJ2-Tg;Rag2-/- and 
pre-TCR/TCR-proficient TJ2-Tg leukemic cells (Figure 3.21E), supporting the notion that 
either TCR expression in leukemic cells may not contribute to Rankl gene regulation, unlike 
normal thymocytes (Hikosaka et al., 2008), or that other regulatory mechanisms operating in 
leukemic cells induce Rankl expression in the absence of pre-TCR or TCR signaling, 
possibly those underlying the high Rankl expression in DN1 thymocytes (Hikosaka et al., 
2008). 
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Figure 3.21. RANK ligand gene expression in TJ2-Tg leukemic cells depends on IKK 
activity. (A-D) Rankl mRNA quantification by RT-qPCR for three independent TJ2-Tg 
leukemic cell samples treated ex vivo for 10 h with either DMSO (control) and (A) an IKK 
inhibitor (IKKi), (B) a pan JAK inhibitor (JAKi), or (C) PMA and ionomycin (PMA+Iono). 
(D) Rankl expression was also determined in samples treated with PMA+Iono and 
PMA+Iono in combination with IKKi and one representative sample is shown. (E) RT-qPCR 
quantification of Rankl expression (normalized to Gapdh expression) in leukemic Rag2-
deficient TJ2-Tg leukemic cells (TJ2-Tg;Rag2-/-; n=6) and control leukemic cells (TJ2-Tg; 
n=4). Results are expressed as mean ± SEM. P-value determined using two-tailed, paired 
Student´s t-test. 
 
 Although Rankl mRNA was consistently expressed in TJ2-Tg leukemic cells, RANKL 
protein expression was absent or weak at the cell surface of freshly collected cells (in vivo), 
as detected by flow cytometry (Figure 3.22A). Upon ex vivo culture, TJ2-Tg leukemic cells 
showed slightly higher RANKL surface levels (Figure 3.22B), which were dramatically 
upregulated following PMA and ionomycin stimulation (Figure 3.22C).  
The observed RANKL cell surface expression following ex vivo culture and PMA and 
ionomycin stimulation could result from a combination of de novo protein synthesis and 
protein subcellular relocalization. By blocking mRNA translation in leukemic cells with 
CHX, we found that RANKL cell surface induction upon either ex vivo culture or 
PMA/ionomycin stimulation depended on de novo protein synthesis (Figure 3.22B-C). 
Supporting our previous findings, we detected Rankl mRNA upregulation in leukemic cells 
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upon ex vivo culture (Figure 3.22D). Therefore, RANKL expression at the surface of TJ2-Tg 
leukemic cells upon ex vivo culture, and probably also after PMA plus ionomycin treatment, 
likely results from enhanced Rankl transcription and translation. 
 
	  
Figure 3.22. RANK ligand cell surface expression in TJ2-Tg leukemic cells is induced 
through NF-κB activation and depends on de novo protein synthesis. Flow cytometry 
immunostaining of RANKL (solid line) or isotype control (gray shading) of TJ2-Tg leukemic 
cells (A) freshly collected (in vivo), (B) cultured ex vivo with vehicle (DMSO) for 22h, and 
(C) treated with PMA+Iono, alone or in combination with cycloheximide (CHX). (D) RT-
qPCR analysis of Rankl mRNA levels in TJ2-Tg leukemic cells freshly collected (0 h) or 
after ex vivo culture for 10 h (n=6). Results for each sample were normalized to Gapdh 
mRNA expression and are represented as the mean of triplicates. P-value determined using 
two-tailed, paired Student´s t-test. 
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4.1. TNFSF SIGNALING IN THE THYMUS OF TEL-JAK2 TRANSGENIC MICE 
 
 
Under physiologic conditions, intercellular communication between developing thymocytes 
and the thymic stroma is critical for both thymocyte differentiation, maturation and selection, 
and thymic stroma development and organization. This crosstalk is largely mediated by 
ligand/receptor interactions between members of the Tumor Necrosis Factor Superfamily 
(TNFSF), such as LTα1β2/LTβR, RANKL/RANK, and CD40L/CD40 (Akiyama et al., 2012; 
Boehm et al., 2003; Lkhagvasuren et al., 2013; Zhu et al., 2007). Notably, unlike prototypical 
TNF receptors, which activate exclusively the classical NF-κB pathway, LTβR, RANK, and 
CD40 activate both the classical and alternative NF-κB pathways using common signaling 
transducers (Akiyama et al., 2012). Through the alternative NF-κB pathway, these signaling 
proteins activate RelB, which is essential for the formation of the thymic medulla (Akiyama 
et al., 2012; Derbinski and Kyewski, 2005). Importantly, it was shown that RelB expression 
in non-hematopoietic stromal cells, most likely in the thymus, favored TEL-JAK2-induced 
murine T-ALL and a more severe malignant phenotype (dos Santos et al., 2008) in this 
animal model of human T-ALL.  
 In recent years, a wide body of evidence has shown that T-cell leukemogenesis 
originates due to genetic aberrations in combination with microenvironmental stimuli such as 
cytokines, growth factors, or adhesion molecules (Medyouf et al., 2011; Silva et al., 2011; 
Uzan et al., 2014; Van Vlierberghe and Ferrando, 2012). In addition, it is currently believed 
that the pro-leukemogenic effects caused by the interaction between malignant and non-
malignant cells in the tumor microenvironment is bidirectional, resembling at least in part, 
the interactions occuring between normal lymphoid cells and their microenvironment in 
lymphoid organs (Herreros et al., 2008). Therefore, we hypothesized that similarly to normal 
thymocytes, T-ALL cells may also establish interactions with non-malignant stromal cells 
through TNFSF/RelB signaling, modulating the microenvironment into a pro-leukemogenic 
niche.  
 To study the role of TNFSF signaling in T-cell leukemogenesis, we used the TJ2-Tg 
mouse model of cortical/mature T-ALL. These mice are characterized by the presence of 
CD4/CD8 DP and CD8 SP leukemic cells expressing surface TCRαβ, CD3 and CD5, and 
responsiveness to TCR stimulation (Carron et al., 2000; dos Santos et al., 2007). Such 
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cortical/mature immunophenotype is also frequent in TAL/LMO T-ALL cases. We first 
assessed the expression of TNFSF ligands in primary TJ2-Tg leukemic cells from diseased 
mice. LTβR ligand-encoding genes (Lta, Ltb and Light) and the RANK ligand-encoding gene 
(Rankl) were highly expressed in leukemic cells, as compared to wild-type thymocytes. 
Conversely, CD40 ligand (Cd40l) expression was not detected in leukemic cells, even though 
it was expressed in wild-type thymocytes. Lta, Ltb, Light and Rankl gene expression in TJ2-
Tg leukemic cells may reflect either the differentiation stage of the cell of origin or result 
from gene expression alterations linked to the oncogenic process itself. On the other hand, the 
lack of CD40l expression, which is highly expressed in CD4 SP but not in CD8 SP and DP 
thymocytes, likely reflects the differentiation stage of leukemic cells (Desanti et al., 2012; 
Hikosaka et al., 2008). In addition, the LTβR and RANK genes were found to be expressed in 
whole thymic lymphomas. Therefore, the presented data suggests that the pattern of LTβR 
and RANK and their cognate ligand expression in thymic lymphomas is similar to that found 
in the normal thymus. Furthermore, similarly to the physiological crosstalk, TJ2-Tg leukemic 
cells expressing the ligands can also potentially interact with their cognate receptors in 
stromal cells and thus modulate the thymic lymphoma microenvironment. The detection of 
low LTβR protein expression in TJ2-Tg leukemic cells and in wild-type thymocytes may be 
derived from a small subset of DN and γδ thymocytes (Silva-Santos et al., 2005), or 
contamination with few DCs that may permeate the strainer used to separate TJ2-Tg 
leukemic cells from thymic lymphoma stromal cells. Nonetheless, the level of Ltbr mRNA 
expression in whole WT thymocytes and TJ2-Tg cells was undetectable like previously 
shown for the former (Seach et al., 2008). 
Despite the high levels of Lta, Ltb and Light expression in TJ2-Tg leukemic cells, 
surface LTβR ligands were barely detectable by flow cytometry, although LTβ protein was 
detected upon leukemic cell permeabilization. Thus, these results suggest that either the 
ligand surface levels are tightly regulated in vivo, or upon LTβR activation on stromal cells, 
the surface level of LTα1β2 in thymocytes is downmodulated possibly due to an 
autoregulatory mechanism to dampen LTβR activation. The fact that we could not detect high 
cell surface levels of LTβR ligands in freshly collected leukemic cells does not exclude the 
possibility that these cells can activate LTβR in thymic lymphomas. In fact, Boehm and 
coworkers (2003) showed that LTβR ligands were not detectable by flow cytometry LTβR-Fc 
staining neither in wild-type nor in Ltbr+/- thymocytes despite the important role the LTβR 
signaling pathway plays in the normal mouse thymus, as demonstrated by the loss of the 
three-dimensional thymic medullary epithelial cell network by systemic administration of 
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LTβR-Fc fusion protein (Boehm et al., 2003). However, LTβR ligands were clearly 
expressed at the surface of mature CD4 SP and CD8 SP thymocytes from Ltbr-/- mice. These 
findings suggest that when LTα1β2 does not interact with LTβR, it is either induced to 
supraphysiological levels or retained in the membrane of leukemic T cells or normal 
thymocytes. 
According with the notion that LTα1β2 heterotrimers are lost from the cell surface 
upon interaction with LTβR, those proteins were found to be upregulated at the leukemic cell 
surface upon ex vivo culture in the absence of stromal cells. Furthermore, these were also 
detected at the surface of leukemic cells collected from TJ2-Tg;Ltbr-/-diseased mice, but not 
TJ2-Tg;Ltbr+/-. Since transplantation of TJ2-Tg leukemic cells into Ltbr+/- or Ltbr-/- mice 
showed that LTα1β2 expression on the surface of these cells were detectable only in a Ltbr-
deficient background, we confirmed that the LTβR-expressing cells interacting with leukemic 
cells, resulting in loss of LTα1β2 from the membrane, are microenvironmental cells.  
Supporting the notion that the effects on surface lymphotoxin expression was directly 
linked to LTβR expression and not due to systemic effects, nor structural defects found in 
LTβR-deficient mice, we used simple co-culture systems to study LTα1β2 cell surface 
expression. We detected surface LTα1β2 on leukemic cells in direct contact with LTβR-
deficient MEFs, but not on leukemic cells in contact with LTβR-expressing MEFs or MS5 
stromal cells. Furthermore, surface lymphotoxin downmodulation depended on direct contact 
with LTβR-expressing cells, since weak downmodulation occurred in co-cultured leukemic 
cells that did not adhere to stromal cells and in leukemic cells cultured with conditioned 
medium collected from co-cultures. The fact that we used two-dimensional (2D) co-cultures, 
which do not mimic the three-dimensional (3D) thymic stromal structure where thymocytes 
relocate through chemotaxis and passive inward flow contacting with virtually all mTECs 
(Hikosaka et al., 2008), may have precluded the downmodulation of LTα1β2 ligands at the 
surface of all TJ2-Tg leukemic cells, specially those non-adhering to stromal cells. 
Furthermore, our results have shown that the interaction of LTα1β2 with soluble extracellular 
region of LTβR (fused to human immunoglobulin Fc) is not sufficient to induce ligand 
downmodulation. This result suggests that LTα1β2 downmodulation may rely on specific 
conformational alterations or on the activation of signaling pathways downstream of LTβR. 
Alternatively, LTα1β2 downmodulation may depend on LTβR immobilization at the surface 
of another cell or adsorbed to plastic. Supporting this notion, it was previously shown that the 
use of soluble or immobilized LTβR as well as other TNFSF member agonists resulted in 
diverse effects, presumably by creating an higher level of receptor clustering in the latter case 
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(Bazzoni and Beutler, 1995; Beyaert and Fiers, 1994; Browning et al., 1996; Degli-Esposti et 
al., 1997; Grell et al., 1995). 
Although the mechanism of surface lymphotoxin downmodulation remains to be 
determined, our data show that it depends on LTβR interaction. It is therefore possible that 
LTα1β2 may be continuously expressed and removed from thymocyte/leukemic cell surface 
by shedding (Young et al., 2010) or internalized as a mechanism used by these cells to detach 
from LTβR-expressing stromal cells after signaling initiation, or to terminate activation of the 
receptor that could potentially lead to deleterious effects on stromal cells, including apoptosis 
(Heikenwalder et al., 2008; Liepinsh et al., 2009). An alternative explanation is that LTβR 
activation in stromal cells induces the expression of specific proteins that may be associated 
with a negative feedback loop acting in vivo to repress the expression of the ligands in T cells 
(Boehm et al., 2003). In addition, it is also possible that low ligand expression at the cell 
surface and decreased valency of the extracellular trigger is compensated by cooperation of 
the LTβR-induced intracellular signaling assemblies. In this model, minimal extracellular 
ligand-induced LTβR clustering would be sufficient to trigger the intracellular signal 
(Sudhamsu et al., 2013). To test this hypothesis, further analysis of the events stemming from 
different levels of receptor oligomerization and the varying lifetime of the oligomerized 
states would be required to understand LTβR activation. Furthermore, the mechanisms 
leading to ligand downmodulation need to be studied using for instance pharmacological 
inhibitors of protein shedding and endocytosis.  
 Regarding the alternative LTβR ligand, LIGHT expression at the cell surface of TJ2-
Tg leukemic cells was never detected neither in freshly collected leukemic cells, nor in cells 
cultured ex vivo. Therefore, either Light mRNA is translated and the protein is stored in 
intracellular compartments, is shed from the cell surface (Morel et al., 2000), or it is not even 
translated. The fact that LIGHT surface expression was not induced after ex vivo culture may 
also be explained by the observed Light mRNA downregulation under these conditions. 
 Likewise, RANKL expression at the surface of TJ2-Tg leukemic cells was also hardly 
detectable by flow cytometry using a RANKL monoclonal antibody. These results can be 
explained by RANKL cleavage from the cell surface by proteases (Lum et al., 1999) and/or 
intracellular storage and restriction of cell surface RANKL presentation only upon RANK 
binding, like previously shown for osteoblasts and osteocytes (Aoki et al., 2010; Honma et 
al., 2013). As proposed above for LTβR, it is possible that intracellular signaling assemblies 
would compensate for the reduced extracellular ligand-induced RANK clutering and trigger 
the intracellular signal. 
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The fact that both LTβR ligands and RANK ligand were expressed in TJ2-Tg cells 
leaves open the question whether LTβR and RANK signaling share redundancy, cooperate 
and/or have synergistic effects, as shown in other contexts (Brunetti et al., 2014; Hemingway 
et al., 2013; Mouri et al., 2011; Rossi et al., 2007). Interestingly, a correlation between Lta 
and Rankl expression was found in primary TJ2-Tg leukemic cells suggesting that these may 
be activated by the same mechanism(s). Furthermore, it raises the possibility that LTβR and 
RANK signaling may cooperate in T-cell leukemogenesis like they cooperate in mTEC 
development and organization (Akiyama et al., 2012; Mouri et al., 2011). 
 
 
4.2. MECHANISM OF TNFSF LIGAND EXPRESSION IN TJ2-TG LEUKEMIC 
CELLS 
 
Several stmuli may underlie LTβR ligand expression in TJ2-Tg leukemic cells. So, we sought 
to determine the mechanism of lymphotoxin gene expression in these cells. Treatment of T 
lymphocytes with PMA and ionomycin leads to T cell activation, resulting in cytokine 
production, cytokine receptor expression, and ultimately cell proliferation. These two agents 
constitute a pharmacological means of activating signaling pathways downstream of pre-
TCR/TCRαβ and other receptors by producing an elevation of intracellular free calcium with 
a calcium ionophore (ionomycin) combined with activation of protein kinase C (conventional 
and novel isoforms) by the PMA phorbol ester. Following stimulation with PMA and 
ionomycin, NF-κB and calcineurin signaling pathways are activated in leukemic T cells 
(Medyouf et al., 2007; dos Santos et al., 2008; Serwold et al., 2010). Importantly, pre-
TCR/TCRαβ signaling transmits either survival or death signals throughout T-cell 
development, and pre-TCR has been shown to cooperate with the TEL-JAK2 fusion protein 
as well as other oncoproteins to induce T-cell leukemia (Bellavia et al., 2002; Campese et al., 
2006; dos Santos et al., 2007; Talora et al., 2006). In agreement with previous reports 
showing that TCR signaling induces lymphotoxin genes in mature thymocytes (Hikosaka et 
al., 2008), PMA and ionomycin treatment induced lymphotoxin gene transcription and 
surface LTα1β2 expression in primary TJ2-Tg leukemic T cells. By treating TJ2-Tg leukemic 
cells with pharmacological inhibitors, we verified that both basal and PMA/ionomycin-
induced lymphotoxin expression was dependent on IKK/NF-kB activity, and that Lta 
expression was also dependent on JAK kinase activity, which is in line with previous reports 
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on T cells (Kuprash et al., 1996; Lu et al., 1998; Paul et al., 1993; Voon et al., 2004). NF-κB 
signaling in T cells can be activated by TCRαβ or pre-TCR signaling (Aifantis et al., 2001; 
Cheng et al., 2011; Moore et al., 1995). Supporting the notion that these receptor complexes 
may upregulate lymphotoxin genes in T-ALL, we observed that Ltb mRNA levels were 
reduced in TJ2-Tg leukemic cells lacking pre-TCR/TCRαβ (Rag2 deficiency). It was 
previously shown that in contrast to Ltb, which is constitutively expressed, Lta expression is 
inducible in thymocytes (Browning et al., 1993). So, our findings support the notion that LTβ 
gene expression in T-ALL may be induced by TCR or pre-TCR signaling in an NF-kB-
dependent manner. On the other hand, LTα may be induced in TJ2-Tg leukemic cells due to 
constitutive TEL-JAK2 activation, in addition to NF-κB activation. Since JAK/STAT 
signaling is often active in T-ALL, this signaling pathway may also upregulate LTA 
expression in these cells. 
 Light mRNA basal levels in TJ2-Tg leukemic cells were also shown to depend on 
IKK/NF-kB activity, but not to be consistently downmodulated by an IKK inhibitor 
following stimulation with PMA and ionomycin. Since calcineurin/NFAT signaling was 
shown to be inactivated ex vivo in TJ2-Tg leukemic cells (Medyouf et al., 2007) and our 
results showed that Light expression was often downregulated or unchanged when leukemic 
cells were cultured ex vivo for 10h, this observation supports the possibility that 
calcineurin/NFAT signaling may underlie Light expression in vivo. This notion is in 
accordance with a previous study showing that calcineurin/NFAT signaling activates Light 
expression in T cells (Castellano et al., 2002). In addition, Light downregulation in ex vivo-
cultured leukemic cells was reversed by PMA and ionomycin stimulation, probably due to 
ionomycin-induced calcineurin/NFAT reactivation (Medyouf et al., 2007) and not NF-κB 
activation. Nevertheless, LIGHT protein expression at the surface of TJ2-Tg cells was not 
detected even after stimulation. 
 Similarly to lymphotoxin, RANKL cell surface expression was induced following 
PMA and ionomycin stimulation. Moreover, further supporting a role for NF-κB in Rankl 
expression induction, treatment with the IKK inhibitor could reduce Rankl mRNA expression 
in cultured cells treated or not with PMA and Ionomycin. Together, these experiments define 
IKK kinases as key regulators of Lta, Ltb, Light, and Rankl expression in TJ2-Tg leukemic 
cells. The mechanisms identified are not exclusive of these leukemic cells since we identified 
the same mechanisms in normal thymocytes. However, the observed gene and protein 
expression levels indicate that their activation is exacerbated in leukemic cells. 
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 Besides NF-κB and JAK/STAT signaling pathways, others have been described to 
induce the expression of TNF ligand family genes. As mentioned before, the study of 
calcineurin/NFAT signaling pathway in these mechanisms has been hindered by the fact that 
when TJ2-Tg leukemic cells are cultured ex vivo, NFAT proteins are inactivated by 
hyperphosphorylation and, as a result, become insensitive to the effect of the calcineurin 
inhibitor cyclosporine A (CsA) (Medyouf et al., 2007). Similarly, the study of Notch 
signaling pathway and its possible impact on LTβR ligand expression is hindered by the 
presence of diverse Notch-activating point mutations (unpublished results), which can render 
TJ2-Tg leukemic cells resistant to Notch inhibition. Furthermore, considering potential 
signaling pathway crosstalk, it would be also worthy to study other signaling pathways 
frequently activated in T-ALL, like the MAPK or PI3K/AKT pathways (Zhao, 2010) in the 
regulation of TNFSF gene expression. 
In future studies, it would also be interesting to study the impact of the activation of 
other receptors known to be expressed in T-ALL (e.g., IL-7R, TNFα, and CCR7) on LTβR 
ligand expression in TJ2-Tg leukemic cells (Buonamici et al., 2009; Scupoli et al., 2007; 
Voon et al., 2004). 
 
 
4.3. IMPACT OF LTβR SIGNALING ABROGATION ON T-CELL 
LEUKEMOGENESIS 
 
Although LTβR is known to be important for microenvironment establishment in solid and 
hematopoietic tumors (Ammirante et al., 2010; Haybaeck et al., 2009; Heinig et al., 2014; 
Rehm et al., 2011), its role in T-cell leukemia has never been explored. Notably, this study 
reveals a non-redundant role for LTβR in TEL-JAK2-induced leukemia. 
 In human T-ALL, leukemic transformation was reported to require at least three 
successive mutations that occur during hematopoietic differentiation and drive normal T-cells 
into uncontrolled cell growth and clonal expansion (Ferrando and Look, 2003). Similarly, 
TJ2-Tg mice develop fatal, oligoclonal leukemia after variable latency (Carron et al., 2000). 
Furthermore, the same TEL-JAK2 fusion protein has been shown to be capable of inducing a 
CML-like disease, B-ALL or a T-ALL disease in other experimental mouse models (Ihle and 
Gilliland, 2007), depending on the cellular compartment where it is expressed. These two 
findings suggest that the basis for the disease heterogeneity may be related to the acquisition 
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by hematopoietic target cells of secondary transforming events and/or microenvironmental 
factors supporting leukemogenesis in addition to the TEL-JAK2 kinase activity. 
Although the absence of LTβR was not sufficient to prevent leukemia progression and 
leukemia-related death, it significantly delayed T-cell leukemia onset in TJ2-Tg;Ltbr-/- mice 
as compared to TJ2-Tg;Ltbr+/- littermates. This delay likely reflects the notion that leukemic 
cells require more time to acquire additional transforming events and/or that 
microenvironment assistance to these cells is affected when the receptor is absent. TJ2-
Tg;Ltbr-/- mice presented a mean survival time of 23 weeks while TJ2-Tg;Ltbr+/- mice 
displayed a mean survival of 15 weeks. Therefore, interference with LTβR signaling resulted 
on average in an 8-week delay in leukemia-derived TJ2-Tg mouse death. These inhibitory 
effects prompt us to reason whether interventions that prevent LTβR signaling after disease 
onset may delay leukemia-related mouse death. For this purpose, it would be interesting to 
use targeting molecules like the LTβR-Fc fusion protein in pre-clinical trials.  
Despite the delayed onset of leukemia in LTβR-deficient mice, the tumor load in 
lymphoid organs and the cell surface marker phenotype of leukemic cells were not 
significantly altered. Although global differences in gene expression may exist, we can 
conclude that the tumors from the two mouse groups under study were phenotypically 
similar. 
 As Ltbr knockout mice do not develop lymph nodes and have altered thymic and 
splenic structures, it was conceivable that the delay in fatal leukemia/lymphoma development 
could be linked with a decreased tumor burden due to impaired lymphoma development in 
these lymphoid tissues, especially in lymph nodes. To discard this possibility, we inhibited 
lymphotoxin signaling in young pre-leukemic TJ2-Tg mice through the administration of 
neutralizing LTβR-Fc fusion protein. Substantiating our previous genetic results, LTβR-Fc 
treatment delayed leukemogenesis, and additionally induced accumulation of leukemic cells 
in the thymus and reduced tumor load in the bone marrow and peripheral blood.  
It was previously reported that leukemia was delayed and thymic tumor load was 
reduced in TJ2-Tg mice without RelB expression (dos Santos et al., 2008). LTβR-deficient 
mice did not present such reduction in thymic tumor load, supporting the idea that receptors 
other than LTβR may activate RelB in stromal cells to support leukemogenesis. 
Alternatively, the similar thymic lymphoma weights could be explained by confounding 
factors such as the absence of lymph nodes or the disturbed export of thymocytes from the 
thymus in LTβR-deficient mice, as compared to LTβR-proficient mice (Boehm et al., 2003).  
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Recently, some studies shed light on LTβR and RANK redundancy in 
osteoclastogenesis (Brunetti et al., 2014; Hemingway et al., 2013). In addition, both receptors 
activate RelB in mTECs (Akiyama et al., 2012). As such, some degree of LTβR and RANK 
redundancy in TEL-JAK2-induced leukemia may explain the fact that the differences found 
in LTβR-deficient TJ2-Tg mice and controls do not differ as much as we expected from the 
results obtained by RelB activation (dos Santos et al., 2008). Consequently, it would be 
important to study if RANK activation is involved in TEL-JAK2-induced leukemia in 
combination with LTβR. 
 
 
4.4. TIMING OF LTβR SIGNALING ACTION IN TEL-JAK2-INDUCED 
LEUKEMOGENESIS 
 
 
To understand how LTβR supports TEL-JAK2-induced leukemogenesis, thymi from pre-
leukemic transgenic mice were analyzed. It was found that before thymic enlargement, a 
population of aberrant, immature T cells characterized by CD8, CD24 and CD25 expression 
expands in the thymus. This cell population is malignant since they engraft and expand in 
Nude recipient mice following transplantation. Conversely, few or no CD8+CD25+ T cells 
were detected in other organs such as the spleen and BM in early stages of leukemia 
development, consistent with the notion that in TJ2-Tg leukemic mice, leukemic cells 
originate in the thymus. Notably, the expansion of CD8+CD25+ T cells in the thymus was 
associated with increased expression of Lta and Ltb.  
 Given that LTβR is expressed in thymic stromal cells, including epithelial cells and 
fibroblasts, but not thymocytes (Seach et al., 2008), our results indicate that emerging LT-
expressing leukemic cells require LTβR-expressing thymic stromal cells for rapid disease 
onset. At terminal phases of TJ2-Tg leukemogenesis, we observed no significant differences 
in tumor burden, indicating that LTβR activation is not absolutely required beyond the initial 
stages of the disease. Also discarding an essential role for LTβR in late stages of T-ALL 
development, engraftment and dissemination of TJ2-Tg leukemic cells transplanted to 
recipient mice through i.v. injection was not LTβR-dependent. However, leukemic cell 
infiltration is variable depending on the transplantation approach, so this experiment should 
be repeated by transplanting TJ2-Tg leukemic cells through intra-thymic injections in order 
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to evaluate the role of LTβR in leukemic cell engraftment in the thymus and dissemination 
from this to other organs. Furthermore, secondary tumors derived from the seeding of a large 
number of full-fledged, highly malignant cells possibly grows more autonomously than 
tumors resulting from a small number of spontaneously transformed cells. In addition, 
ectopic transplantation of tumor cells does not mirror the process of multistage 
carcinogenesis from the normal cells over an extended period of time.  
 The analysis of pre-leukemic mice showed that LTβR-deficiency specifically impairs 
leukemic cell expansion in the thymus in the early stages of disease development, when other 
organs do not present a significant degree of infiltration. Consequently, we conclude that the 
lack of lymph nodes in Ltbr-/- mice does not account for the delayed leukemia onset in TJ2-
Tg mice. 
Altogether our results indicate that stimulation of LTβR-expressing 
microenvironmental cells by emerging malignant thymocytes accelerates early oncogenesis. 
LTβR expression and activation in thymic stromal cells constitutes therefore a non-cell-
autonomous mechanism promoting T-ALL alongside with cell-autonomous mechanisms such 
as pre-TCR signaling (dos Santos et al., 2007). Whether LTβR-expressing 
microenvironmental cells from other organs are also involved in interaction with TJ2-Tg 
leukemic cells should be addressed in future studies. 
 
 
4.5. MECHANISM MEDIATING LTβR SUPPORTIVE ROLE IN T-ALL 
 
  
T-ALL develops from a complex interplay between genetic and microenvironmental factors. 
Indeed, the microenvironment where T-ALL develops may be modulated by these cells to 
gain a selective advantage. Several microenvironmental factors participating in T-ALL 
progression have been identified, including homeostatic cytokines, adhesion molecules, and 
pro-inflammatory mediators (Silva et al., 2011; Uzan et al., 2014; Winter et al., 2001). In 
addition, a link between pro-inflammatory factors and T-ALL development is illustrated by a 
recent report in which IL-18 pro-inflammatory cytokine expression by stromal cells was 
shown to support T-ALL progression (Uzan et al., 2014). Another interleukin essential for T-
cell development and homeostasis, IL-7, has been implicated in T-ALL development through 
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expression by T-ALL microenvironmental cells (Silva et al., 2011). Interestingly, IL-7 and 
IL-18 are both expressed by thymic epithelial cells (Ito et al., 2006; Ribeiro et al., 2013) and 
were shown to act in synergy to promote ex vivo expansion of T lymphoid progenitor cells 
(Gandhapudi et al., 2015), but the significance of these synergistic effects in vivo remains to 
be investigated. Nevertheless, the previous findings support the tumor-promoting effects of 
pro-inflammatory microenvironments in T-ALL. 
 The mechanism(s) by which LTβR signaling contributes to T-ALL development is 
not yet completely understood. Nevertheless, it is clear that the LTβR is linked to its 
expression in stromal cells, most likely from the thymic microenvironment. LTα1β2 reverse 
signaling, as found for other TNFSF ligands (Sun and Fink, 2007), has never been reported, 
so we infer that lymphotoxin expression in leukemic T cells promotes leukemogenesis 
through activation of LTβR in microenvironmental cells. 
 LTα1β2-LTβR signaling was shown to be responsible for generating inflammatory 
microenvironments leading to carcinogenesis (Ammirante et al., 2010; Bjordahl et al., 2013; 
Haybaeck et al., 2009). Furthermore, LTβR may support carcinogenesis either by regulating 
the development and organization of supportive tumor microenvironmental cell networks 
(Heinig et al., 2014; Rehm et al., 2011), or by inducing the expression of LTβR target genes 
in stromal cells that stimulate tumor cell growth and survival (Lau et al., 2014). One of these 
mechanisms or even both may be on the basis of the LTβR-expressing stromal cell supportive 
role in T-ALL development. Therefore, we reason that LTα1β2 expression in emerging 
malignant thymocytes may either be important for mTEC or fibroblastic cell network 
development and/or activate an NF-kB-dependent transcriptional program in thymic 
microenvironmental cells that promotes T-cell leukemogenesis. Cytokines and chemokines 
are relevant candidates, since they are induced by LTβR in stromal cells (Dejardin et al., 
2002; Seach et al., 2008). A possible collaboration between LTβR and RANK, as described 
in other cellular systems (Akiyama et al., 2012), may be involved in T-ALL 
microenvironmental modulation and/or in target gene expression induction. Such 
LTβR/RANK redundancy regarding NF-κB/RelB activation and common target gene 
induction may explain the failure to detect LTβR target gene differential expression in LTβR-
deficient leukemias. 
 Another question that remains unanswered is whether LTβR signaling in the thymic 
microenvironment promotes the survival and/or proliferation of the bulk leukemic cell 
population involved in T-ALL progression, or supports the rare, putative leukemia-initiating 
cell population (Konopleva et al., 2009) underlying T-ALL initiation and maintenance.  So 
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far, only one stroma-derived factor has been described to sustain T-ALL LICs, insulin-like 
growth factor-1 (IGF-1) (Medyouf et al., 2011). This growth factor binds and activates 
insulin-like growth factor-1 receptor (IGFR1), which was shown to be induced by Notch and 
is on its own required for LIC activity in T-ALL (Armstrong et al., 2009). 
 NOTCH1 protein is activated in more that 60% of T-ALL cases (Weng et al., 2004), 
and has been reported to induce the expression of receptors that integrate signals from the 
microenvironment in addition to IGFR1 (Medyouf et al., 2011). These include cytokine 
receptors such as CCR7 (Buonamici et al., 2009; Mirandola et al., 2012), and IL-7R 
(González-García et al., 2009). Notably, these receptors have also been implicated in T-ALL 
development (Buonamici et al., 2009; Qiuping et al., 2004; Silva et al., 2011).  Therefore, 
Notch activation enhances the responsiveness of T-ALL cells to microenvironmental factors. 
The importance of these factors is further supported by the identification of mutations 
constitutively activating the cognate receptors or downstream signaling mediators (e.g., IL-
7R, JAK1, JAK3, PI3K and AKT) that eliminate or reduce dependency on stromal cells (Van 
Vlierberghe and Ferrando, 2012; Zenatti et al., 2011; Zhang et al., 2012). Therefore, the 
possibility that Notch may also modulate the expression of other factors involved in crosstalk 
between T-ALL and stromal cells, like lymphotoxins proteins and RANK ligand is worth 
studying. 
An important aspect of the clinical progression of T-ALL is the dissemination of 
transformed T cell progenitors from the organ of origin, likely the thymus, through the 
bloodstream, leading to high white blood cell counts in the peripheral blood and large tumor 
burden in infiltrated organs, including the bone marrow, spleen, and brain. Although the 
mechanism is not completely understood, some studies have identified few important players 
responsible for leukemic cell export from the thymus and consequent dissemination through 
the bloodstream, including S1P1 and ICAM-1 (Feng et al., 2010). Importantly, the 
confinement of leukemic cells to the thymus, originating large thymic lymphomas, was 
shown to lead to a milder disease phenotype in the T-ALL zebrafish model (Feng et al., 
2010). A more recent study, implicated also TCR, and to a lesser extent common gamma 
chain (γc)-containing receptor signaling in T-ALL egress from the thymus (Hagenbeek et al., 
2014). Although our observations on the impact of LTβR signaling inhibition using LTβR-Fc 
requires further investigation, it is noteworthy that we found a tendency for higher tumor 
burden in the thymus and lower leukemic cell number both in the peripheral blood and 
infiltrating the bone marrow, in combination with improved survival. In accordance with 
these results, LTβR was previously implicated in mature T-cell export from the thymus 
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(Boehm et al., 2003) presumably trough activation of NF-κB-inducing kinase (NIK) (Mouri 
et al., 2011). 
 Finally, the immune system was reported to negatively affect T-ALL development 
(Schneider et al., 2010; Uzan et al., 2014). Since Ltbr knockout mice present signs of 
immunity due to defective cental tolerance (Boehm et al., 2003), we reasoned the immune 
system could have anti-ALL effects in TJ2-Tg mice, similarly to what has been shown for 
prostate cancer in mice (Zhou et al., 2009). However, this possibility seems unlikely because 
evident signs of auto-immunity were detected only in 24-week-old mice (Boehm et al., 
2003), an age when almost all LTβR-proficient TJ2-Tg mice have already died.  
Although the LTβR-dependent mechanism supporting T-cell leukemogenesis in TJ2-
Tg mice requires further investigation, the hypothesis that leukemic T cells upregulate 
LTα1β2 and engage in crosstalk with LTβR-expressing stromal cells to generate a pro-
leukemogenic thymic stromal microenvironment seems the most likely to explain this 
mechanism. However, it remains unclear if the microenvironment favors the occurrence of 
transforming events and/or sustains specifically the survival or proliferation of transformed 
cells over non-transformed cells. 
 
 
4.6. ROLE OF LYMPHOTOXIN IN HUMAN T-ALL 
 
 
Supporting a role for LTα1β2-LTβR signaling in human T-ALL, LTA and LTB mRNA (but 
not LIGHT), as well as lymphotoxin cell surface expression, were detected at variable levels 
in human T-ALL cell lines. Surface lymphotoxin was upregulated by PMA treatment in all T-
ALL cell lines analyzed, in agreement with published data (Browning et al., 1997). 
Moreover, IKK inhibition not only downregulated LTA and LTB mRNAs but also blocked 
PMA-induced lymphotoxin surface expression, thus confirming that lymphotoxin genes are 
regulated by IKK/NF-κB signaling in both mouse and human T-ALL.  
Importantly, LTA and LTB mRNA was also detected in primary patient samples. 
Despite the low number of patient samples analyzed in a preliminary study, two cases 
presented relatively high levels of both LTA and LTB genes, as compared to normal human 
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thymocytes, suggesting that increased lymphotoxin expression may occur in a subset of T-
ALL patients. 
 By performing unsupervised clustering analysis of transcriptomic data, we found that 
TJ2-Tg leukemia presents features of cortical/mature T-cell leukemia. Although no increased 
expression of the TAL1 or LMO1/2 proto-oncogenes was found in TJ2-Tg leukemic cells, 
these cells present molecular features similar to those present in TAL/LMO T-ALL (e.g., 
TCR loci rearrangements, TCR/CD3 surface expression, and CD4/CD8 DP 
immunophenotype). Interestingly, lymphotoxin gene expression was found in T-ALL cells 
from a large cohort, being more pronounced in TAL/LMO T-ALL. Conversely, no significant 
associations were found between LTA/LTB expression and the clinical features of human T-
ALL.  
 Although lymphotoxin expression in human T-ALL cell lines has long been known, 
the present study is the first to our knowledge showing lymphotoxin expression in human T-
ALL primary samples. These findings call for further studies on the role of the LTα1β2-LTβR 
signaling axis in human T-ALL development. 
 
 
4.7. LTβR AS A POSSIBLE THERAPEUTIC TARGET IN HUMAN T-ALL 	  
 
Cell-autonomous alterations are heavily implicated in the origin of T-ALL and 
accordingly have been widely studied. However, only relatively few studies explored the 
microenvironmental factors that contribute to T-ALL expansion and progression. Moreover, 
emerging evidence indicates that solid and hematopoietic malignancies manipulate 
components of the LTα1β2-LTβR signaling axis to modify their tumor microenvironment. 
These alterations create tumor-permissive microenvironments that provide strong selective 
pressure for tumor evolution and growth, protection from immune assaults, or even resistance 
to therapeutic approaches. In this context, the novelty of our study resides in the 
identification of the LTα1β2-LTβR signaling axis as a modulator of the T-cell leukemia 
microenvironments.   
 Notably, LTβR signaling abrogation by LTβR-Fc (baminercept) affected leukemia 
development and dissemination in TJ2-Tg mice, suggesting that inhibition of crosstalk 
between leukemic and stromal cells through this signaling pathway may be involved in 
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different aspects of T-ALL. Moreover, suggesting that LTα1β2-LTβR signaling axis may also 
be involved in human T-ALL development, we found that lymphotoxin genes are expressed 
in human T-ALL cell lines and primary samples, prominently in TAL/LMO T-ALL samples. 
 Altogether, this study contributes to a better understanding of the mechanisms of T-
ALL pathogenesis. Accordingly, the gained knowledge reveals that inhibition of the LTα1β2-
LTβR signaling axis is as a potential novel therapeutic opportunity to target pro-oncogenic 
mechanisms not intrinsic to leukemic cells, which often display high mutation rates leading 
to secondary resistance to therapy.  
 To this end, uncovering the precise mechanism(s) by which this axis supports 
leukemogenesis will be of great value. First, future studies should determine which 
microenvironmental cells and LTβR-derived signals play a role in T-ALL pathogenesis. 
Moreover, the question on how CD8+CD25+ malignant thymocytes expand in LTβR-
proficient thymi should be addressed. In addition, it should be determined if CD8+CD25+ 
malignant thymocytes arising early in the thymus constitute leukemia-initiating cells or bulk 
leukemia cells. Second, we should further address whether lymphotoxin signaling is involved 
in later phases of T-ALL progression in addition to the initial steps in the thymus. Our results 
show a tendency of reduced bloodborne leukemic cell dissemination to distant metastatic 
sites in the absence of LTβR signaling, which should be further examined. Consequently, 
LTβR signaling may be involved in multiple aspects of leukemia development just like it is 
in thymocyte development and export from the thymus. In this line, it would be interesting to 
evaluate if it is also involved in leukemic cell engraftment and growth in peripheral organs 
like it has been shown for malignant B cells in lymph nodes (Rehm et al., 2011) and spleen 
(Heinig et al., 2014). In addition, an in-depth scrutiny on the effects of LTβR-Fc block in 
TJ2-Tg leukemic mice should be considered in larger cohorts of mice. This would contribute 
to evaluate the possibility of interfering with this signaling axis in different phases of the 
disease as a therapeutic approach, or as a preventive strategy. Third, we found some shared 
features between TEL-JAK2-induced leukemia and human T-ALL that support the 
importance of further investigation on the impact of LTβR signaling inactivation. To this end, 
and as a preliminary approach, xenograft models consisting of mice transplanted with human 
primary T-ALL leukemias could be used as a model. Finally, a potential collaboration 
between LTβR and RANK signaling in T-ALL development should be further explored 
either using double knockout mice or simultaneous pharmacological block of both signaling 
axes.  
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 The answer to all these questions may contribute to the development of rational 
therapies targeting the communication between leukemic and stromal cells namely by 
inhibition of LTα1β2-LTβR signaling alone or in combination with RANKL-RANK 
signaling. Importantly, inhibitors for both pathways are already used to treat other 
pathologies or in clinical trials (Denosumab, Amgen; Baminercept, Biogen Idec). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
 
 
 
 
 
	   
 
 
 
 
 
REFERENCES 
MT Fernandes 141 
Adélaïde, J., Pérot, C., Gelsi-Boyer, V., Pautas, C., Murati, A., Copie-Bergman, C., Imbert, 
M., Chaffanet, M., Birnbaum, D., and Mozziconacci, M.-J. (2006). A t(8;9) translocation 
with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 20, 536–537. 
Adolfsson, J., Månsson, R., Buza-Vidas, N., Hultquist, A., Liuba, K., Jensen, C.T., Bryder, 
D., Yang, L., Borge, O.-J., Thoren, L.A.M., et al. (2005). Identification of Flt3+ lympho-
myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult 
blood lineage commitment. Cell 121, 295–306. 
Ahuja, H.G., Foti, A., Bar-Eli, M., and Cline, M.J. (1990). The pattern of mutational 
involvement of RAS genes in human hematologic malignancies determined by DNA 
amplification and direct sequencing. Blood 75, 1684–1690. 
Aifantis, I., Gounari, F., Scorrano, L., Borowski, C., and von Boehmer, H. (2001). 
Constitutive pre-TCR signaling promotes differentiation through Ca2+ mobilization and 
activation of NF-kappaB and NFAT. Nat. Immunol. 2, 403–409. 
Aifantis, I., Raetz, E., and Buonamici, S. (2008). Molecular pathogenesis of T-cell leukaemia 
and lymphoma. Nat. Rev. Immunol. 8, 380–390. 
Akashi, K., Traver, D., Miyamoto, T., and Weissman, I.L. (2000). A clonogenic common 
myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193–197. 
Akiyama, T., Maeda, S., Yamane, S., Ogino, K., Kasai, M., Kajiura, F., Matsumoto, M., and 
Inoue, J. (2005). Dependence of self-tolerance on TRAF6-directed development of thymic 
stroma. Science 308, 248–251. 
Akiyama, T., Shimo, Y., Yanai, H., Qin, J., Ohshima, D., Maruyama, Y., Asaumi, Y., 
Kitazawa, J., Takayanagi, H., Penninger, J.M., et al. (2008). The tumor necrosis factor family 
receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment 
and self-tolerance. Immunity 29, 423–437. 
Akiyama, T., Shinzawa, M., and Akiyama, N. (2012). TNF receptor family signaling in the 
development and functions of medullary thymic epithelial cells. Front. Immunol. 3, 278. 
Akiyama, T., Shinzawa, M., Qin, J., and Akiyama, N. (2013). Regulations of gene expression 
in medullary thymic epithelial cells required for preventing the onset of autoimmune 
diseases. Front. Immunol. 4, 249. 
Alimzhanov, M.B., Kuprash, D.V., Kosco-Vilbois, M.H., Luz, A., Turetskaya, R.L., 
Tarakhovsky, A., Rajewsky, K., Nedospasov, S.A., and Pfeffer, K. (1997). Abnormal 
development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proc. Natl. 
Acad. Sci. U. S. A. 94, 9302–9307. 
American cancer Society (2015). Cancer Facts and Figures 2015. American Cancer Society, 
Inc. 
Ammirante, M., Luo, J.-L., Grivennikov, S., Nedospasov, S., and Karin, M. (2010). B-cell-
derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464, 302–305. 
Anders, R.A., Subudhi, S.K., Wang, J., Pfeffer, K., and Fu, Y.-X. (2005). Contribution of the 
lymphotoxin beta receptor to liver regeneration. J. Immunol. 175, 1295–1300. 
Anderson, D.M., Maraskovsky, E., Billingsley, W.L., Dougall, W.C., Tometsko, M.E., Roux, 
E.R., Teepe, M.C., DuBose, R.F., Cosman, D., and Galibert, L. (1997). A homologue of the 
TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 
175–179. 
REFERENCES	  
MT Fernandes 142 
Androlewicz, M.J., Browning, J.L., and Ware, C.F. (1992). Lymphotoxin is expressed as a 
heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated 
human T cell hybridoma. J. Biol. Chem. 267, 2542–2547. 
Ansel, K.M., Ngo, V.N., Hyman, P.L., Luther, S.A., Förster, R., Sedgwick, J.D., Browning, 
J.L., Lipp, M., and Cyster, J.G. (2000). A chemokine-driven positive feedback loop organizes 
lymphoid follicles. Nature 406, 309–314. 
Aoki, S., Honma, M., Kariya, Y., Nakamichi, Y., Ninomiya, T., Takahashi, N., Udagawa, N., 
and Suzuki, H. (2010). Function of OPG as a traffic regulator for RANKL is crucial for 
controlled osteoclastogenesis. J. Bone Miner. Res. 25, 1907–1921. 
Appert, A., Nam, C.-H., Lobato, N., Priego, E., Miguel, R.N., Blundell, T., Drynan, L., 
Sewell, H., Tanaka, T., and Rabbitts, T. (2009). Targeting LMO2 with a peptide aptamer 
establishes a necessary function in overt T-cell neoplasia. Cancer Res. 69, 4784–4790. 
Arai, F., Miyamoto, T., Ohneda, O., Inada, T., Sudo, T., Brasel, K., Miyata, T., Anderson, 
D.M., and Suda, T. (1999). Commitment and differentiation of osteoclast precursor cells by 
the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) 
receptors. J. Exp. Med. 190, 1741–1754. 
Armstrong, F., Brunet de la Grange, P., Gerby, B., Rouyez, M.-C., Calvo, J., Fontenay, M., 
Boissel, N., Dombret, H., Baruchel, A., Landman-Parker, J., et al. (2009). NOTCH is a key 
regulator of human T-cell acute leukemia initiating cell activity. Blood 113, 1730–1740. 
Arron, J.R., Vologodskaia, M., Wong, B.R., Naramura, M., Kim, N., Gu, H., and Choi, Y. 
(2001). A positive regulatory role for Cbl family proteins in tumor necrosis factor-related 
activation-induced cytokine (trance) and CD40L-mediated Akt activation. J. Biol. Chem. 276, 
30011–30017. 
Asnafi, V., Beldjord, K., Boulanger, E., Comba, B., Le Tutour, P., Estienne, M.-H., Davi, F., 
Landman-Parker, J., Quartier, P., Buzyn, A., et al. (2003). Analysis of TCR, pT alpha, and 
RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-
lymphoid lineage commitment. Blood 101, 2693–2703. 
Asnafi, V., Beldjord, K., Libura, M., Villarese, P., Millien, C., Ballerini, P., Kuhlein, E., 
Lafage-Pochitaloff, M., Delabesse, E., Bernard, O., et al. (2004). Age-related phenotypic and 
oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. 
Blood 104, 4173–4180. 
Aster, J.C., Xu, L., Karnell, F.G., Patriub, V., Pui, J.C., and Pear, W.S. (2000). Essential roles 
for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. 
Mol. Cell. Biol. 20, 7505–7515. 
Bago-Horvath, Z., Schmid, K., Rössler, F., Nagy-Bojarszky, K., Funovics, P., and 
Sulzbacher, I. (2014). Impact of RANK signalling on survival and chemotherapy response in 
osteosarcoma. Pathology 46, 411–415. 
Balgobind, B.V., Van Vlierberghe, P., van den Ouweland, A.M.W., Beverloo, H.B., 
Terlouw-Kromosoeto, J.N.R., van Wering, E.R., Reinhardt, D., Horstmann, M., Kaspers, 
G.J.L., Pieters, R., et al. (2008). Leukemia-associated NF1 inactivation in patients with 
pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 111, 4322–4328. 
Balkwill, F. (2004). Cancer and the chemokine network. Nat. Rev. Cancer 4, 540–550. 
Banks, T.A., Rouse, B.T., Kerley, M.K., Blair, P.J., Godfrey, V.L., Kuklin, N.A., Bouley, 
D.M., Thomas, J., Kanangat, S., and Mucenski, M.L. (1995). Lymphotoxin-alpha-deficient 
REFERENCES 
MT Fernandes 143 
mice. Effects on secondary lymphoid organ development and humoral immune 
responsiveness. J. Immunol. 155, 1685–1693. 
Banks, T.A., Rickert, S., Benedict, C.A., Ma, L., Ko, M., Meier, J., Ha, W., Schneider, K., 
Granger, S.W., Turovskaya, O., et al. (2005). A lymphotoxin-IFN-beta axis essential for 
lymphocyte survival revealed during cytomegalovirus infection. J. Immunol. 174, 7217–
7225. 
Basak, S., Kim, H., Kearns, J.D., Tergaonkar, V., O’Dea, E., Werner, S.L., Benedict, C.A., 
Ware, C.F., Ghosh, G., Verma, I.M., et al. (2007). A fourth IkappaB protein within the NF-
kappaB signaling module. Cell 128, 369–381. 
Bazzoni, F., and Beutler, B. (1995). How do tumor necrosis factor receptors work? J. 
Inflamm. 45, 221–238. 
Bechill, J., and Muller, W.J. (2014). Herpesvirus entry mediator (HVEM) attenuates signals 
mediated by the lymphotoxin β receptor (LTβR) in human cells stimulated by the shared 
ligand LIGHT. Mol. Immunol. 62, 96–103. 
Bekiaris, V., Šedy, J.R., Rossetti, M., Spreafico, R., Sharma, S., Rhode-Kurnow, A., Ware, 
B.C., Huang, N., Macauley, M.G., Norris, P.S., et al. (2013). Human CD4+CD3- innate-like 
T cells provide a source of TNF and lymphotoxin-αβ and are elevated in rheumatoid arthritis. 
J. Immunol. 191, 4611–4618. 
Bell, J.J., and Bhandoola, A. (2008). The earliest thymic progenitors for T cells possess 
myeloid lineage potential. Nature 452, 764–767. 
Bellavia, D., Campese, A.F., Checquolo, S., Balestri, A., Biondi, A., Cazzaniga, G., Lendahl, 
U., Fehling, H.J., Hayday, A.C., Frati, L., et al. (2002). Combined expression of pTalpha and 
Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc. 
Natl. Acad. Sci. U. S. A. 99, 3788–3793. 
Bene, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A., and van’t Veer, 
M.B. (1995). Proposals for the immunological classification of acute leukemias. European 
Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9, 1783–
1786. 
Benekli, M., Baer, M.R., Baumann, H., and Wetzler, M. (2003). Signal transducer and 
activator of transcription proteins in leukemias. Blood 101, 2940–2954. 
Bénézech, C., Mader, E., Desanti, G., Khan, M., Nakamura, K., White, A., Ware, C.F., 
Anderson, G., and Caamaño, J.H. (2012). Lymphotoxin-β receptor signaling through NF-
κB2-RelB pathway reprograms adipocyte precursors as lymph node stromal cells. Immunity 
37, 721–734. 
Berquam-Vrieze, K.E., Nannapaneni, K., Brett, B.T., Holmfeldt, L., Ma, J., Zagorodna, O., 
Jenkins, N.A., Copeland, N.G., Meyerholz, D.K., Knudson, C.M., et al. (2011). Cell of origin 
strongly influences genetic selection in a mouse model of T-ALL. Blood 118, 4646–4656. 
Bertacchini, J., Heidari, N., Mediani, L., Capitani, S., Shahjahani, M., Ahmadzadeh, A., and 
Saki, N. (2015). Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell. Mol. 
Life Sci. Epub ahead of print. 
Beyaert, R., and Fiers, W. (1994). Molecular mechanisms of tumor necrosis factor-induced 
cytotoxicity. What we do understand and what we do not. FEBS Lett. 340, 9–16. 
REFERENCES	  
MT Fernandes 144 
Bista, P., Zeng, W., Ryan, S., Bailly, V., Browning, J.L., and Lukashev, M.E. (2010). TRAF3 
controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta 
receptor. J. Biol. Chem. 285, 12971–12978. 
Bjordahl, R.L., Steidl, C., Gascoyne, R.D., and Ware, C.F. (2013). Lymphotoxin network 
pathways shape the tumor microenvironment. Curr. Opin. Immunol. 25, 222–229. 
Boehm, T., Scheu, S., Pfeffer, K., and Bleul, C.C. (2003). Thymic medullary epithelial cell 
differentiation, thymocyte emigration, and the control of autoimmunity require lympho-
epithelial cross talk via LTbetaR. J. Exp. Med. 198, 757–769. 
Bossen, C., Ingold, K., Tardivel, A., Bodmer, J.-L., Gaide, O., Hertig, S., Ambrose, C., 
Tschopp, J., and Schneider, P. (2006). Interactions of tumor necrosis factor (TNF) and TNF 
receptor family members in the mouse and human. J. Biol. Chem. 281, 13964–13971. 
Browning, J.L., Ngam-ek, A., Lawton, P., DeMarinis, J., Tizard, R., Chow, E.P., Hession, C., 
O’Brine-Greco, B., Foley, S.F., and Ware, C.F. (1993). Lymphotoxin beta, a novel member 
of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. 
Cell 72, 847–856. 
Browning, J.L., Dougas, I., Ngam-ek, A., Bourdon, P.R., Ehrenfels, B.N., Miatkowski, K., 
Zafari, M., Yampaglia, A.M., Lawton, P., and Meier, W. (1995). Characterization of surface 
lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. J. Immunol. 
154, 33–46. 
Browning, J.L., Miatkowski, K., Griffiths, D.A., Bourdon, P.R., Hession, C., Ambrose, C.M., 
and Meier, W. (1996). Preparation and characterization of soluble recombinant heterotrimeric 
complexes of human lymphotoxins alpha and beta. J. Biol. Chem. 271, 8618–8626. 
Browning, J.L., Sizing, I.D., Lawton, P., Bourdon, P.R., Rennert, P.D., Majeau, G.R., 
Ambrose, C.M., Hession, C., Miatkowski, K., Griffiths, D.A., et al. (1997). Characterization 
of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. J. Immunol. 159, 
3288–3298. 
Browning, J.L., Allaire, N., Ngam-Ek, A., Notidis, E., Hunt, J., Perrin, S., and Fava, R.A. 
(2005). Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV 
differentiation and function. Immunity 23, 539–550. 
Brunetti, G., Rizzi, R., Oranger, A., Gigante, I., Mori, G., Taurino, G., Mongelli, T., 
Colaianni, G., Di Benedetto, A., Tamma, R., et al. (2014). LIGHT/TNFSF14 increases 
osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. 
Oncotarget 5, 12950–12967. 
Buckle, C.H., De Leenheer, E., Lawson, M.A., Yong, K., Rabin, N., Perry, M., 
Vanderkerken, K., and Croucher, P.I. (2012). Soluble rank ligand produced by myeloma cells 
causes generalised bone loss in multiple myeloma. PloS One 7, e41127. 
Buonamici, S., Trimarchi, T., Ruocco, M.G., Reavie, L., Cathelin, S., Mar, B.G., Klinakis, 
A., Lukyanov, Y., Tseng, J.-C., Sen, F., et al. (2009). CCR7 signalling as an essential 
regulator of CNS infiltration in T-cell leukaemia. Nature 459, 1000–1004. 
Burger, R., Hansen-Hagge, T.E., Drexler, H.G., and Gramatzki, M. (1999). Heterogeneity of 
T-acute lymphoblastic leukemia (T-ALL) cell lines: suggestion for classification by 
immunophenotype and T-cell receptor studies. Leuk. Res. 23, 19–27. 
REFERENCES 
MT Fernandes 145 
Burkly, L., Hession, C., Ogata, L., Reilly, C., Marconi, L.A., Olson, D., Tizard, R., Cate, R., 
and Lo, D. (1995). Expression of relB is required for the development of thymic medulla and 
dendritic cells. Nature 373, 531–536. 
Campese, A.F., Garbe, A.I., Zhang, F., Grassi, F., Screpanti, I., and von Boehmer, H. (2006). 
Notch1-dependent lymphomagenesis is assisted by but does not essentially require pre-TCR 
signaling. Blood 108, 305–310. 
Capone, M., Hockett, R.D., and Zlotnik, A. (1998). Kinetics of T cell receptor beta, gamma, 
and delta rearrangements during adult thymic development: T cell receptor rearrangements 
are present in CD44(+)CD25(+) Pro-T thymocytes. Proc. Natl. Acad. Sci. U. S. A. 95, 
12522–12527. 
Cardoso, B.A., de Almeida, S.F., Laranjeira, A.B.A., Carmo-Fonseca, M., Yunes, J.A., 
Coffer, P.J., and Barata, J.T. (2011). TAL1/SCL is downregulated upon histone deacetylase 
inhibition in T-cell acute lymphoblastic leukemia cells. Leukemia 25, 1578–1586. 
Carron, C., Cormier, F., Janin, A., Lacronique, V., Giovannini, M., Daniel, M.T., Bernard, 
O., and Ghysdael, J. (2000). TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95, 
3891–3899. 
Casimiro, S., Mohammad, K.S., Pires, R., Tato-Costa, J., Alho, I., Teixeira, R., Carvalho, A., 
Ribeiro, S., Lipton, A., Guise, T.A., et al. (2013). RANKL/RANK/MMP-1 molecular triad 
contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PloS One 
8, e63153. 
Castellano, R., Van Lint, C., Peri, V., Veithen, E., Morel, Y., Costello, R., Olive, D., and 
Collette, Y. (2002). Mechanisms regulating expression of the tumor necrosis factor-related 
light gene. Role of calcium-signaling pathway in the transcriptional control. J. Biol. Chem. 
277, 42841–42851. 
Chai, Q., Onder, L., Scandella, E., Gil-Cruz, C., Perez-Shibayama, C., Cupovic, J., Danuser, 
R., Sparwasser, T., Luther, S.A., Thiel, V., et al. (2013). Maturation of lymph node 
fibroblastic reticular cells from myofibroblastic precursors is critical for antiviral immunity. 
Immunity 38, 1013–1024. 
Chang, Y.-H., Hsieh, S.-L., Chen, M.-C., and Lin, W.-W. (2002). Lymphotoxin beta receptor 
induces interleukin 8 gene expression via NF-kappaB and AP-1 activation. Exp. Cell Res. 
278, 166–174. 
Chaplin, D.D., and Fu, Y. (1998). Cytokine regulation of secondary lymphoid organ 
development. Curr. Opin. Immunol. 10, 289–297. 
Chen, W. (2004). The late stage of T cell development within mouse thymus. Cell. Mol. 
Immunol. 1, 3–11. 
Chen, C.M., You, L.R., Hwang, L.H., and Lee, Y.H. (1997). Direct interaction of hepatitis C 
virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway 
of the lymphotoxin-beta receptor. J. Virol. 71, 9417–9426. 
Chen, J., Jette, C., Kanki, J.P., Aster, J.C., Look, A.T., and Griffin, J.D. (2007). NOTCH1-
induced T-cell leukemia in transgenic zebrafish. Leukemia 21, 462–471. 
Chen, M.C., Hsu, T.L., Luh, T.Y., and Hsieh, S.L. (2000). Overexpression of bcl-2 enhances 
LIGHT- and interferon-gamma -mediated apoptosis in Hep3BT2 cells. J. Biol. Chem. 275, 
38794–38801. 
REFERENCES	  
MT Fernandes 146 
Chen, M.-C., Hwang, M.-J., Chou, Y.-C., Chen, W.-H., Cheng, G., Nakano, H., Luh, T.-Y., 
Mai, S.-C., and Hsieh, S.-L. (2003). The role of apoptosis signal-regulating kinase 1 in 
lymphotoxin-beta receptor-mediated cell death. J. Biol. Chem. 278, 16073–16081. 
Cheng, J., Montecalvo, A., and Kane, L.P. (2011). Regulation of NF-κB induction by 
TCR/CD28. Immunol. Res. 50, 113–117. 
Cheung, T.C., Steinberg, M.W., Oborne, L.M., Macauley, M.G., Fukuyama, S., Sanjo, H., 
D’Souza, C., Norris, P.S., Pfeffer, K., Murphy, K.M., et al. (2009). Unconventional ligand 
activation of herpesvirus entry mediator signals cell survival. Proc. Natl. Acad. Sci. U. S. A. 
106, 6244–6249. 
Chiu, P.P.L., Jiang, H., and Dick, J.E. (2010). Leukemia-initiating cells in human T-
lymphoblastic leukemia exhibit glucocorticoid resistance. Blood 116, 5268–5279. 
Chovatiya, R., and Medzhitov, R. (2014). Stress, inflammation, and defense of homeostasis. 
Mol. Cell 54, 281–288. 
Chung, G.T.-Y., Lou, W.P.-K., Chow, C., To, K.-F., Choy, K.-W., Leung, A.W.-C., Tong, 
C.Y.-K., Yuen, J.W.-F., Ko, C.-W., Yip, T.T.-C., et al. (2013). Constitutive activation of 
distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma. J. Pathol. 231, 311–
322. 
Cochran, D.L. (2008). Inflammation and bone loss in periodontal disease. J. Periodontol. 79, 
1569–1576. 
Cohavy, O., Zhou, J., Ware, C.F., and Targan, S.R. (2005). LIGHT is constitutively 
expressed on T and NK cells in the human gut and can be induced by CD2-mediated 
signaling. J. Immunol. 174, 646–653. 
Colmone, A., Amorim, M., Pontier, A.L., Wang, S., Jablonski, E., and Sipkins, D.A. (2008). 
Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic 
progenitor cells. Science 322, 1861–1865. 
Colotta, F., Allavena, P., Sica, A., Garlanda, C., and Mantovani, A. (2009). Cancer-related 
inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 
1073–1081. 
Coussens, L.M., and Werb, Z. (2002). Inflammation and cancer. Nature 420, 860–867. 
Cowan, J.E., Parnell, S.M., Nakamura, K., Caamano, J.H., Lane, P.J.L., Jenkinson, E.J., 
Jenkinson, W.E., and Anderson, G. (2013). The thymic medulla is required for Foxp3+ 
regulatory but not conventional CD4+ thymocyte development. J. Exp. Med. 210, 675–681. 
Cox, C.V., Martin, H.M., Kearns, P.R., Virgo, P., Evely, R.S., and Blair, A. (2007). 
Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic 
leukemia. Blood 109, 674–682. 
Crazzolara, R., Kreczy, A., Mann, G., Heitger, A., Eibl, G., Fink, F.M., Möhle, R., and 
Meister, B. (2001). High expression of the chemokine receptor CXCR4 predicts 
extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br. J. 
Haematol. 115, 545–553. 
Crist, W.M., Shuster, J.J., Falletta, J., Pullen, D.J., Berard, C.W., Vietti, T.J., Alvarado, C.S., 
Roper, M.A., Prasthofer, E., and Grossi, C.E. (1988). Clinical features and outcome in 
childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a 
Pediatric Oncology Group Study. Blood 72, 1891–1897. 
REFERENCES 
MT Fernandes 147 
Crowe, P.D., VanArsdale, T.L., Walter, B.N., Ware, C.F., Hession, C., Ehrenfels, B., 
Browning, J.L., Din, W.S., Goodwin, R.G., and Smith, C.A. (1994). A lymphotoxin-beta-
specific receptor. Science 264, 707–710. 
Cuesta, S., Kireev, R., Forman, K., García, C., Escames, G., Ariznavarreta, C., Vara, E., and 
Tresguerres, J.A.F. (2010). Melatonin improves inflammation processes in liver of 
senescence-accelerated prone male mice (SAMP8). Exp. Gerontol. 45, 950–956. 
Cupedo, T., Jansen, W., Kraal, G., and Mebius, R.E. (2004). Induction of secondary and 
tertiary lymphoid structures in the skin. Immunity 21, 655–667. 
Daller, B., Müsch, W., Röhrl, J., Tumanov, A.V., Nedospasov, S.A., Männel, D.N., 
Schneider-Brachert, W., and Hehlgans, T. (2011). Lymphotoxin-β receptor activation by 
lymphotoxin-α(1)β(2) and LIGHT promotes tumor growth in an NFκB-dependent manner. 
Int. J. Cancer J. Int. Cancer 128, 1363–1370. 
Darnay, B.G., Haridas, V., Ni, J., Moore, P.A., and Aggarwal, B.B. (1998). Characterization 
of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with 
tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-
terminal kinase. J. Biol. Chem. 273, 20551–20555. 
Darnay, B.G., Ni, J., Moore, P.A., and Aggarwal, B.B. (1999). Activation of NF-kappaB by 
RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-
inducing kinase. Identification of a novel TRAF6 interaction motif. J. Biol. Chem. 274, 
7724–7731. 
Das, S., Sepahi, I., Duthie, A., Clark, S., and Crockett, J.C. (2014). RANK receptor 
oligomerisation in the regulation of NFκB signalling. J. Mol. Endocrinol. 53, 81–91. 
Degli-Esposti, M.A., Davis-Smith, T., Din, W.S., Smolak, P.J., Goodwin, R.G., and Smith, 
C.A. (1997). Activation of the lymphotoxin beta receptor by cross-linking induces chemokine 
production and growth arrest in A375 melanoma cells. J. Immunol. 158, 1756–1762. 
Dejardin, E., Droin, N.M., Delhase, M., Haas, E., Cao, Y., Makris, C., Li, Z.-W., Karin, M., 
Ware, C.F., and Green, D.R. (2002). The lymphotoxin-beta receptor induces different 
patterns of gene expression via two NF-kappaB pathways. Immunity 17, 525–535. 
Derbinski, J., and Kyewski, B. (2005). Linking signalling pathways, thymic stroma integrity 
and autoimmunity. Trends Immunol. 26, 503–506. 
Desanti, G.E., Cowan, J.E., Baik, S., Parnell, S.M., White, A.J., Penninger, J.M., Lane, 
P.J.L., Jenkinson, E.J., Jenkinson, W.E., and Anderson, G. (2012). Developmentally 
regulated availability of RANKL and CD40 ligand reveals distinct mechanisms of fetal and 
adult cross-talk in the thymus medulla. J. Immunol.189, 5519–5526. 
Dhawan, P., Su, Y., Thu, Y.M., Yu, Y., Baugher, P., Ellis, D.L., Sobolik-Delmaire, T., 
Kelley, M., Cheung, T.C., Ware, C.F., et al. (2008). The lymphotoxin-beta receptor is an 
upstream activator of NF-kappaB-mediated transcription in melanoma cells. J. Biol. Chem. 
283, 15399–15408. 
DiDonato, J.A., Mercurio, F., and Karin, M. (2012). NF-κB and the link between 
inflammation and cancer. Immunol. Rev. 246, 379–400. 
Dougall, W.C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., 
Smith, J., Tometsko, M.E., Maliszewski, C.R., et al. (1999). RANK is essential for osteoclast 
and lymph node development. Genes Dev. 13, 2412–2424. 
REFERENCES	  
MT Fernandes 148 
Drutskaya, M.S., Efimov, G.A., Kruglov, A.A., Kuprash, D.V., and Nedospasov, S.A. 
(2010). Tumor necrosis factor, lymphotoxin and cancer. IUBMB Life 62, 283–289. 
Drynan, L.F., Hamilton, T.L., and Rabbitts, T.H. (2001). T cell tumorigenesis in Lmo2 
transgenic mice is independent of V-D-J recombinase activity. Oncogene 20, 4412–4415. 
Dumortier, A., Jeannet, R., Kirstetter, P., Kleinmann, E., Sellars, M., dos Santos, N.R., 
Thibault, C., Barths, J., Ghysdael, J., Punt, J.A., et al. (2006). Notch activation is an early and 
critical event during T-Cell leukemogenesis in Ikaros-deficient mice. Mol. Cell. Biol. 26, 
209–220. 
Eck, M.J., Ultsch, M., Rinderknecht, E., de Vos, A.M., and Sprang, S.R. (1992). The 
structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J. Biol. 
Chem. 267, 2119–2122. 
Eldredge, J., Berkowitz, S., Corin, A.F., Day, E.S., Hayes, D., Meier, W., Strauch, K., Zafari, 
M., Tadi, M., and Farrington, G.K. (2006). Stoichiometry of LTbetaR binding to LIGHT. 
Biochemistry 45, 10117–10128. 
Elewaut, D., Brossay, L., Santee, S.M., Naidenko, O.V., Burdin, N., De Winter, H., Matsuda, 
J., Ware, C.F., Cheroutre, H., and Kronenberg, M. (2000). Membrane lymphotoxin is 
required for the development of different subpopulations of NK T cells. J. Immunol. 165, 
671–679. 
Ettinger, R., Browning, J.L., Michie, S.A., van Ewijk, W., and McDevitt, H.O. (1996). 
Disrupted splenic architecture, but normal lymph node development in mice expressing a 
soluble lymphotoxin-beta receptor-IgG1 fusion protein. Proc. Natl. Acad. Sci. U. S. A. 93, 
13102–13107. 
Van Ewijk, W., Holländer, G., Terhorst, C., and Wang, B. (2000). Stepwise development of 
thymic microenvironments in vivo is regulated by thymocyte subsets. Dev. Camb. Engl. 127, 
1583–1591. 
Fata, J.E., Kong, Y.Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R.A., Elliott, R., Scully, 
S., Voura, E.B., Lacey, D.L., et al. (2000). The osteoclast differentiation factor 
osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41–50. 
Feng, H., Stachura, D.L., White, R.M., Gutierrez, A., Zhang, L., Sanda, T., Jette, C.A., Testa, 
J.R., Neuberg, D.S., Langenau, D.M., et al. (2010). T-lymphoblastic lymphoma cells express 
high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. 
Cancer Cell 18, 353–366. 
Ferrando, A.A., and Look, A.T. (2003). Gene expression profiling in T-cell acute 
lymphoblastic leukemia. Semin. Hematol. 40, 274–280. 
Ferrando, A.A., Neuberg, D.S., Staunton, J., Loh, M.L., Huard, C., Raimondi, S.C., Behm, 
F.G., Pui, C.H., Downing, J.R., Gilliland, D.G., et al. (2002). Gene expression signatures 
define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75–
87. 
Fizazi, K., Lipton, A., Mariette, X., Body, J.-J., Rahim, Y., Gralow, J.R., Gao, G., Wu, L., 
Sohn, W., and Jun, S. (2009). Randomized phase II trial of denosumab in patients with bone 
metastases from prostate cancer, breast cancer, or other neoplasms after intravenous 
bisphosphonates. J. Clin. Oncol. 27, 1564–1571. 
REFERENCES 
MT Fernandes 149 
Foley, G.E., Lazarus, H., Farber, S., Uzman, B.G., Boone, B.A., and Mccarthy, R.E. (1965). 
Continuous Culture of Human Lymphoblasts from Peripheral Blood of a Child with Acute 
Leukemia. Cancer 18, 522–529. 
Force, W.R., Walter, B.N., Hession, C., Tizard, R., Kozak, C.A., Browning, J.L., and Ware, 
C.F. (1995). Mouse lymphotoxin-beta receptor. Molecular genetics, ligand binding, and 
expression. J. Immunol. 155, 5280–5288. 
Force, W.R., Cheung, T.C., and Ware, C.F. (1997). Dominant negative mutants of TRAF3 
reveal an important role for the coiled coil domains in cell death signaling by the 
lymphotoxin-beta receptor. J. Biol. Chem. 272, 30835–30840. 
Force, W.R., Glass, A.A., Benedict, C.A., Cheung, T.C., Lama, J., and Ware, C.F. (2000). 
Discrete signaling regions in the lymphotoxin-beta receptor for tumor necrosis factor 
receptor-associated factor binding, subcellular localization, and activation of cell death and 
NF-kappaB pathways. J. Biol. Chem. 275, 11121–11129. 
Freshney, R. (2006). Basic Principles of Cell Culture. In G. Vunjak-Novakovic and R.I. 
Freshney (Eds.), Culture of Cells for Tissue Engineering (pp. 4–21). New Jersey: John Wiley 
& Sons, Inc. 
Fu, W., and Chen, W. (2004). Roles of chemokines in thymopoiesis: redundancy and 
regulation. Cell. Mol. Immunol. 1, 266–273. 
Fujiwara, S., Yamashita, Y., Choi, Y.L., Wada, T., Kaneda, R., Takada, S., Maruyama, Y., 
Ozawa, K., and Mano, H. (2005). Transforming activity of the lymphotoxin-beta receptor 
revealed by expression screening. Biochem. Biophys. Res. Commun. 338, 1256–1262. 
Fütterer, A., Mink, K., Luz, A., Kosco-Vilbois, M.H., and Pfeffer, K. (1998). The 
lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral 
lymphoid tissues. Immunity 9, 59–70. 
Gachet, S., Genescà, E., Passaro, D., Irigoyen, M., Alcalde, H., Clémenson, C., Poglio, S., 
Pflumio, F., Janin, A., Lasgi, C., et al. (2013). Leukemia-initiating cell activity requires 
calcineurin in T-cell acute lymphoblastic leukemia. Leukemia 27, 2289-2300. 
Gandhapudi, S.K., Tan, C., Marino, J.H., Taylor, A.A., Pack, C.C., Gaikwad, J., Van De 
Wiele, C.J., Wren, J.D., and Teague, T.K. (2015). IL-18 Acts in Synergy with IL-7 To 
Promote Ex Vivo Expansion of T Lymphoid Progenitor Cells. J. Immunol. 194, 3820–3828. 
Ganeff, C., Remouchamps, C., Boutaffala, L., Benezech, C., Galopin, G., Vandepaer, S., 
Bouillenne, F., Ormenese, S., Chariot, A., Schneider, P., et al. (2011). Induction of the 
alternative NF-κB pathway by lymphotoxin αβ (LTαβ) relies on internalization of LTβ 
receptor. Mol. Cell. Biol. 31, 4319–4334. 
Gatumu, M.K., Skarstein, K., Papandile, A., Browning, J.L., Fava, R.A., and Bolstad, A.I. 
(2009). Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren’s 
syndrome in salivary glands of non-obese diabetic mice. Arthritis Res. Ther. 11, R24. 
Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., 
Gautier, L., Ge, Y., Gentry, J., et al. (2004). Bioconductor: open software development for 
computational biology and bioinformatics. Genome Biol. 5, R80. 
Gerby, B., Tremblay, C.S., Tremblay, M., Rojas-Sutterlin, S., Herblot, S., Hébert, J., 
Sauvageau, G., Lemieux, S., Lécuyer, E., Veiga, D.F.T., et al. (2014). SCL, LMO1 and 
Notch1 reprogram thymocytes into self-renewing cells. PLoS Genet. 10, e1004768. 
REFERENCES	  
MT Fernandes 150 
Gibbs, J.B., Oliff, A., and Kohl, N.E. (1994). Farnesyltransferase inhibitors: Ras research 
yields a potential cancer therapeutic. Cell 77, 175–178. 
Gilbert, L.A., and Hemann, M.T. (2010). DNA damage-mediated induction of a 
chemoresistant niche. Cell 143, 355–366. 
Gilbert, L.A., and Hemann, M.T. (2011). Chemotherapeutic resistance: surviving stressful 
situations. Cancer Res. 71, 5062–5066. 
Godfrey, D.I., Kennedy, J., Suda, T., and Zlotnik, A. (1993). A developmental pathway 
involving four phenotypically and functionally distinct subsets of CD3-CD4-CD8- triple-
negative adult mouse thymocytes defined by CD44 and CD25 expression. J. Immunol. 150, 
4244–4252. 
Goldrath, A.W., and Bevan, M.J. (1999). Selecting and maintaining a diverse T-cell 
repertoire. Nature 402, 255–262. 
González-García, S., García-Peydró, M., Martín-Gayo, E., Ballestar, E., Esteller, M., 
Bornstein, R., de la Pompa, J.L., Ferrando, A.A., and Toribio, M.L. (2009). CSL-MAML-
dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in 
early human thymopoiesis and leukemia. J. Exp. Med. 206, 779–791. 
Gough, A.K., Lilley, J., Eyre, S., Holder, R.L., and Emery, P. (1994). Generalised bone loss 
in patients with early rheumatoid arthritis. Lancet 344, 23–27. 
Granger, S.W., Butrovich, K.D., Houshmand, P., Edwards, W.R., and Ware, C.F. (2001). 
Genomic characterization of LIGHT reveals linkage to an immune response locus on 
chromosome 19p13.3 and distinct isoforms generated by alternate splicing or proteolysis. J. 
Immunol. 167, 5122–5128. 
Graux, C., Cools, J., Michaux, L., Vandenberghe, P., and Hagemeijer, A. (2006). 
Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte 
to lymphoblast. Leukemia 20, 1496–1510. 
Gray, D.H.D., Fletcher, A.L., Hammett, M., Seach, N., Ueno, T., Young, L.F., Barbuto, J., 
Boyd, R.L., and Chidgey, A.P. (2008). Unbiased analysis, enrichment and purification of 
thymic stromal cells. J. Immunol. Methods 329, 56–66. 
Grell, M., Douni, E., Wajant, H., Löhden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., 
Lesslauer, W., Kollias, G., Pfizenmaier, K., et al. (1995). The transmembrane form of tumor 
necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. 
Cell 83, 793–802. 
Grimm, M., Renz, C., Munz, A., Hoefert, S., Krimmel, M., and Reinert, S. (2015). Co-
expression of CD44+/RANKL+ tumor cells in the carcinogenesis of oral squamous cell 
carcinoma. Odontol. 103, 36–49. 
Gutierrez, A., Sanda, T., Grebliunaite, R., Carracedo, A., Salmena, L., Ahn, Y., Dahlberg, S., 
Neuberg, D., Moreau, L.A., Winter, S.S., et al. (2009). High frequency of PTEN, PI3K, and 
AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647–650. 
Gutierrez, A., Sanda, T., Ma, W., Zhang, J., Grebliunaite, R., Dahlberg, S., Neuberg, D., 
Protopopov, A., Winter, S.S., Larson, R.S., et al. (2010). Inactivation of LEF1 in T-cell acute 
lymphoblastic leukemia. Blood 115, 2845–2851. 
Gutierrez, A., Kentsis, A., Sanda, T., Holmfeldt, L., Chen, S.-C., Zhang, J., Protopopov, A., 
Chin, L., Dahlberg, S.E., Neuberg, D.S., et al. (2011). The BCL11B tumor suppressor is 
REFERENCES 
MT Fernandes 151 
mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood 
118, 4169–4173. 
Haferlach, T., Kohlmann, A., Wieczorek, L., Basso, G., Kronnie, G.T., Béné, M.-C., De Vos, 
J., Hernández, J.M., Hofmann, W.-K., Mills, K.I., et al. (2010). Clinical utility of microarray-
based gene expression profiling in the diagnosis and subclassification of leukemia: report 
from the International Microarray Innovations in Leukemia Study Group. J. Clin. Oncol. 28, 
2529–2537. 
Hagenbeek, T.J., Wu, X., Choy, L., Sanchez-Irizarry, C., Seshagiri, S., Stinson, J., Siebel, 
C.W., and Spits, H. (2014). Murine Pten(-/-) T-ALL requires non-redundant PI3K/mTOR and 
DLL4/Notch1 signals for maintenance and γc/TCR signals for thymic exit. Cancer Lett. 346, 
237–248. 
Hakozaki, A., Yoda, M., Tohmonda, T., Furukawa, M., Hikata, T., Uchikawa, S., Takaishi, 
H., Matsumoto, M., Chiba, K., Horiuchi, K., et al. (2010). Receptor activator of NF-kappaB 
(RANK) ligand induces ectodomain shedding of RANK in murine RAW264.7 macrophages. 
J. Immunol. 184, 2442–2448. 
Hanada, R., Leibbrandt, A., Hanada, T., Kitaoka, S., Furuyashiki, T., Fujihara, H., 
Trichereau, J., Paolino, M., Qadri, F., Plehm, R., et al. (2009). Central control of fever and 
female body temperature by RANKL/RANK. Nature 462, 505–509. 
Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis. Cell 86, 353–364. 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57–70. 
Hartzell, C., Ksionda, O., Lemmens, E., Coakley, K., Yang, M., Dail, M., Harvey, R.C., 
Govern, C., Bakker, J., Lenstra, T.L., et al. (2013). Dysregulated RasGRP1 responds to 
cytokine receptor input in T cell leukemogenesis. Sci. Signal. 6, ra21. 
Haybaeck, J., Zeller, N., Wolf, M.J., Weber, A., Wagner, U., Kurrer, M.O., Bremer, J., Iezzi, 
G., Graf, R., Clavien, P.-A., et al. (2009). A lymphotoxin-driven pathway to hepatocellular 
carcinoma. Cancer Cell 16, 295–308. 
Hayden, M.S., and Ghosh, S. (2014). Regulation of NF-κB by TNF family cytokines. Semin. 
Immunol. 26, 253–266. 
He, Y., Zha, J., Wang, Y., Liu, W., Yang, X., and Yu, P. (2013). Tissue damage-associated 
“danger signals” influence T-cell responses that promote the progression of preneoplasia to 
cancer. Cancer Res. 73, 629–639. 
Hebert, J., Cayuela, J.M., Berkeley, J., and Sigaux, F. (1994). Candidate tumor-suppressor 
genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in 
primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 84, 
4038–4044. 
Hehlgans, T., Stoelcker, B., Stopfer, P., Müller, P., Cernaianu, G., Guba, M., Steinbauer, M., 
Nedospasov, S.A., Pfeffer, K., and Männel, D.N. (2002). Lymphotoxin-beta receptor immune 
interaction promotes tumor growth by inducing angiogenesis. Cancer Res. 62, 4034–4040. 
Heikenwalder, M., Prinz, M., Zeller, N., Lang, K.S., Junt, T., Rossi, S., Tumanov, A., 
Schmidt, H., Priller, J., Flatz, L., et al. (2008). Overexpression of lymphotoxin in T cells 
induces fulminant thymic involution. Am. J. Pathol. 172, 1555–1570. 
Heinig, K., Gätjen, M., Grau, M., Stache, V., Anagnostopoulos, I., Gerlach, K., Niesner, 
R.A., Cseresnyes, Z., Hauser, A.E., Lenz, P., et al. (2014). Access to follicular dendritic cells 
REFERENCES	  
MT Fernandes 152 
is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. 
Cancer Discov. 4, 1448–1465. 
Heinonen, K.M., and Perreault, C. (2008). Development and functional properties of thymic 
and extrathymic T lymphocytes. Crit. Rev. Immunol. 28, 441–466. 
Hemingway, F., Kashima, T.G., Knowles, H.J., and Athanasou, N.A. (2013). Investigation of 
osteoclastogenic signalling of the RANKL substitute LIGHT. Exp. Mol. Pathol. 94, 380–385. 
Heng, T.S.P., Painter, M.W., and Immunological Genome Project Consortium (2008). The 
Immunological Genome Project: networks of gene expression in immune cells. Nat. 
Immunol. 9, 1091–1094. 
Herreros, B., Sanchez-Aguilera, A., and Piris, M.A. (2008). Lymphoma microenvironment: 
culprit or innocent? Leukemia 22, 49–58. 
Hiai, H., Nishi, Y., Miyazawa, T., Matsudaira, Y., and Nishizuka, Y. (1981). Mouse 
lymphoid leukemias: symbiotic complexes of neoplastic lymphocytes and their 
microenvironments. J. Natl. Cancer Inst. 66, 713–722. 
Hikosaka, Y., Nitta, T., Ohigashi, I., Yano, K., Ishimaru, N., Hayashi, Y., Matsumoto, M., 
Matsuo, K., Penninger, J.M., Takayanagi, H., et al. (2008). The cytokine RANKL produced 
by positively selected thymocytes fosters medullary thymic epithelial cells that express 
autoimmune regulator. Immunity 29, 438–450. 
Homminga, I., Pieters, R., Langerak, A.W., de Rooi, J.J., Stubbs, A., Verstegen, M., 
Vuerhard, M., Buijs-Gladdines, J., Kooi, C., Klous, P., et al. (2011). Integrated transcript and 
genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute 
lymphoblastic leukemia. Cancer Cell 19, 484–497. 
Honda, K., Nakano, H., Yoshida, H., Nishikawa, S., Rennert, P., Ikuta, K., Tamechika, M., 
Yamaguchi, K., Fukumoto, T., Chiba, T., et al. (2001). Molecular basis for 
hematopoietic/mesenchymal interaction during initiation of Peyer’s patch organogenesis. J. 
Exp. Med. 193, 621–630. 
Honma, M., Ikebuchi, Y., Kariya, Y., Hayashi, M., Hayashi, N., Aoki, S., and Suzuki, H. 
(2013). RANKL subcellular trafficking and regulatory mechanisms in osteocytes. J. Bone 
Miner. Res. 28, 1936–1949. 
Hozumi, K., Mailhos, C., Negishi, N., Hirano, K., Yahata, T., Ando, K., Zuklys, S., 
Holländer, G.A., Shima, D.T., and Habu, S. (2008). Delta-like 4 is indispensable in thymic 
environment specific for T cell development. J. Exp. Med. 205, 2507–2513. 
Hsu, H., Lacey, D.L., Dunstan, C.R., Solovyev, I., Colombero, A., Timms, E., Tan, H.L., 
Elliott, G., Kelley, M.J., Sarosi, I., et al. (1999). Tumor necrosis factor receptor family 
member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin 
ligand. Proc. Natl. Acad. Sci. U. S. A. 96, 3540–3545. 
Hu, X., Zimmerman, M.A., Bardhan, K., Yang, D., Waller, J.L., Liles, G.B., Lee, J.R., 
Pollock, R., Lev, D., Ware, C.F., et al. (2013). Lymphotoxin β receptor mediates caspase-
dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of 
NF-κB activation. Carcinogenesis 34, 1105–1114. 
Ihle, J.N., and Gilliland, D.G. (2007). Jak2: normal function and role in hematopoietic 
disorders. Curr. Opin. Genet. Dev. 17, 8–14. 
Indraccolo, S., Minuzzo, S., Masiero, M., Pusceddu, I., Persano, L., Moserle, L., Reboldi, A., 
Favaro, E., Mecarozzi, M., Di Mario, G., et al. (2009). Cross-talk between tumor and 
REFERENCES 
MT Fernandes 153 
endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. 
Cancer Res. 69, 1314–1323. 
Irla, M., Guerri, L., Guenot, J., Sergé, A., Lantz, O., Liston, A., Imhof, B.A., Palmer, E., and 
Reith, W. (2012). Antigen recognition by autoreactive CD4+ thymocytes drives homeostasis 
of the thymic medulla. PloS One 7, e52591. 
Ishida, N., Hayashi, K., Hoshijima, M., Ogawa, T., Koga, S., Miyatake, Y., Kumegawa, M., 
Kimura, T., and Takeya, T. (2002). Large scale gene expression analysis of 
osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 277, 
41147–41156. 
Ito, H., Esashi, E., Akiyama, T., Inoue, J., and Miyajima, A. (2006). IL-18 produced by 
thymic epithelial cells induces development of dendritic cells with CD11b in the fetal 
thymus. Int. Immunol. 18, 1253–1263. 
Itoh, K., Tezuka, H., Sakoda, H., Konno, M., Nagata, K., Uchiyama, T., Uchino, H., and 
Mori, K.J. (1989). Reproducible establishment of hemopoietic supportive stromal cell lines 
from murine bone marrow. Exp. Hematol. 17, 145–153. 
Jenkinson, S.R., Williams, J.A., Jeon, H., Zhang, J., Nitta, T., Ohigashi, I., Kruhlak, M., 
Zuklys, S., Sharrow, S., Adams, A., et al. (2013). TRAF3 enforces the requirement for T cell 
cross-talk in thymic medullary epithelial development. Proc. Natl. Acad. Sci. U. S. A. 110, 
21107–21112. 
Jin, R., Zhang, J., and Chen, W. (2006). Thymic output: influence factors and molecular 
mechanism. Cell. Mol. Immunol. 3, 341–350. 
Jones, D.H., Nakashima, T., Sanchez, O.H., Kozieradzki, I., Komarova, S.V., Sarosi, I., 
Morony, S., Rubin, E., Sarao, R., Hojilla, C.V., et al. (2006). Regulation of cancer cell 
migration and bone metastasis by RANKL. Nature 440, 692–696. 
Josien, R., Wong, B.R., Li, H.L., Steinman, R.M., and Choi, Y. (1999). TRANCE, a TNF 
family member, is differentially expressed on T cell subsets and induces cytokine production 
in dendritic cells. J. Immunol. 162, 2562–2568. 
Juhász, K., Buzás, K., and Duda, E. (2013). Importance of reverse signaling of the TNF 
superfamily in immune regulation. Expert Rev. Clin. Immunol. 9, 335–348. 
Kabashima, K., Banks, T.A., Ansel, K.M., Lu, T.T., Ware, C.F., and Cyster, J.G. (2005). 
Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic 
cells. Immunity 22, 439–450. 
Kajiura, F., Sun, S., Nomura, T., Izumi, K., Ueno, T., Bando, Y., Kuroda, N., Han, H., Li, Y., 
Matsushima, A., et al. (2004). NF-kappa B-inducing kinase establishes self-tolerance in a 
thymic stroma-dependent manner. J. Immunol. 172, 2067–2075. 
Kanazawa, K., and Kudo, A. (2005). Self-assembled RANK induces osteoclastogenesis 
ligand-independently. J. Bone Miner. Res. 20, 2053–2060. 
Kaplan, H.S. (1950). Influence of thymectomy, splenectomy, and gonadectomy on incidence 
of radiation-induced lymphoid tumors in strain C57 black mice. J. Natl. Cancer Inst. 11, 83–
90. 
Kartsogiannis, V., Zhou, H., Horwood, N.J., Thomas, R.J., Hards, D.K., Quinn, J.M., 
Niforas, P., Ng, K.W., Martin, T.J., and Gillespie, M.T. (1999). Localization of RANKL 
(receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal 
tissues. Bone 25, 525–534. 
REFERENCES	  
MT Fernandes 154 
Keats, J.J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., 
Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007). Promiscuous mutations activate the 
noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12, 131–144. 
De Keersmaecker, K., Marynen, P., and Cools, J. (2005). Genetic insights in the pathogenesis 
of T-cell acute lymphoblastic leukemia. Haematologica 90, 1116–1127. 
De Keersmaecker, K., Atak, Z.K., Li, N., Vicente, C., Patchett, S., Girardi, T., Gianfelici, V., 
Geerdens, E., Clappier, E., Porcu, M., et al. (2013). Exome sequencing identifies mutation in 
CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat. 
Genet. 45, 186–190. 
Kelly, J.A., Spolski, R., Kovanen, P.E., Suzuki, T., Bollenbacher, J., Pise-Masison, C.A., 
Radonovich, M.F., Lee, S., Jenkins, N.A., Copeland, N.G., et al. (2003). Stat5 synergizes 
with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma. J. 
Exp. Med. 198, 79–89. 
Kim, D.-H., Kim, E.-M., Lee, E.-H., Ji, K.-Y., Yi, J., Park, M., Kim, K.D., Cho, Y.-Y., and 
Kang, H.-S. (2011). Human papillomavirus 16E6 suppresses major histocompatibility 
complex class I by upregulating lymphotoxin expression in human cervical cancer cells. 
Biochem. Biophys. Res. Commun. 409, 792–798. 
Kim, T.-J., Upadhyay, V., Kumar, V., Lee, K.-M., and Fu, Y.-X. (2014). Innate lymphoid 
cells facilitate NK cell development through a lymphotoxin-mediated stromal 
microenvironment. J. Exp. Med. 211, 1421–1431. 
Kim, Y.-S., Nedospasov, S.A., and Liu, Z.-G. (2005). TRAF2 plays a key, nonredundant role 
in LIGHT-lymphotoxin beta receptor signaling. Mol. Cell. Biol. 25, 2130–2137. 
Kittipatarin, C., and Khaled, A.R. (2007). Interlinking interleukin-7. Cytokine 39, 75–83. 
Klein, U., and Ghosh, S. (2011). The Two Faces of NF-κB Signaling in Cancer Development 
and Therapy. Cancer Cell 20, 556–558. 
Klug, D.B., Carter, C., Crouch, E., Roop, D., Conti, C.J., and Richie, E.R. (1998). 
Interdependence of cortical thymic epithelial cell differentiation and T-lineage commitment. 
Proc. Natl. Acad. Sci. U. S. A. 95, 11822–11827. 
Kondo, M., Weissman, I.L., and Akashi, K. (1997). Identification of clonogenic common 
lymphoid progenitors in mouse bone marrow. Cell 91, 661–672. 
Kong, Y.Y., Yoshida, H., Sarosi, I., Tan, H.L., Timms, E., Capparelli, C., Morony, S., 
Oliveira-dos-Santos, A.J., Van, G., Itie, A., et al. (1999). OPGL is a key regulator of 
osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 
315–323. 
Koni, P.A., Sacca, R., Lawton, P., Browning, J.L., Ruddle, N.H., and Flavell, R.A. (1997). 
Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in 
lymphotoxin beta-deficient mice. Immunity 6, 491–500. 
Konopleva, M., Tabe, Y., Zeng, Z., and Andreeff, M. (2009). Therapeutic targeting of 
microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist. 
Updat. 12, 103–113. 
Krajewska, M., Krajewski, S., Zapata, J.M., Van Arsdale, T., Gascoyne, R.D., Berern, K., 
McFadden, D., Shabaik, A., Hugh, J., Reynolds, A., et al. (1998). TRAF-4 expression in 
epithelial progenitor cells. Analysis in normal adult, fetal, and tumor tissues. Am. J. Pathol. 
152, 1549–1561. 
REFERENCES 
MT Fernandes 155 
Kratz, A., Campos-Neto, A., Hanson, M.S., and Ruddle, N.H. (1996). Chronic inflammation 
caused by lymphotoxin is lymphoid neogenesis. J. Exp. Med. 183, 1461–1472. 
Kuai, J., Nickbarg, E., Wooters, J., Qiu, Y., Wang, J., and Lin, L.-L. (2003). Endogenous 
association of TRAF2, TRAF3, cIAP1, and Smac with lymphotoxin beta receptor reveals a 
novel mechanism of apoptosis. J. Biol. Chem. 278, 14363–14369. 
Kuchimaru, T., Hoshino, T., Aikawa, T., Yasuda, H., Kobayashi, T., Kadonosono, T., and 
Kizaka-Kondoh, S. (2014). Bone resorption facilitates osteoblastic bone metastatic 
colonization by cooperation of insulin-like growth factor and hypoxia. Cancer Sci. 105, 553–
559. 
Kuprash, D.V., Osipovich, O.A., Pokholok, D.K., Alimzhanov, M.B., Biragyn, A., 
Turetskaya, R.L., and Nedospasov, S.A. (1996). Functional analysis of the lymphotoxin-beta 
promoter. Sequence requirements for PMA activation. J. Immunol. 156, 2465–2472. 
Kuprash, D.V., Boitchenko, V.E., Yarovinsky, F.O., Rice, N.R., Nordheim, A., Rühlmann, 
A., and Nedospasov, S.A. (2002). Cyclosporin A blocks the expression of lymphotoxin alpha, 
but not lymphotoxin beta, in human peripheral blood mononuclear cells. Blood 100, 1721–
1727. 
Kwon, B.S., Tan, K.B., Ni, J., Oh, K.O., Lee, Z.H., Kim, K.K., Kim, Y.J., Wang, S., Gentz, 
R., Yu, G.L., et al. (1997). A newly identified member of the tumor necrosis factor receptor 
superfamily with a wide tissue distribution and involvement in lymphocyte activation. J. Biol. 
Chem. 272, 14272–14276. 
Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliott, R., 
Colombero, A., Elliott, G., Scully, S., et al. (1998). Osteoprotegerin ligand is a cytokine that 
regulates osteoclast differentiation and activation. Cell 93, 165–176. 
Lacronique, V., Boureux, A., Valle, V.D., Poirel, H., Quang, C.T., Mauchauffé, M., Berthou, 
C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997). A TEL-JAK2 fusion protein with 
constitutive kinase activity in human leukemia. Science 278, 1309–1312. 
Lacronique, V., Boureux, A., Monni, R., Dumon, S., Mauchauffé, M., Mayeux, P., 
Gouilleux, F., Berger, R., Gisselbrecht, S., Ghysdael, J., et al. (2000). Transforming 
properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 95, 2076–2083. 
Lai, A.Y., and Kondo, M. (2006). Asymmetrical lymphoid and myeloid lineage commitment 
in multipotent hematopoietic progenitors. J. Exp. Med. 203, 1867–1873. 
Lai, A.Y., and Kondo, M. (2008). T and B lymphocyte differentiation from hematopoietic 
stem cell. Semin. Immunol. 20, 207–212. 
Langenau, D.M., Traver, D., Ferrando, A.A., Kutok, J.L., Aster, J.C., Kanki, J.P., Lin, S., 
Prochownik, E., Trede, N.S., Zon, L.I., et al. (2003). Myc-induced T cell leukemia in 
transgenic zebrafish. Science 299, 887–890. 
Lau, T.-S., Chung, T.K.-H., Cheung, T.-H., Chan, L.K.-Y., Cheung, L.W.-H., Yim, S.-F., 
Siu, N.S.-S., Lo, K.-W., Yu, M.M.-Y., Kulbe, H., et al. (2014). Cancer cell-derived 
lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by 
inducing CXCL11 in fibroblasts. J. Pathol. 232, 43–56. 
Lawton, P., Nelson, J., Tizard, R., and Browning, J.L. (1995). Characterization of the mouse 
lymphotoxin-beta gene. J. Immunol. 154, 239–246. 
Lee, S.H., Park, S.G., Lim, S.O., and Jung, G. (2005). The hepatitis B virus X protein up-
regulates lymphotoxin alpha expression in hepatocytes. Biochim. Biophys. Acta 1741, 75–84. 
REFERENCES	  
MT Fernandes 156 
De Leval, L., Bisig, B., Thielen, C., Boniver, J., and Gaulard, P. (2009). Molecular 
classification of T-cell lymphomas. Crit. Rev. Oncol. Hematol. 72, 125–143. 
Liepinsh, D.J., Kruglov, A.A., Galimov, A.R., Shakhov, A.N., Shebzukhov, Y.V., Kuchmiy, 
A.A., Grivennikov, S.I., Tumanov, A.V., Drutskaya, M.S., Feigenbaum, L., et al. (2009). 
Accelerated thymic atrophy as a result of elevated homeostatic expression of the genes 
encoded by the TNF/lymphotoxin cytokine locus. Eur. J. Immunol. 39, 2906–2915. 
Lind, E.F., Prockop, S.E., Porritt, H.E., and Petrie, H.T. (2001). Mapping precursor 
movement through the postnatal thymus reveals specific microenvironments supporting 
defined stages of early lymphoid development. J. Exp. Med. 194, 127–134. 
Von Lintig, F.C., Huvar, I., Law, P., Diccianni, M.B., Yu, A.L., and Boss, G.R. (2000). Ras 
activation in normal white blood cells and childhood acute lymphoblastic leukemia. Clin. 
Cancer Res. 6, 1804–1810. 
Lkhagvasuren, E., Sakata, M., Ohigashi, I., and Takahama, Y. (2013). Lymphotoxin β 
receptor regulates the development of CCL21-expressing subset of postnatal medullary 
thymic epithelial cells. J. Immunol. 190, 5110–5117. 
Lo, J.C., Wang, Y., Tumanov, A.V., Bamji, M., Yao, Z., Reardon, C.A., Getz, G.S., and Fu, 
Y.-X. (2007). Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 
316, 285–288. 
Lomaga, M.A., Yeh, W.C., Sarosi, I., Duncan, G.S., Furlonger, C., Ho, A., Morony, S., 
Capparelli, C., Van, G., Kaufman, S., et al. (1999). TRAF6 deficiency results in osteopetrosis 
and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015–1024. 
Longo, D.L. (2012). Malignancies of Lymphoid Cells. In D.L. Longo, A.S. Fauci, D.L. 
Kasper, S.L. Hauser, J.L. Jameson, J. Loscalzo (Eds.), Harrison´s Principles of Internal 
Medicine, (Vol.1, pp. 919-935). U.S.A.:McGraw-Hill. 
Lovas, A., Radke, D., Albrecht, D., Yilmaz, Z.B., Möller, U., Habenicht, A.J.R., and Weih, 
F. (2008). Differential RelA- and RelB-dependent gene transcription in LTbetaR-stimulated 
mouse embryonic fibroblasts. BMC Genomics 9, 606. 
Lowes, K.N., Croager, E.J., Abraham, L.J., Olynyk, J.K., and Yeoh, G.C.T. (2003). 
Upregulation of lymphotoxin beta expression in liver progenitor (oval) cells in chronic 
hepatitis C. Gut 52, 1327–1332. 
Lu, L., Zhu, J., Zheng, Z., Yan, M., Xu, W., Sun, L., Theze, J., and Liu, X. (1998). Jak-STAT 
pathway is involved in the induction of TNF-beta gene during stimulation by IL-2. Eur. J. 
Immunol. 28, 805–810. 
Lukashev, M., LePage, D., Wilson, C., Bailly, V., Garber, E., Lukashin, A., Ngam-ek, A., 
Zeng, W., Allaire, N., Perrin, S., et al. (2006). Targeting the lymphotoxin-beta receptor with 
agonist antibodies as a potential cancer therapy. Cancer Res. 66, 9617–9624. 
Lum, L., Wong, B.R., Josien, R., Becherer, J.D., Erdjument-Bromage, H., Schlöndorff, J., 
Tempst, P., Choi, Y., and Blobel, C.P. (1999). Evidence for a role of a tumor necrosis factor-
alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family 
member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 274, 
13613–13618. 
Luther, S.A., Bidgol, A., Hargreaves, D.C., Schmidt, A., Xu, Y., Paniyadi, J., Matloubian, 
M., and Cyster, J.G. (2002). Differing activities of homeostatic chemokines CCL19, CCL21, 
REFERENCES 
MT Fernandes 157 
and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. 
Immunol. 169, 424–433. 
Ma, S., Shi, Y., Pang, Y., Dong, F., Cheng, H., Hao, S., Xu, J., Zhu, X., Yuan, W., Cheng, T., 
et al. (2014). Notch1-induced T cell leukemia can be potentiated by microenvironmental cues 
in the spleen. J. Hematol. Oncol. 7, 71. 
Mackay, F., Majeau, G.R., Hochman, P.S., and Browning, J.L. (1996). Lymphotoxin beta 
receptor triggering induces activation of the nuclear factor kappaB transcription factor in 
some cell types. J. Biol. Chem. 271, 24934–24938. 
Madge, L.A., Kluger, M.S., Orange, J.S., and May, M.J. (2008). Lymphotoxin-alpha 1 beta 2 
and LIGHT induce classical and noncanonical NF-kappa B-dependent proinflammatory gene 
expression in vascular endothelial cells. J. Immunol. 180, 3467–3477. 
Mailhos, C., Modlich, U., Lewis, J., Harris, A., Bicknell, R., and Ish-Horowicz, D. (2001). 
Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor 
angiogenesis. Differ. Res. Biol. Divers. 69, 135–144. 
Malinge, S., Monni, R., Bernard, O., and Penard-Lacronique, V. (2006). Activation of the 
NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to 
the accumulation of antiapoptotic IAP proteins and involves IKKalpha. Oncogene 25, 3589–
3597. 
Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related inflammation. 
Nature 454, 436–444. 
Martinet, L., Filleron, T., Le Guellec, S., Rochaix, P., Garrido, I., and Girard, J.-P. (2013). 
High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated 
with Lymphotoxin β-Producing Dendritic Cells in Human Breast Cancer. J. Immunol. 191, 
2001-2008. 
Martins, V.C., Busch, K., Juraeva, D., Blum, C., Ludwig, C., Rasche, V., Lasitschka, F., 
Mastitsky, S.E., Brors, B., Hielscher, T., et al. (2014). Cell competition is a tumour 
suppressor mechanism in the thymus. Nature 509, 465–470. 
Matsuo, K., Owens, J.M., Tonko, M., Elliott, C., Chambers, T.J., and Wagner, E.F. (2000). 
Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 24, 
184–187. 
Matsushima, A., Kaisho, T., Rennert, P.D., Nakano, H., Kurosawa, K., Uchida, D., Takeda, 
K., Akira, S., and Matsumoto, M. (2001). Essential role of nuclear factor (NF)-kappaB-
inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation 
through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I. J. Exp. 
Med. 193, 631–636. 
Maude, S.L., Dolai, S., Delgado-Martin, C., Vincent, T., Robbins, A., Selvanathan, A., Ryan, 
T., Hall, J., Wood, A.C., Tasian, S.K., et al. (2015). Efficacy of JAK/STAT pathway 
inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic 
leukemia. Blood 125, 1759–1767. 
Mauri, D.N., Ebner, R., Montgomery, R.I., Kochel, K.D., Cheung, T.C., Yu, G.L., Ruben, S., 
Murphy, M., Eisenberg, R.J., Cohen, G.H., et al. (1998). LIGHT, a new member of the TNF 
superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 8, 
21–30. 
REFERENCES	  
MT Fernandes 158 
Mavrakis, K.J., Van Der Meulen, J., Wolfe, A.L., Liu, X., Mets, E., Taghon, T., Khan, A.A., 
Setty, M., Setti, M., Rondou, P., et al. (2011). A cooperative microRNA-tumor suppressor 
gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat. Genet. 43, 673–678. 
McEndy, D., Boon, M., and Furth, J. (1944). On the Role of Thymus, Spleen, and Gonads in 
the Development of Leukemia in a High-Leukemia Stock of Mice. Cancer Res. 377–383. 
Medyouf, H., Alcalde, H., Berthier, C., Guillemin, M.C., dos Santos, N.R., Janin, A., 
Decaudin, D., de Thé, H., and Ghysdael, J. (2007). Targeting calcineurin activation as a 
therapeutic strategy for T-cell acute lymphoblastic leukemia. Nat. Med. 13, 736–741. 
Medyouf, H., Gusscott, S., Wang, H., Tseng, J.-C., Wai, C., Nemirovsky, O., Trumpp, A., 
Pflumio, F., Carboni, J., Gottardis, M., et al. (2011). High-level IGF1R expression is required 
for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J. Exp. 
Med. 208, 1809–1822. 
Meijerink, J.P.P. (2010). Genetic rearrangements in relation to immunophenotype and 
outcome in T-cell acute lymphoblastic leukaemia. Best Pract. Res. Clin. Haematol. 23, 307–
318. 
Messer, G., Weiss, E.H., and Baeuerle, P.A. (1990). Tumor necrosis factor beta (TNF-beta) 
induces binding of the NF-kappa B transcription factor to a high-affinity kappa B element in 
the TNF-beta promoter. Cytokine 2, 389–397. 
Milićević, N.M., Nohroudi, K., Milićević, Z., and Westermann, J. (2008). Activation of 
cortical and inhibited differentiation of medullary epithelial cells in the thymus of 
lymphotoxin-beta receptor-deficient mice: an ultrastructural study. J. Anat. 212, 114–124. 
Millet, I., and Ruddle, N.H. (1994). Differential regulation of lymphotoxin (LT), 
lymphotoxin-beta (LT-beta), and TNF-alpha in murine T cell clones activated through the 
TCR. J. Immunol. 152, 4336–4346. 
Minuzzo, S., Agnusdei, V., Pusceddu, I., Pinazza, M., Moserle, L., Masiero, M., Rossi, E., 
Crescenzi, M., Hoey, T., Ponzoni, M., et al. (2015). DLL4 regulates NOTCH signaling and 
growth of T acute lymphoblastic leukemia cells in NOD/SCID mice. Carcinogenesis 36, 
115–121. 
Mirandola, L., Chiriva-Internati, M., Montagna, D., Locatelli, F., Zecca, M., Ranzani, M., 
Basile, A., Locati, M., Cobos, E., Kast, W.M., et al. (2012). Notch1 regulates chemotaxis and 
proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute 
lymphoblastic leukaemia. J. Pathol. 226, 713–722. 
Misawa, K., Nosaka, T., Kojima, T., Hirai, M., and Kitamura, T. (2000). Molecular cloning 
and characterization of a mouse homolog of human TNFSF14, a member of the TNF 
superfamily. Cytogenet. Cell Genet. 89, 89–91. 
Mizukami, J., Takaesu, G., Akatsuka, H., Sakurai, H., Ninomiya-Tsuji, J., Matsumoto, K., 
and Sakurai, N. (2002). Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 
mitogen-activated protein kinase kinase kinase through a signaling complex containing 
RANK, TAB2, and TRAF6. Mol. Cell. Biol. 22, 992–1000. 
Mizuochi, T., Kasai, M., Kokuho, T., Kakiuchi, T., and Hirokawa, K. (1992). Medullary but 
not cortical thymic epithelial cells present soluble antigens to helper T cells. J. Exp. Med. 
175, 1601–1605. 
REFERENCES 
MT Fernandes 159 
Mohtashami, M., Shah, D.K., Kianizad, K., Awong, G., and Zúñiga-Pflücker, J.C. (2013). 
Induction of T-cell development by Delta-like 4-expressing fibroblasts. Int. Immunol. 25, 
601–611. 
Moore, N.C., Girdlestone, J., Anderson, G., Owen, J.J., and Jenkinson, E.J. (1995). 
Stimulation of thymocytes before and after positive selection results in the induction of 
different NF-kappa B/Rel protein complexes. J. Immunol. 155, 4653–4660. 
Morel, Y., Schiano de Colella, J.M., Harrop, J., Deen, K.C., Holmes, S.D., Wattam, T.A., 
Khandekar, S.S., Truneh, A., Sweet, R.W., Gastaut, J.A., et al. (2000). Reciprocal expression 
of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T 
cells: LIGHT down-regulates its own receptor. J. Immunol. 165, 4397–4404. 
Morikawa, S., Tatsumi, E., Baba, M., Harada, T., and Yasuhira, K. (1978). Two E-rosette-
forming lymphoid cell lines. Int. J. Cancer 21, 166–170. 
Mortarini, R., Scarito, A., Nonaka, D., Zanon, M., Bersani, I., Montaldi, E., Pennacchioli, E., 
Patuzzo, R., Santinami, M., and Anichini, A. (2005). Constitutive expression and 
costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-
derived microvesicles. Cancer Res. 65, 3428–3436. 
Moschen, A.R., Kaser, A., Enrich, B., Ludwiczek, O., Gabriel, M., Obrist, P., Wolf, A.M., 
and Tilg, H. (2005). The RANKL/OPG system is activated in inflammatory bowel disease 
and relates to the state of bone loss. Gut 54, 479–487. 
Mouri, Y., Yano, M., Shinzawa, M., Shimo, Y., Hirota, F., Nishikawa, Y., Nii, T., Kiyonari, 
H., Abe, T., Uehara, H., et al. (2011). Lymphotoxin signal promotes thymic organogenesis by 
eliciting RANK expression in the embryonic thymic stroma. J. Immunol. 186, 5047–5057. 
Müller, J.R., and Siebenlist, U. (2003). Lymphotoxin beta receptor induces sequential 
activation of distinct NF-kappa B factors via separate signaling pathways. J. Biol. Chem. 278, 
12006–12012. 
Muller, P., Männel, D.N., and Hehlgans, T. (2001). Functional characterization of the mouse 
lymphotoxin-beta receptor promoter. Eur. Cytokine Netw. 12, 325–330. 
Mullighan, C.G., Phillips, L.A., Su, X., Ma, J., Miller, C.B., Shurtleff, S.A., and Downing, 
J.R. (2008). Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. 
Science 322, 1377–1380. 
Murphy, T.L., and Murphy, K.M. (2010). Slow down and survive: Enigmatic 
immunoregulation by BTLA and HVEM. Annu. Rev. Immunol. 28, 389–411. 
Murphy, M., Walter, B.N., Pike-Nobile, L., Fanger, N.A., Guyre, P.M., Browning, J.L., 
Ware, C.F., and Epstein, L.B. (1998). Expression of the lymphotoxin beta receptor on 
follicular stromal cells in human lymphoid tissues. Cell Death Differ. 5, 497–505. 
Nagai, M., Kyakumoto, S., and Sato, N. (2000). Cancer cells responsible for humoral 
hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces 
osteoclast formation. Biochem. Biophys. Res. Commun. 269, 532–536. 
Naito, A., Azuma, S., Tanaka, S., Miyazaki, T., Takaki, S., Takatsu, K., Nakao, K., 
Nakamura, K., Katsuki, M., Yamamoto, T., et al. (1999). Severe osteopetrosis, defective 
interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes 
Cells 4, 353–362. 
REFERENCES	  
MT Fernandes 160 
Nakano, H., Oshima, H., Chung, W., Williams-Abbott, L., Ware, C.F., Yagita, H., and 
Okumura, K. (1996). TRAF5, an activator of NF-kappaB and putative signal transducer for 
the lymphotoxin-beta receptor. J. Biol. Chem. 271, 14661–14664. 
Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-Hora, M., Feng, J.Q., Bonewald, 
L.F., Kodama, T., Wutz, A., Wagner, E.F., et al. (2011). Evidence for osteocyte regulation of 
bone homeostasis through RANKL expression. Nat. Med. 17, 1231–1234. 
Nau, G.J., Kim, D.K., and Fitch, F.W. (1988). Agents that mimic antigen receptor signaling 
inhibit proliferation of cloned murine T lymphocytes induced by IL-2. J. Immunol. 141, 
3557–3563. 
Nedospasov, S.A., Hirt, B., Shakhov, A.N., Dobrynin, V.N., Kawashima, E., Accolla, R.S., 
and Jongeneel, C.V. (1986). The genes for tumor necrosis factor (TNF-alpha) and 
lymphotoxin (TNF-beta) are tandemly arranged on chromosome 17 of the mouse. Nucleic 
Acids Res. 14, 7713–7725. 
Nedwin, G.E., Naylor, S.L., Sakaguchi, A.Y., Smith, D., Jarrett-Nedwin, J., Pennica, D., 
Goeddel, D.V., and Gray, P.W. (1985). Human lymphotoxin and tumor necrosis factor genes: 
structure, homology and chromosomal localization. Nucleic Acids Res. 13, 6361–6373. 
Ng, O.H., Erbilgin, Y., Firtina, S., Celkan, T., Karakas, Z., Aydogan, G., Turkkan, E., 
Yildirmak, Y., Timur, C., Zengin, E., et al. (2014). Deregulated WNT signaling in childhood 
T-cell acute lymphoblastic leukemia. Blood Cancer J. 4, e192. 
Nishi, Y., Yoshikawa, K., Hiai, H., Notake, K., Shisa, H., and Nishizuka, Y. (1982). 
Formation of symbiotic complex by microenvironment-dependent mouse leukemias and 
thymic epithelial reticular cells. J. Natl. Cancer Inst. 69, 627–637. 
Norris, P.S., and Ware, C.F. (2007). The LT beta R signaling pathway. Adv. Exp. Med. Biol. 
597, 160–172. 
O’Neil, J., Billa, M., Oikemus, S., and Kelliher, M. (2001). The DNA binding activity of 
TAL-1 is not required to induce leukemia/lymphoma in mice. Oncogene 20, 3897–3905. 
Or, Y.Y.-Y., Chung, G.T.-Y., To, K.-F., Chow, C., Choy, K.-W., Tong, C.Y.-K., Leung, 
A.W.-C., Hui, A.B.-Y., Tsao, S.-W., Ng, H.-K., et al. (2010). Identification of a novel 
12p13.3 amplicon in nasopharyngeal carcinoma. J. Pathol. 220, 97–107. 
Palafox, M., Ferrer, I., Pellegrini, P., Vila, S., Hernandez-Ortega, S., Urruticoechea, A., 
Climent, F., Soler, M.T., Muñoz, P., Viñals, F., et al. (2012). RANK induces epithelial-
mesenchymal transition and stemness in human mammary epithelial cells and promotes 
tumorigenesis and metastasis. Cancer Res. 72, 2879–2888. 
Palomero, T., Sulis, M.L., Cortina, M., Real, P.J., Barnes, K., Ciofani, M., Caparros, E., 
Buteau, J., Brown, K., Perkins, S.L., et al. (2007). Mutational loss of PTEN induces 
resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13, 1203–1210. 
Paul, N.L., and Ruddle, N.H. (1988). Lymphotoxin. Annu. Rev. Immunol. 6, 407–438. 
Paul, N.L., Lenardo, M.J., Novak, K.D., Sarr, T., Tang, W.L., and Ruddle, N.H. (1990). 
Lymphotoxin activation by human T-cell leukemia virus type I-infected cell lines: role for 
NF-kappa B. J. Virol. 64, 5412–5419. 
Paul, N.L., Millet, I., and Ruddle, N.H. (1993). The lymphotoxin promoter is stimulated by 
HTLV-I tax activation of NF-kappa B in human T-cell lines. Cytokine 5, 372–378. 
REFERENCES 
MT Fernandes 161 
Pear, W.S., Aster, J.C., Scott, M.L., Hasserjian, R.P., Soffer, B., Sklar, J., and Baltimore, D. 
(1996). Exclusive development of T cell neoplasms in mice transplanted with bone marrow 
expressing activated Notch alleles. J. Exp. Med. 183, 2283–2291. 
Pegoraro, L., Fierro, M.T., Lusso, P., Giovinazzo, B., Lanino, E., Giovarelli, M., Matera, L., 
and Foa, R. (1985). A novel leukemia T-cell line (PF-382) with phenotypic and functional 
features of suppressor lymphocytes. J. Natl. Cancer Inst. 75, 285–290. 
Peirs, S., Van der Meulen, J., Van de Walle, I., Taghon, T., Speleman, F., Poppe, B., and Van 
Vlierberghe, P. (2015). Epigenetics in T-cell acute lymphoblastic leukemia. Immunol. Rev. 
263, 50–67. 
Peschon, J.J., Morrissey, P.J., Grabstein, K.H., Ramsdell, F.J., Maraskovsky, E., Gliniak, 
B.C., Park, L.S., Ziegler, S.F., Williams, D.E., Ware, C.B., et al. (1994). Early lymphocyte 
expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 180, 
1955–1960. 
Petrie, H.T., and Zúñiga-Pflücker, J.C. (2007). Zoned out: functional mapping of stromal 
signaling microenvironments in the thymus. Annu. Rev. Immunol. 25, 649–679. 
Pierer, M., Brentano, F., Rethage, J., Wagner, U., Hantzschel, H., Gay, R.E., Gay, S., and 
Kyburz, D. (2007). The TNF superfamily member LIGHT contributes to survival and 
activation of synovial fibroblasts in rheumatoid arthritis. Rheumatol. Oxf. 46, 1063–1070. 
Poglio, S., Cahu, X., Uzan, B., Besnard-Guérin, C., Lapillonne, H., Leblanc, T., Baruchel, A., 
Landman-Parker, J., Petit, A., Baleydier, F., et al. (2015). Rapid childhood T-ALL growth in 
xenograft models correlates with mature phenotype and NF-κB pathway activation but not 
with poor prognosis. Leukemia 29, 977–980. 
Pokholok, D.K., Maroulakou, I.G., Kuprash, D.V., Alimzhanov, M.B., Kozlov, S.V., 
Novobrantseva, T.I., Turetskaya, R.L., Green, J.E., and Nedospasov, S.A. (1995). Cloning 
and expression analysis of the murine lymphotoxin beta gene. Proc. Natl. Acad. Sci. U. S. A. 
92, 674–678. 
Porritt, H.E., Rumfelt, L.L., Tabrizifard, S., Schmitt, T.M., Zúñiga-Pflücker, J.C., and Petrie, 
H.T. (2004). Heterogeneity among DN1 prothymocytes reveals multiple progenitors with 
different capacities to generate T cell and non-T cell lineages. Immunity 20, 735–745. 
Pui, C.-H., and Evans, W.E. (2006). Treatment of acute lymphoblastic leukemia. N. Engl. J. 
Med. 354, 166–178. 
Pui, C.H., Behm, F.G., Singh, B., Schell, M.J., Williams, D.L., Rivera, G.K., Kalwinsky, 
D.K., Sandlund, J.T., Crist, W.M., and Raimondi, S.C. (1990). Heterogeneity of presenting 
features and their relation to treatment outcome in 120 children with T-cell acute 
lymphoblastic leukemia. Blood 75, 174–179. 
Pui, C.-H., Relling, M.V., and Downing, J.R. (2004). Acute lymphoblastic leukemia. N. Engl. 
J. Med. 350, 1535–1548. 
Pui, C.-H., Robison, L.L., and Look, A.T. (2008). Acute lymphoblastic leukaemia. Lancet 
371, 1030–1043. 
Pui, J.C., Allman, D., Xu, L., DeRocco, S., Karnell, F.G., Bakkour, S., Lee, J.Y., Kadesch, 
T., Hardy, R.R., Aster, J.C., et al. (1999). Notch1 expression in early lymphopoiesis 
influences B versus T lineage determination. Immunity 11, 299–308. 
Qiuping, Z., Jei, X., Youxin, J., Wei, J., Chun, L., Jin, W., Qun, W., Yan, L., Chunsong, H., 
Mingzhen, Y., et al. (2004). CC chemokine ligand 25 enhances resistance to apoptosis in 
REFERENCES	  
MT Fernandes 162 
CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by 
means of livin activation. Cancer Res. 64, 7579–7587. 
Raaijmakers, M.H.G.P. (2010). Regulating traffic in the hematopoietic stem cell niche. 
Haematologica 95, 1439–1441. 
Radtke, F., Wilson, A., Stark, G., Bauer, M., van Meerwijk, J., MacDonald, H.R., and Aguet, 
M. (1999). Deficient T cell fate specification in mice with an induced inactivation of Notch1. 
Immunity 10, 547–558. 
Rehm, A., Mensen, A., Schradi, K., Gerlach, K., Wittstock, S., Winter, S., Büchner, G., 
Dörken, B., Lipp, M., and Höpken, U.E. (2011). Cooperative function of CCR7 and 
lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary 
lymphoid organs. Blood 118, 1020–1033. 
Reinherz, E.L., Kung, P.C., Goldstein, G., Levey, R.H., and Schlossman, S.F. (1980). 
Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and 
leukemic lymphoblasts of T-cell lineage. Proc. Natl. Acad. Sci. U. S. A. 77, 1588–1592. 
Rennert, P.D., Browning, J.L., Mebius, R., Mackay, F., and Hochman, P.S. (1996). Surface 
lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid 
organs. J. Exp. Med. 184, 1999–2006. 
Rezzani, R., Bonomini, F., and Rodella, L.F. (2008). Histochemical and molecular overview 
of the thymus as site for T-cells development. Prog. Histochem. Cytochem. 43, 73–120. 
Ribeiro, D., Melão, A., and Barata, J.T. (2013). IL-7R-mediated signaling in T-cell acute 
lymphoblastic leukemia. Adv. Biol. Regul. 53, 211–222. 
Robison, L.L. (2011). Late effects of acute lymphoblastic leukemia therapy in patients 
diagnosed at 0-20 years of age. Hematology Am. Soc. Hematol. Educ. Program 2011, 238–
242. 
Rodewald, H.R., Ogawa, M., Haller, C., Waskow, C., and DiSanto, J.P. (1997). Pro-
thymocyte expansion by c-kit and the common cytokine receptor gamma chain is essential 
for repertoire formation. Immunity 6, 265–272. 
Röhrl, J., Huber, B., Koehl, G.E., Geissler, E.K., and Hehlgans, T. (2012). Mouse β-defensin 
14 (Defb14) promotes tumor growth by inducing angiogenesis in a CCR6-dependent manner. 
J. Immunol. 188, 4931–4939. 
Rossi, S.W., Kim, M.-Y., Leibbrandt, A., Parnell, S.M., Jenkinson, W.E., Glanville, S.H., 
McConnell, F.M., Scott, H.S., Penninger, J.M., Jenkinson, E.J., et al. (2007). RANK signals 
from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the 
thymic medulla. J. Exp. Med. 204, 1267–1272. 
Ruddle, N.H. (2014). Lymphotoxin and TNF: how it all began-a tribute to the travelers. 
Cytokine Growth Factor Rev. 25, 83–89. 
Sambandam, Y., Sundaram, K., Liu, A., Kirkwood, K.L., Ries, W.L., and Reddy, S.V. 
(2013). CXCL13 activation of c-Myc induces RANK ligand expression in 
stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone 
microenvironment. Oncogene 32, 97–105. 
Sanjo, H., Zajonc, D.M., Braden, R., Norris, P.S., and Ware, C.F. (2010). Allosteric 
regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta 
receptor. J. Biol. Chem. 285, 17148–17155. 
REFERENCES 
MT Fernandes 163 
Santos, S.C., Monni, R., Bouchaert, I., Bernard, O., Gisselbrecht, S., Gouilleux, F., and 
Penard-Lacronique, V. (2001). Involvement of the NF-kappaB pathway in the transforming 
properties of the TEL-Jak2 leukemogenic fusion protein. FEBS Lett. 497, 148–152. 
Dos Santos, N.R., Rickman, D.S., de Reynies, A., Cormier, F., Williame, M., Blanchard, C., 
Stern, M.-H., and Ghysdael, J. (2007). Pre-TCR expression cooperates with TEL-JAK2 to 
transform immature thymocytes and induce T-cell leukemia. Blood 109, 3972–3981. 
Dos Santos, N.R., Williame, M., Gachet, S., Cormier, F., Janin, A., Weih, D., Weih, F., and 
Ghysdael, J. (2008). RelB-dependent stromal cells promote T-cell leukemogenesis. PloS One 
3, e2555. 
Dos Santos, N.R., Ghezzo, M.N., da Silva, R.C., and Fernandes, M.T. (2010). NF-κB in T-
cell Acute Lymphoblastic Leukemia: Oncogenic Functions in Leukemic and in 
Microenvironmental Cells. Cancers 2, 1838–1860. 
Scaffidi, P., Misteli, T., and Bianchi, M.E. (2002). Release of chromatin protein HMGB1 by 
necrotic cells triggers inflammation. Nature 418, 191–195. 
Scheu, S., Alferink, J., Pötzel, T., Barchet, W., Kalinke, U., and Pfeffer, K. (2002). Targeted 
disruption of LIGHT causes defects in costimulatory T cell activation and reveals 
cooperation with lymphotoxin beta in mesenteric lymph node genesis. J. Exp. Med. 195, 
1613–1624. 
Schmiedel, B.J., Nuebling, T., Steinbacher, J., Malinovska, A., Wende, C.M., Azuma, M., 
Schneider, P., Grosse-Hovest, L., and Salih, H.R. (2013). Receptor activator for NF-κB 
ligand in acute myeloid leukemia: expression, function, and modulation of NK cell 
immunosurveillance. J. Immunol. 190, 821–831. 
Schmitt, T.M., Ciofani, M., Petrie, H.T., and Zúñiga-Pflücker, J.C. (2004). Maintenance of T 
cell specification and differentiation requires recurrent notch receptor-ligand interactions. J. 
Exp. Med. 200, 469–479. 
Schneider, B.E., Korbel, D., Hagens, K., Koch, M., Raupach, B., Enders, J., Kaufmann, 
S.H.E., Mittrücker, H.-W., and Schaible, U.E. (2010). A role for IL-18 in protective 
immunity against Mycobacterium tuberculosis. Eur. J. Immunol. 40, 396–405. 
Schneider, U., Schwenk, H.U., and Bornkamm, G. (1977). Characterization of EBV-genome 
negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia 
and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer 19, 621–626. 
Schramek, D., Leibbrandt, A., Sigl, V., Kenner, L., Pospisilik, J.A., Lee, H.J., Hanada, R., 
Joshi, P.A., Aliprantis, A., Glimcher, L., et al. (2010). Osteoclast differentiation factor 
RANKL controls development of progestin-driven mammary cancer. Nature 468, 98–102. 
Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J.C., Williams, I.R., Lee, C.K., 
Gerthner, R., Kitamura, T., Frantsve, J., et al. (2000). Stat5 is essential for the myelo- and 
lymphoproliferative disease induced by TEL/JAK2. Mol. Cell 6, 693–704. 
Scupoli, M.T., Vinante, F., Krampera, M., Vincenzi, C., Nadali, G., Zampieri, F., Ritter, 
M.A., Eren, E., Santini, F., and Pizzolo, G. (2003). Thymic epithelial cells promote survival 
of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. 
Haematologica 88, 1229–1237. 
Scupoli, M.T., Perbellini, O., Krampera, M., Vinante, F., Cioffi, F., and Pizzolo, G. (2007). 
Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human 
thymocytes on bone marrow stroma. Haematologica 92, 264–266. 
REFERENCES	  
MT Fernandes 164 
Seach, N., Ueno, T., Fletcher, A.L., Lowen, T., Mattesich, M., Engwerda, C.R., Scott, H.S., 
Ware, C.F., Chidgey, A.P., Gray, D.H.D., et al. (2008). The lymphotoxin pathway regulates 
Aire-independent expression of ectopic genes and chemokines in thymic stromal cells. J. 
Immunol. 180, 5384–5392. 
Secchiero, P., Corallini, F., Barbarotto, E., Melloni, E., di Iasio, M.G., Tiribelli, M., and 
Zauli, G. (2006). Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) 
in B chronic lymphocytic leukemia (B-CLL) cells. J. Cell. Physiol. 207, 158–164. 
Seleznik, G.M., Zoller, J., O’Connor, T., Graf, R., and Heikenwalder, M. (2014). The role of 
lymphotoxin signaling in the development of autoimmune pancreatitis and associated 
secondary extra-pancreatic pathologies. Cytokine Growth Factor Rev. 25, 125–137. 
Serwold, T., Hochedlinger, K., Swindle, J., Hedgpeth, J., Jaenisch, R., and Weissman, I.L. 
(2010). T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T 
cell. Proc. Natl. Acad. Sci. U. S. A. 107, 18939–18943. 
Shaikh, R.B., Santee, S., Granger, S.W., Butrovich, K., Cheung, T., Kronenberg, M., 
Cheroutre, H., and Ware, C.F. (2001). Constitutive expression of LIGHT on T cells leads to 
lymphocyte activation, inflammation, and tissue destruction. J. Immunol. 167, 6330–6337. 
Shebzukhov, I.V., and Kuprash, D.V. (2011). [Transcriptional regulation of TNF/LT locus in 
immune cells]. Mol. Biol. 45, 56–67. 
Shinkai, Y., Rathbun, G., Lam, K.P., Oltz, E.M., Stewart, V., Mendelsohn, M., Charron, J., 
Datta, M., Young, F., and Stall, A.M. (1992). RAG-2-deficient mice lack mature 
lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855–867. 
Silva, I., and Branco, J.C. (2011). Rank/Rankl/opg: literature review. Acta Reumatol. Port. 
36, 209–218. 
Silva, A., Laranjeira, A.B.A., Martins, L.R., Cardoso, B.A., Demengeot, J., Yunes, J.A., 
Seddon, B., and Barata, J.T. (2011). IL-7 contributes to the progression of human T-cell acute 
lymphoblastic leukemias. Cancer Res. 71, 4780–4789. 
Silva-Santos, B., Pennington, D.J., and Hayday, A.C. (2005). Lymphotoxin-mediated 
regulation of gammadelta cell differentiation by alphabeta T cell progenitors. Science 307, 
925–928. 
Simonin, Y., Vegna, S., Akkari, L., Grégoire, D., Antoine, E., Piette, J., Floc’h, N., Lassus, 
P., Yu, G.-Y., Rosenberg, A.R., et al. (2013). Lymphotoxin signaling is initiated by the viral 
polymerase in HCV-linked tumorigenesis. PLoS Pathog. 9, e1003234. 
Sirinian, C., Papanastasiou, A.D., Zarkadis, I.K., and Kalofonos, H.P. (2013). Alternative 
splicing generates a truncated isoform of human TNFRSF11A (RANK) with an altered 
capacity to activate NF-κB. Gene 525, 124–129. 
Sitnicka, E. (2009). From the bone marrow to the thymus: the road map of early stages of T-
cell development. Crit. Rev. Immunol. 29, 487–530. 
Smirnova, A.S., Ferreira-Silva, K.C., Mine, K.L., Andrade-Oliveira, V., Shulzhenko, N., 
Gerbase-DeLima, M., and Morgun, A. (2008). Differential expression of new LTA splice 
variants upon lymphocyte activation. Mol. Immunol. 45, 295–300. 
Smith, S.D., Morgan, R., Gemmell, R., Amylon, M.D., Link, M.P., Linker, C., Hecht, B.K., 
Warnke, R., Glader, B.E., and Hecht, F. (1988). Clinical and biologic characterization of T-
cell neoplasias with rearrangements of chromosome 7 band q34. Blood 71, 395–402. 
REFERENCES 
MT Fernandes 165 
Soulier, J., Clappier, E., Cayuela, J.-M., Regnault, A., García-Peydró, M., Dombret, H., 
Baruchel, A., Toribio, M.-L., and Sigaux, F. (2005). HOXA genes are included in genetic and 
biologic networks defining human acute T-cell leukemia (T-ALL). Blood 106, 274–286. 
Stoletov, K., and Klemke, R. (2008). Catch of the day: zebrafish as a human cancer model. 
Oncogene 27, 4509–4520. 
Stopfer, P., Männel, D.N., and Hehlgans, T. (2004). Lymphotoxin-beta receptor activation by 
activated T cells induces cytokine release from mouse bone marrow-derived mast cells. J. 
Immunol. 172, 7459–7465. 
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., 
Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment 
analysis: a knowledge-based approach for interpreting genome-wide expression profiles. 
Proc. Natl. Acad. Sci. U. S. A. 102, 15545–15550. 
Sudhamsu, J., Yin, J., Chiang, E.Y., Starovasnik, M.A., Grogan, J.L., and Hymowitz, S.G. 
(2013). Dimerization of LTβR by LTα1β2 is necessary and sufficient for signal transduction. 
Proc. Natl. Acad. Sci. U. S. A. 110, 19896–19901. 
Sun, M., and Fink, P.J. (2007). A new class of reverse signaling costimulators belongs to the 
TNF family. J. Immunol. 179, 4307–4312. 
Takahama, Y. (2006). Journey through the thymus: stromal guides for T-cell development 
and selection. Nat. Rev. Immunol. 6, 127–135. 
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., 
Yokochi, T., Oda, H., Tanaka, K., et al. (2000). T-cell-mediated regulation of 
osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408, 
600–605. 
Talora, C., Cialfi, S., Oliviero, C., Palermo, R., Pascucci, M., Frati, L., Vacca, A., Gulino, A., 
and Screpanti, I. (2006). Cross talk among Notch3, pre-TCR, and Tal1 in T-cell development 
and leukemogenesis. Blood 107, 3313–3320. 
Tamada, K., Shimozaki, K., Chapoval, A.I., Zhai, Y., Su, J., Chen, S.F., Hsieh, S.L., Nagata, 
S., Ni, J., and Chen, L. (2000). LIGHT, a TNF-like molecule, costimulates T cell 
proliferation and is required for dendritic cell-mediated allogeneic T cell response. J. 
Immunol. 164, 4105–4110. 
Tan, W., Zhang, W., Strasner, A., Grivennikov, S., Cheng, J.Q., Hoffman, R.M., and Karin, 
M. (2011). Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis 
through RANKL-RANK signalling. Nature 470, 548–553. 
Thompson, B.J., Buonamici, S., Sulis, M.L., Palomero, T., Vilimas, T., Basso, G., Ferrando, 
A., and Aifantis, I. (2007). The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in 
T cell leukemia. J. Exp. Med. 204, 1825–1835. 
Tlsty, T.D., and Coussens, L.M. (2006). Tumor stroma and regulation of cancer development. 
Annu. Rev. Pathol. 1, 119–150. 
De Togni, P., Goellner, J., Ruddle, N.H., Streeter, P.R., Fick, A., Mariathasan, S., Smith, 
S.C., Carlson, R., Shornick, L.P., and Strauss-Schoenberger, J. (1994). Abnormal 
development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264, 
703–707. 
REFERENCES	  
MT Fernandes 166 
Tosello, V., Mansour, M.R., Barnes, K., Paganin, M., Sulis, M.L., Jenkinson, S., Allen, C.G., 
Gale, R.E., Linch, D.C., Palomero, T., et al. (2009). WT1 mutations in T-ALL. Blood 114, 
1038–1045. 
Totsuka, T., Kanai, T., Nemoto, Y., Tomita, T., Okamoto, R., Tsuchiya, K., Nakamura, T., 
Sakamoto, N., Akiba, H., Okumura, K., et al. (2009). RANK-RANKL signaling pathway is 
critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis. J. 
Immunol. 182, 6079–6087. 
Tremblay, C.S., and Curtis, D.J. (2014). The clonal evolution of leukemic stem cells in T-cell 
acute lymphoblastic leukemia. Curr. Opin. Hematol. 21, 320–325. 
De Trez, C., Schneider, K., Potter, K., Droin, N., Fulton, J., Norris, P.S., Ha, S., Fu, Y.-X., 
Murphy, T., Murphy, K.M., et al. (2008). The inhibitory HVEM-BTLA pathway counter 
regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J. 
Immunol. 180, 238–248. 
Tumanov, A., Kuprash, D., Lagarkova, M., Grivennikov, S., Abe, K., Shakhov, A., 
Drutskaya, L., Stewart, C., Chervonsky, A., and Nedospasov, S. (2002). Distinct role of 
surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues. 
Immunity 17, 239–250. 
Tumanov, A.V., Christiansen, P.A., and Fu, Y.-X. (2007). The role of lymphotoxin receptor 
signaling in diseases. Curr. Mol. Med. 7, 567–578. 
Tumanov, A.V., Koroleva, E.P., Christiansen, P.A., Khan, M.A., Ruddy, M.J., Burnette, B., 
Papa, S., Franzoso, G., Nedospasov, S.A., Fu, Y.-X., et al. (2009). T cell-derived 
lymphotoxin regulates liver regeneration. Gastroenterology 136, 694–704.e4. 
Tzoneva, G., Perez-Garcia, A., Carpenter, Z., Khiabanian, H., Tosello, V., Allegretta, M., 
Paietta, E., Racevskis, J., Rowe, J.M., Tallman, M.S., et al. (2013). Activating mutations in 
the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat. Med. 19, 
368–371. 
Ueno, T., Saito, F., Gray, D.H.D., Kuse, S., Hieshima, K., Nakano, H., Kakiuchi, T., Lipp, 
M., Boyd, R.L., and Takahama, Y. (2004). CCR7 signals are essential for cortex-medulla 
migration of developing thymocytes. J. Exp. Med. 200, 493–505. 
Uzan, B., Poglio, S., Gerby, B., Wu, C.-L., Gross, J., Armstrong, F., Calvo, J., Cahu, X., 
Deswarte, C., Dumont, F., et al. (2014). Interleukin-18 produced by bone marrow-derived 
stromal cells supports T-cell acute leukaemia progression. EMBO Mol. Med. 6, 821–834. 
Vainchenker, W., and Constantinescu, S.N. (2013). JAK/STAT signaling in hematological 
malignancies. Oncogene 32, 2601–2613. 
VanArsdale, T.L., VanArsdale, S.L., Force, W.R., Walter, B.N., Mosialos, G., Kieff, E., 
Reed, J.C., and Ware, C.F. (1997). Lymphotoxin-beta receptor signaling complex: role of 
tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of 
nuclear factor kappaB. Proc. Natl. Acad. Sci. U. S. A. 94, 2460–2465. 
Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, 
N.L., Le Beau, M.M., Hellström-Lindberg, E., Tefferi, A., et al. (2009). The 2008 revision of 
the World Health Organization (WHO) classification of myeloid neoplasms and acute 
leukemia: rationale and important changes. Blood 114, 937–951. 
REFERENCES 
MT Fernandes 167 
Venanzi, E.S., Gray, D.H.D., Benoist, C., and Mathis, D. (2007). Lymphotoxin pathway and 
Aire influences on thymic medullary epithelial cells are unconnected. J. Immunol. 179, 5693–
5700. 
Villablanca, E.J., Zhou, D., Valentinis, B., Negro, A., Raccosta, L., Mauri, L., Prinetti, A., 
Sonnino, S., Bordignon, C., Traversari, C., et al. (2008). Selected natural and synthetic 
retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo. J. Leukoc. 
Biol. 84, 871–879. 
Van Vlierberghe, P., and Ferrando, A. (2012). The molecular basis of T cell acute 
lymphoblastic leukemia. J. Clin. Invest. 122, 3398–3406. 
Van Vlierberghe, P., Pieters, R., Beverloo, H.B., and Meijerink, J.P.P. (2008). Molecular-
genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br. J. Haematol. 143, 
153–168. 
Voon, D.C., Subrata, L.S., and Abraham, L.J. (2001). Regulation of lymphotoxin-beta by 
tumor necrosis factor, phorbol myristate acetate, and ionomycin in Jurkat T cells. J. 
Interferon Cytokine Res. 21, 921–930. 
Voon, D.C., Subrata, L.S., Karimi, M., Ulgiati, D., and Abraham, L.J. (2004). TNF and 
phorbol esters induce lymphotoxin-beta expression through distinct pathways involving Ets 
and NF-kappa B family members. J. Immunol. 172, 4332–4341. 
Voss, M., Lettau, M., Paulsen, M., and Janssen, O. (2008). Posttranslational regulation of Fas 
ligand function. Cell Commun. Signal. 6, 11. 
Wada, H., Masuda, K., Satoh, R., Kakugawa, K., Ikawa, T., Katsura, Y., and Kawamoto, H. 
(2008). Adult T-cell progenitors retain myeloid potential. Nature 452, 768–772. 
Waibel, M., Solomon, V.S., Knight, D.A., Ralli, R.A., Kim, S.-K., Banks, K.-M., Vidacs, E., 
Virely, C., Sia, K.C.S., Bracken, L.S., et al. (2013). Combined targeting of JAK2 and Bcl-
2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to 
JAK2 inhibitors. Cell Rep. 5, 1047–1059. 
Walsh, M.C., and Choi, Y. (2014). Biology of the RANKL-RANK-OPG System in 
Immunity, Bone, and Beyond. Front. Immunol. 5, 511. 
Walsh, N.C., Alexander, K.A., Manning, C.A., Karmakar, S., Karmakar, S.K., Wang, J.F., 
Weyand, C.M., Pettit, A.R., and Gravallese, E.M. (2013). Activated human T cells express 
alternative mRNA transcripts encoding a secreted form of RANKL. Genes Immun. 14, 336–
345. 
Wang, J., and Fu, Y.-X. (2003). LIGHT (a cellular ligand for herpes virus entry mediator and 
lymphotoxin receptor)-mediated thymocyte deletion is dependent on the interaction between 
TCR and MHC/self-peptide. J. Immunol. 170, 3986–3993. 
Wang, J., Chun, T., Lo, J.C., Wu, Q., Wang, Y., Foster, A., Roca, K., Chen, M., Tamada, K., 
Chen, L., et al. (2001). The critical role of LIGHT, a TNF family member, in T cell 
development. J. Immunol. 167, 5099–5105. 
Wang, Y.-G., Kim, K.D., Wang, J., Yu, P., and Fu, Y.-X. (2005). Stimulating lymphotoxin 
beta receptor on the dendritic cells is critical for their homeostasis and expansion. J. 
Immunol. 175, 6997–7002. 
Ware, C.F. (2005). Network communications: lymphotoxins, LIGHT, and TNF. Annu. Rev. 
Immunol. 23, 787–819. 
REFERENCES	  
MT Fernandes 168 
Ware, C.F., Crowe, P.D., Grayson, M.H., Androlewicz, M.J., and Browning, J.L. (1992). 
Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural 
killer cells. J. Immunol. 149, 3881–3888. 
Warzocha, K., Renard, N., Charlot, C., Bienvenu, J., Coiffier, B., and Salles, G. (1997). 
Identification of two lymphotoxin beta isoforms expressed in human lymphoid cell lines and 
non-Hodgkin’s lymphomas. Biochem. Biophys. Res. Commun. 238, 273–276. 
Weber-Nordt, R.M., Egen, C., Wehinger, J., Ludwig, W., Gouilleux-Gruart, V., 
Mertelsmann, R., and Finke, J. (1996). Constitutive activation of STAT proteins in primary 
lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell 
lines. Blood 88, 809–816. 
Weih, F., Carrasco, D., Durham, S.K., Barton, D.S., Rizzo, C.A., Ryseck, R.P., Lira, S.A., 
and Bravo, R. (1995). Multiorgan inflammation and hematopoietic abnormalities in mice 
with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 80, 331–
340. 
Weng, A.P., Ferrando, A.A., Lee, W., Morris, J.P., Silverman, L.B., Sanchez-Irizarry, C., 
Blacklow, S.C., Look, A.T., and Aster, J.C. (2004). Activating mutations of NOTCH1 in 
human T cell acute lymphoblastic leukemia. Science 306, 269–271. 
White, A.J., Withers, D.R., Parnell, S.M., Scott, H.S., Finke, D., Lane, P.J.L., Jenkinson, E.J., 
and Anderson, G. (2008). Sequential phases in the development of Aire-expressing medullary 
thymic epithelial cells involve distinct cellular input. Eur. J. Immunol. 38, 942–947. 
Williams-Abbott, L., Walter, B.N., Cheung, T.C., Goh, C.R., Porter, A.G., and Ware, C.F. 
(1997). The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for 
the receptor specificity, of the membrane-anchored LTalpha1beta2 heterotrimeric ligand. J. 
Biol. Chem. 272, 19451–19456. 
Wilson, C.A., and Browning, J.L. (2002). Death of HT29 adenocarcinoma cells induced by 
TNF family receptor activation is caspase-independent and displays features of both 
apoptosis and necrosis. Cell Death Differ. 9, 1321–1333. 
Wilson, A., MacDonald, H.R., and Radtke, F. (2001). Notch 1-deficient common lymphoid 
precursors adopt a B cell fate in the thymus. J. Exp. Med. 194, 1003–1012. 
Winter, H., van den Engel, N.K., Poehlein, C.H., Hatz, R.A., Fox, B.A., and Hu, H.-M. 
(2007). Tumor-specific T cells signal tumor destruction via the lymphotoxin beta receptor. J. 
Transl. Med. 5, 14. 
Winter, S.S., Sweatman, J.J., Lawrence, M.B., Rhoades, T.H., Hart, A.L., and Larson, R.S. 
(2001). Enhanced T-lineage acute lymphoblastic leukaemia cell survival on bone marrow 
stroma requires involvement of LFA-1 and ICAM-1. Br. J. Haematol. 115, 862–871. 
Wolf, S.S., and Cohen, A. (1992). Expression of cytokines and their receptors by human 
thymocytes and thymic stromal cells. Immunology 77, 362–368. 
Wolf, M.J., Seleznik, G.M., Zeller, N., and Heikenwalder, M. (2010). The unexpected role of 
lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to 
liver and prostate cancer development. Oncogene 29, 5006–5018. 
Wolf, M.J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., 
Simonavicius, N., Egger, M., Wohlleber, D., et al. (2014). Metabolic activation of 
intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer 
via cross-talk with hepatocytes. Cancer Cell 26, 549–564. 
REFERENCES 
MT Fernandes 169 
Wong, B.R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, 
E., Bartlett, F.S., Frankel, W.N., et al. (1997). TRANCE is a novel ligand of the tumor 
necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. 
Chem. 272, 25190–25194. 
Wong, B.R., Josien, R., Lee, S.Y., Vologodskaia, M., Steinman, R.M., and Choi, Y. (1998). 
The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE 
receptor. J. Biol. Chem. 273, 28355–28359. 
Wong, B.R., Besser, D., Kim, N., Arron, J.R., Vologodskaia, M., Hanafusa, H., and Choi, Y. 
(1999). TRANCE, a TNF family member, activates Akt/PKB through a signaling complex 
involving TRAF6 and c-Src. Mol. Cell 4, 1041–1049. 
Worm, M.M., Tsytsykova, A., and Geha, R.S. (1998). CD40 ligation and IL-4 use different 
mechanisms of transcriptional activation of the human lymphotoxin alpha promoter in B 
cells. Eur. J. Immunol. 28, 901–906. 
Wu, M.Y., Wang, P.Y., Han, S.H., and Hsieh, S.L. (1999). The cytoplasmic domain of the 
lymphotoxin-beta receptor mediates cell death in HeLa cells. J. Biol. Chem. 274, 11868–
11873. 
Xiu, Y., Xu, H., Zhao, C., Li, J., Morita, Y., Yao, Z., Xing, L., and Boyce, B.F. (2014). 
Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 
degradation. J. Clin. Invest. 124, 297–310. 
Yang, D., Ud Din, N., Browning, D.D., Abrams, S.I., and Liu, K. (2007). Targeting 
lymphotoxin beta receptor with tumor-specific T lymphocytes for tumor regression. Clin. 
Cancer Res. 13, 5202–5210. 
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., 
Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998). Osteoclast differentiation 
factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to 
TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95, 3597–3602. 
Yokley, B.H., Selby, S.T., and Posch, P.E. (2013). A stimulation-dependent alternate core 
promoter links lymphotoxin α expression with TGF-β1 and fibroblast growth factor-7 
signaling in primary human T cells. J. Immunol. 190, 4573–4584. 
Young, J., Yu, X., Wolslegel, K., Nguyen, A., Kung, C., Chiang, E., Kolumam, G., Wei, N., 
Wong, W.L., DeForge, L., et al. (2010). Lymphotoxin-alphabeta heterotrimers are cleaved by 
metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine 51, 78–86. 
Yu, K.Y., Kwon, B., Ni, J., Zhai, Y., Ebner, R., and Kwon, B.S. (1999). A newly identified 
member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated 
apoptosis. J. Biol. Chem. 274, 13733–13736. 
Zellmer, S., Sickinger, S., Schmidt-Heck, W., Guthke, R., and Gebhardt, R. (2009). 
Heterogeneous expression of suppressor of cytokine signalling 2 (SOCS-2) in liver tissue. J. 
Anat. 215, 176–183. 
Zenatti, P.P., Ribeiro, D., Li, W., Zuurbier, L., Silva, M.C., Paganin, M., Tritapoe, J., Hixon, 
J.A., Silveira, A.B., Cardoso, B.A., et al. (2011). Oncogenic IL7R gain-of-function mutations 
in childhood T-cell acute lymphoblastic leukemia. Nat. Genet. 43, 932–939. 
Zhai, Y., Guo, R., Hsu, T.L., Yu, G.L., Ni, J., Kwon, B.S., Jiang, G.W., Lu, J., Tan, J., 
Ugustus, M., et al. (1998). LIGHT, a novel ligand for lymphotoxin beta receptor and 
REFERENCES	  
MT Fernandes 170 
TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J. 
Clin. Invest. 102, 1142–1151. 
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S.L., Payne-Turner, D., Easton, J., Chen, 
X., Wang, J., Rusch, M., et al. (2012). The genetic basis of early T-cell precursor acute 
lymphoblastic leukaemia. Nature 481, 157–163. 
Zhao, W.-L. (2010). Targeted therapy in T-cell malignancies: dysregulation of the cellular 
signaling pathways. Leukemia 24, 13–21. 
Zhao, L., Liu, L., Gao, J., Yang, Y., Hu, C., Guo, B., and Zhu, B. (2014). T lymphocytes 
maintain structure and function of fibroblastic reticular cells via lymphotoxin (LT)-B. BMC 
Immunol. 15, 33. 
Zhong, Y., Jiang, L., Hiai, H., Toyokuni, S., and Yamada, Y. (2007). Overexpression of a 
transcription factor LYL1 induces T- and B-cell lymphoma in mice. Oncogene 26, 6937–
6947. 
Zhou, P., Fang, X., McNally, B.A., Yu, P., Zhu, M., Fu, Y.-X., Wang, L., Liu, Y., and Zheng, 
P. (2009). Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in 
mice with genetic predisposition. Proc. Natl. Acad. Sci. U. S. A. 106, 17134–17139. 
Zhu, M., Chin, R.K., Tumanov, A.V., Liu, X., and Fu, Y.-X. (2007). Lymphotoxin beta 
receptor is required for the migration and selection of autoreactive T cells in thymic medulla. 
J. Immunol. 179, 8069–8075. 
Zinetti, M., Agyekum, S., Evans, T., Polak, J., and Cohen, J. (1998). The role of 
lipopolysaccharide, pro-inflammatory cytokines and bacterial superantigens in the 
transcriptional regulation of lymphotoxin alpha and beta in mouse splenocytes. Cytokine 10, 
940–947. 
 
 
 
 
 
 
 
